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Summary 
Background: Opioids are used to treat moderate to severe pain, including that 
associated with surgery, cancer and infection. Findings from a range of species and 
methodologies have demonstrated that whereas some opioids are immunoneutral (e.g. 
buprenorphine), others can be immunosuppressive (e.g. morphine) or 
immunostimulatory (e.g. tramadol). This study compared the effects of commonly used 
opioids on the potential to mount protective immunity against bacterial infections 
(neutrophil/monocyte phagocytosis and oxidative burst responses) and cancer (NK cell 
cytotoxicity/activation), as well as T cell activation and cytokine production. 
Methodology: Peripheral blood was obtained from healthy volunteers and the 
influence of clinically relevant concentrations of morphine, tramadol, fentanyl, 
buprenorphine, methadone, oxycodone, diamorphine and codeine on neutrophil and 
monocyte phagocytosis of E.coli and oxidative burst responses to fMLP, PMA and 
E.coli were determined by flow cytometry. Their effects on NK cell cytotoxicity in IL-2 
stimulated, platelet-free peripheral blood mononuclear cells (PBMCs) and NK and T 
cell activation in IL-2 and anti-CD3/28 mAb stimulated PBMCs were also assessed. 
Cytokine production by anti-CD3/28 mAb and IL-2 stimulated PBMCs was determined 
using a cytometric bead array technique. 
Results: The only consistent, statistically significant effect was that methadone, 
oxycodone and diamorphine inhibited the production of IL-6 in IL-2 stimulated PBMCs, 
which could impair the acute phase response. There was however marked variability 
between individuals, both in their baseline and the effect of opioids, this was especially 
evident for morphine, tramadol, fentanyl and buprenorphine in the phagocytic and 
oxidative burst response to E.coli. 
Conclusion: These findings suggest that opioid choice could influence the 
susceptibility to bacterial or fungal infection, but have little effect on anti-cancer or anti-
viral protection. Clinical studies aimed at assessing the in vivo effects of opioid 
administration on immune function in relevant patient groups are required in order to 
assess the clinical significance of opioid choice.  
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CHAPTER 1 
 
1. INTRODUCTION 
 
1.1 Background 
Opioids are potent analgesic drugs that are used in the clinical management of 
moderate to severe pain, including pain associated with surgery, cancer and infections. 
Opioids are also used for other indications, such as the control of diarrhoea, 
breathlessness (dyspnoea) and cough. Morphine, tramadol, fentanyl, buprenorphine, 
methadone, oxycodone, diamorphine and codeine are among the most commonly used 
opioids (Klepstad et al., 2011, Pergolizzi et al., 2008). By acting on the same receptors 
that are utilised by the ubiquitous endogenous opioid system, opioids prescribed for 
pain, diarrhoea, dyspnoea or cough also affect virtually every organ system in the body 
(Table 1.1). Opioid receptors are also present on activated immune cells and opioids 
have the potential to affect the immune system (Borner et al., 2008). As this effect is 
not immediately evident and with few well designed clinical studies on the subject, 
opioid-induced immune modulation is often not considered in the clinical setting (Brack 
et al., 2011, Sacerdote, 2008). 
 
Table 1.1: Effects of opioids on different organ systems. 
System  Effects  
Gastrointestinal Constipation, xerostomia, nausea and vomiting, delayed gastric emptying, 
gastro-oesophageal reflux, constriction of the sphincter of Oddi 
Neurological Analgesia, delirium, hallucinations, sedation, myoclonus, hyperalgesia, 
seizures, headaches, euphoria, dysphoria, dependency 
Cardiovascular Bradycardia, hypotension 
Pulmonary Respiratory depression, decreased cough reflex, non-cardiogenic 
pulmonary oedema 
Urological Urine retention, decreased urine production 
Endocrinological Hypogonadism/sexual dysfunction, osteoporosis 
Immunological Possible effects on neutrophil, macrophage, natural killer cell, T cell and 
cytokine function 
 
The immune system has a crucial role in controlling and potentially eradicating disease 
in patients with cancer and infection (viral, bacterial, fungal and parasitic), thus 
anything that impairs its functional capacity might alter the clinical course of patients 
with cancer or infections. Previous in vitro and in vivo studies have shown that clinically 
used opioids have different effects on the immune system. Although previous studies 
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have used different methodologies and assessed different cell types, in general they 
have reported that some opioids have no effects on immune function (buprenorphine), 
whereas others are immunosuppressive (morphine, fentanyl), or even 
immunostimulatory (tramadol) (Budd, 2006, Gaspani et al., 2002, Shavit et al., 2004). 
The choice of prescribed opioids in clinical practice might therefore be critical in 
patients with cancer or infection who are dependent on an intact immune system to 
help control their disease. Patients with cancer may be prescribed opioids at any stage 
of their illness, for pain associated with potentially curative surgery or radiotherapy, 
through to the final stages of their illness. If patients have curative treatment, they may 
also need opioids to control symptoms caused by the treatment and it is vital that such 
medications do not increase the risk of any residual disease becoming clinically 
significant. Despite numerous studies evaluating the effect of some opioids on certain 
aspects of immune function, the effects of a range of opioids on multiple immune 
parameters have yet to be systematically assessed. This is the focus of this 
programme of work. 
 
Although components of the adaptive immune system, such as T and B cells, are vital 
in the protection against cancer and infections, the first line of immune defence is 
provided by components of the innate immune system (Friedman et al., 2003, Li and 
Xu, 2008). Innate immune cells of the monocyte-macrophage lineage and neutrophils 
are involved in the direct control of bacterial and fungal infections, whereas natural 
killer (NK) cells are involved in anti-viral and anti-tumour immunity. All immune cells 
develop by sequential differentiation of haematopoietic pluripotent progenitor cells 
(Figure 1-1). 
 
As well as consisting of immune cells as detailed in Table 1.2, immune protection also 
involves anatomical barriers such as the skin and mucous membranes, defences such 
as increased body temperature and lowering pH (in inflammatory tissue) as well as a 
variety of soluble factors such as lysozymes, interferons and complement (Galley et al., 
2000). 
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Figure 1-1: Development of immune cells. 
All haematopoietic cells, including immune cells, are derived by differentiation from pluripotent progenitor 
cells. These initially develop into lymphocytes (Lø) which then further differentiate into T or B cells, before 
becoming a particular lymphocyte subset (i.e. CD4
+
 T helper cells (TH) or CD8
+
 cytotoxic T cells (Tc), these 
constitute the adaptive immune system. Natural killer (NK) cells are derived from the lymphoid lineage and 
form part of the innate immune system. The other line of differentiation for pluripotent progenitor cells is to 
become myeloid cells, which can differentiate into antigen-presenting cells (APCs) which can become 
dendritic cells (DCs) or peripheral blood monocytes (Mo) or tissue-resident macrophages (Mø). Myeloid 
cells can also become granulocytes (or polymorphonuclear cells; PMNs), giving rise to basophils (Bø), 
eosinophils (Eø) and neutrophils (Nø), all of which are part of the innate immune system. Adapted from 
Cotran et al., 2010.  
 
 
1.2 The innate immune system 
The evolutionarily older innate immune system provides natural defence against 
pathogens and cancer without the need for previous exposure to a foreign antigen. The 
innate immune system is not only the sole arm of immunity in more primitive animals 
(pre-Gnathostomes), but also forms a very important part of the immune response in 
organisms that possess an adaptive immune system. Even in more evolved animals, 
cells of the innate immune system (monocytes/macrophages, neutrophils, NK cells) 
provide an instant immune response by eradicating bacteria, fungi and virally-infected 
cells as well as providing some defence against cancerous cells. However, in these 
more evolved animals, adaptive immune cells can stimulate or suppress the innate 
immune cells, providing greater flexibility of the immune response. 
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Table 1.2: Role and activation pattern of the main immune cells. 
Cell Role Activators Mechanism of activity Immune test of activity Arm 
Dendritic cell Antigen 
presentation 
Multiple, including: 
bacterial products 
and cytokines 
Presentation of antigenic peptides in 
the context of MHC class I and II 
molecules and the delivery of 
essential co-stimulatory molecules 
Up-regulation of surface molecules 
(CD80, CD86, ICAM-1), the release of 
cytokines and T cell activation 
Innate 
Natural 
killer cell 
Anti-tumour 
Anti-viral 
 
Multiple, including: 
the lack of MHC 
class I expression 
Release of cytotoxic molecules 
(granzymes, perforin)  
Activation antigen expression (CD69, 
CD94) 
Cytotoxicity 
Innate 
Neutrophil Anti-bacterial 
/fungal  
opsonisation Phagocytosis and oxidative burst Phagocytosis and oxidative burst Innate 
Monocyte- 
Macrophage 
lineage 
Anti-bacterial 
/fungal 
Opsonisation 
Antigen presentation 
Phagocytosis and oxidative burst Phagocytosis and oxidative burst Innate 
CD4
+
 T cell Immune 
coordination/ 
regulation 
Antigenic peptides 
presented by MHC 
class II plus essential 
co-stimulatory 
molecules 
Regulating the activity of other 
immune cells 
CD69 and CD25 expression 
Induction of antigen-specific immune 
responses 
Adaptive 
CD8
+
 T cell Cytotoxicity Antigenic peptides 
presented by MHC 
class I 
Induction of apoptosis by 
i) release of cytotoxins (perforin, 
granulysin, granzymes)  
ii) direct cell-cell contact, by up 
regulating surface Fas ligand  
CD69 and CD25 expression 
Cytotoxicity 
Adaptive 
B cell Antibody 
production 
Antigens binding to 
surface 
immunoglobulin with 
help from CD4
+
 T 
cells 
Antibody production Antibody secretion Adaptive 
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A characteristic feature of innate immune cells is that they deliver the same immune 
response irrespective of previous encounters with pathogens. This contrasts with the 
amplified responses that are generated on subsequent encounters with immunological 
challenges that are characteristic of adaptive immune responses. Innate immune cells 
also present antigen to naïve and memory cluster of differentiation (CD) 4+ and CD8+ T 
cell populations, via dendritic cells (DCs) and monocytes/macrophages respectively.  
 
1.2.1 Immune surveillance and anti-tumour immunity 
The monitoring function of the immune system to recognise and react against aberrant 
cells, including infected and cancerous cells, arising within the body is known as 
‘immunosurveillance’. Cancer immunosurveillance reduces the potential for the primary 
cancer cells to develop and prevents the establishment of subsequent 
micrometastases. The initial eradication of newly developed tumour cells is principally 
carried out by NK cells. Strictly speaking, it is only this “un-primed” phase of immune-
tumour interaction that is immunosurveillance. Once the tumour has become 
established, a number of complex immune-tumour interactions take place, for which 
the terms ‘immunoediting’ and ‘immunosculpting’ have been coined to describe this 
dynamic relationship (Reiman et al., 2007). These processes not only involve cells of 
the innate immune system, but also cytokines and T cell subsets (Reiman et al., 2007). 
As the tumour evolves, this may also involve down-regulation of major 
histocompatibility complex (MHC; human leukocyte antigen [HLA] in humans) class I 
and II antigens (Kim et al., 2007), which decreases the ability of adaptive immune cells 
to recognise the tumour.  
 
Decreased or absent MHC class I expression is frequently associated with an invasive 
and metastatic tumour phenotype (Bubenik, 2003, Garrido and Algarra, 2001). 
Although this renders cells invisible to cytotoxic attack by CD8+ cytotoxic T cells (which 
require MHC class I molecules to be expressed on their target cells), the loss of this 
expression renders tumour cells to be more susceptible to the cytotoxic effects of NK 
cells which target and kill MHC class I negative (‘missing self’) cells (Joncker et al., 
2009, Ljunggren and Karre, 1990). This is particularly important in the context of anti-
tumour immunity, as 60-90% of tumours can be MHC class I negative (Bubenik, 2003, 
Garrido and Algarra, 2001).  
 
Cancer cells differ from most pathogens that interact with the immune system, as they 
evolve from normal host cells after developing gene mutations. This ultimately leads to 
unregulated proliferation, a reduced sensitivity to apoptotic signals and cytotoxicity by 
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immune cells, and an alteration in the presentation of surface antigens which would 
initially promote the immune response (Pawelec, 2004). These changes eventually 
allow some malignant cells to escape from immune recognition. The ability of immune 
surveillance for cancer cells varies for the different stages of tumour development. 
During the initial stages, malignant tissue is only exposed to immune cells after 
angiogenesis and the emission of danger signals (Fuchs and Matzinger, 1996). Once 
this occurs there is a selection pressure on the malignant cells by the immune system 
and the malignant cells continue to generate additional escape mechanisms, including 
tumour-derived soluble factors, which can result in an immune-resistant tumour.  
 
The importance of the immune system in the protection against cancer has been 
demonstrated in a number of studies. A large retrospective cohort study of kidney 
transplant recipients compared the incidence of cancer when immunosuppression was 
reduced or stopped with that of patients on full immunosuppression (van Leeuwen et 
al., 2010). This showed that for some types of cancer (non-Hodgkin's lymphoma, lip 
cancer and melanoma) the incidence was higher when patients were on 
immunosuppression, whereas the incidence of leukaemia, lung, kidney and urinary 
tract cancers remained the same. Thyroid cancer was elevated in patients on dialysis 
(van Leeuwen et al., 2010). Chronic renal failure and dialysis are also likely to be 
immunosuppressive, albeit potentially affecting different immune cells. Although there 
are many confounding factors, it is likely that the immune system is involved in the 
elimination of some cancers more than others and this may be reflected in the 
suppression of certain types of immune cell, necessary for the control of a particular 
cancer at a particular time. 
 
It has been demonstrated in vitro that activated NK cells function as effector cells 
against tumour target cells (Ames et al., 1987, Grimm et al., 1982). In vivo, NK cells 
penetrating into a solid tumour from the circulation are only a small portion of the total 
leukocyte population infiltrating the tumour (Menon et al., 2004). The observation that 
HLA class I antigen down regulation is associated with an improved survival of patients 
with breast carcinoma (Madjd et al., 2005), non-small cell lung carcinoma (Ramnath et 
al., 2006), uveal melanoma (Jager et al., 2002), and colon cancer (Menon et al., 2002) 
demonstrates the importance of NK cells in tumour surveillance and their potential 
therapeutic value. Although NK cell infiltration into malignant tumours has been related 
to a favourable outcome (Ishigami et al., 2000, Villegas et al., 2002), these studies 
used CD57 to identify NK cells which is a non-specific marker and thus it is impossible 
to be certain if this effect is purely due to NK cells. Using more specific NK and T cell 
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labelling it has been shown that tumours showing loss of MHC class I are infiltrated 
more by CD8+ T cells (Sandel et al., 2005). It may be that the CD8+ cytotoxic T cells 
have already killed the tumour cells that they have activity against; leaving the MHC 
class I negative tumour cells remaining, which have maintained the ability to attract 
CD8+ cytotoxic T cells. This finding indicates that NK cells may be more important in 
preventing metastatic spread rather than the growth of the primary tumour. 
 
It has been reported that patients with colorectal carcinoma who have a high NK cell 
cytotoxicity against K562 target cells (a human erythroleukaemic cell line) had less 
disease progression and a better survival compared to those with a low NK cell 
cytotoxicity (Liljefors et al., 2003). There was also a correlation between the patients’ 
serum interleukin (IL)-2 concentrations and NK cell cytotoxicity, against K562 cells, 
again indicating that NK cell activity is important in the control of tumours, at least when 
tested in vitro (Liljefors et al., 2003).  
 
NK cell cytotoxicity in the blood of 42 patients with colon cancer was measured before 
and one year after surgery and compared to control patients without cancer (Nüssler et 
al., 2007). Patients without metastasis at diagnosis had an increased NK cell 
cytotoxicity before surgery compared to control patients. In contrast, patients with 
metastatic disease at presentation had a decreased NK cell cytotoxicity compared to 
controls. One year after surgery, patients who remained free of metastasis had 
sustained NK cell cytotoxicity, whereas patients who developed metastasis had 
markedly decreased NK cell cytotoxicity. Retrospectively, the patients who developed 
metastasis already had reduced NK cell cytotoxicity prior to the “curative” colorectal 
surgery. Overall, metastatic spread was associated with decreased NK cell cytotoxicity 
(Nüssler et al., 2007). 
 
Other studies have shown that a high NK cell cytotoxicity at diagnosis correlates with a 
good prognosis in patients with a variety of cancers, whereas low NK cell cytotoxicity 
may indicate early relapse (Gonzalez et al., 1998, Nakamura et al., 2000, Schantz and 
Ordonez, 1991, Taketomi et al., 1998). 
 
The relationship between the suppression of NK cell cytotoxicity and the promotion of 
tumour metastasis has been studied in relation to alcohol (Ben-Eliyahu et al., 1996). 
Fischer 344 male rats were administered intraperitoneal ethanol and 1 hr later 
MADB106 cells (a NK cell-sensitive, rat mammary adenocarcinoma cell line which 
metastasises to the lungs) were injected into their tail vein. Three weeks later, the 
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lungs were removed and metastases counted or tumour retention measured using 
radioisotope uptake. There was a subgroup of rats which had selective in vivo 
depletion of NK cells with clone 3.2.3 monoclonal antibody (mAb) which recognises rat 
NK cells (Chambers et al., 1989). There was a marked increase in tumour load in the 
NK cell depleted rats and an intermediate tumour load in the ethanol treated rats, 
compared to control. NK depletion or ethanol had no effect when experiments were 
carried out using C4047 cells, an NK insensitive lung tumour cell line. The effect of 
ethanol on lung metastasis was present only if the MADB106 tumour cells were 
injected when ethanol levels were high, i.e. 1 hr after the intraperitoneal delivery of 
ethanol (Ben-Eliyahu et al., 1996). This suggests that even a transitory decrease in NK 
cell function may have a long term detrimental effect on cancer control. 
 
1.2.1.1 Regulation of natural killer cell activation 
Insight into the regulation of NK cell activity was provided when it was found that IL-2, 
interferon (IFN)- and more recently IL-15 augmented NK cell cytotoxicity (Handa et al., 
1983, Henney et al., 1981, Zhang et al., 2011). Activated T cells produce IL-2, which is 
an important physiological activator of NK cells in vivo. Patients with advanced 
colorectal cancer (Hjelm Skog et al., 2001) and advanced non-small cell lung cancer 
(Orditura et al., 2000) had higher IL-2 serum levels than controls. IL-12 is also 
important, as in a rat tumour model, prophylactic IL-12 reduced post-operative 
metastasis, an effect which was mediated by increased prevalence of NK cells, rather 
than an increase in individual NK cell cytotoxicity (Schwartz et al., 2008).  
 
In vivo, the overall level of NK cell activation results from a complex interaction of 
multiple stimulatory and inhibitory signals. There are many different stimulatory signals 
of different relative potencies, including both cytokines and direct cell-cell contact 
signals, i.e. the NKG2D NK cell receptor (Saito et al., 2011). These stimulatory signals 
would be balanced against the potential array of inhibitory signals including inhibitory 
NK cell receptors such as killer immunoglobulin-like receptor (Al Omar et al., 2011) to 
modulate the overall activation status of the NK cell (Figure 1-2). 
 
One of the most potent inhibitors of NK cell activation is MHC class I, so much so that it 
is often considered that NK cells will only kill MHC class I negative (‘missing self’) cells 
(Ljunggren and Karre, 1990). Although tumour cells expressing MHC class I are less 
susceptible to NK cells, if there is otherwise an overwhelming balance of stimulatory 
signals to the NK cells then they will kill MHC class I expressing tumour cells. 
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Figure 1-2: NK cell interactions and effector mechanisms. 
NK cell activation results from a complex interaction of multiple stimulatory and inhibitory signals. One of 
the major inhibitory signals is from MHC class I via the heterodimeric CD94-NKG2 NK receptor family and 
the killer immunoglobulin-like receptor (KIR) receptors. There are a variety of cytokines which can activate 
NK cells including IL-12 and IL-18 (from macrophages and dendritic cells) which can induce NK cells to 
produce IFN-. IL-2 and IL-15 are also key activating cytokines. NK cells can also have direct cell-cell 
interactions with dendritic or T cells. NK cells principally have their effect by the production of cytotoxic 
granules (granzymes, granulysin and perforins) and by the production of cytokines (IFN- and TNF-). 
 
 
Although typically under the influence of CD4+ T cells, a subgroup of murine NK cells 
have been shown to have a reciprocal control over adaptive immune responses by 
producing IL-10, these have been termed regulatory NK cells (Yoshida et al., 2010). 
Some murine NK cells have also been shown to have antigen specific properties and 
have the capacity to develop immunological memory (Paust et al., 2010). 
 
1.2.2 Innate anti-infective immunity  
As well as protecting against cancer, the innate immune system is also the principal 
effector arm against invading pathogenic organisms. Neutrophils and the monocyte-
macrophage lineage are the main immune cells which ingest and kill extracellular 
bacteria and fungi. The regulation of these functions is described in the following 
sections. 
 
1.2.2.1 Regulation of neutrophil function 
Neutrophils, along with monocytes, are the principal innate immune effector cells that 
are involved in the control of bacterial and fungal infection and removal of foreign 
material by phagocytosis and subsequent oxidative burst reaction. Unactivated 
neutrophils roll along microvascular walls with low affinity interactions with endothelial 
cells. During inflammation, chemotactic factors and pro-inflammatory cytokines recruit 
neutrophils, causing activation of neutrophil 2-integrins and high-affinity binding to 
endothelial cells (Zarbock and Ley, 2008). They then migrate along a chemotactic 
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gradient towards the site of inflammation, before penetrating the endothelial layer at the 
site of inflammation, where they congregate and adhere to extracellular matrix 
components such as laminin and fibronectin.  
 
After the chemoattractants have guided the neutrophils to the site of inflammation, they 
can then phagocytose the bacteria, fungi or foreign material. The attachment of these 
to the cell surface of the neutrophil induces receptor clustering and activation resulting 
in intracellular scaffolding (actin-myosin contractile system) and signalling changes, 
including nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B), which 
initiate the formation of the phagosome and its internalisation. Phagocytosis is 
enhanced by opsonisation of the foreign material with immunoglobulin G (IgG) or 
complement component 3b (C3b), as neutrophils express immunoglobulin fragment 
crystallisable (Fc) and complement C3b receptors (Schutze et al., 1991).  
 
Neutrophils are regulated by many factors including platelets, cytokines, bioactive 
lipids, neuroendocrine hormones, histamine, and adenosine, and the relative balance 
of these determines the level of neutrophil activation. Some cytokines enhance 
neutrophil function, whereas others are inhibitory. IL-1, IL-6 and Tumour Necrosis 
Factor (TNF)- are potent neutrophil priming agents, which contribute to the activation 
of nicotinamide adenine dinucleotide phosphate oxidase. IL-8 is a potent 
chemoattractant which synergises with IFN- and TNF-, to amplify neutrophil 
cytotoxicity against bacteria, protozoa and fungi. IFN- also amplifies antibody-
dependent cytotoxicity of neutrophils. Neutrophils can also produce IL-1, IL-6, IL-8, and 
TNF- which have autocrine and paracrine effects (Mantovani et al., 2011). IL-4 and IL-
10 are anti-inflammatory and inhibit IL-8, TNF- and IL-1 release, blocking neutrophil 
activation. Glucocorticoids, prostaglandins, adrenaline and -endorphin inhibit the 
oxidative burst activity of neutrophils (Peterson et al., 1987, Trabold et al., 2007).  
 
1.2.2.2 Regulation of monocyte function 
Monocytes circulate in the blood and have a substantial splenic reserve (Swirski et al., 
2009). Once migrated out of the circulation, monocytes differentiate into different types 
of macrophages or DCs in specific tissues. They are involved in the killing of bacteria 
and fungi and the removal of foreign material by phagocytosis and oxidative burst. 
They also interact with and modulate the adaptive immune response by the production 
of cytokines, either being stimulatory by secreting the pro-inflammatory TNF- and IL-
12 or by inhibiting CD4+ T cell function by IL-10 production (Said et al., 2010).  
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The binding of pathogens to monocytes induces cell surface receptor clustering and 
activation and intracellular scaffolding and signalling changes, including NF-B, which 
initiates the process of phagosome formation and subsequent internalisation. Opsonins 
such as C3b and IgG coat the bacteria or fungi to be phagocytosed increasing the 
ability of monocytes to internalise the organism into a phagosome before the 
subsequent oxidative burst reaction (Schutze et al., 1991).  
 
The activation cascade in monocytes includes adenylyl cyclase and phospholipase C 
(PLC) stimulation by dissociated G-protein receptor subunits, which increases the 
second messengers cyclic adenosine monophosphate (cAMP), inositol trisphosphate 
and Ca2+. These activate intracellular pathways affecting cell metabolism, motility, gene 
expression and cell division. 
 
Lipopolysaccharide (LPS), a component of the outer membrane of Gram-negative 
bacteria, including Escherichia coli (E.coli), binds to Toll-like receptor (TLR) 4, in a 
complex with MD2. This then activates the MyD88-dependent pathway which recruits 
the IL-1 receptor–associated kinases (IRAK) and leads to the activation of NF-B and 
mitogen-activated protein kinase (MAPK). The MAPK pathway activates the 
extracellular signal-regulated kinases (ERK) and c-Jun terminal kinases (JNK) 
pathways, as well as the early response transcription factor, activator protein-1 (AP-1), 
which is composed of proteins belonging to the c-Jun and c-Fos families (Aderem and 
Ulevitch, 2000). TLR4 also stimulates a Toll/Interleukin-1 receptor-domain-containing 
adapter-inducing interferon-β (TRIF) dependent pathway that activates interferon 
regulatory factor (IRF) 3 and NF-B. Both these pathways lead to the production of pro-
inflammatory cytokines and activation of immune responses (Kawai and Akira, 2010).  
 
 
1.3 The adaptive immune system 
Unlike the innate immune system, the phylogenetically more advanced adaptive 
immune system allows for a more coordinated and specific responses to pathogens 
and tumours. However, both immune arms are essential, as an effective adaptive 
immune response requires priming and takes time to initially develop. Plus, as the 
adaptive immune system evolved on the background of the innate immune system, 
some of its function is in the more specific control and modulation of innate immunity. 
The adaptive immune responses exhibit specificity, memory and amplification. 
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The principal mediators of adaptive immunity are T and B cells. T cells are so called as 
they mature in the thymus and are categorised into CD4+ T cells (‘T helper cells’) and 
CD8+ T cells (‘cytotoxic T cells’) (Liew, 2002). Several subtypes of CD4+ T cells 
coordinate the immune response, including TH1, TH2, TH9, TH17, TH22 and 
immunoregulatory T (Treg) cells, described in section 2.8). CD4
+ T cells become 
activated when antigenic peptides that are associated with MHC class II expressed on 
antigen-presenting cells (APCs) are presented to them and recognised by 
appropriately-specific T cell receptors (TCRs). CD8+ T cells are involved in the selected 
killing of tumour cells, virally infected cells and transplanted tissue to which the 
adaptive immune response has been primed by binding to cells that express antigenic 
determinants in the context of cell surface MHC class I via their TCR. MHC class I is 
ubiquitously expressed on the surface of nucleated cells, other than some virally-
infected cells and tumour cells. CD8+ T cells kill their target cells by the release of 
cytotoxins such as perforin (Ambach et al., 2001), granulysin (Stenger et al., 1998) and 
serine proteases such as granzymes (Bots and Medema, 2006). Granzymes also have 
a pro-inflammatory role by propagating immune signals (Cullen et al., 2010). 
 
B cells are so called as they were originally identified as being matured in the bursa of 
Fabricius in birds. No such structure exists in mammals, in most of which immature B 
cells are derived in the bone marrow. When activated by a specific antigen, and with 
co-stimulation from CD4+ T cells, B cells mature into plasma cells. The main function of 
plasma cells is to produce antibodies as the humoral immune response. However, it 
has recently been shown that B cells might have more diverse roles which include the 
regulation of CD4+ T cell responses (Lund and Randall, 2010), with these so called 
regulatory B cells producing cytokines, such as IL-10, to suppress T cell activity (Amu 
et al., 2010). 
 
Cytokines are a family of cell signalling protein based molecules that are primarily 
secreted from both innate and adaptive immune cells (principally CD4+ T cells and 
macrophages) which regulate both humoral and cellular immune responses. There are 
many cytokines, each with specific cell surface receptor(s), initiating intracellular 
signalling cascades on binding to their receptor, resulting in alterations in transcription 
factors and subsequent gene transcription. There are several classification methods for 
cytokines, including both structural and functional, with the latter being most useful 
clinically and experimentally. There are two main groups of cytokines with this 
classification. The pro-inflammatory type 1 TH cell cytokines (IL-2, IFN- and TNF-, 
TNF-), which stimulate cellular immune responses and can inhibit humoral immunity, 
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and the anti-inflammatory type 2 TH cell cytokines (IL-3, IL-4, IL-5, IL-9, IL-10 and IL-
13), which suppress cellular immune responses and promote humoral immunity (Figure 
1-3) (Cutolo et al., 1998, Klein et al., 2004, Logani et al., 2011, Serreze et al., 2001, 
Teixeira et al., 2005, Yates et al., 2000).  
 
 
Figure 1-3: Effects of cytokines produced by TH1 and TH2 cells. 
Naïve CD4
+
 T helper cells (TH0) under cytokine influence either differentiate into TH1 or TH2 cells. IL-12 
and IFN- promote the differentiation towards TH1 cells and thereby enhance the cellular immune 
response. IL-4, IL-6 and IL-10 promote differentiation towards TH2 cells and enhance antibody (humoral) 
responses. The cytokines produced by the predominant arm of this response feedback to further enhance 
differentiation along that arm and inhibit the other arm. The TH1 response drives cellular immune 
activation. The TH2 response drives humoral immunity (Cutolo et al., 1998, Klein et al., 2004, Logani et al., 
2011, Serreze et al., 2001, Teixeira et al., 2005, Yates et al., 2000). 
 
 
1.3.1 Regulation of T cell activation 
The primary function of the immune system is to protect the organism against invading 
pathogens. This need for the immune system to react to foreign antigens has to be 
balanced against reactivity against self. Thus, the primary aim of the healthy immune 
system is to be able to destroy non-self, while not damaging self. If the immune 
regulatory balance is too far towards immune activation then the host may be at 
increased risk of autoimmune disease as well as producing an excessive immune 
response to foreign antigens causing tissue damage, as in hypersensitivity reactions. 
However, if it is too much towards suppression of the immune response then this may 
increase the host’s susceptibility to infectious diseases and cancer. There are many 
inbuilt mechanisms, both central and peripheral, to modulate this balance, primarily to 
induce and maintain immune tolerance to self.  
 
For T cells, central tolerance is established in the thymus, but as some T cells ‘escape’ 
this clonal deletion process (auto-reactive T cells) there are mechanisms in the 
periphery to control this. Populations of Treg cells are considered to be the major 
mediator of this by controlling the presence and activity of self-reactive T cells in the 
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periphery (Shalev et al., 2011). Treg cells also control excessive immune responses to 
foreign antigens, preventing potential damage to the host (Shalev et al., 2011). 
 
Cytokines are important in the fine tuning of the immune response and the profile of 
cytokines to which T cells are exposed dictates whether they are activated or inhibited, 
and defines their differentiation and functional properties (Wan and Flavell, 2009). In 
the case of the CD8+ cytotoxic T cells this would result in either increased or decreased 
target cell killing.  
 
T cell activation is induced by cell surface receptors that modulate signal transduction 
pathways. This involves the TCR which recognises antigenic peptides in the context of 
MHC and co-stimulatory signals from professional APCs such as DCs. The TCR is a 
heterodimer, with 95-98% of T cells having an  and  chain, and 2-5% having  and  
chains (so called / T cells, which can recognise antigens directly) (Morita et al., 
2000). The TCR complex consists of the TCR, CD3 and -chains. Once the antigenic 
peptide/MHC complex on the APC binds to the TCR complex, the fate of the T cell 
depends on the delivery of essential co-stimulatory signals (Acuto and Michel, 2003). In 
TH cells, CD4 interacts with MHC class II and in CD8
+ cytotoxic T cells, CD8 interacts 
with MHC class I.  
 
The recognition of MHC class I and class II increases specificity and binding affinity, as 
well as recruits cell signalling molecules, such as lymphocyte-specific protein tyrosine 
kinase (Lck). CD28 is a co-stimulatory receptor constitutively expressed on T cells, 
which binds B7.1 (CD80) and B7.2 (CD86) on APCs. Triggering of both the TCR and 
CD28 potently activates the T cell (Acuto and Michel, 2003). Essential co-stimulatory 
signals can only be delivered by professional APCs and only these cells can activate 
naïve T cells. Previously activated T cells are not dependent on co-stimulatory signals 
and so can be activated by non-professional APCs such as monocytes and 
macrophages. The interaction of naïve T cells with professional APCs in the absence 
of co-stimulatory signals, which can be achieved using ‘immature’ DCs and/or by 
blocking co-stimulation leads to T cell non-responsiveness or anergy (Smith-Garvin et 
al., 2009). 
 
T cell activation via the TCR induces receptor clustering, which activates tyrosine 
kinases on the intracellular surface of the plasma membrane. These phosphorylate 
tyrosine residues in the receptors which allow binding of additional kinases and other 
signalling molecules, including PLC-1, triggering intracellular signalling. Activated 
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PLC-1 cleaves membrane phosphatidylinositol bisphosphate into two signalling 
molecules, the diffusible inositol trisphosphate, and diacylglycerol, which remains 
bound to the intracellular surface of the plasma membrane. Inositol trisphosphate 
opens Ca2+ channels in the endoplasmic reticulum, allowing Ca2+ to enter the cytosol, 
which in turn opens plasma membrane Ca2+ channels, allowing further Ca2+ influx. 
Diacylglycerol binds protein kinase C (PKC) and anchors it to the inside of the cell 
membrane where it is activated by the Ca2+ influx. PKC is a serine/threonine kinase 
with several roles in cell activation, including via the NF-B and MAPK/ERK signal 
transduction pathways. Raised Ca2+ levels also activate calmodulin, which stimulates 
other Ca2+-dependent enzymes within the cell. Receptor phosphorylation triggers signal 
transducers and activators of transcription (STATs) to form homodimers or 
heterodimers, which can translocate to the nucleus where they bind to regulatory sites 
in the gene promoter region, inducing gene transcription (Smith-Garvin et al., 2009). 
These signalling pathways are common to many intracellular signalling pathways in 
immune cells and eventually converge in the cell nucleus to modify patterns of gene 
transcription.  
 
Although the innate and adaptive immune systems are typically considered separately, 
there is a great deal of interconnectivity between them. For example, neutrophils and 
monocytes (innate immune cells) preferentially recognise bacteria that are opsonised 
(coated) with antibodies that have been produced by B cells (adaptive immune cells) 
which in turn have received ‘help’ from CD4+ T cells (adaptive immune cells) (Figure 
1-4). Cytokines are also produced by activated innate and adaptive immune cells and 
can exert a plethora of effects on all immune cells.  
 
 
 
Figure 1-4: Interaction of adaptive and innate immune systems.  
CD4
+ 
T helper cells (TH) recognise an antigen (Ag) and provide “help” to B cells (B) which produce 
antibodies. These antibodies bind to invading pathogens (e.g. bacteria) enhancing their recognition by 
neutrophils (Nø) and monocytes (Mø) and subsequent eradication of the bacteria by phagocytosis and 
oxidative burst. 
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Optimal functioning of both the innate and the adaptive immune systems in patients 
with infections or cancer is critical, and anything which influences this might have 
significant effects on their clinical status. Many factors are known to inhibit immune 
function, including pain, surgery and general anaesthesia (Kawasaki et al., 2007, Page, 
2003). It is also possible that certain opioids could further inhibit immune function and 
aggravate the problem of reduced immunosurveillance (Budd, 2006, Sacerdote, 2008). 
The following sections explore the actions of opioids and the differences between 
them. 
 
 
1.4 Molecular actions of opioids 
Although prescribed opioids principally work by modulating the effects of the 
endogenous opioid system, they also have a range of non-opioid effects (discussed in 
section 1.5). Endogenous opioids bind to specific opioid receptors (Table 1.3) and 
these interactions help to maintain the homeostasis of many of the body’s organs. It is 
the modulation of these receptors, as well as non-opioid effects, by prescribed opioids 
which is responsible for their desired and unwanted effects (see Table 1.1).  
 
Table 1.3: Endogenous opioid agonists and their opioid receptor binding patterns. 
Endogenous opioid Receptor 
-Endorphin  (and ) 
Dynorphin A  (and ) 
Enkephalins  (and ) 
Endomorphins  
Morphine  
Nociceptin/orphanin FQ ORL1 
 
The principal endogenous opioid peptides and the type(s) of opioid receptor to which they bind with the 
highest affinity. In brackets are the receptors to which these peptides bind with lower affinity. The 
endorphins, dynorphins, enkephalin and endomorphins are the classical endogenous opioids; opioid 
receptor-like-1 (ORL1), the nociceptin/orphanin FQ peptide receptor, has sequence homology with the 
classical opioid receptors, but has a different signalling system. Although typically used exogenously, 
endogenous morphine produced by immune cells, has been described (Glattard et al., 2010, Stefano et 
al., 2008a, Zhu et al., 2005). 
 
 
1.4.1 Opioid receptors  
The opioid receptor is a seven-transmembrane domain GTP-binding protein (G 
protein)-coupled receptor (GPCR). GPCRs are a superfamily of diverse receptors 
which evolved over 800 million years ago and are present in fungi, invertebrates and 
vertebrates (Peroutka and Howell, 1994). There are several groups of GPCR, with the 
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largest group being the type 1, rhodopsin-like, family of receptors, which includes the 
opioid receptors. Numerous other receptors are also classified into this group, including 
those for acetylcholine, cannabinoids, catecholamines, chemokines (i.e. IL-8), 
histamine and serotonin. 
 
There are three classical opioid receptors: ,  and  (MOR, KOR and DOR), and the 
non-classical opioid receptor-like 1 (ORL1), which are principally responsible for the 
effects of both endogenous and prescribed opioids. Of these, the MOR is generally 
considered the most important opioid receptor for mediating the effects of prescribed 
opioids. The more recently discovered ORL1 receptor has sequence homology with the 
classical opioid receptors, but it has a different signalling system, with the 
nociceptin/orphanin FQ peptide as its endogenous ligand (Chiou et al., 2007).  
 
All of these receptors have subtypes which are thought to be splice variants, as each 
receptor only has one gene (Dietis et al., 2011). For example, numerous splice variants 
of the MOR have been identified, with at least 14 human MOR isoforms (Pan, 2005), 
with various affinities for morphine and its derivatives, which suggests that different 
morphine concentrations may activate specific receptor subtypes. For example, the 3 
receptor binds morphine, but is not activated by endogenous opioid peptides. 
Interestingly, it only has 6 transmembrane domains (Makman et al., 1995, Stefano et 
al., 1993). 
 
Opioid receptors can form homodimers (i.e. two MORs) or heterodimers (i.e. MOR and 
DOR) and can also form heterodimers with other GPCRs on immune cells, including 
chemokine receptors (Suzuki et al., 2002). Dimerisation enhances ligand binding 
combinations and modulates receptor signalling transduction, it can also influence 
receptor internalisation and degradation properties (Faras-Melainis et al., 2009, 
Rozenfeld and Devi, 2007), and is in part responsible for the interindividual variability in 
response to opioids (Chakrabarti et al., 2010). 
 
1.4.2 Opioid receptor signalling  
Opioids bind to different points of the binding cleft which is made up of the 
transmembrane and extracellular domains of the seven-transmembrane opioid 
receptor. The specificity of ligand-receptor binding at different sites on the receptor is 
dependent on the type of opioid. Opioid alkaloids bind within the transmembrane 
portion of the receptor, whereas large peptidyl ligands bind to the extracellular loops 
(Watson et al., 1996). 
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The intracellular domains (principally the second and third intracellular loops) of the 
opioid receptor are coupled to a heterotrimeric G-protein complex, which is inhibitory 
under normal circumstances (Gi). The binding of opioid agonists to the binding cleft 
induces a conformational change in this GPCR and this initiates a downstream chain of 
secondary messenger signalling events. Initially, guanosine diphosphate (GDP) 
dissociates from the -subunit of the G-protein, and is replaced by guanosine 
triphosphate (GTP). The G and the G subunits are then liberated and can now 
interact with downstream transduction pathways. These include the opening of G-
protein activating inwardly rectifying potassium (GIRK) channels (Henry et al., 1995), 
which causes hyperpolarisation of the cell, making it more refractory to depolarisation 
and decreases the presynpatic release of vesicles, through de-activation of Ca2+ 
channels (Ikeda et al., 2000). These vesicles contain excitatory transmitters, such as, 
acetylcholine, glutamate, calcitonin gene related peptide and substance P (Yaksh, 
1997). By activating G-proteins, opioids also have inhibitory effects at voltage-gated 
Ca2+ channels (Yaksh, 1997).  
 
Opioid receptor activation also results in intracellular effects which are mediated by the 
secondary messengers cAMP, cyclic guanosine monophosphate (cGMP), PLC and 
PKC (Kelly et al., 2008, Rubovitch et al., 2003, Stefano et al., 2008b). Opioids inhibit 
adenylyl cyclase decreasing cAMP formation. Opioid receptor activation, via certain G-
proteins, stimulates PLC, increasing the release of Ca2+ from intracellular stores, which 
activates several kinases, including PKC and MAPK (Law et al., 2000). These kinases 
have many functions, one of which is to phosphorylate opioid receptors and cause 
receptor desensitisation, reducing opioid responsiveness (Law et al., 2000). Opioids 
also increase nitric oxide (NO) and cGMP (Stefano et al., 2008b) (Figure 1-5). 
 
The action of morphine on immune cells may be due to an effect via the 3 receptor, 
with is linked to a nitric oxide synthase (NOS) molecule, producing NO when morphine 
activates this receptor (Cadet et al., 2003). The N-methyl D-aspartate (NMDA) receptor 
is also linked to NOS and the opioid receptor interacts with the NMDA receptor (Law et 
al., 2000). Furthermore, it has been shown that human monocytes are inactivated 
morphologically (going from amoeboid to round) when NO levels increase and had a 
rebound enhancement of activation and chemotaxis when NO levels subsequently 
decreased (Magazine et al., 2000).  
 
35 | P a g e  
 
 
Figure 1-5: Intracellular opioid signalling cascades.  
In the resting state the opioid receptor (GPCR) is bound to G and G subunits and guanosine 
diphosphate (GDP). On opioid binding, GDP dissociates and is replaced by guanosine triphosphate (GTP), 
the G and the G subunits then interact with downstream pathways. These include the opening of G-
protein activating inwardly rectifying potassium (GIRK) channels and inhibition of voltage gated calcium 
channels (VGCC). Phospholipase C (PLC) is activated, increasing intracellular calcium and activating 
protein kinase C (PKC) and mitogen-activated protein kinase (MAPK). These then activate NF-B and 
extracellular signal-regulated kinases (ERK) and c-Fos which regulate gene transcription. Nitric oxide 
synthase (NOS) is activated, increasing nitric oxide (NO) and cyclic guanosine monophosphate (cGMP). 
During acute opioid exposure, adenylyl cyclase (AC) is inhibited and cyclic adenosine monophosphate 
(cAMP) levels are decreased. This decrease in cAMP inhibits protein kinase A (PKA) which is involved in 
sugar and lipid metabolism, as well as gene transcription via cAMP response element-binding (CREB). 
 
The duration of activation of the opioid receptor and its ability to signal is dependent on 
the dissociation of the G-protein subunits, which requires GTP binding. This is 
negatively regulated by GTP hydrolases, which convert GTP to GDP, causing re-
association of the G-protein to its inactive form. This process is also under the control 
of regulators of G-protein signalling proteins which activate GTPase, terminating 
receptor activation (Tso and Wong, 2003). 
 
During prolonged opioid exposure, the response of the receptor and its downstream 
mechanisms becomes attenuated, a process which has been termed ‘tolerance’. This 
phenomenon is seen with many other drugs and the evidence for its occurrence and 
multiple underlying mechanisms are becoming clearer. These result from diverse 
cellular and intercellular events including: reduced internalisation consequent on ligand 
binding; receptor down-regulation; impaired ability of the opioid receptor to activate G-
proteins with a subsequent inhibition of downstream effects, such as in the secondary 
messengers, protein kinase-A (PKA) and PKC. The latter are responsible for key 
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events such as activating NMDA receptors, increasing intracellular Ca2+ influx which 
activates NOS, promoting NO as well as superoxide formation. These changes can 
occur quickly as in the case of receptor desensitisation or can take longer when gene 
transcription is affected, such as in the up-regulation of adenylyl cyclase (Law et al., 
2000, Nestler, 2004). Opioid receptor desensitisation and down-regulation require 
receptor phosphorylation by kinases, such as G-protein receptor kinases, PKA, PKC, 
calcium-calmodulin dependent protein kinase-II and tyrosine kinase (Borgland, 2001). 
 
There is a constant background recycling of opioid receptors as they are endocytosed 
and then either returned to the cell surface or degraded in lysosomes (Finn and 
Whistler, 2001, Keith et al., 1998). Endocytosis is a clathrin-mediated process. The 
activated receptor is phosphorylated by G-protein receptor kinases and then binds to -
arrestin and dynamin, which prevents further coupling of the receptor and the G-protein 
(Ahn et al., 2002, Luttrell and Lefkowitz, 2002). Small phosphorylase-rich endosomes 
are formed (Ferguson, 2001), in which the receptor is dephosphorylated and returned 
resensitised to the cell surface (von Zastrow et al., 2003), available for further ligand 
binding and activation. 
 
Endocytosis is affected by the activation of opioid receptors by certain agonists. Once 
endocytosed, the receptor cannot undergo further activation, but is ready for further 
activation if returned to the cell membrane. The level of receptor activation versus the 
endocytosis is variable between opioids (Martini and Whistler, 2007). Opioids which do 
not induce opioid receptor endocytosis, such as morphine, are more likely to induce 
tolerance compared with those that do induce opioid receptor internalisation, such as 
methadone (Borgland, 2001, Lopez-Gimenez and Milligan, 2010, Whistler et al., 1999). 
However, over time it is likely that all opioids induce some degree of tolerance.  
 
In Jurkat immune cell lines and neural cells, the MORs localise to the membrane and 
undergo internalisation after agonist binding (Trafton et al., 2000). In neurons, the MOR 
agonist [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO) causes rapid receptor 
internalisation, whereas morphine causes little internalisation (Trafton et al., 2000). In T 
cells internalisation in response to DAMGO is slower (Borner et al., 2008). 
 
Morphine, at nanomolar concentrations, has been shown to increase NF-B activation 
and TNF- production in macrophages, which was blocked by the non-selective opioid 
receptor antagonist, naloxone. At micromolar concentrations, morphine suppressed 
NF-B, which was not inhibited by naloxone. This suggests that only the effect of low 
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concentrations of morphine on NF-B is mediated through opioid receptors (Roy et al., 
1998b). Morphine has also been shown to inhibit NF-B activity in LPS stimulated 
neutrophils and monocytes, and decrease the gene transcription of pro-inflammatory 
cytokines. This was dependent on NO and blocked by naloxone (Welters et al., 2000a). 
 
In summary, opioids by binding to the seven-transmembrane G-protein coupled opioid 
receptor induce a host of intracellular effects, by modulating a range of intracellular 
secondary messengers and transcription factors. Most previous studies have used 
morphine as the test opioid, however there are many differences between opioids 
which, along with their non-opioid effects, are explored in the next section. 
 
 
1.5 Opioid pharmacology  
Most of the commonly used opioids principally elicit their effects by binding to the MOR. 
However, they can have very different physicochemical properties and pharmacological 
actions on other opioid and non-opioid receptor systems which may also be 
responsible for the differential effects between opioids (Keiser et al., 2009). These 
effects are outlined under the individual opioids below, and include effects on the 
monoaminergic system (serotonin and noradrenaline), muscarinic receptors, NMDA 
receptor and even the innate immune TLR’s.  
 
Our understanding of which receptors bind these ligands has previously been 
investigated at the molecular level using binding assays, but is now being explored by 
in silico techniques using detailed computer modelling approaches. In silico techniques, 
alongside biochemical approaches to define these profiles experimentally, has vastly 
expanded our understanding of the diversity of receptor binding affinities of the different 
opioids to a range of receptors (Keiser et al., 2009).  
 
Although opioids have some similarities, namely binding to the opioid receptor, the 
disparate structure and binding profile of opioids results in differences in their effect 
profile, including antinociceptive and immunosuppressive effects (Keiser et al., 2009, 
Sacerdote et al., 1997). 
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1.5.1 Morphine 
Morphine is a naturally occurring opiate alkaloid which primarily elicits its analgesic 
effects by agonistic activity at the MOR (Figure 1-6); it is also a low affinity agonist at 
the DOR and KOR (Kristensen et al., 1995). It is one of several opiates that are derived 
from the opium poppy, Papaver somniferum (Vallejo et al., 2011) and has been shown 
to be produced endogenously in humans (Glattard et al., 2010, Stefano et al., 2008a). 
Morphine is the most commonly used “strong” opioid for pain control and is 
administered orally and parenterally. As it is hydrophilic it does not readily cross the 
blood-brain barrier to gain access to the central nervous system (CNS) in which it 
produces its analgesic effects. It thus has the potential to cause significant systemic 
toxicity (Clark et al., 2004) on other organ systems (Table 1.1), as greater systemic 
concentrations are required in order to enable sufficient morphine to cross the blood-
brain barrier and induce adequate analgesic effects (Figure 1-14). Morphine does not 
cause internalisation of the MOR and tolerance may develop to its effects (Lopez-
Gimenez and Milligan, 2010). 
 
Morphine is principally glucuronidated in the liver by UDP-glucuronosyl transferase-2B7 
to morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) (Christrup, 
1997), the latter having analgesic properties (Smith et al., 2009). In vivo it is not only 
important to consider the effects of morphine on the immune system, but also those of 
its active metabolites M6G and M3G. It has been suggested that M6G binds to a MOR 
subtype which is different to that of morphine (Rossi et al., 1996). Although M6G has a 
better efficacy to side effect profile than morphine (Kilpatrick and Smith, 2005) it has 
been shown to induce immunosuppression in the rat (Carrigan and Lysle, 2001). In 
vivo, in vitro and in silico techniques have shown that morphine and M3G are TLR4 
agonists which might not only impact upon hyperalgesic states of microglial origin, but 
also potentially directly influence innate immunity (Hutchinson et al., 2010, Lewis et al., 
2010). 
 
 
Figure 1-6: Schematic diagram showing 
the molecular structure of morphine. 
Morphine has a molecular weight of 285.3 
g/mol and is a moderately potent MOR agonist  
Image from Pub Chem (NIH) 
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1.5.2 Tramadol  
Tramadol is a synthetic opioid (Figure 1-7) which has a dual mechanism of analgesic 
action as it binds with low affinity to MORs and activates central monoaminergic 
pathways by inhibiting uptake of serotonin and noradrenaline, increasing their 
extracellular concentration (Grond and Sablotzki, 2004). Compared with morphine, 
tramadol has 6000 times less affinity for the MOR, a 600-fold lower affinity for the DOR 
and a 75-fold lower affinity for the KOR (Raffa, 1996), but has the ability to activate 
other GPCRs, such as the 5-hydroxytryptamine (5-HT) receptor (Driessen and 
Reimann, 1992) and the noradrenaline receptor (Driessen et al., 1993). The 
formulation of tramadol is as a racemic mixture in which the (+) enantiomer of tramadol 
binds to opioid receptors and inhibits serotonin uptake, and the (−) enantiomer of 
tramadol inhibits the uptake of noradrenaline (Frink et al., 1996, Raffa et al., 1993). 
Tramadol has lipophilic properties (Alhashemi and Kaki, 2003), which enables it to 
have good gastrointestinal absorption and penetration into the CNS. It is demethylated 
by CYP2D6 in the liver to O-desmethyltramadol, an active metabolite. 
 
 
 
1.5.3 Fentanyl 
Fentanyl is a very potent, lipophilic, synthetic MOR agonist. It is approximately 100 
times the potency of morphine and due to its lipophilicity it can be administered in 
transdermal and mucosally absorbed preparations (Figure 1-8). Due to its rapid 
penetration into the CNS, fentanyl causes less systemic, especially gastrointestinal 
tract, toxicity (Figure 1-14), it also causes less somnolence compared with morphine 
(Clark et al., 2004). Fentanyl has very low affinities for the KOR and DOR (Maguire et 
al., 1992) and may interact with serotonin receptors as the analgesia produced by 
fentanyl is attenuated by 5-HT1A receptor antagonists (Clarke and Ward, 2000). 
Fentanyl is principally metabolised by N-dealkylation to the inactive metabolites 
norfentanyl and hydroxyfentanyl by cytochrome P450 (CYP) 3A4 in the small intestine 
Figure 1-7: Schematic diagram showing 
the molecular structure of tramadol. 
Tramadol (±) cis-2-[(dimethylamino)methyl] -1-
(3-methoxyphenyl) cyclohexanol hydrochloride 
has a molecular weight of 263.4 g/mol (299.8 
for tramadol hydrochloride) and it is a weak 
MOR agonist and an inhibitor of 
norepinephrine and serotonin reuptake. 
Image from Pub Chem (NIH) 
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and liver (Feierman and Lasker, 1996). In vitro and in silico techniques have shown 
that fentanyl is a TLR4 receptor agonist and might have a direct influence on innate 
immune function (Hutchinson et al., 2010). 
 
 
 
1.5.4 Buprenorphine 
Buprenorphine is a synthetic opioid derived from the naturally occurring opiate thebaine 
(Figure 1-9). It is a potent MOR agonist (it is a partial agonist at very high 
concentrations, exhibiting full agonist properties at concentrations used clinically), from 
which it has a slow dissociation. It has partial antagonistic activity at the KOR and is a 
low affinity antagonist at the DOR (Evans and Easthope, 2003). It is also a low affinity 
agonist at the non-classical ORL1 receptor (Huang et al., 2001). Buprenorphine is 
associated with less dependence and tolerance compared with other commonly used 
opioids and has a role not only in chronic pain, but also in opioid dependent patients 
(Negus and Woods, 1995). It has been shown to have less of an effect on the 
respiratory drive centres compared to fentanyl (Dahan et al., 2005, Dahan et al., 2006).  
 
 
 
Buprenorphine is metabolised by N-dealkylation to norbuprenorphine, which other than 
being a potent full agonist at the DOR, has similar receptor binding profiles to the 
Figure 1-8: Schematic diagram showing 
the molecular structure of fentanyl. 
Fentanyl, N-Phenyl-N-(1-(2-phenylethyl)-4-
piperidinyl) propanamide, has a molecular 
weight of 336.5 g/mol and is a very potent, 
lipophilic, MOR agonist  
Image from Pub Chem (NIH) 
Figure 1-9: Schematic diagram showing the 
molecular structure of buprenorphine. 
Buprenorphine (17-(cyclopropylmethyl)-α-(1,1-dimethyl 
ethyl)-4, 5-epoxy-18, 19-dihydro-3-hydroxy-6-methoxy-α-
methyl-6, 14-ethenomorphinan-7-methanol) has a 
molecular weight of 467.3 g/mol. It is a potent MOR 
agonist, a low affinity ORL1 agonist and a KOR and DOR 
antagonist. It is weakly acidic with limited solubility in 
water. 
Image from Pub Chem (NIH) 
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parent molecule (Huang et al., 2001). There are complex interactions between opioid 
receptors, including dimerisations which can be between the same or different types of 
opioid receptors (van Rijn et al., 2010), leading to different receptor internalisation and 
degradation properties. This alters the intracellular actions of opioids when different 
subtypes of opioid receptor are activated (He et al., 2011, Schramm and Honda, 2010) 
as potentially occurs with the wide binding properties of buprenorphine. In vitro and in 
silico techniques have shown that buprenorphine is a TLR4 receptor agonist and might 
directly affect immune cells (Hutchinson et al., 2010). 
 
1.5.5 Methadone 
Methadone is a synthetic, lipophilic MOR agonist which is used as both an analgesic 
and in patients with drug dependency (Figure 1-10). It is a potent MOR agonist, NMDA 
antagonist (Ebert et al., 1995), muscarinic M3 antagonist (Keiser et al., 2007) and 
inhibits serotonin re-uptake (Codd et al., 1995). Methadone is thought to cause less 
tolerance compared with morphine, and this might be due to its ability to bind to the 
NMDA receptor (Ebert et al., 1995) and/or its ability to induce receptor endocytosis 
(Martini and Whistler, 2007). In a Xenopus oocyte model, the biological activity of 
methadone was due to its MOR agonist properties and its ability to inhibit NMDA 
receptors (Callahan et al., 2004). 
 
 
 
Methadone has a long half-life and large distribution volume in humans. It is N-
demethylated by several isoforms of the cytochrome P450 enzyme system, especially 
the CYP2B6 and CYP3A4 isotypes (Clark, 2008), to the inactive metabolites 2-
ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-
diphenylpyraline (EMDP) (Oda and Kharasch, 2001). These enzymes are highly 
polymorphic (Ferrari et al., 2004, Zanger et al., 2007) and have the potential to cause a 
great deal of interindividual variation when methadone is used in vivo. Methadone has 
Figure 1-10: Schematic diagram showing 
the molecular structure of methadone. 
Methadone, 6-(dimethylamino)-4,4-diphenyl-3-
hepatanone hydrochloride, has a molecular 
weight of 309.4 g/mol (345.9 for methadone 
hydrochloride) and is a potent MOR agonist 
having antagonistic actions at the NMDA 
receptor and also inducing MOR endocytosis. 
Image from Pub Chem (NIH) 
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two enantiomeric forms, (R and S isomers), each with differing pharmacological 
properties. However, the racemic mixture is the form which is commonly used in clinical 
and laboratory studies (Inturrisi, 2005). R-methadone has a 10-fold higher affinity for 1 
and 2 receptors than S-methadone, it also binds with low affinity to the  and  
receptors (Kristensen et al., 1995). In vitro and in silico studies have shown that both 
enantiomers of methadone are TLR4 receptor agonists potentially having a direct 
influence on innate immune cells (Hutchinson et al., 2010). 
 
1.5.6 Oxycodone 
Oxycodone is a semi-synthetic opioid (Figure 1-11), derived from thebaine. It is a MOR, 
KOR and weak DOR agonist (Ordonez Gallego et al., 2007). Having KOR agonist 
activity, it may have a more sex-specific and oestrogen-dependent effect on pain 
(Chakrabarti et al., 2010, Lawson et al., 2010). As it has activity at several opioid 
receptor subtypes, oxycodone could potentially have different activation and 
internalisation properties on opioid receptor heterodimers (He et al., 2011, Schramm 
and Honda, 2010). In vitro and in silico techniques have shown that oxycodone is a 
TLR4 receptor agonist and it might have a direct effect on innate immune cell function 
(Hutchinson et al., 2010). Compared with morphine it has a lower incidence of CNS 
adverse effects, it is twice as potent orally, and has a higher and more predictable oral 
bioavailability (Lenz et al., 2009). There are however gender differences in the serum 
concentrations of oxycodone (Andreassen et al., 2011). Oxycodone is principally 
metabolised by hepatic O-demethylation by CYP2D6 and CYP3A4 to oxymorphone, 
also a potent opioid analgesic (Andreassen et al., 2011, Samer et al., 2010). 
Oxycodone is also N-dealkylated to noroxycodone during first-pass metabolism.  
 
 
 
1.5.7 Diamorphine 
Diamorphine (heroin; diacetylmorphine) is a 3,6-diacetyl ester synthesised from 
morphine, which greatly enhances its water and lipid solubility compared to the parent 
Figure 1-11: Schematic diagram showing 
the molecular structure of oxycodone. 
Oxycodone, 14-hydroxydihydrocodeinone, has 
a molecular weight of 315.4 g/mol (351.8 for 
oxycodone hydrochloride) and is a MOR, KOR 
and weak DOR agonist. 
Image from Pub Chem (NIH) 
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compound (Figure 1-12). The half-life of diamorphine in vivo is 3 min (Inturrisi et al., 
1984, Rentsch et al., 2001), as it is quickly hydrolysed back to morphine by sequential 
deacetylation of two ester bonds (Salmon et al., 1999). Initially, it is rapidly 
deacetylated to 6-monoacetylmorphine, which then undergoes a slower subsequent 
deacetylation to morphine (Rossi et al., 1996). Once hydrolysed to morphine it then 
behaves the same as morphine, but being so soluble and lipophilic, diamorphine 
readily penetrates into the CNS, the main site for analgesic effect, before deacetylation 
occurs. In vivo, this may also influence its immune effects during acute administration, 
depending on the body compartment of the immune cell under consideration. For 
example, diamorphine is likely to remain in the peripheral circulation for less time 
compared with morphine or oxycodone. Although morphine contributes significantly to 
diamorphine’s pharmacological effects (Cone et al., 1993, Inturrisi et al., 1984), it has 
been reported that diamorphine directly binds to a MOR variant, different to that of 
morphine (Rossi et al., 1996). Diacetylmorphine been shown to degrade to 6-
monoacetylmorphine and morphine in cell culture (Hutchinson and Somogyi, 2002) and 
thus it could have an effect in vitro either directly or after conversion to morphine (Rossi 
et al., 1996). 
 
 
 
1.5.8 Codeine 
Codeine is a weak opiate which has about one tenth of the potency of morphine 
(Figure 1-13). Like morphine, it is a naturally occurring opiate alkaloid which is derived 
from the opium poppy, Papaver somniferum. Codeine is a pro-drug of morphine which 
is principally converted to its active form by CYP2D6 enzymes in the liver. Leukocytes 
have also been shown to express CYP2D6 (Zhu et al., 2005) and can convert codeine 
into morphine in vitro. Eight percent of Caucasians are slow metabolisers for this 
enzyme and do not significantly convert codeine to morphine, and do not derive any 
analgesic benefits from the drug. Similarly this group would be less likely to have any 
Figure 1-12: Schematic diagram showing 
the molecular structure of diamorphine. 
Diamorphine, 3,6-diacetyl-morphine, has a 
molecular weight of 369.4 g/mol and is 
deacetylated to morphine, a potent, lipophilic, 
MOR agonist. 
Image from Pub Chem (NIH) 
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clinical immune effects from codeine, as it and its 6-glucuronide metabolite only bind 
very weakly to the MOR and have even less affinity for the other opioid receptors 
(Mignat et al., 1995). However, codeine has been shown to have effects outwith those 
due to its conversion to morphine and these might be mediated by its metabolite 
codeine-6-glucuronide (Lotsch et al., 2006). About 2% of Caucasians are extensive 
metabolisers for CYP2D6 enzymes and these people get enhanced morphine-derived 
effects from codeine (Kirchheiner et al., 2007). 
 
 
 
1.5.9 Summary 
These commonly prescribed opioids are structurally very different which causes 
differences in their pharmacokinetics, pharmacodynamics and receptor binding profiles 
(Table 1.4). As our knowledge of the effects of opioids expands, these structural 
dissimilarities cause a different effect profile of these drugs, not only in analgesic 
potency and propensity to induce tolerance, but also in the likelihood to cause different 
toxicities. The differences between the constipating effect of some opioids has been 
extensively studied. There are both animal (Meert and Vermeirsch, 2005) and clinical 
(Clark et al., 2004, Tassinari et al., 2008) studies that show the more lipid-soluble 
opioids such as fentanyl and buprenorphine are less likely to cause constipation, 
compared with water-soluble opioids such as morphine and oxycodone, while 
maintaining the same degree of analgesic effect. This is probably caused by their 
reduced time in the systemic circulation as well as the lower peripheral concentration 
needed for a CNS concentration to induce an equivalent analgesic effect (Figure 1-14).  
 
Other toxicities which have been studied, show that buprenorphine causes less 
respiratory depression compared to fentanyl (Dahan et al., 2005, Dahan et al., 2006) 
and fentanyl causes less somnolence compared with morphine (Clark et al., 2004). It is 
likely that this heterogeneous group of drugs will have differing effects on immunity. 
Figure 1-13: Schematic diagram showing 
the molecular structure of codeine. 
Codeine, 3-methylmorphine, has a molecular 
weight of 299.4 g/mol and is pro-drug of 
morphine. It is a weak MOR agonist (after 
conversion to morphine). 
Image from Pub Chem (NIH) 
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Although there has been many studies investigating the effect of some opioids on 
certain immune cells in various models and even a proposal of how opioid structure 
might affect immune activity (Sacerdote et al., 1997), this has never been 
systematically studied. 
 
 
Figure 1-14 Schematic showing the effect of lipophilicity on opioid distribution. 
Hydrophilic opioids such as morphine (M) need much greater concentrations in the systemic circulation 
(vascular system) to cross the blood-brain barrier and cause a similar analgesic effect in the central 
nervous system when compared with lipophilic opioids like fentanyl (F). This is likely to contribute to the 
differences in their peripheral effect profile. Adapted from Twycross, 1997. 
 
Table 1.4: Principal pharmacological properties of commonly-used opioids. 
Opioid Pharmacology 
Morphine MOR agonist, TLR4 receptor agonist, hydrophilic 
Tramadol  Weak MOR agonist, serotonin and noradrenaline re-uptake 
inhibition, lipophilic 
Fentanyl Potent MOR agonist, TLR4 receptor agonist, lipophilic  
Buprenorphine Partial MOR agonist, DOR antagonist, ORL1 agonist, TLR4 
receptor agonist, lipophilic 
Methadone MOR agonist, may also have NMDA antagonist properties, TLR4 
receptor agonist, lipophilic 
Oxycodone MOR agonist, also has KOR agonist properties, TLR4 receptor 
agonist, hydrophilic 
Diamorphine Pro-drug of morphine, converted by deacetylation. May have 
direct effect on MOR subtype, lipophilic, high water solubility 
Codeine Pro-drug of morphine, converted principally by CYP 2D6, 
hydrophilic 
 
 
1.6 Expression of MOR on immune cells  
As the principal effect of opioids is initiated by binding to the transmembrane and 
extracellular domains of the opioid receptor on the cell surface, for in vitro opioids to 
have an effect on immune cells, it is likely to be necessary for these cells to express 
Morphine 
Fentanyl 
46 | P a g e  
 
opioid receptors. However, certain opioids may also have direct effects on immune 
cells mediated via non-opioid mechanisms, such as those described in Table 1.4. In 
vivo, opioids may also modulate immune function via indirect effects, by actions on the 
CNS and the release of immune mediators (described in section 1.9), as well as by 
direct effects on the immune cells expressing opioid receptors (Wei et al., 2003).  
 
In MOR knockout (MOR-/-) mice, chronic morphine administration has been shown not 
to induce changes in the immune system, whereas their wild-type counterparts 
exhibited splenic and thymic atrophy, with decreased lymphocyte numbers. In the 
thymus there was also an alteration of lymphocyte distribution (Gaveriaux-Ruff et al., 
1998, Roy et al., 1998a). NK cell cytotoxicity was also markedly decreased by 
morphine in mice with MORs. This indicates that the effects of opioids on lymphocytes 
and NK cells are likely to be mediated via MORs (Gaveriaux-Ruff et al., 1998, Roy et 
al., 1998a). Baseline immune parameters (including size and lymphocyte population of 
lymphoid organs, NK cell cytotoxicity, lymphocyte proliferation and immunoglobulin 
production), in the MOR-/- mice were no different to those in wild-type mice (Gaveriaux-
Ruff et al., 1998), indicating that intrinsic immune function is not dependent on the 
MOR. 
 
There is currently no definitive way to demonstrate the presence of functional opioid 
receptors on immune cells; data from radioligand binding studies using 3H-naloxone as 
well as polymerase chain reaction (PCR) analysis are discrepant (Borner et al., 2009, 
Kraus, 2009, Williams et al., 2007). The most relevant evidence is that which is based 
on the demonstration of functional effects. As early as 1979, evidence demonstrating 
that morphine suppressed rosette formation by activated T cells, that this effect was 
enhanced by met-enkephalin, and that both effects were inhibited by naloxone, 
suggested the presence of opioid receptors on human peripheral blood T cells (Wybran 
et al., 1979). Despite this functional evidence for the presence of opioid receptors on 
immune cells, not all studies have confirmed this. One possibility for the discrepancy is 
that opioid receptor expression might depend upon the activation status of the immune 
cell. In a study investigating healthy volunteer-derived resting peripheral blood 
mononuclear cells (PBMCs), the classical opioid receptors could not be detected with 
PCR, antibody or ligand studies; ORL1 was expressed in these PBMCs (Williams et al., 
2007). Another study in peripheral lymphocytes from healthy humans showed no 
specific binding of ,  and  radioligands to their cell membranes (Palm et al., 1996). 
Some of the discrepancy might be due to a 5′ truncated splice variant (where the 
messenger ribonucleic acid [mRNA] has been shortened and not detected by certain 
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PCR primers) of the human MOR gene, OPRM1. This splice variant produces a 6 
transmembrane 3 receptor which preferentially binds morphine, but not endogenous 
opioid peptides; these receptors have been identified in a murine monocytes cell line 
(Makman et al., 1995) and human neutrophils and monocytes (Cadet et al., 2003). 
 
Opioid receptors have been demonstrated on Mytilus (blue mussel) immunocytes and 
human monocytes, and on these cells morphine counteracts the stimulatory effect of 
TNF- and IL-1 (Stefano et al., 1993). It has been suggested that morphine may have 
a role in calming or terminating the state of immune alertness. Using PCR and Western 
blot analysis of human and monkey lymphocytes, Suzuki and colleagues have shown 
that directly applying morphine to these cells increases OPRM1 gene transcription and 
protein synthesis (Suzuki et al., 2000). Using a MOR antibody and a Western blot 
analysis, MORs were detected on human neutrophils and their expression was 
increased by LPS stimulation (Glattard et al., 2010). 
  
It has been reported that the OPRM1 gene is not transcribed in unstimulated or resting 
T cells and that these cells do not constitutively express MOR in this inactive state 
(Borner et al., 2008, Kraus et al., 2001). However, when activated by a physiological 
relevant stimulus (using mAbs that bind to CD3 and CD28) MOR mRNA is increased in 
both human T cells and Jurkat cells (an immortalised T cell line). This indicates that 
OPRM1 gene expression depends on the activation status of the T cells. Morphine has 
been shown to have a suppressive effect by inhibiting the amount of IL-2 mRNA 
production in anti-CD3 and anti-CD28 mAb activated human T cells. This effect of 
morphine was mediated via the MOR, both because of the need for prior activation to 
induce MOR expression and as its effect was blocked by Phe-Cys-Tyr-D-Trp-Arg-Thr-
Pen-Thr amide (CTAP), a MOR specific antagonist (Borner et al., 2008).  
 
Some of the discrepancies in these studies could be due to the immune cell type used, 
its level of activation, the methodology used to detect the opioid receptor and in the 
case of PCR, the primer sequence used. This is compounded by the non-constitutive 
expression of MOR in immune cells, and that when it is expressed by cytokine-
induction, MOR mRNA is at a very low level (~1% of that in neurons) (Borner et al., 
2007). Even if opioid receptors are detected, either as transcript or protein, it is 
functionality which is of primary importance. If the detection of MOR mRNA at very low 
levels requires nested PCR to produce sufficient amplification for detection, then its 
clinical relevance could be questioned. However, it has been shown that very low 
levels of mRNA can produce functional MOR proteins in T cells (Borner et al., 2007). 
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1.6.1 Regulation of opioid receptor expression 
Various extracellular signals are involved in the control of OPRM1 gene transcription. 
These include hormones, such as oestrogen (Quinones-Jenab et al., 1997) and drugs, 
such as cocaine (Azaryan et al., 1996). The effects of cytokines on the regulation of 
OPRM1 gene transcription in lymphocytes and the pathways via which these effects 
are mediated have been extensively investigated. Cytokines are among the most 
potent physiological regulators of OPRM1 gene transcription and cell surface opioid 
receptor expression in immune and neuronal cells (Kraus, 2009). The transcriptional 
effects of cytokines on some genes may either be via direct effects on transcription 
factors or indirectly due to induction of secondary cytokines (Kraus et al., 2001, Kraus 
et al., 2003). 
 
Opioid receptor expression and the effect of opioids might also be different depending 
on the subject group and the conditions studied. In vivo morphine and methadone 
induced a potent and persistent down-regulation of opioid binding sites in murine 
splenocytes (Patrini et al., 1996). Former heroin addicts on methadone maintenance 
treatment have been reported to exhibit a reduced lymphocyte binding of 3H-naloxone, 
and decreased levels of MOR and DOR mRNA (Toskulkao et al., 2010). This could 
mean that the effects of opioids on immune cells could be modulated by previous 
exposure, and there could thus be a difference between different experimental groups. 
Further differences are possible between different groups studied, as they may 
produce different MOR splice variants (Vousooghi et al., 2009). Patients on 
methadone-maintained treatment have increased OPRM1 deoxyribonucleic acid (DNA) 
methylation in lymphocytes (Nielsen et al., 2009). Non-opioid receptor actions of 
opioids could also be differentially affected within different study cohorts, as opioid 
addiction or maintenance therapy groups may have different PBMC NMDA receptor 
subunit expression (Roozafzoon et al., 2010).  
 
The OPRM1 gene has many polymorphisms, most of which are in the promoter region 
(Hoehe et al., 2000). If these affect the binding sites for transcription factors then they 
can alter the regulation of the gene. NF-B is important in regulation of OPRM1 gene 
transcription and there are many NF-B binding sites on this gene, including three in 
the promoter region. There are polymorphisms within the NF-B binding site and within 
a STAT6 element, the latter of which impairs regulation of the gene by cytokines such 
as IL-4 (Borner et al., 2002, Kraus et al., 2001, Kraus et al., 2003). The MOR promoter 
contains cytokine response elements, including NF-IL6. 
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Induction of MOR expression has been shown to occur in response to IL-1 (Mohan et 
al., 2010), IL-4 (Kraus et al., 2001, Trafton et al., 2000), IL-6 (Borner et al., 2004) and 
TNF (Borner et al., 2002, Kraus et al., 2003). In contrast, IFN- down-regulates OPRM1 
gene transcription (Kraus et al., 2006). These mechanisms are described below and in 
Figure 1-15. 
 
1.6.2 Interleukin-1 
IL-1 induces the expression of the MOR in endothelial cells, however both IL-1 and IL-
1 are needed simultaneously (Vidal et al., 1998). IL-1 activates several transcription 
factors, including NF-IL6, NF-B, c-Jun and c-Fos (O'Neill, 1995). IL-1β increased 
MOR mRNA in SK-N-SH cells (a human neuroblastoma cell line) (Mohan et al., 2010). 
 
1.6.3 Interleukin-4 
IL-4 induces OPRM1 gene transcription in human T cells, neutrophils, DCs, immune 
cell lines (Raji, U-937, and HMEC-1) and rat neurons. Transfection experiments in Raji 
and SH SY5Y cells (a human neuroblastoma cell line) with reporter gene constructs 
have directly linked the IL-4 effect to the cis-active MOR promoter (Kraus et al., 2001). 
IL-4, via STAT5 and STAT6, activates transcription of the OPRM1 gene (Borner et al., 
2006, Hou et al., 1994). The IL-4-responsive elements of the human OPRM1 gene 
promoters are STAT6 binding sites. Furthermore, allelic variation within the IL-4–
responsive element/STAT6 binding site of OPRM1 promoter reduces responsiveness 
of the gene to IL-4 to approximately 50% (Kraus et al., 2001). 
 
In an in vitro model using Jurkat E6.1 cells, cannabinoids acting on the CB2 receptor 
induced OPRM1 gene transcription via IL-4 and the transcription factors STAT6 and 
GATA3. The MORs were shown to be functional, as morphine caused phosphorylation 
of MAPK in those cells stimulated by cannabinoids (Borner et al., 2006).  
 
1.6.4 Interleukin-6 
IL-6 has been shown to induce an up-regulation of MOR mRNA in SH SY5Y cells 
(Borner et al., 2004). IL-6 activates the Janus kinase (JAK) family of tyrosine kinases 
(Heinrich et al., 2003b) which phosphorylates and activates STAT1 and STAT3 
transcription factors, which bind to the IL-6 response element, located on the promoter 
of the human OPRM1 gene. These increase OPRM1 gene transcription and MOR 
mRNA expression (Borner et al., 2004). 
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IL-6 can also activate the JAK pathway which involves the G-proteins Ras and Raf. 
This then activates MAPK, which stimulated the transcription factors STAT1, STAT3, 
NF-IL-6, NF-B and AP-1 which can all be involved in the downstream signalling of IL-6 
(Borner et al., 2004).  
 
1.6.5 Tumour Necrosis Factor 
TNF up-regulates the transcription of the OPRM1 gene via the transcription factor NF-
B in both neurons (Borner et al., 2002) and immune cell lines (Raji and U937) (Kraus 
et al., 2003). Stimulation of Raji cells with TNF has been reported to induce OPRM1 
gene transcription within 6 hr, and a neutralising antibody approach has shown this to 
be mediated by TNF receptor 2 (Kraus et al., 2003). 
 
1.6.6 Interferon-gamma 
In T cells and in SH SY5Y cells, OPRM1 gene transcription is down regulated by IFN-, 
in which it inhibits the IL-4-mediated induction of gene transcription (Kraus et al., 2006).  
 
1.6.7 Activator protein-1 
The AP-1 transcription factor family, which includes c-Jun and c-Fos, have an 
important role in T cell differentiation and apoptosis. They may also be important in 
OPRM1 gene transcription, as there are AP-1 elements within the OPRM1 gene 
promoter (Borner et al., 2002, Kraus et al., 1995). c-Jun is activated by phosphorylation 
by JNK which in turn is activated by cytokines or stress. c-Fos is phosphorylated by 
PKC, PKA and MAPK. 
 
1.6.8 Cannabinoid agonists 
Like opioids, cannabinoids can also modulate immune functions, with 
tetrahydrocannabinol suppressing pro-inflammatory cytokine production from murine T 
helper cells (Klein et al., 2004). Whereas MORs are normally not expressed, 
cannabinoid receptors are constitutively expressed by immune effector cells (Borner et 
al., 2004, Kraus et al., 2001, Kraus et al., 2003). Activation of cannabinoid CB2 
receptors has been shown to increase the transcription of the OPRM1 gene via 
induction of IL-4, STAT6 and GATA3 (Bidlack et al., 2006, Borner et al., 2006, Klein et 
al., 2004). The cannabinoid CB1 receptor might inhibit the effects of neuronal TNF- 
(Rossi et al., 2011) and decrease MOR transcription (Paldyova et al., 2007). 
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1.6.9 Summary 
It has been demonstrated that opioid receptor expression is under the regulatory 
control of numerous cell signals (Figure 1-15) and it is likely to be altered in states of 
immune activation such as inflammation and cancer. It is therefore possible that the 
detected effect of opioids on immunity is dependent on the study model. This would be 
particularly relevant in human healthy volunteer vs. clinical studies and with regards to 
the activation status of cell populations that are used for in vitro studies.  
 
Although lymphocytes are capable of synthesising opioid receptors, this might only 
occur when they are activated. Thus, the effects of opioids on the immune system in 
health and disease might differ. In health, where there is no lymphocyte activation and 
no expression of opioid receptors on these cells, any influence that opioids have on 
immunity is likely to be indirectly mediated via neuro-immune mechanisms. In diseased 
conditions, such as cancer or infection, in which immune activation is present, 
lymphocytes might express low levels of MORs and prescribed opioids would have 
both direct peripheral immune modulating effects, as well as CNS mediated neuro-
immune effects. 
 
 
Figure 1-15: Illustration of the various promoters of OPRM1 gene transcription. 
TNF-, IL-1, IL-4 and IL-6 via specific activators of gene transcription, are all involved in the up-regulation 
of OPRM1 gene transcription. Cannabinoids acting on the cannabinoid CB2 receptor and opioids by 
phosphorylating STAT5, both act via IL-4, and subsequent phosphorylation of STAT6 and GATA3 to 
induce OPRM1 gene transcription. The AP-1 transcription factors (c-Jun and c-Fos) are activated by JNK 
(c-Jun terminal kinases) and PKC, PKA and MAPK. Cannabinoids via the cannabinoid CB1 receptor can 
inhibit TNF-. P indicates activated by phosphorylation.  
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1.7 Neuro-immune interactions of opioids 
There are bidirectional connections between the nervous and immune systems. The 
nervous system can communicate with the immune system via endocrine mediators, 
sympathetic nervous system (SNS) innervation of lymphoid organs and by the 
cholinergic parasympathetic nervous system. The reciprocal communication from the 
immune to the nervous system is principally mediated by cytokines (Kin and Sanders, 
2006, Wrona, 2006). 
 
Not only is there evidence that different types of immune cells can express the opioid 
receptor, but it has also been shown that certain immune cells, including neutrophils 
and T cells, can contain and release endogenous opioids, including endogenous 
morphine (Labuz et al., 2010, Zhu et al., 2005). These opioids might be involved in 
modulation of pain transmission, but could also have a role in immune modulation, with 
endogenous opioids acting as autocrine and paracrine immune signals (Zhu et al., 
2005). From an evolutionary perspective, this action might have developed to modulate 
the local immune response to injury, as T cells can have a variable effect on pain 
modulation (Costigan et al., 2009, Labuz et al., 2009, Liang et al., 2008) which can be 
due to their neuroanatomical location, subtype of T cell and the cytokines released 
(Hutchinson et al., 2008, Liang et al., 2008, Mika, 2008). 
 
As well as having central analgesic actions, opioids can also act at peripheral sites to 
modulate pain transmission (Stein and Lang, 2009). There is an interaction between 
immune cell-derived opioid peptides and opioid receptors on sensory nerves (Figure 
1-16). During inflammation, opioid receptors are up-regulated in the peripheral nerve 
endings of sensory neurons (Stein and Lang, 2009). Immune cells migrate to injured 
tissues directed by chemokines and adhesion molecules and under stressful conditions 
or in response to corticotrophin-releasing factor and IL-1, can secrete opioids which 
inhibit pain and decrease immune alertness (Machelska and Stein, 2006). 
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Figure 1-16: Illustration of the peripheral neuro-immune interaction. 
Lymphocytes (Lø) migrate out of the blood vessels into areas of inflammation where they can secrete 
endogenous opioid peptides, including endogenous morphine. These can act on peripheral sensory 
neurons to reduce pain and also on opioid receptors on their cell membrane (autocrine) and nearby 
immune cells (paracrine) to reduce immune activation and inflammation. Adapted from Machelska and 
Stein, 2006, Stein and Lang, 2009, Zhu et al., 2005. 
 
 
1.8 Immunomodulatory actions of opioids 
It might seem unintuitive that pain-killing drugs which work by interfering with the 
endogenous opioid system can influence immunity. However, it becomes self-evident 
that this is likely to be the case given that the endogenous opioid system has multiple 
effects on homeostasis and immune defence mechanisms, in addition to the 
modulation of pain (Table 1.1). It has even been said that if opioids had not been used 
as analgesics and had been discovered by immunologists, then the endogenous 
opioids would have been classified as cytokines (Vallejo et al., 2004). This is because 
opioids exhibit the principal properties that are associated with cytokines; they are 
produced by immune cells and they have autocrine, paracrine and endocrine sites of 
action. They also exhibit functional redundancy and pleiotropy, and have effects that 
are dose- and time-dependent (Peterson et al., 1998). It is therefore possible that 
exposure to opioids can potentially have many effects on the immune system. 
 
It has been known that morphine affects immune cells for over 100 years, when 
Cantacuzene showed that morphine administered to guinea pigs suppressed 
phagocytosis and leukocyte trafficking (Cantacuzene, 1898, Friedman et al., 2003, 
Vallejo et al., 2004). Since then, research has emphasised the often detrimental effect 
of opioids on the immune system (Brack et al., 2011, Budd, 2006, Sacerdote, 2008). 
These reports have been published across the spectrum of basic science and clinical 
medical journals and include cellular, animal and human studies. However, they have 
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principally used in vitro approaches and experimental animal models (Brack et al., 
2011, Budd, 2006). The majority of this work has been conducted using a variety of 
methodological approaches, and has tended to evaluate the effect of morphine on one 
or two aspects of immunity without the ability to compare doses, duration of opioid 
therapy or immune activation status between studies (Brack et al., 2011, Budd, 2006, 
Sacerdote, 2008). There has been few well-designed clinical studies to test the in vitro 
and animal findings in patients, and until these have been done it is difficult to know the 
importance of opioid-induced immune modulation in relevant patient groups (Brack et 
al., 2011, Sacerdote, 2008).  
 
Furthermore, as stated earlier, immune activation status may be critical for the 
expression of opioid receptors on T cells and their ability to respond directly to opioids 
(Borner et al., 2008). This might limit the value of studies using resting lymphocytes in 
the laboratory. It also potentially limits the value of using healthy volunteers, as they 
are likely to have a different immune activation status compared to patients with cancer 
or infection, with the result that any direct effect of opioids on lymphocytes might not be 
evident in healthy volunteers without lymphocyte activation (Borner et al., 2009). 
 
The immunological properties of opioids are complex and their effects depend upon 
which opioid is used and the study methodology. Some opioids such as morphine have 
been reported to be immunosuppressive, whereas buprenorphine might be ‘immune 
neutral’ and tramadol may enhance immune function (Budd, 2006, Sacerdote et al., 
1997). There is a clear need to systematically explore the effects of the commonly-
used opioids on those key aspects of the immune system that are involved in immune 
surveillance and protective anti-tumour and anti-pathogen immunity. 
 
The following sections outline the previous literature which describe the mechanisms of 
opioid-mediated immunosuppression (1.9) and the receptors by which this occurs 
(1.9.1); whether this is mediated by direct effect of opioids on the immune cells or via 
central mechanisms (1.10) and the kinetics of these effects (1.11). Then the other in 
vivo studies which have assessed the effects of opioids on NK cells, phagocytosis and 
oxidative burst, T cells and cytokine production that are not already described in earlier 
sections will be reviewed (1.12). In vitro studies, which are methodologically related to 
the current study, are principally discussed in the Results, in which they are critically 
evaluated in comparison with the current study. 
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1.9 Mechanisms of opioid-mediated immunosuppression 
Opioids could influence immune function via direct effects on immune cells and/or 
indirectly via centrally-mediated mechanisms and the systemic production and release 
of immunomodulatory mediators. The direct mechanism would depend on responsive 
immune cells expressing appropriate opioid receptors or via non-opioid actions of 
opioid drugs (i.e. via TLR4). The indirect mechanism would depend on opioids 
influencing centrally-produced mediators such as immunosuppressive glucocorticoids 
that are released as a result of hypothalamic pituitary adrenal (HPA) axis activation. 
 
Many of the studies dissecting the mechanisms of opioid-mediated immunomodulation, 
including if it is a direct effect on immune cells, whether it is MOR dependant or if it is 
mediated by release of immunomodulatory mediators, have used morphine. Many of 
the studies in this section will thus be based on morphine and may not be generalisable 
to all opioids. For example, in mice, a 75 mg pellet of subcutaneous morphine caused 
atrophy of the spleen and thymus, and to attenuate lymphocyte proliferative responses 
to T and B cell mitogens within 72 hr (Bryant et al., 1987). As well as causing thymic 
and splenic atrophy by suppressing hematopoietic cell development, morphine has 
also been shown, by inducing apoptosis, to reduce macrophage and B cell numbers in 
the mouse spleen (Singhal et al., 1998). In a healthy volunteer study, morphine has 
been shown to decrease NK cell cytotoxicity and antibody-dependent cellular 
cytotoxicity (Yeager et al., 1995). The evidence for whether these effects of morphine 
on the immune system are mediated by the MOR and the involvement of central and 
peripheral mechanisms will be explored in the following sections. 
 
1.9.1 Opioid receptors subtypes mediating the effects of opioids on 
immunity 
Many studies have evaluated the relative importance of the different opioid receptors in 
the mediation of the effects of opioids on immunity. The two principal methods used are 
gene knockout models and specific opioid receptor agonists or antagonists (Table 1.5). 
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Table 1.5: Selective opioid receptor agonists and antagonists. 
 Agonists Antagonists 
MOR Endomorphin 1 and DAMGO CTAP, CTOP, -funaltrexamine 
KOR U50,488H, U69,593 Nolbinaltorphimine, nor-binaltorphimine 
DOR DSLET (2) and DPDPE (1); Naltriben, naltrindole 
The different selective opioid receptor agonists and antagonists used in the studies exploring the relative 
roles of opioid receptors subtypes in immune effects. Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr amide 
(CTOP); Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr amide (CTAP), [D-Pen
2,5
]-enkephalin (DPDPE); D-Ser2-
Leu-Enkephalin-Thr
6
 (DSLET); [D-Ala
2
, N-MePhe
4
, Gly-ol]-enkephalin (DAMGO). 
 
Gaveriaux-Ruff and colleagues assessed the capacity of splenic NK cells, from 
C57BL/6 mice, to kill YAC-1 cells (a NK cell sensitive murine T lymphoblastoma target 
cell line) using a 51Cr release assay (Gaveriaux-Ruff et al., 1998). They also studied T 
and B cell proliferation in response to concanavalin A (Con A; a T cell mitogen) and 
LPS (a B cell mitogen) using a 3H-thymidine uptake assay, and used an enzyme-linked 
immunosorbent assay (ELISA) to assess antibody production. Flow cytometry was 
used to assess the distribution of CD4+ T cells, CD8+ T cells and B cells in the thymus 
and spleen. Mice were given saline as a control or treated with increasing doses of 
morphine intraperitoneally every 12 hr for 6 days, up to a maximum of 100 mg/kg. 
Before morphine, there was no difference between wild-type and MOR-/- mice with 
regard to the above assays. Morphine-treated wild-type mice exhibited lymphoid organ 
atrophy, a diminished CD4+:CD8+ cell ratio in the thymus and reduction in NK cell 
cytotoxicity. In MOR-/- mice, morphine administration had no effect on immunity, 
analgesia, reward or physical dependence (Gaveriaux-Ruff et al., 1998). 
 
The effects of 0.6 mg of morphine, as a single intraperitoneal injection, on lymphocyte 
function in wild-type, MOR+/- and MOR-/- C57BL/6J female mice, 3 hr after morphine 
administration has been evaluated (Weber et al., 2006). Splenic NK cell cytotoxicity 
against YAC-1 cells was measured using a 51Cr release assay. The responsiveness of 
splenic T cells to phytohaemagglutinin (PHA; a T cell mitogen), Con A, and anti-CD3 
mAbs was determined on the basis of 3H-thymidine uptake. Morphine suppressed all of 
these immune parameters in wild-type animals, had no effect on these in MOR-/- mice 
and partially inhibited NK cell cytotoxicity (but had no effect on T cell responsiveness) 
in MOR+/- mice (Weber et al., 2006). 
 
Tomassini and colleagues assessed the role of opioid receptor subtypes in the effect of 
morphine on phagocytosis by murine peritoneal macrophages (Tomassini et al., 2003). 
Wild-type C3HeB/FeJ and C57B/L6 female mice and MOR-/- C57B/L6 mice, had 
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intraperitoneal injections of thioglycollate and were killed after 5 days when peritoneal 
macrophages were isolated. Phagocytosis was evaluated by the ability of 
macrophages to ingest opsonised sheep red blood cells (SRBCs) over 20 min, as 
measured by microscopic examination. Selective  (DAMGO) and 2 (D-Ser2-Leu-
Enkephalin-Thr6; DSLET), but not  (U50,488H) agonists, inhibited Fc-mediated 
phagocytosis, indicating that  and 2 opioid receptors are responsible for the 
transduction of the opioid signal (Tomassini et al., 2003). 
 
This group further evaluated the role of opioid receptor subtypes in murine Fc-mediated 
phagocytosis, using a similar methodology (Tomassini et al., 2004). C3HeB/FeJ or 
C57B/L6 female mice had intraperitoneal injections of thioglycollate, were killed after 5 
days and peritoneal macrophages were isolated. Phagocytosis was assessed by the 
ability of macrophages to ingest opsonised SRBCs over 20 min as measured by 
microscopic examination. Selective opioid receptor agonists (: endomorphin 1 and 
DAMGO; 1: D-Pen2,5-enkephalin [DPDPE]; 2: DSLET and : U50,488H) were added 
30 min prior to addition of SRBCs. In a subgroup of mice, opioid antagonists (: Phe-
Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr amide [CTOP]; : naltriben; and : nor-
binaltorphimine) were added 30 min prior to the agonist. They found that  and 2 
receptors, but not  receptors, mediated the effects of opioids on Fc-mediated 
phagocytosis by murine peritoneal macrophages. Furthermore,  and 2 agonists 
interacted, suggesting a cooperative mechanism of action which might be due to / 
heterodimers (Tomassini et al., 2004).  
 
Heterodimerisation of  and  opioid receptors have been reported in the nervous 
system (George et al., 2000), with this oligomerisation having a role in opioid synergy 
(Gomes et al., 2000). It might be that opioids have a variable effect on different immune 
parameters via a complex interaction with  and  opioid receptors. Dimerised opioid 
receptors behave differently than the individual receptors, such that morphine can 
induce internalisation of the GPCR complex when it binds to a / receptor chimera, 
whereas it cannot when it binds to a MOR monomer (Roth and Willins, 1999). This is 
likely to have implications in the development of opioid tolerance. 
 
Roy and colleagues assessed the role of the MOR in the effects of morphine on 
immune function using MOR-/- mice (Roy et al., 1998a). Although morphine suppressed 
peritoneal macrophage phagocytosis and secretion of TNF- in wild-type mice, it did 
not affect these in MOR-/- mice, indicating that these effects are MOR mediated. 
58 | P a g e  
 
Morphine also reduced spleen and thymus weight, PHA-induced T cell proliferation, 
and macrophage secretion of IL-1 and IL-6; however these effects remained in MOR-/- 
mice, suggesting they might be mediated by KOR, DOR or non-opioid receptors. It may 
also be a combination of these, as the unselective opioid antagonist naltrexone partly 
reversed the effects of morphine in both wild-type and MOR-/- mice (Roy et al., 1998a). 
 
Szabo and colleagues used specific agonists and antagonists to assess the relative 
importance of the opioid receptors on the ability of peritoneal macrophages from 
female C3HeB/FeJ mice to phagocytose Candida albicans (Szabo et al., 1993). 
Morphine suppressed phagocytosis, which was reversed by CTAP, a MOR antagonist, 
but not by  (nor-binaltorphimine) or  (naltrindole) antagonists. However, selective  
(DAMGO),  (U50,488H) and  (DPDPE) opioid agonists, dose-dependently 
suppressed phagocytosis, and these effects were blocked by the respective receptor-
selective antagonists. It was concluded that all three opioid receptors may be involved 
in the modulation of macrophage function and morphine’s effect is via the MOR (Szabo 
et al., 1993). 
 
 
1.10 Central and peripheral mediation of opioid-induced 
immunosuppression  
The evidence described above indicates that all opioid receptor subtypes might be 
involved in the effect of opioids on immune function but the principal actions of 
morphine are mediated via the MOR. The CNS contains many opioid receptors and it is 
well established that opioids (both endogenous and prescribed) acting at these 
receptors modulate pain (Zubieta et al., 2001). The CNS and immune systems are 
intimately connected, with CNS outflow to the spleen (via the SNS) and adrenal glands 
(via the HPA axis) being able to release immune modulating agents to influence the 
immune system (Felten et al., 1985). As a consequence, as well as having a direct 
effect on immune cells, opioids might also have an indirect effect on immunity via an 
action in the CNS by releasing immunomodulatory mediators. Figure 1-17, below, 
illustrates the main pathways through which opioids can affect immune function. The 
indirect action can only be assessed when drug exposure takes place in vivo, as it is 
mediated by opioid receptors in non-immune cells. Thus, although in vivo studies 
enable all the potential actions of opioids to be evaluated, they have a complexity that 
is absent from in vitro studies, potentially making it more difficult to dissect out the 
underlying mechanisms. 
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1.10.1 Evidence that opioid-induced immunomodulation is peripherally 
mediated 
In vitro experiments indicate that immune dysfunction by morphine is mediated via 
direct interactions with MORs on immune cells (Borner et al., 2008). It has been 
demonstrated that in vitro morphine decreases the phagocytic activity of macrophages 
and that this effect is blocked by the opioid antagonist naltrexone (Roy et al., 1998a, 
Szabo et al., 1993). In vitro  (morphine and DAMGO) and  (U50,488H and U69,593) 
opioid agonists inhibited antibody production, by acting directly on murine splenic cells, 
which was blocked by naloxone (Guan et al., 1994, Taub et al., 1991). 
 
Wang and colleagues assessed the relative importance of the direct effects of chronic 
morphine on lymphocytes and macrophages compared with its effects via the SNS and 
HPA axis using wild-type and MOR-/- Balb/c X C57BL/6 mice (Wang et al., 2002). To 
assess the role of the HPA axis, mice were infused with corticosterone at 
concentrations found in morphine-treated mice. The role of the SNS and 
catecholamines was assessed by administering chlorisondamine (an SNS ganglionic 
blocker) to mice and implanting 75 mg morphine pellets subcutaneously 1 hr later. 
Animals were killed 48 hr after this and cell suspensions made from thymus, spleen, 
and peritoneal lymph nodes. These were incubated with 5 g/ml Con A and 
proliferation was measured using a 3H-thymidine uptake assay. Con A induced IL-1, 
IL-2, IFN-, and TNF- levels were measured using ELISAs. Morphine decreased 
splenocyte proliferation and IFN- levels and increased macrophage IL-1 and TNF- 
levels. None of these effects depended on corticosteroids. Thymic cellularity and 
thymocyte proliferation were partially suppressed by corticosteroids. Blocking the SNS 
only partially reversed the suppressive effects of morphine on splenic-lymphocyte 
proliferation and IFN- levels. They also showed that in wild-type animals, the MOR 
was expressed in thymic, splenic and lymph node lymphocytes, and peritoneal 
macrophages. The authors concluded that the immune effects of morphine are mostly 
mediated directly by the MOR on lymphocytes and macrophages when delivered in 
vivo to mice, although there may be a contributing role from the SNS and HPA axis 
(Wang et al., 2002).  
 
Rojavin and colleagues assessed the effects of in vitro and in vivo morphine on 
peritoneal macrophage phagocytosis of Candida albicans during a 30 min assay 
(Rojavin et al., 1993). A 75 mg morphine pellet implanted subcutaneous into mice 
inhibited peritoneal macrophage phagocytosis. In vitro morphine dose-dependently 
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decreased phagocytosis. The suppressive effects of morphine in vitro and in vivo were 
blocked by naltrexone, indicating that morphine can interact with opioid receptors on 
macrophages and directly decrease phagocytosis (Rojavin et al., 1993). 
 
The 3 receptor is a morphine sensitive and opioid peptide insensitive MOR, formed as 
a splice variant of the OPRM1 gene mRNA (Cadet et al., 2003). 3 receptors have 
been detected on granulocytes and have been shown to mediate the inhibitory effects 
of in vitro morphine on granulocyte chemotaxis (Makman et al., 1995, Stefano et al., 
1993). Furthermore, 3 opioid receptors, by a NO dependent mechanism, mediate 
morphological changes in human monocytes, induced by a direct action of morphine 
(Magazine et al., 1996).  
 
Previous in vitro studies have demonstrated effects of certain opioids on different 
immune cells, meaning the opioid must be having a direct action on the cell (Bonnet et 
al., 2008, Casellas et al., 1991, Sheen et al., 2007, Tomassini et al., 2003, Tsujikawa et 
al., 2009, Welters et al., 2000b, Wu et al., 2009). These in vitro studies are described in 
the Results. 
 
1.10.2 Evidence that opioid-induced immunomodulation is centrally 
mediated 
To evaluate the central vs. peripheral effects of opioids, the in vivo actions of morphine 
(which crosses the blood-brain barrier) and peripherally acting N-methylmorphine 
(which does not cross the blood-brain barrier), have been assessed in rodents 
(Hernandez et al., 1993, Shavit et al., 1986). Hernandez and colleagues have shown 
that subcutaneous morphine in the Sprague-Dawley rat suppressed Con A stimulated 
lymphocyte proliferation, increased corticosterone and was analgesic, whereas 
peripherally administered N-methylmorphine had no effect on these parameters. When 
applied directly into the anterior hypothalamus or intracerebroventricularly, both 
morphine and N-methylmorphine inhibited lymphocyte proliferation, elevated plasma 
corticosterone levels and induced similar analgesic responses (Hernandez et al., 
1993). Subcutaneous and intracerebroventricular administration of morphine, but not 
subcutaneous N-methylmorphine, produced a naltrexone-reversible suppression of 
splenic NK cell cytotoxicity in the male Fischer 344 rat, using a 51Cr release assay and 
YAC-1 target cells (Shavit et al., 1986). 
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Furthermore, by directly injecting morphine into specific neuroanatomical sites in the rat 
brain, it has been shown that opioid receptors in the caudal region of the peri-
aqueductal grey (PAG) mediate morphine induced suppression of splenic NK cell 
function (Gomez-Flores and Weber, 2000, Hernandez et al., 1993, Lysle et al., 1996, 
Weber and Pert, 1989), whereas its inhibitory effects on blood lymphocyte proliferation 
to Con A stimulation are mediated via MORs in the anterior hypothalamus (Hernandez 
et al., 1993). 
 
Lewis rats have been treated with intracerebroventricular DAMGO (MOR agonist), 
DPDPE (DOR agonist), or U69,593 (KOR agonist) and killed 1 hr later (Nelson et al., 
2000). Single-cell splenic suspensions were generated and NK cell cytotoxicity, T cell 
proliferation to Con A and leukocyte numbers were evaluated. NK cell cytotoxicity was 
measured with a 51Cr release assay using splenic leukocytes and YAC-1 target cells. 
Splenic T cells were stimulated with 0.5 and 5.0 µg/ml Con A and proliferation was 
measured using a 3H-thymidine uptake assay. DAMGO suppressed NK cell cytotoxicity 
and Con A stimulated T cell proliferation. DPDPE and U69,593 had no effects. There 
was no difference in splenic leukocyte numbers between rats treated with saline or any 
of the opioid agonists. Intracerebroventricular N-methylnaltrexone (a peripherally acting 
MOR antagonist) attenuated the suppressive activity of DAMGO on NK cell cytotoxicity 
and stimulated T cell proliferation to Con A (Nelson et al., 2000). This indicates that the 
opioid-mediated inhibition in NK cell cytotoxicity and splenic T cell proliferation to Con 
A are at least partly mediated by CNS MORs. 
 
Wistar rats received 40 g of intrathecal morphine which caused an elevation of serum 
adrenocorticotropic hormone (ACTH) concentration and had a suppressive effect on 
splenic NK cell cytotoxicity (measured by a release of europium from labelled YAC-1 
cells) and Con A induced IL-2 and TNF- production (Zhang et al., 1998). TNF- levels 
were not affected. Naloxone injected into the PAG, after the intrathecal morphine, 
partially antagonised the inhibition of NK cell cytotoxicity and the elevation of ACTH 
concentrations. However, it did not affect the Con A induced IL-2 production or splenic 
TNF- activity, indicating that morphine can affect aspects of immune function by a 
spinal mechanism which is partly mediated via the PAG. Naloxone alone decreased 
ACTH levels which indicates that endogenous opioid peptides regulate ACTH secretion 
(Zhang et al., 1998). 
 
Lysle and colleagues investigated the immune effects of morphine and N-
methylnaltrexone injected into distinct positions in male Wistar rats brains (Lysle et al., 
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1996). Single injections of morphine into the lateral ventricle of the rat caused a dose-
dependent decrease in splenic T and B cell proliferation (to Con A, PHA and LPS), 
splenic NK cell cytotoxicity (using a 51Cr release assay and YAC-1 target cells), IL-2 
and IFN- production. Injection of morphine into the caudal PAG inhibited NK cell 
cytotoxicity, but not lymphocyte or cytokine function. N-methylnaltrexone injection into 
the PAG antagonised the inhibitory effect of morphine on NK cell cytotoxicity (Lysle et 
al., 1996). This indicates that opioid receptor activation in the caudal region of the PAG 
is involved in the effect of morphine on splenic NK cell cytotoxicity, and other brain 
regions regulate the effect of morphine on lymphocyte proliferation and cytokine 
production. 
 
Fecho and colleagues investigated the effect of acute morphine (15 mg/kg injected 
subcutaneously) on the SNS and the HPA axis, in male Lewis rats (Fecho et al., 1996). 
Chlorisondamine (a SNS ganglionic blocker) and adrenalectomised rats were used to 
assess these responses. The adrenalectomised rats were given exogenous 
corticosterone and killed 1 hr after the morphine injection. Splenic and whole blood 
lymphocytes were activated with mitogens and proliferation measured using 3H-
thymidine assays. IFN- was measured using an ELISA. Splenic NK cell cytotoxicity 
was measured against 51Cr-labelled YAC-1 cells. Morphine inhibited splenic 
lymphocyte proliferation to Con A, LPS and ionomycin with phorbol 12-myristate 13-
acetate (PMA; an activator of PKC), which was blocked by both chlorisondamine and 
adrenalectomy. Morphine also inhibited splenic lymphocyte proliferation to PHA and 
IFN- production, which was blocked by chlorisondamine, but not adrenalectomy. 
Morphine inhibited Con A and PHA induced blood lymphocyte proliferation, which was 
blocked by adrenalectomy, but not chlorisondamine and splenic NK cell cytotoxicity, 
which was not affected by chlorisondamine or adrenalectomy (Fecho et al., 1996).  
 
Overall, these results imply that both sympathetic and adrenal activity are involved in 
mediating the inhibitory effects of morphine on the proliferative response of splenic 
lymphocytes to Con A, LPS and ionomycin with PMA. The inhibitory effect of morphine 
on splenic lymphocyte proliferation to PHA and IFN- production is mediated by the 
SNS (rather than the HPA axis). The capacity of morphine to inhibit proliferative 
responses of peripheral T cells to Con A or PHA involves HPA activity (rather than 
SNS). However, neither sympathetic nor HPA activity seems to mediate morphine's 
inhibition on splenic NK cell cytotoxicity, suggesting that this might be a direct, rather 
than a centrally mediated, effect of morphine (Fecho et al., 1996). 
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In a series of experiments, Saurer and colleagues investigated the central effects of 
morphine on splenic NK cells in male Lewis rats. They showed that acute morphine (15 
mg/kg subcutaneous) modulates splenic NK cell cytotoxicity (against 51Cr-labelled 
YAC-1 cells) via central D1 dopamine receptors in the nucleus accumbens shell, as 
microinjection of SCH-23390 (a D1 receptor antagonist) into this area, antagonised the 
effect of morphine on NK cells. Furthermore, NK cell cytotoxicity was reduced when 
SKF-38393 (a D1 receptor agonist) was microinjected (Saurer et al., 2006a). They then 
showed that this effect of SKF-38393 was reversed by the selective neuropeptide Y 
(NPY) Y1 receptor antagonist, BIBP3226. BIBP3226 also blocked the inhibition of 
morphine on splenic NK cells (Saurer et al., 2006b). NPY is released upon sympathetic 
activation and produces direct and dose-dependent inhibitory effects on NK activity in 
vitro (Nair et al., 1993). Splenic lymphocytes in rats have been shown to express NPY 
Y1 receptors (Bedoui et al., 2002). 
 
There are two principal pathways which mediate the central immunosuppressive 
effects of morphine. First, acute administration enhances opioid activity in the PAG 
which in turn activates the SNS. The SNS innervates lymphoid organs, such as the 
spleen, and this activation of the SNS induces the release of immunosuppressive 
biological amines which suppress NK cell cytotoxicity (Irwin et al., 1988). Second, 
prolonged use of opioids increases activity in the HPA axis and leads to the production 
of immunosuppressive glucocorticoids. This, in turn, decreases NK cell cytotoxicity 
(Mellon and Bayer, 1998).  
 
There may however be a 3rd central pathway (or at least an additional arm to the SNS 
pathway) by which morphine may reduce splenic NK cell cytotoxicity. By activating D1 
receptors in the nucleus accumbens shell, morphine increases the release of NPY from 
SNS, which acts on peripheral NPY Y1 receptors on NK cells, inhibiting their activity 
(Saurer et al., 2006a, Saurer et al., 2006b). 
 
1.10.2.1 Sympathetic nervous system  
Lymphoid tissues including the spleen, thymus, bone marrow, lymph nodes (and the 
lymphocytes they contain) and the adrenal medulla, are innervated by noradrenergic 
and peptidergic neurons of the SNS which can modulate their function (Felten et al., 
1985). It has also been shown in healthy humans that the catecholamine adrenaline 
transiently reduced the responses of mononuclear cells to Con A and PHA (Crary et 
al., 1983).  
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The -adrenergic receptor may be involved in the immunomodulatory effects of opioids. 
In rats, morphine, -endorphin and DAMGO increase catecholamine release from the 
adrenal medulla and peripheral sympathetic nerves. This is due to MOR activation in 
specific brain areas, including the hypothalamic paraventricular nucleus and brainstem 
nucleus of the solitary tract (Appel et al., 1986, Van Loon et al., 1981). Radioligand 
binding studies have demonstrated the presence of -adrenergic receptors on human 
peripheral blood lymphocytes (Borst et al., 1990, Khan et al., 1986, Williams et al., 
1976) providing a physiological basis for this hypothesis. 
 
Fecho and colleagues used male Lewis rats to investigate the role of -adrenergic 
receptors in the immunoregulatory properties of morphine (Fecho et al., 1993). Nadolol 
(an unselective -adrenoreceptor antagonist), atenolol (a 1-selective antagonist) and 
ICI-118,551 (a 2-selective antagonist) were administered prior to subcutaneous 
morphine (15 mg/kg). The proliferation of splenic leukocytes in response to Con A, 
PHA, LPS, and ionomycin with PMA were measured. Splenic NK cell cytotoxicity was 
evaluated with a 51Cr release assay using YAC-1 target cells. The -adrenoreceptor 
antagonists did not affect blood leukocyte proliferation (in response to Con A and 
PHA), splenic NK cell cytotoxicity, or total spleen and blood leukocyte counts. All of the 
-adrenoreceptor antagonists completely blocked the suppressive effects of morphine 
on the proliferative response of lymphocytes to Con A, PHA, LPS and ionomycin with 
PMA. This suggests that -adrenergic receptors are involved in the suppressive effects 
of morphine on splenic T and B lymphocytes. The authors postulated that in order to 
have these effects morphine has a central action on the SNS innervating the spleen via 
-adrenoreceptors (Fecho et al., 1993). 
 
1.10.2.2 Hypothalamic-pituitary-adrenal axis 
The paraventricular nucleus of the hypothalamus, the anterior lobe of the pituitary 
gland and the cortices of the adrenal glands, and the feedback interactions between 
them constitute the HPA axis. This is an important part of the neuroendocrine system 
and is activated by stress. Morphine also activates this pathway by increasing 
hypothalamic corticotrophin-releasing factor levels, causing the secretion of ACTH from 
the anterior pituitary, stimulating the release of adrenal corticosteroids (Nikolarakis et 
al., 1989). Corticosteroids have an inhibitory effect on immune function (Cox et al., 
1982). As described previously, Hernandez and colleagues have shown that both 
intracerebroventricular and subcutaneous morphine in the rat increased corticosterone 
and suppressed Con A stimulated lymphocyte proliferation (Hernandez et al., 1993).  
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Borman and colleagues assessed the effect of morphine on plasma cortisol 
concentration and NK cell cytotoxicity in pigs (Borman et al., 2009). Pietrain crossbreed 
male pigs were injected with morphine (0.5, 1 or 5 mg/kg) or saline. The effect of pre-
treatment with 1 mg/kg naloxone was also evaluated. Samples were taken before 
morphine administration and 15, 60,120,180 and 240 min after morphine. PBMCs were 
isolated to assess NK cell cytotoxicity against YAC-1 target cells, which was measured 
using a 51Cr-release assay. The percentage and total number of NK cells were counted 
using microscopy. Plasma cortisol concentration was measured using a 
radioimmunoassay. Morphine (0.5 mg/kg) induced a stimulation of NK cell cytotoxicity 
for at least 4 hr, whereas 1 mg/kg induced an initial stimulation of NK cell cytotoxicity 
(within 1 hr), with subsequent suppression. 5 mg/kg of morphine suppressed NK cell 
cytotoxicity at 3 hr without any initial stimulation. These effects were all naloxone 
sensitive. NK cell numbers decreased with 1 and 5 mg/kg of morphine from 2 hr 
onwards, with no effect of naloxone pre-treatment. All doses of morphine increased 
plasma cortisol levels at all time-points, with no effect of naloxone pre-treatment. 
However, naloxone alone also increased plasma cortisol concentration (Borman et al., 
2009).  
 
This study indicates that morphine increases plasma cortisol levels, but that there is a 
discrepancy in its effect on NK cell cytotoxicity. It is likely that cortisol is just one of 
several factors involved in mediating the effect of morphine and that cortisol’s 
suppressive effects may be more important in chronic opioid administration, especially 
at higher doses of morphine.  
 
1.10.3 Summary  
As well as potentially having direct effects on immune cells, depending on their 
activation status, opioids may also have indirect effects on the immune system by two 
main nervous system pathways. In acute administration, opioids may activate the SNS, 
which not only directly innervates primary and secondary lymphoid organs but can also 
activate the release of immunosuppressive catecholamines. There might be a separate 
central effector mechanism via the release on NPY. During chronic opioid 
administration, activation of the HPA axis, mediated through immunosuppressive 
glucocorticoids, may be more important in the effect of opioids on immune function 
(Figure 1-17). 
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Figure 1-17: Peripheral and central mechanisms of opioid-induced immune suppression.  
Opioids can act directly on immune cells if they are expressing opioid receptors (especially  opioid 
receptors; MOR), some opioids might also activate Toll like receptor 4 (TLR4). The centrally-mediated 
route of immune suppression depends on the duration of administration of the opioid. If opioids are 
administered acutely the potential immune effects are thought to be mediated via the peri-aqueductal grey 
(PAG) and sympathetic nervous system (SNS). Some opioids might also inhibit NK cells by an action on 
the nucleus accumbens shell (NAS) and release of neuropeptide Y (NPY) acting via Y1 receptors (Y1R). 
During chronic administration the effect is via the hypothalamic-pituitary-adrenal axis (HPA axis) releasing 
suppressive glucocorticoids. 
 
 
1.11 Kinetics of opioid effects on immune function 
The previous section outlined the studies which focused on the mechanism of the 
effect of opioids on immunity; this section includes those studies which primarily focus 
on the time course of opioid action. Studies not included in these sections are 
presented in section 1.12, where the literature on the effects of opioids on the different 
types of immune cells is discussed, this includes the majority of the in vivo studies.  
 
The pharmacological, cellular and potential clinical effects of opioids and the time 
course for these have been studied. These studies assessed the rate of onset and 
offset of immune effects. Other studies have elucidated the effect of immune tolerance 
to opioids and also the effects of opioid withdrawal. 
 
Bryant and colleagues investigated the time course of chronic treatment by 
subcutaneously implanting a 75 mg morphine pellet into male C3H/HeN mice (Bryant 
et al., 1988). Splenic and thymic weight and cellularity, as well as mitogen simulated 
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(1.0 g/ml Con A or 0.5 g/ml LPS) in vitro lymphocyte proliferation (using a 3H-
thymidine uptake assay) were assessed 6, 12, 24, 48, 72, 96 or 120 hr after morphine 
pellet implantation and compared to placebo-treated mice. T cell proliferation to Con A 
was reduced at 48 and 72 hr only. B cell proliferation to LPS was reduced at 24, 48 and 
72 hr. Both responses had normalised by 96 hr. Splenic and thymic atrophy also 
occurred in morphine-treated mice which peaked at 48 to 72 hr (Bryant et al., 1988). 
 
To assess tolerance to the immunological effects of morphine, Lewis rats consumed a 
drinking solution containing morphine (0.2, 0.4, or 0.6 mg/ml) or water without 
morphine for 20 days (West et al., 1997). They were then administered a subcutaneous 
injection of morphine (15 mg/kg) or saline and killed 1 hr later. Splenic lymphocytes 
were stimulated with Con A, PHA and LPS (all at 0.5, and 5.0 mg/ml) and proliferation 
measured using a 3H-thymidine uptake assay. Splenocyte IFN- production to Con A 
was determined using an ELISA. NK cell cytotoxicity was evaluated against 51Cr-
labelled YAC-1 target cells after a 5-hr incubation. In the rats that were exposed to no 
morphine or 0.2 mg/ml of morphine, the injection of morphine suppressed splenic NK 
cell cytotoxicity, mitogen-stimulated splenic T and B cell proliferation and IFN- 
production. In the rats that consumed the two highest concentrations of morphine, the 
injection of morphine did not suppress NK cell cytotoxicity, but did suppress the 
mitogen-stimulated splenic T and B cell proliferation and IFN- production (West et al., 
1997). These findings suggested that tolerance to the suppressive effect of morphine 
on NK cell activity, but not to mitogen-stimulated splenic T and B cell proliferation and 
IFN- production, occurs within 20 days.  
 
The differential effect on immunity may be due to different pathways regulating the 
effect of morphine on the different immune cells. Whereas the SNS might be important 
for the effect of morphine on splenic immune cells, the effect of morphine on immune 
cells in the blood may occur via activation of the HPA axis (Fecho et al., 1996). The 
effect of morphine on splenic NK cells may be mediated by a separate pathway 
involving the opioid receptors in the caudal region of the PAG (Lysle et al., 1996, 
Weber and Pert, 1989), and not involve the sympathoadrenal pathways or the HPA 
axis (Fecho et al., 1993, Fecho et al., 1996). 
 
Bhaskaran and colleagues assessed the effect of low-dose morphine on inducing 
tolerance to the immune modulating effects of larger morphine doses (Bhaskaran et al., 
2007). For these experiments, male FVB/N mice were administered high‐dose 
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morphine (40 mg/kg) every 12 hr for 10 days, with or without morphine priming (1 
mg/kg) 3 hr before the high‐dose morphine. Peritoneal macrophages were elicited 
using intraperitoneal thioglycollate on day 8 and removed 2 days later, when the mice 
were killed. Bone marrow was also removed at this point. The macrophages were 
incubated with opsonised E.coli for 1 hr at 37°C and, in order to assess the ability of 
macrophages to contain the phagocytosed bacteria, supernatants from control and 
morphine-treated cells were put onto agar plates to determine survival and bacterial 
colonies after incubation for 24 hr. High‐dose morphine decreased the ability of 
macrophages to contain and kill bacteria and promoted apoptosis of macrophages. 
Morphine priming stopped all these effects of high‐dose morphine. High-dose morphine 
enhanced macrophage P38 MAPK phosphorylation, which was attenuated by 
morphine priming. SB202190 (P38 MAPK phosphorylation inhibitor) attenuated high‐
dose morphine mediated macrophage apoptosis (Bhaskaran et al., 2007). This study 
suggests that morphine priming induces tolerance to the immune effects of high-dose 
morphine, via modulation of a P38 MAPK mechanism. 
 
The effect of in vitro morphine and methadone on human macrophages previously 
exposed to methadone in vivo was assessed (Delgado-Velez et al., 2008). Blood was 
collected from previous intravenous heroin users who were on methadone (between 80 
– 120 mg/day) for at least one year, and a healthy control population. Human 
monocyte-derived macrophages (hMDMs) were produced from both these groups. The 
monocytes from the methadone group were cultured with 400 ng/ml of methadone. The 
effect of 30 min and 24 hr exposure to 10−13 – 10−5 M of morphine (equivalent to 10−5 – 
2853 ng/ml) and 10−12 – 10−6 M of methadone (equivalent to 10−4 – 309 ng/ml) on 
hMDMs from the control group was assessed. The effect of methadone withdrawal was 
tested by culturing hMDMs from the methadone patients in opioid-free media. 
Phagocytosis was measured by counting the number of macrophages which had 
internalised one or more opsonised SRBC. Acute exposure of hMDMs to morphine 
dose-dependently inhibited their phagocytic activity. Methadone exposure resulted in a 
U-shaped dose-response curve, with maximal inhibition occurring at 10−9 M of 
methadone (≈ 0.3 ng/ml). Exposure to morphine or methadone for 24 hr resulted in 
normalisation of phagocytosis, suggesting that tolerance to these opioids had 
developed. Phagocytosis was suppressed again when these opioids were withdrawn 
from chronically-exposed and opioid tolerant hMDMs (Delgado-Velez et al., 2008).  
 
Pacifici and colleagues examined the time course of the immunomodulatory effects of 
in vivo morphine and methadone in male C57BL6 mice (Pacifici et al., 1994). Single 
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dose subcutaneous morphine (20 mg/kg) and methadone (12.5 mg/kg) were 
administered and blood was collected at 20, 40, and 80 min as well as 2 and 24 hr after 
drug treatment. Elicited peritoneal neutrophils and macrophages were collected. 
Neutrophil phagocytosis and killing was assessed radiochemically using 3H-uridine 
labelled Candida albicans. Splenic leukocytes were used as effector cells in the NK cell 
cytotoxicity assay, which was measured by a 4-hr incubation with 51Cr-labeled YAC-1 
target cells. Morphine stimulated neutrophil phagocytosis and increased Candida killing 
at 20 and 40 min; both parameters returned to baseline at 2 hr, and were reduced at 24 
hr. Neutrophil phagocytosis and killing were unaffected by methadone. Neither 
morphine nor methadone affected NK cell cytotoxicity at any time point (Pacifici et al., 
1994). The peak immune activation of morphine correlates to peak plasma levels and 
the reduction in immune function occurred when morphine was no longer detectable, 
potentially representing a withdrawal state. 
 
Martucci and colleagues studied the effects of acute and chronic fentanyl and 
buprenorphine administration on the immune responsiveness of splenocytes in male 
Swiss mice (Martucci et al., 2004). In the acute part of the study, subcutaneous 
fentanyl (0.25 mg/kg) or buprenorphine (5 mg/kg) were administered and the mice 
were killed 1 hr later. Several immune parameters were assessed: a 3H-thymidine 
uptake assay was used to measure Con A-induced splenocyte proliferation (2 day 
incubation), a 51Cr-release assay was used to evaluate the killing of YAC-1 target cells 
by splenic NK cells (4-hr incubation) and ELISAs were used to measure IL-2 and IFN- 
production in the supernatants of the activated splenocytes. The single dose of fentanyl 
rapidly decreased lymphocyte proliferation. Buprenorphine did not affect lymphocyte 
proliferation and neither opioid affected splenic NK cell cytotoxicity, IL-2 or IFN- 
production. In the chronic phase of this study, the effect of fentanyl and buprenorphine 
at 1, 3 and 7 days were determined, by implantation of subcutaneous pumps 
continuously infusing fentanyl (7.5 g/hr), buprenorphine (12.5 g/hr) or saline. After 24 
hr, fentanyl reduced all measured parameters. By 3 days, NK cell cytotoxicity had 
returned to normal, whereas lymphocyte proliferation, IL-2 and IFN- production only 
returned to baseline levels by 7 days. Buprenorphine did not affect any of the 
measured parameters. In this model, tolerance to the fentanyl-induced reduction in NK 
cell cytotoxicity occurred after 3 days, whereas tolerance for all of the other immune 
parameters occurred within 7 days. In an additional arm to this study, mice were 
administered the 7 day infusion, as above, and then received twice the dose of fentanyl 
or buprenorphine for 1 or 3 days, before being killed. Neither fentanyl nor 
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buprenorphine affected any of the measured immune parameters in this experiment, 
suggesting that once immunological tolerance to fentanyl had developed, increasing 
the dose did not overcome it. This indicates that development of tolerance to opioid-
induced immunosuppression may occur, at least in the case of fentanyl, as 
buprenorphine did not affect any of the immune parameters tested in this study 
(Martucci et al., 2004). 
 
The time course of the development of tolerance to the various aspects of immune 
function and the effect of opioid withdrawal is vital for the evaluation of pre-clinical 
studies as well as the potential clinical impact. For example, it may be that immune 
function in heroin (diamorphine) abusers normalises once they commence methadone 
maintenance therapy (Novick et al., 1989, Sacerdote et al., 2008). This might be due to 
the regular dosing and longer half-life of methadone which results in a steady plasma 
concentration. However, the effect of lifestyle changes of people stopping a heroin 
addiction in normalising immune function cannot be underestimated. The studies 
described in the following section, help to elucidate the effects of opioids on key 
immune parameters that are involved in anti-tumour and anti-infective immunity, as well 
as in immune regulation. 
 
 
1.12 Effects of opioids on specific aspects of immune function 
This section summarises the data from previous in vivo studies which have assessed 
the influence of morphine, tramadol, fentanyl, buprenorphine, methadone, oxycodone, 
diamorphine and codeine on NK cell cytotoxicity, phagocytosis and oxidative burst of 
neutrophils and monocytes, T cell function and cytokine production. It is organised 
according immune cell function, rather than cell type (although there is overlap), as this 
division is more important for determining the potential effects of these opioids on 
disease processes. This is also reflected in the organisation of the experiments in the 
current study. 
 
The immunomodulatory effect of morphine on certain aspects of the immune system 
has been extensively studied using many different methodologies. There is much less 
known about the effect of other opioids on the different components of immune 
function. Furthermore, as previously described, many of the potential mechanisms of 
opioid-induced immunomodulation have been elucidated using morphine.  
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1.12.1 Natural killer cell cytotoxicity 
NK cell cytotoxicity is critical in the control of viral infections and in tumour 
immunosurveillance. There has been a range of studies assessing the effect of some 
opioids (and even comparing two opioids) on this parameter in animal and human 
models. 
 
In two similar studies (in terms of NK cell cytotoxicity) by Carpenter and colleagues, 
female C3H/HeN mice were alloimmunised with C57BL/6J mouse splenocytes and 
administered subcutaneous morphine (50 mg/kg) daily. After 11 days the mice were 
killed, splenic lymphocytes removed and NK cell cytotoxicity evaluated using a 4 hr 
assay with 51Cr-labelled YAC-1 cells. Morphine exposure had no effect on splenic NK 
cell cytotoxicity (Carpenter et al., 1995, Carpenter et al., 1994). 
 
Gaspani and colleagues compared the effects of morphine and tramadol on NK cell 
cytotoxicity and tumour progression using a rat surgical model of tumour metastasis 
(Gaspani et al., 2002). For this, Fischer 344 male rats either underwent a sham 
laparotomy operation or were just handled, 5 hr after which MADB106 cells were 
injected into the tail vein. Three subcutaneous injections of morphine (10 mg/kg), 
tramadol (20 or 40 mg/kg) or saline were administered 30 min before surgery or 
handling, immediately after surgery (or 15 min after handling), and 5 hr after 
surgery/handling (at the time of tumour cell injection). 10 mg/kg morphine and 40 
mg/kg tramadol have been shown to be equianalgesic in rats (Bianchi and Panerai, 
1998). Twenty one days after surgery, rats were killed and visible surface lung 
metastases counted. Splenocyte NK cell cytotoxicity was measured against YAC-1 
target cells using a 51Cr release assay. In the non-surgical group, 40 mg/kg tramadol 
increased NK cell cytotoxicity (20 mg/kg of tramadol non-significantly increased NK cell 
cytotoxicity), whereas 10 mg/kg of morphine decreased NK cell cytotoxicity. Surgery 
itself reduced NK cell cytotoxicity and this correlated with increased numbers of lung 
metastases. Morphine did not influence surgery-induced effects, whereas tramadol 
dose-dependently increased NK cell cytotoxicity and reduced metastasis in the surgical 
group (Gaspani et al., 2002).  
 
Overall, the effect of tramadol on NK cell cytotoxicity following surgery might be the 
summation of two independent effects. First, the stimulation of NK activity which is also 
present in non-operated rats, due to serotonin re-uptake inhibition; second, the 
prevention of surgical pain together with the decrease in NK cell cytotoxicity which pain 
itself would cause (Gaspani et al., 2002). It is the (+) enantiomer of tramadol which 
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inhibits serotonin uptake and its immunostimulatory effect is inhibited by metergoline, a 
serotoninergic antagonist (Sacerdote et al., 1999). Increased serotoninergic tone leads 
to stimulation of NK cell cytotoxicity and lymphocyte proliferation (Clancy et al., 1991, 
Mossner and Lesch, 1998). D-fenfluoramine and fluoxetine (serotonin re-uptake 
inhibitors) increase serotonin levels which stimulate NK cell activity and lymphocytes in 
young male and old female rats (Clancy et al., 1991, Sacerdote et al., 1999).  
 
Shavit and colleagues studied the effect of fentanyl on NK cell cytotoxicity and how this 
influenced tumour metastasis in male Fischer 344 rats (Shavit et al., 2004). This study 
consisted of three separate experiments. In the first experiment, the rats were injected 
subcutaneously with 0.1 or 0.3 mg/kg fentanyl or saline; 2 hr or 6 hr before, at the 
same time as, or 1 hr after having radiolabelled MADB106 tumour cells injected into 
their tail vein. Lung tumour retention (LTR) was assessed 4 hr after the injection of the 
tumour cells, by killing the rats and removing their lungs to measure their radioactive 
content. LTR is the ratio of radioactivity measured in the lungs to the radioactivity in the 
injected tumour cell suspension and is a measure of tumour load. This showed that 
there was a significant, dose-dependent, increase in LTR when fentanyl was 
administered 2 hr before, at the same time as or 1 hr after having the tumour cells 
injected. Fentanyl administration 6 hr before tumour inoculation did not affect LTR. In a 
second experiment a single subcutaneous dose of 0.15 mg/kg fentanyl or saline was 
administered 1 hr before MADB106 tumour injection. Three weeks later, the rats were 
killed and the number of visible surface lung metastases was counted. In the rats 
receiving fentanyl there were significantly more metastases. In the third experiment, the 
impact of a single subcutaneous dose of 0.15 mg/kg fentanyl on the cytotoxicity of NK 
cells and on LTR within the same animal was studied. Blood was taken 1 hr after 
fentanyl administration to assess NK cell cytotoxicity (using a whole blood assay, with a 
4-hr incubation with 51Cr-labelled YAC-1 target cells). This was followed by an 
intravenous injection of radiolabelled MADB106 tumour cells. Fentanyl not only 
inhibited NK cell cytotoxicity, but also caused an increase in LTR within the same 
animal (Shavit et al., 2004). This series of experiments shows that fentanyl suppresses 
NK cell cytotoxicity and that this correlates with increased tumour growth and 
metastasis when fentanyl is administered around the time of tumour cell inoculation.  
 
Male albino Wistar rats were administered oral morphine (20 or 40 mg/kg/day) or 
methadone (15 or 30 mg/kg/day) for 6 weeks (Van Der Laan et al., 1996). 
Lymphocytes from the spleen, lungs and peritoneal fluid were isolated. The number of 
NK cells in each organ was determined as was cytotoxicity for an individual NK cell and 
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the total NK activity in each of the organs. NK cell cytotoxicity of the lymphoid cells 
from these organs was measured using a 51Cr labelled YAC-1 as target cells. Morphine 
reduced the number of NK cells in the spleen and overall splenic NK cell cytotoxicity, 
but cytotoxicity per NK cell was unaffected. Peritoneal NK cell cytotoxicity was 
increased by morphine, but there was no change in the number of NK cells in the 
peritoneum. Only high-dose morphine increased the total lung cytotoxicity and there 
was only a trend for increased lung NK cell cytotoxicity and NK cell number. High-dose 
methadone decreased total splenic NK cell cytotoxicity, although it did not affect 
individual cell NK activity, and there was only a trend for decreased cell numbers. 
Peritoneal NK cell number was dose-dependently reduced by methadone, as was total 
NK cell cytotoxicity. In the lungs, methadone reduced cell numbers, individual cell and 
total organ NK cell cytotoxicity (Van Der Laan et al., 1996). Chronic morphine and 
methadone reduced splenic NK cell cytotoxicity. Morphine stimulated peritoneal and 
pulmonary NK cell cytotoxicity, whereas methadone was inhibitory.  
 
Yeager and colleagues investigated the in vivo effects of different dosing regimens of 
morphine on NK cell cytotoxicity in 16 healthy volunteers (Yeager et al., 1995). The 
volunteers took 30 mg of oral slow release morphine the night before intravenous 
morphine, in low dose (0.025 mg/kg loading dose followed by 0.015 mg/kg/h for 24 hr) 
and high dose (0.05 mg/kg loading dose followed by 0.03 mg/kg/h for 24 hr) arms of 
the study. Two out of seven volunteers in the low dose and three out of nine volunteers 
in the high dose arms needed a 50% dose reduction due to side effects. Peripheral 
blood was taken five times: 1 week before the morphine, during the morphine infusion 
(at 2 and 24 hr), and 1 and 7 days after the morphine administration. Both spontaneous 
NK cell cytotoxicity and IFN- stimulated NK cell cytotoxicity in PBMC preparations 
were assessed against 51Cr-labelled K562 target cells (4-hr incubation). Suppression of 
NK cell cytotoxicity occurred at 2 hr and 24 hr after the onset of morphine 
administration in both groups. The reduction of NK cell cytotoxicity recovered within 24 
hr in the low dose group, but remained at 24 hr after the infusion was stopped in the 
high dose group (Yeager et al., 1995).  
 
Yeager and colleagues also evaluated the in vivo effects of short-term intravenous 
fentanyl (3 g/kg bolus followed by 1.2 g/kg/hr infusion over 2 hr) on multiple immune 
parameters in seven healthy human volunteers (Yeager et al., 2002). NK cell 
cytotoxicity was assessed before fentanyl administration, at the end of the infusion, and 
at 1 and 24 hr after completion of the infusion. PBMCs were isolated by density 
gradient centrifugation and NK cell cytotoxicity was evaluated using these PBMCs as 
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effector cells against 51Cr-labelled K562 target cells. Fentanyl increased NK cell 
cytotoxicity at the end of the infusion, which returned to baseline within 1 hr. The 
increased NK cell cytotoxicity was due to an increase in the proportion of CD16+ cells 
in peripheral blood (possibly due to recruitment of NK cells into the circulation), rather 
than the activity of the individual NK cells (Yeager et al., 2002).  
 
Rapid transient increases in NK cell numbers and cytotoxicity have been described in 
healthy volunteers after a subcutaneous injection of adrenaline and noradrenaline due 
to a  adrenergic-mediated recruitment of NK cells (Schedlowski et al., 1996). NK cells 
are rapidly recruited from lymphoid organs such as the spleen and released from 
endothelia of the blood vessels (the marginal pool), which is dependent on 2 
adrenoceptors being expressed on NK cells (Benschop et al., 1997). Fentanyl does not 
affect peripheral catecholamine concentrations (Tandonnet et al., 1991), although 
stress has been shown to increase catecholamine-induced leukocytosis (Benschop et 
al., 1996). It might be that in this study (Yeager et al., 2002) that NK cells were 
released from the marginal pool, increasing total NK cell cytotoxicity and that this might 
not be directly related to the fentanyl, but the stress from the procedure. 
 
Jacobs and colleagues assessed the in vivo effects of an intravenous bolus of 0.2 
g/kg fentanyl on cellular immune function in seven healthy male volunteers (Jacobs et 
al., 1999). Blood was taken before, and 15 and 30 min after the fentanyl. PBMCs were 
isolated by density gradient centrifugation and were either used as the effector cells in 
the NK cell cytotoxicity experiment (evaluated using a 4-hr incubation with 51Cr labelled 
K562 target cells) or stained with anti-CD16 and anti-CD56 mAb for flow cytometric 
assessment of NK cell numbers. Fentanyl did not influence individual NK cell 
cytotoxicity, but increased the number of circulating NK cells (CD16+ and CD56+), by 
more than 250% within 15 min and this was maintained at 30 min (Jacobs et al., 1999).  
 
NK cell numbers and cytotoxicity were evaluated in male current heroin (diamorphine) 
abusers, long-term (>10 yr) methadone maintained previous heroin abusers and 
healthy individuals (Novick et al., 1989). NK cell cytotoxicity was measured using 51Cr 
labelled K562 as target cells and PBMCs (isolated by density gradient centrifugation) 
as effector cells. Heroin abusers exhibited a reduced NK cell cytotoxicity compared 
with methadone subjects and controls (which were similar), but NK cell numbers in all 
three groups were similar (Novick et al., 1989). The current heroin abusers were 
undergoing inpatient detoxification, which may have induced opioid withdrawal effects 
on the NK cells, rather than the diamorphine directly affecting the cells.  
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A clinical study of 30 patients undergoing surgery for uterine carcinoma compared the 
influence of morphine and tramadol on NK cell function in the post-operative period 
(Sacerdote et al., 2000). All patients were administered fentanyl as well as anaesthetic 
medications (thiopental, succinylcholine, isoflurane, nitrous oxide and pancuronium), 
and an intramuscular injection of 10 mg morphine or 100 mg tramadol immediately 
after surgery. Peripheral blood was taken both before opioid administration and 2 hr 
after. NK cell cytotoxicity, using isolated PBMCs, against 51Cr-labeled K562 target cells 
(4-hr incubation) was assessed before the operation, immediately after surgery and 2 
hr post-operatively. NK cell cytotoxicity was not affected by the surgery or by morphine 
(trend for inhibition only); however, patients receiving tramadol exhibited an increased 
NK cell cytotoxicity at 2 hr. The analgesic effects were similar at this time point 
(Sacerdote et al., 2000). 
 
Beilin and colleagues investigated the effects of two doses of fentanyl on NK cell 
cytotoxicity in a randomised trial of 40 patients undergoing surgery for malignant or 
benign conditions (Beilin et al., 1996). For the high-dose fentanyl group, a single dose 
of 75-100 pg/kg intravenous fentanyl was used at the beginning of surgery, and for the 
low dose group 1 pg/kg intravenous fentanyl was administered with the option of a 
further 5 pg/kg of fentanyl being used during the surgery. The other anaesthetic 
medications also differed between groups. The high-dose fentanyl group received 
pancuronium at the beginning of surgery, with or without isoflurane during the surgery. 
The low dose fentanyl group received thiopental, succinylcholine and N2O in addition to 
isoflurane and pancuronium. At the end of surgery, neostigmine and atropine were 
administered to both groups. Peripheral venous blood was collected at the time of 
induction for baseline values, 60 min after surgery had commenced, then at 24 and 48 
hr post-operatively. PBMCs were isolated using gradient centrifugation and were frozen 
at -70°C until they were used as the effector cells for the NK cell cytotoxicity assay. NK 
cell cytotoxicity was measured using 51Cr labelled K562 target cells (4-hr incubation). 
The effect of a 24 hr stimulation with IL-2 or IFN-/ of the patients PBMCs on NK cell 
cytotoxicity was also studied in vitro. Initially, both concentrations of fentanyl induced a 
similar reduction in NK cell cytotoxicity, with a peak effect at 24 hr post-operatively. 
However, by 48 hr after surgery, NK cell cytotoxicity had returned to baseline levels in 
patients receiving low-dose fentanyl, whereas NK cell cytotoxicity was still significantly 
reduced after the higher dose of fentanyl. No differences were found between patients 
having surgery for malignant or benign conditions. The suppressive effect of fentanyl at 
24 hr was reversed in the IL-2 or IFN-/ stimulation experiments. These results 
indicate that despite different anaesthetic drugs being used, the high dose of fentanyl 
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caused a more prolonged reduction of NK cell cytotoxicity. The long-term impact or 
overall outcome of different doses of fentanyl were not determined (Beilin et al., 1996). 
 
In summary, the in vivo effects of morphine tramadol, fentanyl, buprenorphine, 
methadone and diamorphine on NK cell function have been assessed in variable 
models, including animal, healthy human and patient studies (from the sections 1.9 - 
1.12.1). There are discrepancies in the results of these studies which might, in part at 
least, be explained by the differing methodologies, species used, dose and duration of 
opioid administration. However, in general the literature reports that morphine, fentanyl, 
methadone and diamorphine (heroin) decrease NK cell cytotoxicity in vivo (although 
short-term in vivo exposure to fentanyl in humans increases NK cell numbers and 
cytotoxicity), buprenorphine does not affect NK cell cytotoxicity and tramadol enhances 
it. This change in NK cell cytotoxicity correlates with tumour growth and metastasis in 
rodent models (Gaspani et al., 2002, Shavit et al., 2004). 
 
1.12.2 Phagocytosis 
Phagocytosis is the process by which particles are engulfed and is one of the ways 
which neutrophils and monocytes control bacterial and fungal infection as well as 
remove foreign material. Several studies have assessed the effect of some opioids 
(and even compared two opioids) on phagocytosis in animal and human models. 
 
Shirzad and colleagues evaluated the in vivo effects of tramadol and morphine on the 
phagocytic activity of murine peritoneal phagocytes in BALB/c mice (Shirzad et al., 
2009). The mice were divided into three groups: the first were given twice daily 
intraperitoneal morphine: 20 mg/kg on day 1, 40 mg/kg on day 2, 60 mg/kg on day 3 
and 80 mg/kg for the following seven days. The second group was treated with 
tramadol using the same dose regimen as for morphine. The third group was given 
saline. Although tramadol is reported to have 20% the potency of morphine, in a pilot 
study, mice treated with tramadol at equianalgesic doses to those of morphine 
experienced seizures and lower doses of tramadol were therefore used. On days 3, 5 
and 10 the mice were killed, peritoneal fluid collected and the cells isolated and 
incubated with opsonised SRBCs. The number of phagocytes and the number of 
SRBCs engulfed by each individual peritoneal phagocyte (phagocytic index) were 
counted using a microscope. There was no difference between the three groups at 
days 3 and 5, but at day 10 tramadol increased the number of peritoneal phagocytes 
as well as the phagocytic index, whereas morphine decreased the number of peritoneal 
phagocytes as well as the phagocytic index compared with saline. The number of 
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phagocytic cells in the peritoneal cavity increased in all three groups over the 10 days, 
which may have been due to the repeated intraperitoneal injections. This study 
indicates that the chronic administration of tramadol stimulates peritoneal 
phagocytosis, whereas morphine suppresses phagocytosis in murine peritoneal 
macrophages. However, their acute administration is less likely to be significant 
(Shirzad et al., 2009). 
 
Tubaro and colleagues assessed the in vivo effect of morphine and methadone on 
murine neutrophils and macrophages, and rabbit alveolar macrophages (Tubaro et al., 
1987). Male CD1 mice and male New Zealand rabbits were administered twice daily 
morphine at 10 mg/kg on day 1, 20 mg/kg on day 2, 30 mg/kg on day 3, 40 mg/kg on 
day 4; or methadone at 2.5 mg/kg on day 1, 5 mg/kg on day 2, 7.5 mg/kg on day 3, 10 
mg/kg on days 4 to 6 days. Peritoneal exudates (containing neutrophils and 
macrophages) were elicited and obtained from the mice. Alveolar macrophages were 
obtained from the rabbit. Phagocytosis of Candida albicans was measured 
radiochemically by the uptake of 3H-uridine. Morphine, but not methadone inhibited 
murine neutrophil and macrophage phagocytosis, both after a single dose and at 3 
days. By 6 days, methadone had also begun to inhibit neutrophil phagocytosis, but not 
to the same extent as morphine. In rabbit alveolar macrophages, morphine reduced 
phagocytosis more than methadone (Tubaro et al., 1987). 
 
The in vivo effect of morphine on neutrophil phagocytosis and killing was evaluated in 
16 male rhesus monkeys (Liu et al., 1992). All animals were initially given 
intramuscular injections of saline, with nine monkeys subsequently being administered 
morphine. The 8-hourly morphine dose for the 1st week was 1 mg/kg, followed by 3 
mg/kg for the 2nd week and 5 mg/kg for the 3rd and 4th weeks. Blood was taken 2 hr 
after the first daily injection, neutrophils were isolated and their ability to phagocytose 
Candida albicans blastospores over a 45-min incubation was assessed using 
fluorescent microscopy. Phagocytosis was not affected by morphine (Liu et al., 1992).  
 
Yeager and colleagues assessed the in vivo effects of short-term intravenous fentanyl 
(3 g/kg bolus followed by 1.2 g/kg/hr infusion over 2 hr) in seven healthy human 
volunteers (Yeager et al., 2002). Neutrophils were isolated from whole blood and their 
phagocytosis was assessed before fentanyl, at the end of the infusion, and 1 and 24 hr 
after completion of the infusion. The proportion of neutrophils phagocytosing Candida 
in 15 min was microscopically counted. Fentanyl did not affect neutrophil phagocytosis 
(Yeager et al., 2002).  
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Tubaro and colleagues studied neutrophil and monocyte activity in intravenous drug 
users on regular prescribed morphine (approximately 170 mg/day) or methadone 
(approximately 39 mg/day) treatment (Tubaro et al., 1985). Although not a “clean” 
study owing to non-compliance in the methadone group (as detected by drug 
screening), this likely reflects the clinical reality. Neutrophils and monocytes were 
isolated from peripheral blood using density centrifugation. Opsonised Candida 
albicans was used to assess phagocytosis, by microscopically counting the number of 
fungi phagocytosed. Intravenous drug users maintained on morphine exhibited a 
reduction in both neutrophil and monocyte phagocytic activity relative to controls. In 
contrast, phagocytosis was unaffected in those maintained on methadone (Tubaro et 
al., 1985).  
 
In summary, the in vivo effect of opioids on phagocytosis has not been extensively 
studied. From the few previous in vivo studies, it seems that morphine suppresses 
phagocytosis more than methadone, that fentanyl might be immune-neutral in terms of 
phagocytosis and that tramadol might enhance phagocytosis. However, in view of 
differing methodological approaches, leading to sometimes conflicting results, 
comparative conclusions about the effect of opioids on phagocytosis cannot be made.  
 
1.12.3 Oxidative burst reaction 
After foreign materials, including bacteria and fungi, are phagocytosed into an 
intracellular phagosome, they are degraded or killed, in part by the oxidative burst 
reaction. This reaction involves the rapid release of reactive oxygen species (O2
− and 
H2O2) and is critical in the control of bacterial and fungal infections. Limited studies 
have assessed the effect of morphine, fentanyl and methadone (and even compared 
morphine and methadone) on the oxidative burst reaction in animal and human 
models. 
 
Tubaro and colleagues investigated the in vivo effects of morphine and methadone on 
murine neutrophils and macrophages, and rabbit alveolar macrophages (Tubaro et al., 
1987). Male CD1 mice and male New Zealand rabbits were administered twice daily 
morphine at 10 mg/kg on day 1, 20 mg/kg on day 2, 30 mg/kg on day 3, 40 mg/kg on 
day 4; or methadone at 2.5 mg/kg on day 1, 5 mg/kg on day 2, 7.5 mg/kg on day 3, 10 
mg/kg on day 4 to 6 days. Neutrophil- and macrophage-rich peritoneal exudate cells 
were elicited and removed from the mice. Alveolar macrophages were obtained from 
the rabbit. O2
-
 production was evaluated in Con A and Cytochalasin E stimulated 
neutrophils and PMA stimulated macrophages using a superoxide dismutase 
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inhibitable reduction of ferricytochrome c. Morphine inhibited the oxidative burst 
reaction of murine neutrophils and macrophages, and rabbit macrophages. Although 
methadone also inhibited the oxidative burst reaction in murine neutrophils and rabbit 
macrophages, this was less pronounced than morphine; methadone had no effect on 
murine macrophages (Tubaro et al., 1987). 
 
Liu and colleagues evaluated the effect of morphine on neutrophil killing in 16 male 
rhesus monkeys (Liu et al., 1992). All animals were initially given intramuscular 
injections of saline, with nine animals subsequently being administered morphine. The 
8-hourly morphine dose for the 1st week was 1 mg/kg, followed by 3 mg/kg for the 2nd 
week and 5 mg/kg for the 3rd and 4th weeks. Blood was taken 2 hr after the first daily 
injection, neutrophils were isolated and their ability to kill Candida albicans 
blastospores over a 45-min incubation was assessed using fluorescent microscopy. 
Morphine caused a transient reduction (between 3 and 5 weeks) in the ability of 
neutrophils to kill blastospores, which returned to baseline after this time (Liu et al., 
1992).  
 
Jacobs and colleagues assessed the in vivo effects of an intravenous bolus of 0.2 
g/kg fentanyl on cellular immune function in seven healthy male volunteers (Jacobs et 
al., 1999). Blood was taken before, and 15 and 30 min after the fentanyl. Neutrophils 
were isolated by sedimentation, and activated by a 20-min incubation with PMA, E.coli 
or a combination of TNF and N-Formyl-Methionyl-Leucyl-Phenylalanine (fMLP; a 
synthetic, chemotactic peptide which mimics the activity of bacterially-derived 
peptides). Flow cytometry was used to assess oxidative burst activity, as measured by 
the oxidation of dihydrorhodamine to fluorescent rhodamine. Fentanyl had no effect on 
the oxidative burst reaction of neutrophils (Jacobs et al., 1999).  
 
Tubaro and colleagues evaluated neutrophil and monocyte activity in intravenous drug 
users taking regularly prescribed morphine (170 mg/day) or methadone (39 mg/day) 
(Tubaro et al., 1985). In the methadone group, drug screening revealed that other 
opioids were also taken, reflecting the clinical reality. Neutrophils and monocytes were 
isolated from peripheral blood using density centrifugation. O2
-
 production was 
evaluated both in PMA stimulated neutrophils and monocytes using a superoxide 
dismutase inhibitable reduction of ferricytochrome c. Candida albicans viability was 
assessed by using methylene blue staining. Intravenous drug users taking morphine 
had a reduction in the ability of neutrophils and monocytes to kill Candida albicans. 
Methadone reduced the killing ability of neutrophils, to a lesser degree than morphine, 
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but increased the killing by monocytes. The authors speculate this latter effect may be 
due to other unspecified substances taken by this group. Superoxide anion production 
was decreased only in neutrophils by morphine and to a lesser extent by methadone 
(Tubaro et al., 1985). 
 
In summary, the in vivo effect of opioids on the oxidative burst reaction has not been 
extensively studied. From the limited data available it might be that morphine and 
methadone suppress the ability of neutrophils and monocytes/macrophages to perform 
the oxidative burst reaction and that fentanyl might not affect this response. 
 
1.12.4 T cell function 
The T cell population comprises both CD4+ T helper cells and CD8+ cytotoxic T cells, 
which help to coordinate the immune response and provide the adaptive arm of 
immune cytotoxicity, respectively. Several studies have assessed the effect of certain 
opioids on these adaptive immune cells in various in vivo conditions which are 
described below. 
 
In two similar studies (in terms of cytotoxic T cell activity) by Carpenter and colleagues, 
female C3H/HeN mice were alloimmunised with C57BL/6J mouse splenocytes and 
treated with subcutaneous morphine (50 mg/kg) daily. A subgroup of mice also 
received the MOR alkylating agent -funaltrexamine. After 11 days the mice were killed 
and splenic lymphocytes and peritoneal leukocytes were removed. CD8+ cytotoxic T 
cell activity was assayed using a 4 hr assay with 51Cr-labelled EL-4 cells. Chronic 
morphine exposure decreased splenic and peritoneal cytotoxic T cell activity. -
funaltrexamine reversed the morphine-induced suppression of CD8+ cytotoxic T cell 
activity, indicating that this is a MOR mediated effect (Carpenter et al., 1995, Carpenter 
et al., 1994). 
 
The effect of burns and morphine on splenic T cell proliferation has been investigated 
in C57BL/6 mice (Alexander et al., 2005). The mice were given a 6.25, 12.5 or 25% 
total body surface area burn or a sham procedure. The mice were either untreated or 
administered a 2 mg/kg/day subcutaneous morphine infusion. Splenocytes were 
isolated for in vitro analysis 1, 4, or 7 days later. The splenocytes were incubated with 
anti-CD3 for 48 hr and T cell proliferation was determined spectrophotometrically by 
measuring 5-bromo-2-deoxyuridine uptake by splenocytes. Neither the 6.25% burn nor 
morphine alone altered splenic T cell proliferation to anti-CD3. In contrast, morphine 
treatment of mice with a 6.25% burn suppressed splenic T cell proliferation at 4 and 7 
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days. Morphine treatment did not increase the suppressed T cell proliferative 
responses associated with larger burns of 12.5% and 25%. It is possible that the larger 
burns have maximal suppressive effects on T cells, which cannot be added to by 
morphine (Alexander et al., 2005). 
 
Yeager and colleagues evaluated the in vivo effects of short-term intravenous fentanyl 
(3 g/kg bolus followed by 1.2 g/kg/hr infusion over 2 hr) in seven healthy volunteers 
(Yeager et al., 2002). Blood was taken before fentanyl administration and at 1 and 24 
hr after completion of the infusion. PBMCs were isolated by density gradient 
centrifugation and kept in liquid N2 until assayed. The proportions of leukocyte sub-
populations (CD3, CD4, CD8, CD14, CD16, CD19, CD57, CD64 and HLA class I) was 
determined using flow cytometry of PBMCs. T cell proliferation in response to a 3-day 
incubation with Con A was assessed using a 3H-thymidine uptake assay. The effect of 
fentanyl on antibody response to pneumococcal vaccination was determined using an 
ELISA. Fentanyl increased the percentage of CD8+ T cells in peripheral blood (at the 
end of the infusion, which remained at 24 hr), but had no other effect on any of these 
immune parameters (Yeager et al., 2002). 
 
Jacobs and colleagues assessed the in vivo effects of an intravenous bolus of 0.2 
g/kg fentanyl on cellular immune function in seven healthy male volunteers (Jacobs et 
al., 1999). Blood was taken before, and 15 and 30 min after the fentanyl. PBMCs were 
isolated by density gradient centrifugation and stained with mAbs to CD3, CD4 and 
CD19 and measured by flow cytometry. These lymphocyte subtypes were not affected 
by fentanyl (Jacobs et al., 1999).  
 
Lymphocyte subset composition in current heroin (diamorphine) abusers, long-term 
(>10 yr) methadone maintained previous heroin abusers and healthy individuals have 
been compared (Novick et al., 1989). Lymphocyte subsets were measured using mAbs 
and flow cytometry in whole blood. Heroin abusers had higher absolute numbers of 
CD2+, CD3+, CD4+ and CD8+ cells compared with methadone patients and controls, 
which were similar (Novick et al., 1989). The current heroin abusers were undergoing 
inpatient detoxification, which might have induced withdrawal effects on the lymphocyte 
subsets rather than the diamorphine directly affecting the cells.  
 
In a clinical study of 30 patients undergoing surgery for uterine carcinoma, the effect of 
morphine and tramadol on T cell function was compared in the post-operative period 
(Sacerdote et al., 2000). All patients had anaesthetic medications as well as fentanyl. 
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Patients were given an intramuscular injection of 10 mg morphine or 100 mg tramadol 
immediately post-operatively. Peripheral blood was taken before surgery, immediately 
post-operatively (before morphine and tramadol administration, but after fentanyl) and 
2 hr post-surgery. PBMCs were isolated by density gradient centrifugation. PHA-
induced T cell proliferation was assessed at these time points using a 3H-thymidine 
uptake assay. Although anaesthesia/surgery suppressed T cell proliferation (measured 
immediately post-operatively, before the administration of tramadol or morphine), 
patients receiving morphine continued to exhibit suppressed T cell proliferation at 2 hr, 
whereas patients administered tramadol had pre-surgical responses at this time. There 
was no difference in the analgesic effects (Sacerdote et al., 2000). 
 
In summary, there are a few studies assessing the in vivo effect of morphine, tramadol, 
fentanyl, methadone and diamorphine on T cell function, across a range of 
experimental conditions. Morphine has been shown to have suppressive effects on T 
cells and fentanyl might be neutral. There have not been enough previous in vivo 
studies into the effects of the other opioids on T cells to draw any definitive conclusions 
about their effects.  
 
1.12.5 Cytokines  
Cytokines are cell signalling molecules that are secreted from a variety of cells, 
including immune cells. They have several roles, including being involved in the 
regulation of humoral and cellular immune responses. As discussed in section 1.6, 
cytokines play a key role in the expression of opioid receptors on immune cells (Kraus, 
2009). However, opioids also impact on cytokine production. Several studies have 
assessed the effect of opioids on cytokines. The in vivo studies are described below. 
 
In a murine model of chronic morphine exposure and Streptococcus pneumoniae 
infection, CB6F1 male mice were implanted with a 75 mg morphine or placebo pellet 24 
hr before nasal S. pneumoniae inoculation (Wang et al., 2005b). Mice were killed 4, 24 
and 48 hr after inoculation and TNF-, IL-1, and IL-6 were measured in lung lavages 
and tissue using ELISAs. Morphine reduced TNF-, IL-1, and IL-6 levels at 4 hr, but 
increased them at 24 and 48 hr. Mice administered morphine had a greater bacterial 
load and higher mortality (87% for morphine vs. 20% for placebo at 1 week). Morphine 
impaired the host immune response, altered cytokine production and increased 
susceptibility to S. pneumoniae infection (Wang et al., 2005b). 
 
Female B6C3F1 mice were administered subcutaneous morphine for 5 days (20 mg/kg 
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twice a day on day 1, then on day 2, a 75 mg morphine pellet was implanted) before 
being killed (Bhargava et al., 1994). Splenocytes were removed and stimulated in vitro 
with anti-CD3 mAb for 2 days. Peritoneal macrophage were elicited with thioglycolate 
and stimulated by LPS for 2 days. Cytokine secretion was measured by spectroscopy. 
Morphine decreased splenic IL-2 and IL-4, but did not affect peritoneal macrophage 
TNF- production (Bhargava et al., 1994). 
 
Lysle and colleagues administered a single dose of subcutaneous morphine (0, 5, 10, 
15 or 25 mg/kg) to male Lewis rats which were killed 1 hr later (Lysle et al., 1993). 
Blood, spleen and mesenteric lymph nodes were removed. Splenic and lymph node 
cells were incubated in vitro with Con A for 48 hr to activate T cells. IFN- was 
measured using an ELISA and IL-2 using a CTLL-2 proliferation assay. Morphine 
induced a dose-dependent suppression of IL-2 and IFN- production in splenic 
lymphocytes, whereas IL-2 and IFN- production by the mesenteric lymph node cells 
were not affected (Lysle et al., 1993).  
 
The effect of a single subcutaneous injection of 20 mg/kg morphine and diamorphine 
on the production of IL-1, IL-2, IL-10, TNF- and IFN- by cultured splenocytes from 
C57/BL mice were assessed using ELISAs (Pacifici et al., 2000). Both opioids 
increased production of IL-1, IL-2, TNF- and IFN- at 20 and 40 min after 
administration. At 24 hr, production of these cytokines was inhibited, with only a partial 
recovery at 48 hr. Morphine and diamorphine had a stimulatory effect on the release of 
IL-10 at 24 hr, decreasing it by 48 hr (Pacifici et al., 2000).  
 
Martucci and colleagues administered 20 mg/kg subcutaneous morphine to C57BL/6 
mice, from which peritoneal macrophages and splenocytes were harvested 1 hr later 
(Martucci et al., 2007). Peritoneal macrophages were incubated with or without LPS 
and splenocytes with or without Con A. Production of IL-1, IL-2, IL-4, IL-10, IL-12p70, 
TNF- and IFN- were measured using ELISAs. Morphine reduced unstimulated and 
LPS stimulated macrophage production of the pro-inflammatory cytokines IL-1, IL-12 
and TNF-, and the anti-inflammatory cytokine IL-10. Morphine decreased Con A 
stimulated splenocytes production of IL-1, IL-2, IL-4, IL-10 and IFN-, and also 
unstimulated splenocyte production of IL-1 and IL-2 (Martucci et al., 2007).  
 
The effect of burns and morphine on TH cell cytokine production was assessed in 
C57BL/6 mice (Alexander et al., 2005). The mice were given a 6.25% total body 
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surface area burn or a sham procedure and were either untreated or treated with a 2 
mg/kg/day subcutaneous morphine infusion. Plasma and splenocytes were isolated for 
in vitro analysis 1, 4 or 7 days later. The splenocytes were incubated with anti-CD3 for 
48 hr and the stimulated T cell production of IL-2, IL-10 and IFN- were measured 
using ELISAs. There was an increase in IL-10 production to morphine, both in the 
sham and burnt mice, whereas morphine increased the IFN- levels in sham animals, 
but not the burnt mice. The relative increase in IL-10 to IFN- concentrations in burnt 
mice receiving morphine suggests a shift in the T cells towards a TH2 type phenotype, 
based on cytokine production profiles (Alexander et al., 2005). The TH2 cell phenotype 
could be immunosuppressive, as the cytokines produced by TH2 cells promote humoral 
immunity and suppress the differentiation towards the TH1 cell phenotype which 
activates the cellular immune response.  
 
Sacerdote and colleagues compared the effects of buprenorphine and methadone 
maintenance treatment on cytokine levels in heroin addicts, using PHA stimulated 
PBMCs collected from these groups (Sacerdote et al., 2008). Current heroin addicts 
exhibited a reduced secretion of IL-4, IFN- and TNF-, whereas the secretion of IL-2 
was normal. All of these parameters were normal in methadone and buprenorphine 
groups, demonstrating that both buprenorphine and methadone maintenance 
preserves immune function (Sacerdote et al., 2008). This could be due to lifestyle 
changes, as well as differential modulatory effects of the opioids on immunity. 
 
Blood taken from heroin (diamorphine) addicts and healthy volunteers, was stimulated 
in vitro with PHA or LPS and levels of IFN- and IL-10 were measured by ELISAs 
(Azarang et al., 2007). In heroin addicts, there was a decrease in IFN- and an 
increase in IL-10 production. This suggests that heroin addiction leads to a polarisation 
of CD4+ cells towards the TH2 response (Azarang et al., 2007). 
 
The effects of morphine, tramadol and fentanyl have been compared in a post-
operative study (Liu et al., 2006). For this, 150 patients were randomised to receive 
morphine, fentanyl or tramadol (all in combination with droperidol) via a patient 
controlled analgesia (PCA) device after upper abdominal surgery. IL-2 was measured 
pre-operatively and 1, 3 and 24 hr after surgey. The patients were all administered 
midazolam, propofol, fentanyl, vecuronium and either isoflurane or enflurane during 
surgery. NF-B was measured using an Eletrophoretic Mobility Shift Assay, and IL-2 
using an ELISA. Despite showing similar analgesia, morphine decreased IL-2 levels, 
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whereas tramadol and fentanyl increased it. The inhibitory effect of morphine on IL-2 
production was related to its suppression of NF-B. These findings indicate that 
morphine is likely to be immune suppressing, whereas fentanyl and tramadol might 
have an immune enhancing effect. (Liu et al., 2006). 
 
In a randomised, placebo-controlled trial, the effect of tramadol on the production of 
pro-inflammatory and anti-inflammatory responses in 40 lung cancer patients 
undergoing pulmonary lobectomy was assessed (Wang et al., 2005a). Patients were 
administered intravenous tramadol (1.5 mg/kg bolus with a 0.5 mg/kg/hr infusion) or 
saline 5 min before surgery. All patients had fentanyl (2 g/kg) as well as midazolam, 
propofol, vecuronium, diazepam, atropine and enflurane general anaesthesia intra-
operatively. Epidural lidocaine, bupivacaine and fentanyl (5 g/kg) were used for 3 
days post-operatively. Blood was taken before surgery, 90 min after the start of surgery 
and at 4 and 24 hr after surgery. The blood was centrifuged, serum removed and 
stored at -80C for measurement of IL-2, sIL-2R (soluble IL-2 receptors – a marker of 
immune activation), IL-6, and IL-10 using ELISAs. IL-2 was increased at 4 hr after 
surgery in patients receiving tramadol, but was reduced at 4 and 24 hr after surgery in 
the saline group. sIL-2R was increased at 4 and 24 hr after surgery in patients 
receiving saline, but only at 24 hr in the tramadol group. IL-6 and IL-10 were increased 
during and after surgery similarly in both groups. Tramadol did not alter the IL-6/IL-10 
response, but enhanced IL-2 production and delayed the increase of sIL-2R (Wang et 
al., 2005a). This could be due to a direct effect of tramadol or due to a reduced 
requirement for enflurane as a consequence of tramadol’s analgesic action given that 
inhaled anaesthetic drugs contribute to post-operative immunosuppression (Brand et 
al., 1997). Malignancy and the other medications might also influence cytokine release. 
 
In summary, there have been many studies assessing the levels of some cytokines in 
response to several opioids. These studies have a varied methodology, with different 
species studied in different settings. In general, morphine has mixed effects on pro- 
and anti-inflammatory cytokines in murine models making it difficult to draw definitive 
conclusions about its overall effect. However, it did decrease IL-2 production following 
surgery and could potentially be clinically deleterious. The data on the other opioids are 
sparse, but buprenorphine appears to be immune neutral in terms of cytokine 
production and tramadol enhanced IL-2 levels and might even have beneficial clinical 
effects on the immune system. These clinical assumptions would need confirmation in 
long term patient studies.  
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1.13 Conclusion 
The interactions of opioids with the immune system are highly complex and their 
differential immunological effects depend on their molecular structure, receptor binding 
profiles and non-opioid mediated effects (i.e. serotinergic re-uptake inhibition and TLR4 
agonism). Numerous in vivo studies have already been conducted assessing the effect 
of some commonly used opioids on certain aspects of immune function.  
 
The immunomodulatory effects of morphine, a MOR agonist, are the most 
comprehensively studied. Although the literature described above shows mixed results, 
due to differing methodologies, in general it tends to suppress NK cell cytotoxicity, 
phagocytosis, oxidative burst, T cell activation, and IL-1, IL-2, IL-4, IL-6, IL-12 and IFN-
 (Shirzad et al., 2009, Tubaro et al., 1987, Van Der Laan et al., 1996).  
 
Tramadol binds with low affinity to the MOR and inhibits neuronal uptake of serotonin 
and noradrenaline. These actions convey the analgesic action of tramadol, and its 
serotonergic effect also appears to confer unique immunomodulatory properties on 
tramadol. In general the literature reports that tramadol increases NK cell cytotoxicity, 
phagocytosis, lymphocyte proliferation and IL-2 production (Gaspani et al., 2002, 
Sacerdote et al., 2000).  
 
Fentanyl, a potent MOR agonist, has limited studies, showing mixed effects on NK cell 
cytotoxicity and CD8+ cells, decreasing IL-2 and IFN- production and not influencing 
phagocytosis and oxidative burst (Beilin et al., 1996, Jacobs et al., 1999, Shavit et al., 
2004, Yeager et al., 2002).  
 
Buprenorphine, with its mixed opioid receptor binding profile, does not influence NK cell 
cytotoxicity and cytokine production (Martucci et al., 2004). This might be as it does not 
activate the SNS or the HPA axis, and does not affect the release of monoamines, 
corticosterone and corticosterone-binding globulin levels (D'Elia et al., 2003, Gomez-
Flores and Weber, 2000).  
 
Methadone is a MOR agonist which induces MOR internalisation and also has NMDA 
antagonistic properties. It has shown mixed effects on NK cell cytotoxicity, 
phagocytosis, oxidative burst and does not affect the T cell response (Tubaro et al., 
1987, Van Der Laan et al., 1996).  
 
Oxycodone, a MOR and KOR agonist, has not previously been studied.  
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Diamorphine, a pro-drug of morphine, reduces NK cell cytotoxicity in heroin abusers 
(Novick et al., 1989). It has mixed effects on cytokines, but tends to increase IL-1 and 
IL-10, and decrease IFN- levels (Azarang et al., 2007).  
 
Codeine, a naturally occurring opiate alkaloid and pro-drug of morphine, has not been 
studied, although after in vivo conversion to morphine, it is likely to have the same 
effects as morphine. 
 
There are many experimental differences between the studies and often the methods 
used for stimulating the different types of immune cells are not physiological and the 
overall effect of these opioids has to be taken in the context of the clinical situation and 
the most common reason for their prescription, pain (discussed further in section 4.8). 
 
Methodological differences between the studies include:  
 different animals and species 
 male vs. female 
 immune activation status 
 peripheral whole blood vs. PBMCs vs. isolation of cells vs. splenic cells 
 the method of cell removal and cell activation status 
 incubation times with opioids at dissimilar concentrations 
 the effect of opioid tolerance and withdrawal 
 total cell numbers 
 E:T cell ratios 
 effector and target cells 
 incubation times 
 immune outcome measurement 
 different mitogens at variable concentration and durations  
 opsonisation 
 
Unfortunately, not all studies mention all the relevant variables in their methodology 
making it even more difficult to compare and extrapolate their results. 
 
To fully elucidate the effect of each of the opioids on the different immune cells and the 
consequence of this in disease necessitates a range of studies and methodologies 
ranging from cellular to clinical. In vitro studies enable very tight control over the cells 
assessed and potential intracellular pathways, but might tell little about the whole 
organism. Animal studies can use a specific strain of rodent which is known to have a 
certain response and several of these “identical” animals can be studied under various 
conditions. Although the use of healthy participants avoids the confounding effects of 
coexisting diseases, surgical trauma or pain, they might have a different immune 
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activation status. In the clinical setting in which opioids are administered, their 
interactions with other components of the human pain and inflammatory response need 
to be considered, it is also not possible to control all the variables which might affect 
their immunity (see section 4.8, Effect of pain on immune function).  
 
Despite the wealth of studies for certain opioids, especially morphine, the potential 
impact of other opioids, like oxycodone and codeine have never been assessed on any 
immune parameter. Most other opioids have been evaluated to some extent on certain 
aspects of immune function, but there is not always consistency between these effects 
which might result from the wide ranging methodologies which have been used. More 
comprehensive and systematic studies assessing and comparing the effects of a range 
of opioids on many aspects of immune function are needed. Until there is definitive 
clinical data of these possible consequences, immunomodulation is another potential 
adverse effect of opioids that clinicians should take into consideration when deciding 
the “best” opioid for an individual patient. 
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1.14 Study Hypothesis, Aim and Objectives  
 
Study Hypothesis: That morphine, tramadol, fentanyl, buprenorphine, methadone, 
oxycodone, diamorphine and codeine have differential effects on NK cell activation and 
cytotoxicity; neutrophil and monocyte phagocytosis and oxidative burst responses; T 
cell responsiveness; and cytokine production. 
 
Study Aim: To evaluate the effects of morphine, tramadol, fentanyl, buprenorphine, 
methadone, oxycodone, diamorphine and codeine on multiple aspects of innate and 
adaptive immune function. 
 
Study Objectives: To systematically compare the influence of morphine, tramadol, 
fentanyl, buprenorphine, methadone, oxycodone, diamorphine and codeine on: 
1. NK cell cytotoxicity against K562 human erythroleukaemic target cells 
2. NK cell activation (measured by CD69 expression) to anti-CD3/anti-CD28 mAbs 
and IL-2 
3. Phagocytosis of E.coli by peripheral blood neutrophils and monocytes 
4. Neutrophil and monocyte oxidative burst responses to E.coli, PMA (an activator 
of PKC) and fMLP (a chemotactic peptide) 
5. CD4+ and CD8+ T cell activation to anti-CD3/anti-CD28 mAbs, as measured on 
the basis of CD25 and CD69 expression. 
6. Cytokine production by unstimulated as well as IL-2 and anti-CD3/anti-CD28 
mAb activated PBMCs 
 
The analysis of NK cell cytotoxicity provides insight into the potential effects of these 
opioids on innate immune protection against tumours and viral infection. 
 
The analysis of neutrophil and monocyte function provides insight into the potential 
effects of opioids on innate immune protection against bacterial and fungal infections. 
 
The analysis of CD4+ T cells and cytokine production provides insight into the potential 
effects of these opioids on the regulation of the immune system. 
 
The analysis of CD8+ T cells provides insight into the potential effects of these opioids 
on adaptive immune protection against tumours and viral infection. 
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CHAPTER 2 
 
2. MATERIALS AND METHODS 
 
2.1 Ethics 
Ethical approval for this study was obtained from the University of Sheffield Medical 
School Research Ethics Committee (Reference Number: SMBRER102).  
 
2.2 Blood samples  
Peripheral blood was obtained from healthy volunteers by appropriately trained staff 
following written informed consent. Venepuncture was performed using a 21-Gauge 
needle and blood was collected into lithium heparin BD Vacutainers (BD Biosciences, 
Oxford, UK). An aliquot of whole blood was used for the determination of neutrophil 
and monocyte phagocytosis and oxidative burst responses. PBMCs were isolated from 
the blood for the analysis of NK cell cytotoxicity, NK and T cell phenotype/activation 
status and cytokine studies. 
 
2.3 Volunteers  
To minimise the effect of interindividual variability both with the immune assays and in 
the response to opioids a small cohort of male and female volunteers were used 
throughout the study. One concern was that the interindividual variability could be so 
large that any effect of opioids on immune function would be hidden. Using the same 
volunteers for the range of immune assays also enables comparison of individuals 
across these tests. The fixed cohort of volunteers was healthy and not on any 
medications. The age range was 25 – 33 years old, with four males and three females. 
Gender-related differences in the proliferative ability of murine T and B cells in vivo 
have been reported (Gabrilovac and Marotti, 2000) and although this is also likely to be 
true in the volunteers, a mixed sample was more representative of the clinical situation. 
 
All volunteers were of a similar age, as advancing age affects innate and adaptive 
immune function (immunosenescence). This primarily affects T cells, but can also 
influence NK cells (Bird, 2010, Desai et al., 2010). Although many patients receiving 
opioids are older, for this study a relatively young, healthy cohort was used in order to 
minimise the potential influence of immunosenescence on the variability of the 
measured parameters. Healthy volunteers had not undertaken any recent exercise 
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prior to blood sampling, as this could influence immune function by affecting both the 
endogenous opioid and the serotonergic systems (Mazzardo-Martins et al., 2010), as 
well as cytokine and TLR expression (Gleeson, 2007). Although moderate exercise is 
immune enhancing, strenuous exercise is suppressive (Gleeson, 2007, Shephard and 
Shek, 1999). Exercise also increases myokine (such as IL-6) production (Pedersen, 
2011). None of the volunteers had recent vaccinations. They did not smoke, as this 
might negatively impact on immunity, especially innate immune function (Molloy, 2010).  
 
We did not control for menstrual cycle in the female volunteers, although oestrogen 
levels might be important, especially with KOR agonists (Lawson et al., 2010). 
Although none of the volunteers had overt infection, subclinical infection, which is very 
prevalent and likely to lead to immune activation, was not excluded. Although none of 
the volunteers were fasting, as this can increase the production of endogenous opioids, 
including morphine (Molina et al., 1995), overall nutrition, which is vital for effective 
immune functioning (Chandra, 1999), was not assessed. Differing levels of stress, 
which tends to impair immune response (Ben-Eliyahu et al., 2007) by glucocorticoid 
(Elftman et al., 2010) and endogenous opioid release (Shavit et al., 1984) were not 
controlled for, either between the volunteers or for each volunteer at different time 
points. As there could be alterations in immune responses at different times of the day 
(Keller et al., 2009), all blood samples were all taken in the morning or early afternoon. 
However, there was no strict time schedule. Although all these factors are important 
and controlling for them will decrease variability and improve the reliability of the 
results, clinically there is likely to be differences in many of these factors. 
 
 
2.4 Opioids 
Morphine, tramadol, fentanyl, buprenorphine, methadone, oxycodone, diamorphine and 
codeine were obtained from the Pharmacy Department at the Royal Hallamshire 
Hospital, Sheffield. Each opioid was diluted to the appropriate concentration, as 
described in the following section, either with growth medium or phosphate buffered 
saline (PBS) prior to each experiment. 
 
2.4.1 Relevance of opioid concentrations to immune cell activation 
In order to ensure that the experimental regimen is as applicable to the clinical scenario 
as possible, the literature regarding plasma concentrations of morphine, tramadol, 
fentanyl, buprenorphine, methadone, oxycodone, diamorphine and codeine in 
volunteer studies and in patients treated with opioids was reviewed.  
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The activation of opioid receptors and the triggering of downstream events by opioids 
and their potential non-opioid receptor mediated mechanism(s) of action are likely to 
depend on the concentration of opioid in the cellular microenvironment (Liu et al., 
1992). Although plasma concentrations of opioids can be measured in patient and 
human volunteer groups, generally the dose of opioid prescribed is titrated to 
efficacy/toxicity, and only rarely are plasma concentrations measured. Even when 
plasma opioid concentrations are measured (usually in early clinical trials), their 
relationship to opioid concentrations present in the microenvironment of immune 
effector cells is unknown. Despite these limitations, it is important to consider the 
potential concentrations of opioid in the in vivo immune cell environment and use opioid 
concentrations that equate with those found in patients treated with exogenous opioids. 
  
In vivo, pharmacologically-active, free opioid concentrations are lower because they 
are protein bound; for example, 80% of fentanyl is bound to plasma protein 
(Meuldermans et al., 1982) and is taken up by erythrocytes (Bower, 1982).  
 
T cells normally reside in the lymph nodes until such time as APCs/DCs present 
specific antigen to them, at which time they become activated. The activated population 
clonally expands, initially in the lymph nodes, before emigrating into the circulation and 
migrating to the site of inflammation. Thus for T cells, the opioid concentration in the 
lymph node is potentially critical if it is to affect them during activation, especially if this 
is the point at which opioid receptors are transcribed and expressed by the T cell 
(Borner et al., 2008). In contrast, plasma and tissue opioid concentrations are relevant 
to circulating NK cells, neutrophils and monocytes. As it is difficult to precisely quantify 
the peri-T cell opioid concentration in vivo on the basis of currently available 
information, this in vitro study used concentrations of opioids which approximate to the 
in vivo plasma concentrations that are found in patients. It is accepted that 
interindividual variability of patient responses to opioid analgesics, including genetic 
and drug-drug interactions might result in wide variations in effective levels between 
individuals.  
 
This interindividual variability is, in part, due to opioid receptor gene polymorphisms 
(Hoehe et al., 2000) and splice variants of opioid receptors (Pan, 2005, Pan et al., 
2001). As more than half of the opioid receptor gene polymorphisms are within the 
promoter region, their primary influence is on gene transcription (Kraus et al., 2003). 
This is of prime importance as the potential effect of the opioid on immune cells will not 
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only depend on its local concentration, but also on the level of expression of 
appropriate receptors on the cells and the affinity at which the opioid binds to each of 
these receptors. 
 
Tumour vascularisation will influence the numbers of NK and T cells able to penetrate 
into the tumour as well as intratumoural opioid levels, further impacting on their 
immunoregulatory potential. As there is poor circulation and perfusion in the tumour 
microenvironment there are likely to be low opioid levels here. Although the literature is 
mixed, recent studies suggest that opioids can inhibit angiogenesis (Afsharimani et al., 
2011, Koodie et al., 2010, Martin et al., 2010) and might have a tumour-promoting 
effect by phosphorylating the epidermal growth factor receptor (Fujioka et al., 2011), 
making the opioid-tumour interaction even more complex in the clinical setting.  
 
2.4.2 Clinically relevant plasma concentrations of opioids 
Plasma concentrations of opioids in clinical practice, as reported from published trials, 
were reviewed. Below are summaries of the data found clinically, which were used to 
determine the opioid concentrations to be used in this study. These concentrations 
were then compared to previous immunological in vitro studies. This enabled the 
concentrations used in the study to approximate those that would be found in patients.  
 
2.4.2.1 Morphine  
In a post-operative trial of four patients using a PCA device, plasma morphine levels in 
venous blood samples were measured at 3, 6, 12, 18, 24 and 36 hr post operation. The 
median total morphine dose delivered in the 36 hr was 19.5 mg. Median plasma 
concentrations of morphine are shown in Table 2.1 (Santos et al., 2008). 
 
Table 2.1: Median morphine plasma concentration over time in four patients using PCA. 
Hours post operation 3 6 12 18 24 36 
Median morphine plasma 
level (ng/ml) 
13.1 18.9 53.0 28.9 13.9 15.4 
 
A randomised controlled trial of 14 patients with cancer compared a 5 mg bolus of 
either intraosseous or intravenous morphine, the peak plasma morphine concentration 
(± SD) was 235 (± 107) and 289 (± 197) ng/ml respectively (Von Hoff et al., 2008). 
 
In a study of 50 post-operative patients on morphine, with 225 concentration-time data 
points, the measured concentrations of morphine varied widely, although these peaked 
in the region of 200 ng/ml (Mazoit et al., 2007). 
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In a double-blind randomised controlled trial for the treatment of cancer pain, 
controlled-release morphine was compared with controlled-release oxycodone. Mean 
plasma concentrations (± SE) were measured at 0 (trough) and 3 hr after last dose of 
morphine, and were 21.3 (± 2.8) and 57.0 (± 9.7) ng/ml respectively (Mucci-LoRusso et 
al., 1998). 
 
Opioid plasma concentrations were measured in nine patients who were being 
converted from morphine to methadone. The maximum morphine concentration was 
51.8 ng/ml, with a range of 17 – 86 ng/ml (Mercadante et al., 2003). 
 
These clinically relevant in vivo plasma concentrations were evaluated in the context of 
those used in previous in vitro immunological studies: 
 20, 40 and 80 ng/ml (Beilin et al., 2005) 
 3 pg/ml – 32 g/ml (0.003 – 32,000 ng/ml) (Fuggetta et al., 2005) 
 10 – 1,000 nM (2.85 – 285.4 ng/ml) (Greeneltch et al., 2005) 
 10-8 M; (3 ng/ml) (Wang et al., 2006) 
 100 and 500 nM (28 and 143 ng/ml) (Lazaro et al., 2000) 
 0 – 10−5 M (0 – 2,853 ng/ml) (Delgado-Velez et al., 2008) 
 10-10 – 10-6 M (0.03 – 285 ng/ml) (Szabo et al., 1993) 
 38 mg/ml (3.8 x107 ng/ml) (Liu et al., 2006) 
 2,000 and 200,000 ng/ml (Rao et al., 2004) 
 
2.4.2.2 Tramadol  
In a volunteer study of tramadol pharmacokinetics in relation to CYP2D6 phenotype, 
five subjects who were poor metabolisers and 19 subjects who were extensive 
metabolisers were given a single oral 100 mg dose of racemic tramadol; the plasma 
concentrations are shown in Table 2.2 (Garcia-Quetglas et al., 2007). 
 
Table 2.2: Maximal tramadol concentrations in volunteers with differing 
CYP2D6 phenotypes 
CYP2D6 
phenotype 
Tramadol Cmax (mg/l) SD 
Extensive 
metabolisers 
1.136 0.048 
Poor metabolisers 1.145 0.086 
 
In a post-operative study, 3 mg/kg of intravenous tramadol was administered to 174 
patients. This resulted in plasma tramadol levels ranging between 55 and 1,100 ng/ml 
(Stamer et al., 2007). 
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In a randomised trial of 98 patients using racemic tramadol PCA after gynaecological 
surgery, serum tramadol levels of 590 ± 410 ng/ml were detected (Grond et al., 1999). 
 
The reported serum concentrations in 40 patients using a tramadol PCA for post-
operative analgesia (average dose administered in 4 hr was 102.8 mg) after major 
surgery, has been reported to be between 20.2 and 986.3 ng/ml, with a median 
concentration of 287.7 ng/ml (Lehmann et al., 1990). 
 
After a single intravenous dose of 100 mg tramadol in 30 otherwise healthy patients 
undergoing elective orthopaedic surgery, the serum concentration of tramadol was in 
the region of 1 µg/ml (Gan et al., 2002). 
 
These clinically relevant in vivo plasma concentrations were evaluated in the context of 
those used in previous in vitro immunological studies: 
 5, 10 and 20 μg/ml (5,000, 10,000 and 20,000 ng/ml) (Beilin et al., 2005) 
 7.5 mg/ml (7.5 x106 ng/ml) (Liu et al., 2006) 
 
2.4.2.3 Fentanyl 
In an immunological in vivo study in seven healthy volunteers, serum fentanyl levels 
were analysed 15 and 30 min after the intravenous administration of 0.2 g/kg fentanyl. 
After 15 min the mean fentanyl concentration (± SD) was 1.91 ng/ml (± 1.17) and 30 
min after injection it was 0.67 ng/ml (± 0.23) (Jacobs et al., 1999). 
 
The pharmacokinetic properties of effervescent fentanyl buccal tablets have been 
evaluated in a phase I, open-label, crossover study of single-doses of 100, 200, 400 
and 800 g in adult volunteers. The plasma fentanyl concentrations remained 
reasonably stable for around 4 hr following administration and are presented in Table 
2.3 (Darwish et al., 2006). 
 
Table 2.3: Maximum plasma fentanyl concentrations 
in volunteers administered buccal fentanyl. 
Fentanyl tablets Cmax (ng/ml) SD 
100 µg 0.25 0.14 
200 µg 0.40 0.18 
400 µg 0.97 0.53 
800 µg 1.59 0.90 
 
Plasma opioid concentrations have been measured at 5-hr intervals during the first 25 
hr during conversion from transdermal fentanyl to methadone in 18 patients receiving 
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palliative care. The plasma concentrations are in Table 2.4 (Mercadante et al., 2007).  
 
Table 2.4: The plasma concentration of fentanyl after cessation of therapy. 
Time after 
stopping fentanyl 
(hours) 
Fentanyl concentration 
median (ng/ml) 
Fentanyl concentration 
range (ng/ml) 
5 15 9 – 21 
10 11 7 – 16 
15 10 7 – 14 
20 10 8 – 13 
25 8 5.7 – 10.8 
 
 
Serum fentanyl concentrations in a randomised controlled trial of 10 patients 
undergoing cardiac surgery were in the region of 5.8 ng/ml (Thomson et al., 2000). 
 
Plasma fentanyl concentrations in a perioperative study of elderly and middle-aged 
patients have been measured. Fentanyl was given as a bolus (7.5 g/kg) then as a 
continuous intravenous infusion (0.1 g/kg/min) during cardiac surgery to two groups of 
patients, those over 75 and those under 60 years old. The plasma concentrations of 
fentanyl in an arterial blood sample at the point of stopping the infusion was 6 ng/ml in 
the over 75 group and 2 ng/ml in the under 60 group. Two hours after the cessation of 
the infusion, the fentanyl concentration was 4 and 2 ng/ml in the over 75 and under 60 
group respectively (Pesonen et al., 2009). 
 
These clinically relevant in vivo plasma concentrations were also evaluated in the 
context of those used in previous in vitro immunological studies: 
 5, 10 and 20 ng/ml (Schneemilch et al., 2005) 
 0.01, 0.1, 1, 10, 100 M (3, 30, 300, 3,000, 30,000 ng/ml) (House et al., 1995) 
 4.16 x10-8 M (14.0 ng/ml) (Larsen et al., 1998) 
 5 and 50 ng/ml (Jaeger et al., 1998) 
 20 and 40 M (5,700 and 11,400 ng/ml) (Jacobs et al., 1999) 
 20 ng/ml (Liu et al., 2006) 
 2, 20 and 200 ng/ml (Wu et al., 2009) 
 20 and 2,000 ng/ml (Rao et al., 2004) 
 
2.4.2.4 Buprenorphine  
A single intravenous dose of 0.002 mg/kg of buprenorphine was administered to 12 
healthy male volunteers in a randomised, double-blind, placebo-controlled, crossover 
trial. Blood samples were collected at 0.5, 1, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, and 8 hr. 
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Plasma buprenorphine concentration peaked at 10 ng/ml at 30 min, and was 1 ng/ml 
after 1 hr (Escher et al., 2007). 
 
In a randomised clinical trial of 57 opioid-dependent volunteers on opioid maintenance 
therapy, plasma concentrations with sublingual liquid or tablet formulations of 
buprenorphine have been compared. Subjects received between 8 mg liquid sublingual 
liquid and 32 mg tablets sublingual. Peak plasma buprenorphine concentrations were 
dose- and formulation-dependent, but were between 3.4 and 6.2 ng/ml (Chawarski et 
al. 2005). 
 
In a healthy volunteer study, either 1 mg intravenous or 8 mg sublingual buprenorphine 
were administered. The maximum plasma buprenorphine concentration was in the 
region of 10 ng/ml (Everhart et al., 1997). 
 
Watson and colleagues compared single-dose 0.3 and 0.6 mg intravenous 
buprenorphine given to 19 patients post-operatively and showed a peak plasma 
buprenorphine concentration at just over 10 ng/ml (Watson et al. 1982). 
 
There are no previous in vitro immunological studies with which these clinically relevant 
in vivo plasma concentrations can be compared. 
 
2.4.2.5 Methadone 
Plasma opioid concentrations have been measured at 5-hr intervals during the first 25 
hr during conversion from transdermal fentanyl to methadone in 18 patients receiving 
palliative care. The results are presented in Table 2.5 (Mercadante et al., 2007).  
 
Table 2.5: Plasma methadone concentration after commencement of therapy. 
Time after starting 
methadone (hours) 
Methadone concentration 
median (ng/ml) 
Methadone concentration 
range (ng/ml) 
5 2 0–5 
10 119 70–169 
15 140 78–202 
20 169 113–223 
25 245 162–327 
 
The maximum methadone concentration in a study of nine patients which were being 
converted from morphine to methadone was reported to be 172 ng/ml; with a range of 
46 – 298 ng/ml (Mercadante et al., 2003). 
 
98 | P a g e  
 
In a study of patients on methadone maintenance therapy, their peak plasma 
methadone concentration was in the region of 450 ng/ml (Dyer et al., 2001). 
 
These clinically relevant in vivo plasma concentrations were evaluated in the context of 
those used in previous in vitro immunological studies:  
 0 – 10−5 M (0 – 3,094 ng/ml) (Delgado-Velez et al., 2008) 
 10-18 – 10-6 M (3x10-10 – 309 ng/ml) (Molitor et al., 1992) 
 0.0001 – 100M (0.03 – 30,940 ng/ml) (Thomas et al., 1995b) 
 
2.4.2.6 Oxycodone 
Oxycodone was used for post-operative pain treatment at a dose of 0.05 mg/kg 
intravenously. This dose was used three times and oxycodone concentration was 
checked at 0, 15 and 45 min after each dose. Levels were 5 – 15 ng/ml at time 0 
(trough), 20 – 30 ng/ml at 15 min and 10 – 20 ng/ml at 45 min post dose (Pesonen et 
al., 2009).  
 
In a randomised, double-blind study for the treatment of cancer-associated pain, the 
plasma concentrations of controlled-release oxycodone were measured at point 0 
(trough) and 3 hr after last dose of oxycodone. The dose range of oxycodone was 40-
400 mg/day. The mean plasma concentrations (± SE) were 33.3 (4.2) and 58.5 (6.9) 
ng/ml at 0 and 3 hr respectively (Mucci-LoRusso et al., 1998). 
 
In a cross-sectional study of over 400 patients with cancer pain taking oral oxycodone 
(median daily dose 60 [range 10 – 760] mg), the mean serum oxycodone concentration 
was 161 nM (≈ 51 ng/ml), with a 95% confidence interval of 139 – 183 nM (≈ 44 – 58 
ng/ml) (Andreassen et al., 2011). 
 
There are no previous in vitro immunological studies with which these clinically relevant 
in vivo plasma concentrations can be compared. 
 
2.4.2.7 Diamorphine 
As diamorphine is rapidly hydrolysed by sequential deacetylation after administration in 
vivo, few studies have measured systemic diamorphine concentrations (Rook et al., 
2006). Those that have showed that diamorphine is only present in the systemic 
circulation for minutes. It is considered a pro-drug of morphine, with many of its 
pharmacological effects coming from this metabolite (Cone et al., 1993, Inturrisi et al., 
1984). As diamorphine is converted by rapid deacetylation to morphine and is reported 
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to be twice as potent as morphine (Robinson et al., 1991), diamorphine concentrations 
that were half those of morphine were used in this study. 
 
Some studies have assessed morphine concentration after diamorphine administration 
(Table 2.6). In a paediatric study, 0.1 mg/kg of diamorphine was administered by both 
the intravenous (n=12) and intranasal routes (n=12) and the morphine concentration 
over time was measured using a radioimmunoassay. The median (and range) 
maximum plasma concentration (Cmax) for morphine was 36.1 (13.7 – 82.7) M (≈ 
10,260 [3,905 – 23,570] ng/ml) for the intranasal group and 108.6 (76.5 – 480.1) M (≈ 
30,951 [21,803 – 136,829] ng/ml) for the intravenous group (Kidd et al., 2009).  
 
Table 2.6: Plasma morphine concentrations following diamorphine 
administration. 
Diamorphine 
dose (mg) 
Route  N Cmax (M) Reference 
6-12 intranasal/ 
intramuscular 
6 60 – 66 (Cone et al., 
1993) 
4-52 Intramuscular/ 
intravenous/ 
oral 
11 53 – 490 (Inturrisi et al., 
1984) 
40 Intranasal/ 
intravenous 
4 701 – 1,157 (Mitchell et al., 
2006) 
 
These clinically relevant in vivo plasma concentrations were evaluated in the context of 
that used in a previous in vitro immunological study:  
• 0.0001 – 100M (0.0369 – 36,940 ng/ml) (Thomas et al., 1995b) 
 
2.4.2.8 Codeine 
Single doses of oral codeine (60 or 120 mg) administered to 19 volunteers resulted in a 
mean (± SE) peak codeine plasma concentration of 214.2 ± 27.6 ng/ml for the 60 mg 
dose and 474.3 ± 77.0 ng/ml for the 120 mg dose (Kim et al., 2002). 
  
In a study of 10 volunteers, plasma concentrations of codeine and morphine were 
measured after a single oral dose of 60 mg codeine. This resulted in a mean (± SD) 
peak codeine plasma concentration of 88.1 ng/ml (± 25.1) (Shah and Mason, 1990). 
 
In a healthy volunteer study, a single dose of 60 mg oral codeine has been shown to 
result in a mean peak codeine plasma concentration of 159 ng/ml (Findlay et al., 1978).  
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These clinically relevant in vivo plasma concentrations were also evaluated in the 
context of that used in a previous in vitro immunological study: 
• 0.1 – 5 g/ml (100 – 5,000 ng/ml) (Sheen et al., 2007) 
 
2.4.3 Summary 
The findings presented above (and summarised in Table 2.7) defined the 
concentrations of morphine, tramadol, fentanyl, buprenorphine, methadone, 
oxycodone, diamorphine and codeine which were used in the in vitro studies described 
herein (Table 2.8). Although the concentrations used in the current study were centred 
on those which have been reported/detected in volunteer and clinical studies, five-fold 
higher and lower concentrations were also used in order to explore dose-dependent 
effects. Five-fold dilutions were used to enable a wide range of concentrations to be 
assessed, whilst still being able to potentially detect differences around the clinically 
relevant range. 
 
Table 2.7: Summary of opioid concentrations in previous studies. 
Opioid  Plasma concentrations Cmax  
Morphine 13 – 53, 21 – 57, 289 ng/ml 289 ng/ml 
Tramadol 288, 1,145ng/ml 1,145 ng/ml 
Fentanyl 2 – 6, 8 – 15 ng/ml 15 ng/ml 
Buprenorphine 3, 6, 10 ng/ml 10 ng/ml 
Methadone 2 – 245 ng/ml 245 ng/ml 
Oxycodone 5 – 20, 33 – 59, 44 – 58 ng/ml 59 ng/ml 
Diamorphine  Rapidly hydrolysed to morphine n/a 
Codeine 88, 159, 214 ng/ml 214 ng/ml 
 
 
Table 2.8: Opioid concentrations used in this study. 
Opioid Stock 
concentrations 
Final concentrations used in this study 
(ng/ml) 
Morphine  10 mg/ml 20 100 500 2,500 
Tramadol  50 mg/ml 80 400 2,000 10,000 
Fentanyl  50 μg/ml 0.8 4 20 100 
Buprenorphine 300 μg/ml 0.8 4 20 100 
Methadone 10 mg/ml 20 100 500 2,500 
Oxycodone 10 mg/ml 4 20 100 500 
Diamorphine  5 mg/ml 10 50 250 1,250 
Codeine 60 mg/ml 16 80 400 2,000 
The concentrations used in this study relate to those that are found clinically, with the maximal clinical 
concentration falling in the middle of the concentrations used, with 5x dilutions above and below the 
clinical maximum plasma concentration. In the NK cell cytotoxicity assay, the central two concentrations 
were used. In the phagocytosis and oxidative burst assay the maximum concentration was used in 
addition to this. In the T cell and cytokine assays all concentrations were used (with the addition of a 
supra-maximal concentration, approximately 10x that of the top concentration, shown in the T cell section). 
The diamorphine concentration was extrapolated from the morphine plasma concentration as it is 
approximately twice as potent.  
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It is interesting to note that the relative concentrations detected in clinical studies and 
used in this study, do not necessarily relate to the relative potency of the opioids used 
clinically (which are used when converting patients between the opioids). This is 
because the oral dose does not directly correlate to the plasma concentration, due to 
first pass metabolism, protein binding, excretion and in vivo enzymatic activity. There 
are also differences in whether the opioids are administered as a single dose or are in 
steady state, and due to differing half-lives, which is variable between the opioids. 
 
 
2.5 Influence of opioids on natural killer cell cytotoxicity  
NK cells are critical in the control of cancer and viral infections and this study examined 
the influence of opioids on their cytotoxic capacity and responsiveness to activation. 
The NK cell cytotoxicity assay assesses the ability of NK cells (effector cells within the 
PBMC population) at different effector:target (E:T) ratios to kill target cells. The target 
cell used in these studies is the K562 human erythroleukaemic cell line, which is highly-
sensitive to NK cell killing, but resistant to killing by CD8+ cytotoxic T cells as it is MHC 
class I negative. The killing of K562 cells by unstimulated and IL-2 stimulated PBMCs 
following a 3-hr incubation is determined using a multicolour flow cytometry assay.  
 
For this, K562 cells are labelled with MitoTracker™ Green (MTG; Invitrogen Ltd., 
Paisley, UK), a fluorescent mitochondrial dye, prior to inclusion in the assay, and at the 
end of the assay cells are incubated with propidium iodide (PI; Sigma-Aldrich, 
Gillingham, UK) a fluorescent DNA stain which only labels non-viable cells. The 
proportion of killed K562 target cells (MTG+ and PI+) is then determined by flow 
cytometry (Hopkinson et al., 2007). The effector cell population used in these assays 
are PBMCs, of which 10 – 15% are CD16+/56+ NK cells. 
 
2.5.1 Isolation of peripheral blood mononuclear cells 
This study used PBMCs as the effector cell population. PBMCs were isolated from 
whole blood using a density gradient method. For this, whole blood was collected from 
healthy volunteers and diluted 1:1 with PBS at room temperature. Diluted blood (10 ml) 
was carefully layered onto 10 ml Nycoprep 1.077 (Axis-Shield POCAS, Oslo, Norway) 
density gradient separation medium. Samples were centrifuged at 300 xg for 30 min at 
4°C with the brake off (so as not to disrupt the layers generated during the 
centrifugation). Aggregated erythrocytes and the more dense granulocytes sediment to 
leave a layer of PBMCs and platelets at the interphase (Figure 2-1). The interface was 
removed using a Pasteur pipette. As platelets are sensitive to activation and can be 
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activated by the Vacutainer blood collection system and anticoagulant (Mody et al., 
1999), and as platelet-derived secretory products can inhibit NK cell cytotoxicity (Skov 
Madsen et al., 1986) and cause a variable response in this assay (Hopkinson et al., 
2007), platelets were removed from the PBMC preparation using a second density 
gradient separation step. For this, 10 ml of Nycoprep 1.068 (made by diluting 4 parts of 
Nycoprep 1.077 with 1 part PBS) was layered under 10 ml of the interface using a 
needle and syringe. Samples were centrifuged at 400 xg for 15 min at 4°C (break off). 
The supernatant containing the platelets was removed and the pellet containing the 
PBMCs was re-suspended and washed twice in PBS (300 xg, 5 min, 4°C). 
 
 
 
Figure 2-1: Isolation of PBMCs from whole blood.  
Illustration of the different layers after centrifugation using a density separation media (left), and after the 
removal of the PBMC interface layer (right). Platelets are found throughout the different layers after 
density gradient centrifugation with NycoPrep 1.077. As they are also present in the PBMC layer, they are 
removed by a second density gradient centrifugation step. 
 
PBMCs were re-suspended in 1 ml of Roswell Park Memorial Institute (RPMI) 1640 
growth medium containing 10% v/v fetal bovine serum (FBS; Invitrogen Ltd., Paisley, 
UK), 100 g/ml streptomycin and 100 U/ml penicillin (termed RPMI*), counted using a 
Neubauer haemocytometer and re-suspended at 5x106 viable cells/ml in RPMI*.  
 
PBMCs (2x105 cells/well) were incubated with media alone (unstimulated) or stimulated 
with a final concentration of 100 U/ml (50 ng/ml) recombinant human IL-2 (Miltenyi 
Biotec) in the presence or absence of different opioid concentrations (Table 2.9) for 3 
days (37°C, 5% v/v CO2, 100% humidity) in 96-well microtitre plates (final volume 250 
l). The cytotoxic potential of these cells and their activation status was then 
determined. 
  
PBMCs were harvested and the contents of replicate wells were pooled. Cells were 
then centrifuged at 300 xg, for 5 min at 4°C and washed in order to remove the opioids, 
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as these might directly affect the K562 cells (Sergeeva et al., 1993) and have been 
shown to induce apoptosis at clinical concentrations (10-8 M of morphine; equivalent to 
3 ng/ml) (Hatsukari et al., 2007). PBMCs were re-suspended at 5x106/ml in RPMI*. 
 
Table 2.9: Opioid concentrations used for the NK cell assays. 
Opioid Final opioid concentrations used for the 
NK cell assays (ng/ml) 
Morphine  100 500  
Tramadol  400 2,000  
Fentanyl  4 20  
Buprenorphine 4 20  
Methadone 100 500  
Oxycodone 20 100  
Diamorphine  50 250  
Codeine 80 400  
 
2.5.2 K562 cells 
The target cell for the NK cell cytotoxicity assay is the highly NK cell sensitive human 
erythroleukaemic K562 cell line, purchased from the Health Protection Agency Culture 
Collection (formally European Cell and Culture Collection, Porton Down, UK). K562 
stocks were stored in liquid N2 in 90% FBS and 10% dimethyl sulfoxide (DMSO). Once 
thawed, cells were incubated at 37°C, 5% v/v CO2 in RPMI* growth medium containing 
2 mM L-glutamine (Invitrogen Ltd., Paisley, UK) and passaged (1:43 dilution) twice 
weekly. K562 cells were fluorescently labelled with MTG on the day of each 
experiment. For this, 8x106 K562 cells were incubated with MTG (final concentration 75 
nM) in 2 ml RPMI growth medium at 37°C for 20 min (Hopkinson et al., 2007). Cells 
were then centrifuged at 500 xg for 5 min at 4°C, washed with 5 ml of growth medium 
three times before being re-suspended in 1 ml of growth media and then counted using 
a haemocytometer. Cells were finally re-suspended at 1x106 cells/ml.  
 
2.5.3 Natural killer cell cytotoxicity assay  
For the cytotoxicity assay, 25 l of MTG-labelled K562 target cells (1x106 cells/ml) were 
added to 500, 250, 125 or 62.5 l of the PBMC preparation (5x106 cells/ml) in 12x75 
polycarbonate tubes, to give E:T ratios of 100:1, 50:1, 25:1 and 12.5:1 respectively. 
The incubation volume was made up to 525 l with RPMI*. Tubes were vortexed then 
centrifuged at 1,000 xg for 3 min at 4°C. Samples were then incubated at 37°C for 3 hr 
and then kept on ice in the dark until analysis by flow cytometry. PI was added to the 
samples 10 min before flow cytometric analysis. The proportions of viable (MTG+PI-) 
and non-viable (MTG+PI+) K562 target cells was determined using a BD LSRII flow 
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cytometer (Hopkinson et al., 2007) (Figure 2-2). Unstained and MTG-labelled K562 
cells that had not been incubated with PBMCs were used as controls for setting up the 
negative fluorescence and compensation values respectively. After the addition of PI, 
the MTG-labelled K562 cells were used as a measure of background death. 
 
 
 
Figure 2-2: Representative dot plot for the NK cell 
cytotoxicity assay. 
This shows MitoTracker Green vs. Propidium Iodide fluorescence 
and indicates the live (lower right, red) and dead (upper right, green) 
MTG
+
 K562 target cell populations. The proportion of dead target 
cells, which reflects NK cell cytotoxicity, is calculated from these two 
populations. 
 
Traditionally NK cell cytotoxicity has been measured using 51Cr labelled target cells, 
with the level of 51Cr released into the assay supernatant determined by a  counter. 
Flow cytometry, which accurately determines the number of live/dead target cells has 
been demonstrated to correlate with the 51Cr release assay (Kane et al., 1996, Shi et 
al., 1987). 
 
NK cells can be influenced by a number of factors, including immunological and 
endocrinological, and there is potential inter- and intra-individual variability for this 
assay over time (Hopkinson et al., 2007, Jacobs et al., 1999, Motzer et al., 2003). 
Using the same methodology as the current study, baseline NK cell cytotoxicity 
between individuals (n=5) varied between 15 and 60% (at the 100:1 E:T ratio) and 
interassay variability over a 3 week period were up to 32% (Hopkinson et al., 2007). In 
another study, interassay variabilities for NK cell cytotoxicity were up to 46% (Motzer et 
al., 2003). These effects were minimised in the current study by using a small cohort of 
healthy volunteers and by removing the platelet-mediated effects.   
105 | P a g e  
 
2.5.3.1 Calculation of natural killer cell cytotoxicity  
For each E:T cell ratio, NK cell cytotoxicity was represented by the proportion of K562 
cells which were dead (number of MTG+PI+ K562 cells / total number of MTG+ labelled 
K562 cells x 100) (Figure 2-2). This value was then corrected for background target cell 
death (i.e. the proportion of dead cells in the control K562 sample, without any NK 
cells). In this way, only actual NK cell killing is evaluated.  
 
NK cell cytotoxicity is typically expressed as the degree of cytotoxicity (proportion of 
dead target cells) at the different E:T ratios (usually 100:1, 50:1, 25:1 and 12.5:1), or at 
a single E:T ratio. NK cell cytotoxicity has also been expressed as area under the 
cytotoxic curve (AUCC), a composite calculation of cytotoxicity which incorporates all 
four E:T ratios (Sheeran et al., 1988) as this approach increases the reproducibility and 
reduces the variability of the assay (Hopkinson et al., 2007). Sheeran first calculated 
the AUCC using Simpson’s rule, in which the cytotoxicities at the E:T cell ratios of 
12.5:1, 25:1, 50:1 and 100:1 are expressed as A, B, C and D respectively, Figure 2-3 
(Sheeran et al., 1988). The following formula is then used to calculate the AUCC: 
AUCC = [(12.5xA)+(12.5xB)+(25xC)+(50xD)+(12.5xA)+(25xB)+(50xC)]/2 
 
Figure 2-3: Calculating the area under the NK cell cytotoxicity curve 
(AUCC). 
Using Simpson’s rule (Sheeran et al., 1988), AUCC was calculated using AUCC = 
[(12.5xA)+(12.5xB)+(25xC)+(50xD)+(12.5xA)+(25xB)+(50xC)]/2. In which A, B, C and 
D are the measured cytotoxicities at effector:target (E:T) cell ratios of 12.5:1, 25:1, 
50:1, and 100:1, respectively. Modified from Hopkinson et al., 2007. 
 
In the current study, NK cell cytotoxicity was determined using PBMC populations, not 
purified NK cells. The proportion of NK (CD16+/56+) cells in this population was 
therefore determined by flow cytometry (see next section) and the value for the AUCC 
was adjusted for its NK cell content (to correct for individual variability in the prevalence 
of NK cells) by dividing the AUCC by the proportion of cells in the PBMC preparation 
which are CD16+/56+, expressed as decimal:  
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Corrected AUCC = AUCC(1/Z) 
Where Z is the proportion of cells in the PBMC preparation which are 
CD16+/56+, expressed as decimal (i.e. for a sample containing 11% 
CD16+/56+ cells, Z=0.11) 
 
The uncorrected AUCC provides a measure of the overall cytotoxic potential of the 
samples, whereas the corrected AUCC provides insight into differences in NK cell 
cytotoxic potential which are not related to changes in the proportion of NK cells in the 
sample under investigation. Both parameters have been calculated in the current study. 
 
2.5.4 Effect of opioids on the activation status of lymphocyte 
subpopulations 
In addition to assessing the influence of opioids on the cytotoxic potential of NK cell 
cytotoxicity, the influence of morphine, tramadol, fentanyl, buprenorphine, methadone, 
oxycodone, diamorphine and codeine on unstimulated and IL-2 induced expression of 
the activation markers CD25 and CD69 by CD4-CD8-CD16+CD56+ viable NK cell 
populations was determined by multiparameter flow cytometry. By labelling the PBMCs 
with mAbs to six CD antigens (Table 2.10), identification of specific cells and the 
activation status of those cells can be determined. 
 
Table 2.10: The CD antigens analysed, their expression and function. 
Target 
antigen 
Immune cell expression Functions 
CD4 T cell subsets: TH1, TH2 and Treg cells 
(two thirds of peripheral T cells). Low 
expression on monocytes and 
macrophages 
MHC class II co-receptor. Binds Lck 
on cytoplasmic side of membrane 
CD8 T cell subsets: cytotoxic T cells (one 
third of peripheral T cells) 
MHC class I co-receptor. Binds Lck on 
cytoplasmic side of membrane. 
CD16/56 NK cells  CD16 is a low affinity FcγRIII receptor 
CD56 (also known as N-CAM) 
mediates cell-cell contact and binding 
CD25 Expressed on activated T cells, B 
cells, NK cells and monocytes 
Alpha chain of the IL-2 receptor. 
Activation antigen 
CD69 Expressed on activated T cells, B 
cells, NK cells and macrophages  
Early activation antigen. Functional 
role in immune regulation. Contributes 
to lymphocyte retention in secondary 
lymphoid tissue  
 
The monoclonal antibodies to target antigens, used to identify lymphocyte subtypes and their activation 
status by flow cytometry. Lck (leukocyte-specific protein tyrosine kinase), N-CAM (Neural Cell 
Adhesion Molecule), Treg (regulatory T cell). 
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CD4 is a glycoprotein which is expressed on the surface of T helper cells, Treg cells, 
monocytes, macrophages, and DCs. In T cells it is a co-receptor, which along with the 
TCR initiates an intracellular activation cascade via Lck, after interaction with a MHC 
class II molecule on an APC. IL-2 produced by CD4+ T cells controls the activation of 
CD8+ cytotoxic T cells via CD25 up-regulation (Obar et al., 2010). 
 
CD8 is principally expressed on the surface of cytotoxic T cells and, to lesser degrees, 
on NK and DCs. CD8, like CD4, is a transmembrane glycoprotein that acts as a co-
receptor with the TCR, however, CD8 binds to, and recognises antigen presented in 
the context of MHC class I molecules. Functionally, CD8 is a dimer and binds with high 
affinity to MHC class I ensuring that the cytotoxic T cell and target cell are tightly bound 
during antigen induced activation. 
 
CD16 is the low affinity FcγRIII receptor, which binds the Fc region of immunoglobulins. 
CD56 or N-CAM (Neural Cell Adhesion Molecule) is involved in cell-cell interactions 
and growth. A mAb mix containing both CD16 and CD56 was used to identify NK cells 
in this study. The majority of NK cells (about 95%) express low levels of CD56 and high 
levels of CD16. There is also a smaller proportion of NK cells which express high levels 
of CD56 and are CD16 negative, these NK cells cannot bind immunoglobulin as they 
lack the low affinity Fc receptor, CD16; they are involved in cytokine release and have 
been termed regulatory NK cells (Yoshida et al., 2010). These two types of NK cells 
were not distinguished in the current study.  
 
The assessment of lymphocyte activation provides information about the potential 
ability of the immune system to function normally and is a means to evaluate how this 
could be affected by opioids. Traditionally, lymphocyte activation in vitro has been 
assessed using proliferation markers such as DNA synthesis. Although requiring fewer 
cells, these techniques do not enable the responsiveness of individual cell subsets to 
be determined. The detection of activation antigens such as CD25 and CD69 on cell 
subsets by flow cytometry is a more definitive approach for measuring lymphocyte 
responsiveness in mixed cell populations (Maino et al., 1995, Simms and Ellis, 1996). 
 
CD25 is the -chain of the IL-2 receptor, which heterotrimerises with the -chain, and 
common -chain to form the complete IL-2 receptor. When activated by the binding of 
IL-2, this receptor is involved in the activation and maintenance of immune responses 
and lymphocyte development. It is also critical in the promotion of proliferation and 
differentiation of T cells, NK cells and B cells, as well as being involved in the 
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elimination of self-reactive T cells (Castriconi et al., 2007, Curfs et al., 1997). 
 
CD69 is an early activation antigen which is a member of the NK cell gene complex 
family (Testi et al., 1994). Unactivated NK cells express very low levels of CD69, but it 
is expressed by NK cells activated by IL-2, IL-12 and IFN- (Gerosa et al., 1993). 
CD69 can be expressed by T cells within 30 min of TCR activation (Maino et al., 1995). 
Although 3H-thymidine uptake lymphocyte proliferation assays are still often considered 
the standard for assessing T cell activation, CD69 expression by flow cytometry has 
been demonstrated to be correlate well with 3H-thymidine and also provides definitive 
information on the responsiveness of cell subsets in a complex mixture (Mardiney et 
al., 1996, Simms and Ellis, 1996). The measurement of CD69 expression by flow 
cytometry has also been shown to be a more sensitive measure of T cell activation 
than proliferation studies such as the 3H-thymidine uptake assays, although this 
depends on the method of activation used, as polyclonal stimuli (e.g. anti-CD3 mAb, 
staphylococcal enterotoxin B) induce CD69 expression, whereas oligoclonal stimuli 
(such as tetanus toxoid) do not (Simms and Ellis, 1996). 
 
Although used as a lymphocyte activation marker, CD69 might also function as an 
immunoregulator. Initial in vitro data indicated that CD69 might act as a stimulatory 
receptor, yet more recent in vivo studies have disputed this (Sancho et al., 2005). 
CD69 might be a negative regulator of the immune response, in part by increasing the 
production of transforming growth factor (TGF)- by CD4+ T cells (Sancho et al., 2003). 
Evidence for this inhibitory effect of CD69 has come from studies in which the down-
regulation of CD69 expression by CD69 mAbs reduces TGF- levels, increases NK cell 
cytotoxicity and leads to a reduction in tumour growth (Esplugues et al., 2005). CD69 
also contributes to lymphocyte retention in secondary lymphoid tissue (Shiow et al., 
2006). 
 
For the multi-parameter flow cytometry, 1.5x105 PBMCs were washed with 1 ml of PBS 
containing 10% v/v FBS (staining buffer) and centrifuged at 300 xg, for 5 min at 4°C. 
The supernatant was removed using a vacuum aspirator and the cell pellet was re-
suspended in 10 l of staining buffer. The potential for non-specific mAb binding was 
reduced by pre-incubating cells with 0.5 l normal mouse serum for 15 min at room 
temperature, following which a mixture of fluorescently-labelled mAbs was added 
(Table 2.11). All of the volumes of mAbs used were based on the manufacturers’ 
recommendations and produced definitive separations of the cell populations under 
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investigation. Control samples either had no mAb added or were incubated with 
appropriate, fluorescently-conjugated isotype-matched control immunoglobulins. All 
tubes were incubated for 30 min in the dark at 4°C, after which cells were washed twice 
in 1 ml staining buffer (300 xg, 5 min, 4°C) and then re-suspended in 250 l staining 
buffer and kept on ice prior to flow cytometry. Either 2.5 l (1 l/100 l cell suspension) 
of 7-Aminoactinomycin D viability stain (Cambridge Biosciences, Cambridge, UK) was 
added to the sample 5-10 min before analysis, or 1.5 l per 1.5x105 cells (after a 1 in 
10 dilution in PBS) of blue fixable live/dead viability stain (Invitrogen Ltd., Paisley, UK), 
was incubated with the sample for 30 min in the dark at 4°C. 
 
The 7-Aminoactinomycin D viability stain was used in the initial studies. However, its 
broad emission spectrum resulted in spectral overlap into other detectors which 
required considerable compensation. The blue fixable live/dead viability stain is excited 
by the UV laser and its emission spectrum is distinct from that of the other 
flurochromes used. This reduced the amount of compensation that was required and 
allowed cells to be fixed prior to analysis. 
 
Table 2.11: Details of the fluorescently-labelled monoclonal antibodies used. 
Specificity Fluorochrome Volume added 
(manufacturers’ 
recommendations) 
Clone number 
(supplier) 
CD4 Pacific Blue  
(PB) 
1.5 l (after 1:10 
dilution in PBS) 
RPA-T4 
(BioLegend) 
CD8a Alexa Fluor™ 700 
(AF700) 
1.5 l (after 1:20 
dilution in PBS) 
RPA-T4 
(BioLegend) 
CD16/56 Fluorescein 
isothiocyanate (FITC) 
1.5 l LNK16/MEM-188  
(AbD Serotec) 
CD25 R-Phycoerythrin (PE) 1.5 l MEM-181  
(AbD Serotec) 
CD69 Allophycocyanin (APC) 3 l FN50 (BioLegend) 
 
Samples were analysed using a BD™ LSRII flow cytometer and BD Biosciences 
FACSDiva™ acquisition and data analysis software. PBMCs were identified on the 
basis of their size and granularity, as represented by their forward and side light scatter 
characteristics (FSc vs. SSc) respectively (Figure 2-4). Spectral overlap between 
fluorochromes was corrected for using compensation beads. For this, each of the 
mAbs were added to 1 drop of anti-murine IgG-coated beads and 1 drop of negative 
control beads (BD Biosciences) in 12x75 mm polycarbonate tubes. An additional 
control tube was incubated in the absence of mAb. The fluorescent emission of the 
mAb stained beads were determined and used to set the compensation values using 
the FACSDiva software. 
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During flow cytometry the lymphocytes are identified on their size and granularity. 
Doublets (two adherent cells) and dead cells are then excluded in order to ensure the 
CD fluorescent marker analysis is performed on single, viable cells (Figure 2-4). NK 
cells are detected by the further gating of these PBMCs on the basis of CD16/56 
expression (Figure 2-5). The expression of the appropriate antigens by these cells is 
then determined (Figure 2-6). Initial studies revealed that IL-2 stimulation alone had no 
effect on the expression of CD25 by CD4-CD8-CD16-CD56+ NK cells and as a 
consequence only data on CD69 expression are presented in the Results (Figure 2-6). 
 
 
Figure 2-4: Representative flow cytometry plots for PBMCs. 
This shows the PBMCs (gated population) defined by their size (forward scatter - FSc) and granularity 
(side scatter – SSc; top left). These cells are then gated by size (forward scatter height) and area (forward 
scatter area), removing doublets (which can have mixed CD antigen binding properties), to allow only 
single cells to be analysed (top right). These single PBMCs are then assessed for viability with 7-
Aminoactinomycin D (7AAD; viability stain), removing dead cells from the analysis (which can have 
atypical CD antigen binding properties), to allow only viable single cells to be analysed (bottom left). 
These single viable PBMCs are then analysed for CD4 (conjugated to Pacific blue) and CD8 (conjugated 
to Alexa Fluor™ 700; AF700) binding (bottom right), before each of these lymphocyte subtypes have their 
activation status assessed by CD69 and CD25 expression. 
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Figure 2-5: Histogram of CD16 and CD56 expression by PBMCs. 
The expression of CD16 and CD56 as detected by a anti-CD16/CD56 mAb. 
The population of the cells expressing CD16 or CD56 are NK cells. 
 
 
 
 
 
 
 
 
 
Figure 2-6: Overlay histograms of CD25 and CD69 expression by NK cells. 
CD25 (left panel) and CD69 expression (right panel) by CD16
+
/56
+
 NK cells in unstimulated and 
IL-2 stimulated PBMC preparations, with and without 100 ng/ml of morphine. 
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2.6 Influence of opioids on neutrophil and monocyte function  
Neutrophils and monocytes are innate immune cells which play a central role in the 
control of bacterial and fungal infection, as well as in the removal of dead cells and 
foreign material. The control of infection principally involves phagocytosis of the target 
cell/material and the subsequent generation of a cytotoxic oxidative burst reaction. 
 
Initially, the effect of different incubation times with one concentration of morphine, 
tramadol and fentanyl on neutrophil and monocyte phagocytosis and oxidative burst 
responses were assessed. Subsequent experiments evaluated the influence of a single 
incubation time with morphine, tramadol, fentanyl, buprenorphine, methadone, 
oxycodone, diamorphine and codeine at variable concentrations (Figure 2-7 and Table 
2.12). 
 
Figure 2-7: Sequence for the phagocytosis and oxidative burst assays. 
Sequence of studies into the effects of different pre-incubation times with, and concentration of 
morphine, tramadol and fentanyl on neutrophil and monocyte phagocytosis and oxidative burst 
responses. Buprenorphine, methadone, oxycodone, diamorphine and codeine were assessed at 
the single time point of 60 min, as per the second stage of this experiment. 
 
Previous studies have reported on inter- and intra-individual variability in neutrophil and 
monocyte and phagocytosis and oxidative burst responses. These effects were 
minimised in the current study by using a relatively fixed cohort of healthy volunteers 
and by using a validated commercial kit PHAGOBURST
® test kit (Orpegen Pharma) 
with high intra-assay precision (manufacturer’s information from data sheet). However, 
other factors, both genetic and environmental (i.e. diet) which were not compensated 
for, as well as different individual responses to opioids might also influence the 
perceived reproducibility of the data generated.  
 
2.6.1 Effects of opioids on neutrophil and monocyte phagocytosis 
To investigate the effect of opioids on the phagocytic response of neutrophils and 
monocytes, a whole blood, flow cytometric approach was performed using the 
PHAGOBURST
® test kit (Orpegen Pharma). For this, heparinised whole blood (50 l) 
was incubated for 0, 30, 60 and 120 min (section 2.6.1.2) at 37°C with 50 l of opioid or 
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PBS (as a control). Samples were then incubated with 10 l FITC-labelled opsonised 
E.coli for 10 min at 37°C. Control tubes containing 10 l FITC-labelled opsonised E.coli 
were incubated for 10 min at 4°C. This made the incubation time with the opioid 10 min 
longer than specified, with the 0 min opioid incubation being for 10 min, along with the 
stimulation. At the end of the incubation period, all tubes were transferred to ice and 50 
l of quenching solution was added. This quenches the fluorescence of adherent, non-
phagocytosed FITC-E.coli. Erythrocytes were then lysed by incubating samples with 3 
ml of FACSLyse™ (BD Biosciences) for 20 min at room temperature, after which 
samples were washed twice in PBS (5 min, 250 xg, 4°C). This test has been 
demonstrated to have high intra-assay precision with Coefficients of Variation of 0.2% 
for the proportion of neutrophils phagocytosing E.coli and 1.5% for the MFI of this 
response, and 1.1% for the proportion of monocytes phagocytosing E.coli and 3.6% for 
the MFI of this response (PHAGOBURST® test kit data sheet, Orpegen Pharma). 
 
The proportion of cells phagocytosing FITC-E.coli and the amount of E.coli that has 
been phagocytosed (median fluorescent intensity, MFI) were then analysed using a BD 
Biosciences FACSCalibur™ flow cytometer utilising BD Biosciences CELLQuest 
acquisition and analysis software. It has been demonstrated that the phagocytic index 
(by microscopically counting the number of erythrocytes ingested by 100 phagocytes) 
is a more sensitive parameter of phagocytic activity than just the number of phagocytes 
ingesting erythrocytes (Tomassini et al., 2004). In the current study this is taken further 
by using flow cytometry to accurately analyse (Kampen et al., 2004) at least 5,000 cells 
and measuring the absolute uptake of E.coli per cell and per population of cells, as well 
as the proportion of cells ingesting E.coli. Opsonised E.coli is also physiologically 
relevant in terms of host defence against infection. 
 
2.6.1.1 Flow cytometric acquisition and analysis  
Neutrophil and monocyte populations were identified on the basis of their size and 
granularity (FSc and SSc light scatter characteristics respectively) and confirmed using 
CD11b and CD14 mAb staining (for neutrophils and monocytes respectively). Data 
acquisition regions were plotted around these two populations (Figure 2-8) and data on 
a minimum of 5,000 cells in the monocyte region and more than 10,000 cells in the 
neutrophil region were collected. The proportion of cells which were positive for 
fluorescence and the intensity of this fluorescent signal (MFI) were recorded (Figure 
2-9). Prior to acquisition, control samples were used to set the voltages (sensitivity) for 
the fluorescence signal. 
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Figure 2-8: Representative flow cytometry dot plot for lysed whole blood. 
This shows the three main populations of leucocytes in whole blood defined by their different size, forward 
scatter (FSc) and granularity, side scatter (SSc). Although the monocytes are gated during acquisition (to 
ensure at least 5,000 events), data on the more granular neutrophils are also acquired in order to enable 
the fluorescent signals generated by these two cell types to be analysed separately. 
 
 
 
Figure 2-9: Representative overlay histograms illustrating the phagocytosis of 
E.coli by neutrophils and monocytes and the influence of morphine. 
Fluorescent histograms for neutrophils (left panel) and monocytes (right panel) following 
incubation with FITC-E.coli for 10 min at 4°C and 37°C, with and without 100 ng/ml of morphine. 
 
2.6.1.2 Phagocytosis time course experiments 
To optimise the incubation time with opioids, initial kinetics experiments were 
performed. For these, heparinised whole blood (50 l) was incubated at 37°C for 0, 30, 
60 and 120 min with 50 l of morphine (100 ng/ml final concentration), tramadol (400 
ng/ml final concentration), fentanyl (4 ng/ml final concentration) or 50 l of PBS (as a 
control). As neutrophils do not survive well in vitro, cultures needed to be kept as short 
as possible. However, up to 5 hr is unlikely to have any effect on viability (Welters et 
al., 2000a).  
 
The findings relating to the influence of incubating whole blood for different times with 
morphine (Figure 2-10), tramadol (Figure 2-11) and fentanyl (Figure 2-12) on the ability 
of neutrophils and monocytes to phagocytose E.coli are presented below.  
Lymphocytes
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Figure 2-10: Effect of incubation time with morphine on neutrophil and monocyte 
phagocytosis. 
The proportion of neutrophils and monocytes phagocytosing FITC-E.coli (left panel) and the intensity of 
the phagocytic response (median channel of fluorescent intensity, MFI; right panel). Whole blood was 
incubated with 100 ng/ml of morphine for the indicated times (0, 30, 60 and 120 min) prior to assessing the 
phagocytosis of FITC-E.coli, with a further 10-min incubation. Data are means ± SEM from 3 independent 
experiments. 
 
Figure 2-11: Effect of incubation time with tramadol on neutrophil and monocyte 
phagocytosis. 
The proportion of neutrophils and monocytes phagocytosing FITC-E.coli (left panel) and the intensity of 
the phagocytic response (median channel of fluorescent intensity, MFI; right panel). Whole blood was 
incubated with 400 ng/ml of tramadol for the indicated times (0, 30, 60 and 120 min) prior to assessing the 
phagocytosis of FITC-E.coli, with a further 10-min incubation. Data are means ± SEM from 3 independent 
experiments. 
 
Figure 2-12: Effect of incubation time with fentanyl on neutrophil and monocyte 
phagocytosis. 
The proportion of neutrophils and monocytes phagocytosing FITC-E.coli (left panel) and the intensity of 
the phagocytic response (median channel of fluorescent intensity, MFI; right panel). Whole blood was 
incubated with 4 ng/ml of fentanyl for the indicated times (0, 30, 60 and 120 min) prior to assessing the 
phagocytosis of FITC-E.coli, with a further 10-min incubation. Data are means ± SEM from 3 independent 
experiments. 
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Incubation of whole blood for 0, 30, 60 and 120 min with clinically relevant 
concentrations of morphine, tramadol and fentanyl had a greater effect on the intensity 
of the neutrophil and monocyte phagocytic response to E.coli (which correlates to the 
number of bacteria phagocytosed) than on the proportion of neutrophils and monocytes 
that phagocytosed the E.coli. Although there was a trend for a decrease in the 
proportion of neutrophils and monocytes performing phagocytosis with longer 
incubation times, this was less dramatic when compared to the effect on the intensity of 
the phagocytic response, which occurred with even the shortest incubation times. The 
exception to this was the effect of fentanyl on neutrophil phagocytosis, where the no 
opioid control was at a very low level. Although the short incubation times inhibited the 
total number of E.coli that were phagocytosed by monocytes, the longer incubation 
times tended to inhibit this further. For neutrophils, longer incubation times had no 
additional impact on the ability of these cells to phagocytose the bacteria.  
 
These results informed the next series of experiments which investigated the effect of 
different concentrations the opioids (Table 2.12) at a fixed pre-incubation time of 60 
min at 37°C on neutrophil and monocyte phagocytosis (presented in the Results). An 
incubation time of 60 min was used, as 120 min did not induce a consistently greater 
inhibition of phagocytosis and to minimise the total incubation period. 
 
 
Table 2.12: Opioid concentrations used for phagocytosis and oxidative burst assays. 
Opioid Final opioid concentrations used for 
phagocytosis and oxidative burst assays 
(ng/ml) 
Morphine  20 100 500  
Tramadol  80 400 2,000  
Fentanyl  0.8 4 20  
Buprenorphine 0.8 4 20  
Methadone 20 100 500  
Oxycodone 4 20 100  
Diamorphine  10 50 250  
Codeine 16 80 400  
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2.6.2 Effects of opioids on neutrophil and monocyte oxidative burst 
responses 
Once internalised, the phagosome containing the pathogens fuses with a lysosome 
containing digestive enzymes to form a phagolysosome. These digestive enzyme 
(oxygen-independent) and oxygen-dependent (oxidative burst reaction) degradation 
become the next vital step in the elimination of the pathogen. 
 
The effect of opioids on the various pathways that are responsible for inducing the 
oxidative burst in neutrophils and monocytes was assessed using the PHAGOBURST
® 
test kit (Orpegen Pharma). Oxidative burst responses were induced using opsonised 
E.coli (physiological stimulus), PMA (a potent stimulus directly activating PKC) and 
fMLP (a synthetic peptide which mimics the activity of bacterial peptides; a relatively 
weak stimulus). This test has been shown to have high intra-assay precision with 
Coefficients of Variation of 0.1% for the proportion of neutrophils undergoing the 
oxidative burst reaction to E.coli and 4.8% for the MFI of this response, and 1.1% for 
the proportion of monocytes undergoing the oxidative burst reaction to E.coli and 6.5% 
for the MFI of this response (PHAGOBURST
® test kit data sheet, Orpegen Pharma). 
 
The oxidative burst reaction is characterised by the rapid release of reactive oxygen 
species (superoxide radical, H2O2) as part of the oxygen-dependent degradation in 
phagolysosomes. Neutrophils and monocytes use nicotinamide adenine dinucleotide 
phosphate oxidase to reduce O2 to oxygen free radicals and then H2O2. They then use 
myeloperoxidase to further combine H2O2 with Cl
- to produce hypochlorite. This 
reaction is vital for the killing of potential pathogens, as well as for degrading 
internalised particles. A failure of phagocytic cells to kill organisms that they have 
engulfed because of defects in the enzymes that produce free radicals results in 
chronic granulomatous disease. This consists of a range inherited disorders which 
present in childhood with severe, recurrent bacterial and fungal infections (Dinauer, 
2007).  
 
Neutrophils and monocytes are able to detect the presence of infection by binding 
bacterial peptides containing N-formylmethionine, or fMet, a modified amino acid that is 
used for the initiation of all proteins synthesised in prokaryotes. The receptor which 
recognises these peptides is known as the fMLP receptor. 
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Pathogen-associated molecular patterns, such as bacterial LPS, are conserved small 
molecular motifs that are associated with pathogens. They are recognised by TLRs, 
TLR4 in the case of LPS, and other pattern or pathogen recognition receptors, located 
on cells of the innate immune system. LPS binds to TLR4 (in a complex with MD2), 
which then activates the MyD88-dependent pathway, recruiting IRAKs and activating 
NF-B and MAPK. TLR4 also has an effect via a TRIF-dependent pathway that 
activates IRF3 and NF-B. Both these pathways lead to the production of pro-
inflammatory cytokines (Kawai and Akira, 2010). The MAPK pathway activates the 
ERK and JNK pathways and the early response transcription, AP-1 (c-Jun/c-Fos 
combination) (Aderem and Ulevitch, 2000).  
 
Neutrophils and monocytes are activated by similar intracellular pathways to those that 
are modulated when opioid receptors are activated. G-protein subunits, dissociated by 
activation, stimulate adenylyl cyclase and PLC, producing the secondary messenger’s 
cAMP, inositol trisphosphate and Ca2+. These activate intracellular pathways affecting 
cell metabolism, motility, gene expression, and cell division. Opioids could potentially 
interfere with these G-protein targets or the secondary messengers, as there is overlap 
in the intracellular transduction pathways of opioids and in the activation pathways via 
which fMLP, PMA and E.coli trigger neutrophils and monocytes. 
 
PMA is a very potent stimulus and PMA-induced neutrophil and monocyte responses 
might be influenced if an opioid interferes with PKC signal transduction. E.coli is of an 
intermediate potency and the stimulus which most closely mimics the mechanism of 
activation to which neutrophils or monocytes have evolved to elicit an oxidative burst. 
E.coli are gram negative bacteria which contain LPS in their cell wall and will, among 
other mechanisms, bind to and activate TLR4. In the clinical situation, and in this 
assay, E.coli are opsonised and thus they will also bind to Fc receptors and C3b 
complement receptors on neutrophils and monocytes. By using fMLP as a weak 
stimulus (designated as a ‘low’ control in the assay kit), the potential for opioids to 
increase or prime neutrophils or monocytes to perform the oxidative burst reaction can 
be assessed. Furthermore, these three stimuli activate the cells via different pathways 
and modifications in their stimulatory effects might provide some insight into the 
different pathways and mechanisms involved in the effects of opioids on neutrophils 
and monocytes. 
 
When stimulated to undergo the oxidative burst, neutrophils and monocytes produce 
reactive oxygen species (superoxide anion, H2O2, hypochlorous acid) which oxidise 
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dihydrorhodamine 123 to its fluorescent derivative rhodamine 123 (Rothe and Valet, 
1994). This is then detected by flow cytometry analysis. Reactive nitrogen 
intermediates such as peroxynitrite, which might be important in bacteria killing, were 
not evaluated and the synthesis of the oxygen intermediates O2
- and HO2 cannot be 
assessed (van Pelt et al., 1996).  
 
Flow cytometric acquisition and analysis was the same as for phagocytosis (described 
in section 2.6.1.1), with the proportion of neutrophils and monocytes positive for the 
fluorescence of the oxidative burst reaction and the intensity of this signal being 
recorded (Figure 2-13 - Figure 2-14). This correlated to the activity of the oxidative 
burst reaction. Prior to acquisition, control samples were used to set the voltages 
(sensitivity) for the fluorescence signal. 
 
 
Figure 2-13: Overlay histograms for the oxidative burst reaction. 
Comparison of the stimulatory effect of the negative control (no stimulation), fMLP (weak stimulus), 
PMA (potent stimulus) and E.coli (physiological stimulus) on the oxidative burst activity for 
neutrophils (left panel) and monocytes (right panel). 
 
 
Figure 2-14: Representative overlay histograms illustrating the oxidative burst 
activity and the influence of diamorphine. 
Fluorescent histograms of the oxidative burst reaction to E.coli for neutrophils (left panel) and 
monocytes (right panel) with and without 250 ng/ml of diamorphine. Whole blood was incubated 
(37°C) with diamorphine or saline for 1 hr before assessing the oxidative burst response to E.coli 
(10-min incubation) using flow cytometry (negative control included for comparison). 
fMLP 
Negative control
E.coli
PMA
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2.6.2.1 Oxidative burst time course experiments 
As with the phagocytosis experiments, in initial experiments 50 l of heparinised whole 
blood were pre-incubated with 50 l of morphine (100 ng/ml final concentration), 
tramadol (400 ng/ml final concentration), fentanyl (4 ng/ml final concentration) or 50 l 
of PBS (as a control) for 0, 30, 60 or 120 min prior to the addition of the stimulus. 
Samples were then incubated for 10 min at 37°C with 10 l fMLP (5 M final 
concentration), 10 l PMA (8.1 M final concentration) or 10 l opsonised E.coli (1x109 
bacteria/ml) in 12x75 mm Falcon polycarbonate tubes. 10 l of washing solution was 
added to the negative control. This made the incubation time with the opioid 10 min 
longer than specified above, with the 0 min opioid incubation being for 10 min, whilst 
being stimulated. 
 
At the end of the incubation period, 10 l of dihydrorhodamine 123 substrate solution 
(one disk reconstituted with 1 ml washing solution 60 min prior to use) was added to 
each tube, after which tubes were mixed and incubated at 37°C for 10 min. 
Erythrocytes were lysed by incubating samples with 3 ml of FACSLyse™ for 20 min, 
then samples were washed twice in PBS (5 min, 250 xg, 4°C). The proportion of cells 
undergoing the oxidative burst and its intensity were then analysed using a BD 
Biosciences FACSCalibur™ flow cytometer utilising BD Biosciences CELLQuest 
acquisition and analysis software. 
 
The influence of varying incubation time with morphine (Figure 2-15, Figure 2-16), 
tramadol (Figure 2-17, Figure 2-18) and fentanyl (Figure 2-19, Figure 2-20) on the 
ability of neutrophils and monocytes to perform the oxidative burst reaction is illustrated 
below.  
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Figure 2-15: Effect of incubation time with morphine on neutrophil oxidative burst 
reaction. 
The proportion of neutrophils undergoing the oxidative burst reaction (left panel) and the intensity of the 
oxidative burst response (median channel of fluorescent intensity, MFI; right panel). Whole blood was 
incubated with 100 ng/ml of morphine for the indicated times (0, 30, 60 and 120 min) prior to assessing the 
oxidative burst reaction stimulated by fMLP, PMA and E.coli, with a further 10-min incubation. Data are 
means ± SEM from 3 independent experiments. 
 
 
 
 
 
  
Figure 2-16: Effect of incubation time with morphine on monocyte oxidative burst 
reaction. 
The proportion of monocytes undergoing the oxidative burst reaction (left panel) and the intensity of the 
oxidative burst response (median channel of fluorescent intensity, MFI; right panel). Whole blood was 
incubated with 100 ng/ml of morphine for the indicated times (0, 30, 60 and 120 min) prior to assessing the 
oxidative burst reaction stimulated by fMLP, PMA and E.coli, with a further 10-min incubation. Data are 
means ± SEM from 3 independent experiments. 
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Figure 2-17: Effect of incubation time with tramadol on neutrophil oxidative burst 
reaction. 
The proportion of neutrophils undergoing the oxidative burst reaction (left panel) and the intensity of the 
oxidative burst response (median channel of fluorescent intensity, MFI; right panel). Whole blood was 
incubated with 400 ng/ml of tramadol for the indicated times (0, 30, 60 and 120 min) prior to assessing the 
oxidative burst reaction stimulated by fMLP, PMA and E.coli, with a further 10-min incubation. Data are 
means ± SEM from 3 independent experiments. 
 
 
 
 
 
  
Figure 2-18: Effect of incubation time with tramadol on monocyte oxidative burst 
reaction. 
The proportion of monocytes undergoing the oxidative burst reaction (left panel) and the intensity of the 
oxidative burst response (median channel of fluorescent intensity, MFI; right panel). Whole blood was 
incubated with 400 ng/ml of tramadol for the indicated times (0, 30, 60 and 120 min) prior to assessing the 
oxidative burst reaction stimulated by fMLP, PMA and E.coli, with a further 10-min incubation. Data are 
means ± SEM from 3 independent experiments. 
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Figure 2-19: Effect of incubation time with fentanyl on neutrophil oxidative burst reaction. 
The proportion of neutrophils undergoing the oxidative burst reaction (left panel) and the intensity of the 
oxidative burst response (median channel of fluorescent intensity, MFI; right panel). Whole blood was 
incubated with 4 ng/ml of fentanyl for the indicated times (0, 30, 60 and 120 min) prior to assessing the 
oxidative burst reaction stimulated by fMLP, PMA and E.coli, with a further 10-min incubation. Data are 
means ± SEM from 3 independent experiments. 
 
 
 
 
 
  
Figure 2-20: Effect of incubation time with fentanyl on monocyte oxidative burst reaction. 
The proportion of monocyte undergoing the oxidative burst reaction (left panel) and the intensity of the 
oxidative burst response (median channel of fluorescent intensity, MFI; right panel). Whole blood was 
incubated with 4 ng/ml of fentanyl for the indicated times (0, 30, 60 and 120 min) prior to assessing the 
oxidative burst reaction stimulated by fMLP, PMA and E.coli, with a further 10-min incubation. Data are 
means ± SEM from 3 independent experiments. 
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Clinically relevant concentrations of morphine, tramadol and fentanyl over 0, 30, 60 and 
120 min tended to inhibit neutrophil and monocyte oxidative burst reactions, although 
the effects were dependent on the stimulus, opioid and, in some cases, the exposure 
time. 
 
Morphine only inhibited the stimulatory effect of E.coli on the proportion of neutrophils 
undergoing the oxidative burst reaction, which was independent of incubation time. The 
intensity of this response (MFI) was also inhibited (except at 120 min). For longer 
incubation times, morphine inhibited the intensity of the neutrophil oxidative burst 
response to PMA activation. Although monocytes produced a less vigorous response 
compared to neutrophils, morphine inhibited the proportion of monocytes undergoing 
the oxidative burst reaction to E.coli at all-time points and the effect of PMA at longer 
incubation times. The magnitude of this response, although small at baseline, was also 
marginally inhibited when the monocytes were stimulated with PMA or E.coli. 
 
Tramadol inhibited the proportion of neutrophils undergoing the oxidative burst reaction 
in response to both fMLP and E.coli, which was independent of the incubation time. 
Although the intensity of this response to all stimuli was very low, there might be a 
trend for this to be inhibited by tramadol. The only effect on monocytes was to time-
dependently inhibit the proportion of cells undergoing the oxidative burst response to 
E.coli. 
 
Fentanyl inhibited the proportion of neutrophils undergoing E.coli-induced oxidative 
burst and its intensity at all-time points. It also decreased the intensity of response to 
PMA in a time-dependent manner. Fentanyl reduced the proportion of monocytes 
undergoing the oxidative burst in response to E.coli, at all-time points, although the 
effects were more pronounced as the incubation time increased. The intensity of this 
response was also decreased, except at 0 min pre-opioid incubation. 
 
On the basis of these results the subsequent series of experiments assessed the effect 
of different concentrations of opioids at a fixed pre-incubation time of 60 min at 37°C on 
the oxidative burst reaction by neutrophils and monocytes. Three concentrations of 
each opioid were evaluated (Table 2.12), these are presented in the Results. An 
incubation time of 60 min was used, as 120 min did not induce a consistently greater 
inhibition of the oxidative burst response and to minimise the total incubation period. 
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2.7 Effect of opioids on the responsiveness of peripheral blood 
mononuclear cells populations to polyclonal stimulation 
CD4+ T cells are central to the coordination of immune responses and CD8+ T cells are 
involved in the killing of virally infected cells or tumour cells expressing MHC class I. 
The influence of opioids on the susceptibility of these lymphocyte populations to 
polyclonal activation using anti-CD3/anti-CD28 mAb coated beads (on the basis of 
CD25 and CD69 activation marker induction) was determined. As evidence suggests 
that opioid receptors are only expressed on activated lymphocytes (Borner et al., 2008, 
Kraus, 2009), these experiments compared the influence of opioids on the 
responsiveness of activated T cell populations. This also might more closely reflect the 
potential effects of opioids on the immune status of patients with cancer or infection. 
During the incubation of PBMCs with anti-CD3/anti-CD28 mAb coated beads, the T 
cells become activated, secreting cytokines and activating other cells in the culture 
(Figure 2-21), again more closely reflecting what might be happening physiologically. 
 
 
Figure 2-21: Effect of CD3 and CD28 receptor activation on T cells, in PBMC preparations. 
Using anti-CD3/anti-CD28 mAb coated beads, T helper (Th) cells were activated in a physiological 
manner, leading to cytokine production. This can activate other immune cells, including dendritic cells 
(DCs) monocytes (Mø), natural killer cells (NK) and B cells (B), producing further cytokines and activation 
of the immune response. 
 
Anti-CD3/anti-CD28 mAb coated beads activate T cells by binding to the CD3 subunit 
of the TCR with concomitant signalling via the CD28 co-stimulatory receptor. Mitogens, 
such as Con A, activate signal transduction pathways and promote mitosis. Although 
mitogens are often used to activate lymphocytes, they do not mirror the in vivo 
activation pathways as closely as anti-CD3/anti-CD28 mAb coated beads. 
 
Two types of commercially-available anti-CD3/anti-CD28 mAb coated beads are Dynal 
Dynabeads® (Invitrogen Ltd., Paisley, UK) which are potent activators of the TCR 
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pathway inducing cell expansion and activation, and the less potent Treg Suppression 
Inspector beads (Miltenyi Biotec). The latter are designed for the analysis of Treg cell 
activation and subsequent suppression of T responder cells, hence their name. Both 
these beads activate cells via the same pathways, as occurs physiologically. It is the 
concentration of anti-CD3/anti-CD28 mAbs on the surface of these beads which 
dictates their different potencies, with the Miltenyi beads being coated with lower 
concentrations of both mAbs. 
 
For these experiments, PBMCs were isolated as described above (Section 2.5.1), 
viable cells were counted using trypan blue dye exclusion and re-suspended at 2x106 
cells/ml. Anti-CD3/anti-CD28 mAb coated beads at a 1:1 bead:cell ratio were added. In 
order to reduce error between samples, the beads were added to the all the cells that 
required stimulating, these were mixed and subsequently aliquoted. To the 
unstimulated cells, an equivalent volume of medium was added. 105 l of the bead/cell 
mix (2x105 cells) or the unstimulated cells were pipetted into 96-well round-bottomed 
plates. RPMI* (100 l) was added to the unstimulated and ‘no opioid’ control stimulated 
wells and 100 l of opioid (diluted in RPMI* to the concentrations in Table 2.13) were 
added to the appropriate wells containing stimulated cells. Plates were then incubated 
for 1, 2, 3, 4 or 5 days at 37°C, 5% v/v CO2 and 100% humidity. 
 
Table 2.13: Opioid concentrations used in experiments assessing the influence of 
opioids on Miltenyi anti-CD3/anti-CD28 mAb stimulated PBMC populations. 
Opioid Final concentrations used for the T cell assays 
(ng/ml) 
Morphine  20 100 500 2,500 25,000 
Tramadol  80 400 2,000 10,000 100,000 
Fentanyl  0.8 4 20 100 1000 
Buprenorphine 0.8 4 20 100 750 
Methadone 20 100 500 2,500 25,000 
Oxycodone 4 20 100 500 25,000 
Diamorphine  10 50 250 1,250 12,500 
Codeine 16 80 400 2,000 150,000 
These assays used the lower 4 concentrations, representing 5 times dilutions around the therapeutic 
range (the lower 4 concentrations in the table). In some of the experiments a much larger concentration 
(the concentration on the right in the table) was also used in order to assess if very high concentrations 
had an effect on T cell activation. 
 
After the appropriate incubation time, cells were harvested, counted using a 
haemocytometer and 1.5x105 cells were transferred to 1.5 ml microfuge tubes for flow 
cytometric staining and analysis. After the first centrifugation, supernatants were 
removed and stored at -80°C for subsequent cytokine analyses. The expression of 
CD25 and CD69 by CD4+ and CD8+ T cells was determined using multi-parameter flow 
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cytometry as described previously (Figure 2-22). The expression of CD25 and CD69 on 
CD16+CD56+ NK cells which is induced as a bystander effect of T cell activation in the 
PBMC preparations were also examined. All experiments included a viability stain and 
only the data derived from viable single-cell populations was analysed due to non-
specific mAb binding to non-viable and doublet cell populations (Figure 2-4). 
 
 
Figure 2-22: Representative overlay histograms illustrating the expression of CD25 and 
CD69 on unstimulated and stimulated T cell subpopulations and the effect of morphine. 
Comparison of CD69 expression (left panels) and CD25 expression (right panels) on unstimulated and 
Miltenyi anti-CD3/anti-CD28 mAb stimulated CD4
+
 (top panels) and CD8
+
 (bottom panels) T cells, and 
how this is influenced by 2,500 ng/ml of morphine in a 3 day PBMC culture.  
 
 
Appropriate controls (unstained and non-reactive isotype matched) were used for 
unstimulated, stimulated no opioid and opioid tubes. Table 2.13 indicates the 
concentrations of the opioids used for these assays. In subsequent assays, the 
influence of extremely high concentrations of each opioid (morphine 25,000 ng/ml; 
tramadol 100,000 ng/ml; fentanyl 1000 ng/ml; buprenorphine 750 ng/ml; Methadone 
25,000 ng/ml; oxycodone 25,000 ng/ml; diamorphine 12,500 ng/ml; codeine 150,000 
ng/ml) on T cell responsiveness to polyclonal stimulation and the consequential 
bystander activation of NK cells were assessed. 
 
Initial experiments explored CD25 and CD69 expression on CD4+ and CD8+ T cells in 
response to activation with Dynal and Miltenyi anti-CD3/anti-CD28 mAb coated beads 
at different bead:cell ratios and the kinetics of this activation.  
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2.7.1 Kinetics of anti-CD3/anti-CD28 mAb coated bead-induced activation  
Preliminary experiments assessed the kinetics of CD4+ and CD8+ T cell activation in 
response to Dynal and Miltenyi anti-CD3/anti-CD28 mAb coated beads by examining 
the activation over 5 days. The proportion of cells expressing CD25 and CD69 and the 
intensity of this expression were assessed in two volunteers in order to characterise the 
activation response profile to these stimuli. These are presented separately for each 
volunteer below (Figure 2-23 - Figure 2-26). 
 
   
Figure 2-23: Effect of Dynal and Miltenyi anti-CD3/anti-CD28 mAb coated beads on CD25 
expression by CD4
+
 and CD8
+
 T cells (Volunteer 1). 
The proportion (%) of CD4
+
 and CD8
+
 T cells expressing CD25 (left panel) and the intensity of this 
expression on the positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with either Dynal or Miltenyi anti-CD3/anti-CD28 mAb coated beads for between 1 and 5 days 
prior to assessing CD25 expression. The unstimulated (unstim) average is a composite of the unstimulated 
control value from each of the 5 days. 
 
  
Figure 2-24: Effect of Dynal and Miltenyi anti-CD3/anti-CD28 mAb coated beads on CD69 
expression by CD4
+
 and CD8
+
 T cells (Volunteer 1). 
The proportion (%) of CD4
+
 and CD8
+
 T cells expressing CD69 (left panel) and the intensity of this 
expression on the positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with either Dynal or Miltenyi anti-CD3/anti-CD28 mAb coated beads for between 1 and 5 days 
prior to assessing CD69 expression. The unstimulated (unstim) average is a composite of the unstimulated 
control value from each of the 5 days. 
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Figure 2-25: Effect of Dynal and Miltenyi anti-CD3/anti-CD28 mAb coated beads on CD25 
expression by CD4
+
 and CD8
+
 T cells (Volunteer 2). 
The proportion (%) of CD4
+
 and CD8
+
 T cells expressing CD25 (left panel) and the intensity of this 
expression on the positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with either Dynal or Miltenyi anti-CD3/anti-CD28 mAb coated beads for between 1 and 5 days 
prior to assessing CD25 expression. The unstimulated (unstim) average is a composite of the unstimulated 
control value from each of the 5 days. 
 
  
Figure 2-26: Effect of Dynal and Miltenyi anti-CD3/anti-28 mAb coated beads on CD69 
expression in CD4
+
 and CD8
+
 T cells (Volunteer 2). 
The proportion (%) of CD4
+
 and CD8
+
 T cells expressing CD69 (left panel) and the intensity of this 
expression on the positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with either Dynal or Miltenyi anti-CD3/anti-CD28 mAb coated beads for between 1 and 5 days 
prior to assessing CD69 expression. The unstimulated (unstim) average is a composite of the unstimulated 
control value from each of the 5 days. 
 
 
A similar pattern of CD4+ and CD8+ T cell activation (measured by cell surface 
expression of CD25 and CD69) in response to the two different anti-CD3/anti-CD28 
mAb coated beads was apparent in both volunteers, although the Dynal beads induced 
more activation than the Miltenyi beads. CD25 expression was increased after 1 day of 
stimulation and the proportion of cells expressing this activation marker continued to 
increase expression over 3 days, after which it plateaued, close to 100% with the Dynal 
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bead and less than 50% with the Miltenyi bead stimulus. The intensity of CD25 
receptor expression increased over the first 3 days before decreasing and was many 
orders of magnitude greater with the Dynal beads than with the Miltenyi beads. CD69, 
being an earlier marker of activation, peaked sooner, within 1-2 days, before beginning 
to decrease over the remainder of the 5 days, although it continued to be expressed at 
high levels throughout this time.  
  
These initial experiments which also assessed the activation of PBMC subpopulations 
with different Dynal bead:cell ratios revealed that almost 100% of cells were activated 
and expressed CD69 after 24 hr at the 1:1 bead:cell ratio. At lower bead ratios, some 
cells were being activated maximally, with other cells remaining unactivated. 
 
On the basis of these activation kinetics experiments, a 3-day incubation with Miltenyi 
anti-CD3/anti-CD28 mAb coated beads was selected as an approach to assess the 
effect of opioids on T cell activation. This gave sub-maximal stimulation and thereby 
would enable enhancing as well as suppressive effects to be detected. This is also 
critical as these co-cultures should be incubated for at least 3 days to allow for T cell 
activation and subsequent cytokine production, which enables a more physiological 
microenvironment to be replicated in vitro. 
 
The effect of Miltenyi anti-CD3/anti-CD28 mAb coated beads on NK cell activation was 
also assessed in this assay. For this the PBMCs were isolated and activated as 
described above and the expression of CD69 and CD25 by CD16+ and CD56+ NK cells 
determined.  
 
 
2.8 Influence of opioids on cytokine secretion by activated peripheral 
blood mononuclear cells 
The supernatants from the Miltenyi anti-CD3/anti-CD28 mAb coated bead PBMC 
stimulation assays and IL-2 stimulated PBMCs, as well as unstimulated samples 
(described above) were harvested and stored at -80°C until they were aliquoted and 
cytokine levels analysed using BD Bioscience Cytometric Bead Arrays (CBAs) and a 
BD FACSArray™ flow cytometer. The underlying principle of the assay is that 
populations of beads that are labelled with different levels of two fluorescent molecules, 
in order to confer upon them distinctive fluorescent properties, are coated with 
antibodies to the appropriate cytokines. The beads are then incubated with the sample 
(or known concentrations of cytokines in order to generate a standard dose-response 
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curve), and the bound cytokine is detected using a secondary ‘capture’ antibody that is 
conjugated to a third fluorochrome. The beads are then identified on the basis of their 
fluorescence and the intensity of capture antibody binding is quantified (Figure 2-27 - 
Figure 2-28).  
 
 
 
Figure 2-27: Schematic of cytometric bead analysis system. 
Each set of beads are labelled with different intensity of two flurochromes (represented by different grades 
of red) to enable detection by the BD FACSArray™, and specific positioning on a two dimensional 
acquisition grid (Figure 2-28). The beads are also coated with a specific antibody to a cytokine, enabling 
binding of that cytokine. There are also labelled capture antibodies (green) which detect a different epitope 
on the cytokine, the amount of fluorescence, and hence concentration, of the cytokine is determined by the 
amount of binding of this labelled capture antibody. In this diagram three different bead types are 
represented, each specifically detecting a cytokine (denoted as blue, yellow and pink). 
 
 
 
 
 
 
Figure 2-28: Acquisition grid on the BD FACSArray™. 
Each bead subset has a specific position determined by the intensity of two flurochromes on the bead (on 
red and near infrared, NIR). Each of the 30 different potential positions represents an individual cytokine, 
which can be further analysed to determine its concentration by the intensity of the capture antibody. 
NIR-A 
Red-A 
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Although ELISAs are traditionally the “standard” for the quantification of ligands and 
especially cytokines, there is a vast literature comparing bead assay detection and 
ELISAs (Elshal and McCoy, 2006). The majority of these studies have shown good 
correlations between bead array assays and ELISAs, however the degree of 
correlation does vary, due to the antibodies used in each of the assays and how these 
comparisons were made. Both ELISAs and CBAs show similar results, provided the 
same clones of antibodies are used; and the same assay and antibodies should be 
used for all tests which are to be compared (Elshal and McCoy, 2006). 
 
Cytokines are cell signalling molecules primarily secreted from immune cells which 
regulate both humoral and cellular immune responses. The functional classification is 
used clinically and experimentally, creating two groups. The type 1 TH cell cytokines, 
which are pro-inflammatory, enhance the cellular immune response (i.e. IFN-, TNF-), 
and type 2 TH cell cytokines (i.e. IL-4, IL-10, IL-13) which promote antibody (humoral) 
immunity and can suppress cellular immune responses (Figure 2-29) (Cutolo et al., 
1998, Logani et al., 2011, Serreze et al., 2001, Teixeira et al., 2005, Yates et al., 2000). 
 
 
 
 
Figure 2-29: Differentiation of TH cells. 
Naïve CD4
+
 T helper cells (TH0) under cytokine influence differentiate into TH1, TH2 or other T cell sub-
populations. IL-12 and IFN- promote the differentiation towards TH1 cells and thereby enhance the cellular 
immune response. IL-4, IL-6 and IL-10 promote differentiation towards TH2 cells and enhance antibody 
(humoral) responses. The cytokines produced by the predominant arm of this response feedback to further 
enhance differentiation along that arm and inhibit the other arm. The TH1 response drives cellular 
immunity, with activation of the monocyte-macrophage lineage (Mø), natural killer cells (NK) and CD8
+
 
cytotoxic T cells (Tc). The TH2 response drives humoral immunity by activating mast cells (M), eosinophils 
(Eø) and B cells (B), increasing antibody production (Cutolo et al., 1998, Klein et al., 2004, Logani et al., 
2011, Serreze et al., 2001, Teixeira et al., 2005, Yates et al., 2000). 
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There are several subgroups of T cells having different immunological roles which are 
in part classified by their pattern of cytokine production. As well as the classical TH1 
and TH2 cells, these now include TH9, TH17, TH22 and Treg cells. 
 
TH1 cells are involved in the cellular immune response against intracellular pathogens. 
They are characterised by the production of pro-inflammatory cytokines (IFN-, IL-2, 
and lymphotoxin-). These cytokines stimulate the phagocytosis and destruction of 
microbial pathogens by macrophages and other lymphocytes (Kapsenberg, 2003, Liew, 
2002). When TH1 cells produce IFN-, this prompts macrophages to produce TNF and 
oxygen free radicals which kill microorganisms within phagosomes and lysosomes. 
 
TH2 cells are involved in the humoral immune response against extracellular 
pathogens. They are characterised by the production of IL-4, IL-5, IL-6, IL-10, and IL-
13 (Kapsenberg, 2003, Liew, 2002). IL-4 stimulates antibody production and IL-5 
stimulates an eosinophil response toward large extracellular parasites. On the other 
hand, when TH2 cells produce IL-4 and IL-10, these cytokines block the microbial killing 
that is activated by IFN-.  
 
TH9 cells are characterised by the production of IL-9 and IL-10 (Dardalhon et al., 2008). 
Their differentiation is promoted by TGF- in combination with IL-4, this is enhanced by 
IL-21 (Wong et al., 2010). They are thought to be involved in intestinal response to 
helminthes and in allergy, however further studies are needed to reveal the function of 
these cells in pathogen clearance and inflammatory diseases (Ma et al., 2010). 
 
TH17 cells are involved in the host defence against extracellular pathogens (van de 
Veerdonk et al., 2009). They do not produce classical TH1 or TH2 cytokines such as 
IFN- or IL-4, but produce IL-17A and IL-22 (Fouser et al., 2008). IL-6, IL-23 and TGF- 
promote the differentiation of naïve TH cells towards the TH17 phenotype. TH17 cells 
have an important role in autoimmune tissue injury (Ferraccioli and Zizzo, 2011). IL-
17A increases the induction of pro-inflammatory cytokines such as TNF, IL-6, and IL-
1. 
 
TH22 cells produce IL-22, IL-23 and TNF- but not IFN-, IL-4, or IL-17. They are pro-
inflammatory and have a role in epidermal immunity and promote angiogenesis, 
fibrosis and wound healing (Eyerich et al., 2009).  
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Regulatory T cells produce IL-4, IL-10, IFN- and TGF-, which promote the 
differentiation of naïve TH cells toward the Treg phenotype. They tend to inhibit the 
immune response and maintain immune self-tolerance (Shalev et al., 2011). 
 
Cytokines are induced by specific stimuli, including bacterial products, and can activate 
and induce differentiation in many cell types as well as modulating the production of 
other cytokines. This complex regulatory network of cytokines may ultimately result in 
the eradication of the pathogen or if the cytokine balance is suboptimal then this will be 
deleterious to the host (either due to overwhelming infection or autoimmunity/allergy). 
The production of specific cytokines in response to infection or tumour may determine 
the clinical outcome (Lucey et al., 1996, Watkins et al., 1995). 
 
Preliminary studies analysed the effect of opioids on the concentrations of IL-1, IL-2, 
IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IFN-, IFN-, TNF- and IP-10 in the 
supernatants of the cell cultures. 
 
IL-1 is a member of the IL-1 cytokine family, produced as a precursor, Pro-IL-1, by 
activated macrophages, monocytes, fibroblasts and DCs, it is subsequently cleaved by 
caspase 1 to its active form, IL-1. It enhances the inflammatory response against 
infection, and is involved in cell proliferation, differentiation, and apoptosis. IL-1 
increases the expression of adhesion factors on endothelial cells to enable 
transmigration of leukocytes to sites of inflammation and can have effects at 
femtomolar concentrations (Dinarello, 1994). It also increases body temperature by an 
effect on the hypothalamic thermoregulatory centre. IL-1 is associated with an 
increased sensitivity to inflammatory pain (Gabay et al., 2010), both peripherally and in 
the CNS where it induces cyclooxygenase-2. The two forms of IL-1 bind to the same 
physiologically active receptor, IL-1R1, which is composed of two related subunits that 
transmit intracellular signals via activation of the MAPK/JNK signalling pathway, 
leading to activation of the NF-B complex (Kuno and Matsushima, 1994). This 
pathway overlaps with the TLR and IL-18 receptor signalling pathways. 
 
IL-2 is important in the inflammatory response against infection. It is a member of the 
IL-2 subfamily of cytokines, which includes IL-4, IL-7, IL-9, IL-15 and IL-21. It is 
produced by activated T cells, mainly CD4+ cells, often in response to IL-1β produced 
by monocytes and DCs (when in PBMC culture). IL-2 produced by activated T cells can 
have an autocrine effect, inducing further activation, receptor expression and IL-2 
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production, stimulating the growth, differentiation, proliferation and survival of antigen-
selected T and B cells (Curfs et al., 1997). IL-2 also activates NK cells (although their 
receptors are of lower affinity compared with T and B cells), which promotes defence 
against tumours (Castriconi et al., 2007). IL-2 signals through a receptor complex 
consisting of IL-2 receptor  (CD25), IL-2 receptor  (CD122) and a common  chain 
(c), which is shared by this subfamily of cytokine receptors. Binding of IL-2 activates 
the Ras/MAPK, JAK/STAT and PI 3-kinase/Akt signalling pathways. Antigen binding to 
the TCR stimulates the secretion of IL-2 and the expression of IL-2 receptors on T 
cells.  
 
IL-4 induces differentiation of naïve CD4+ T cells to TH2 cells and when activated by IL-
4, TH2 cells secrete IL-4. It also enhances TH2 cell proliferation and the proliferation of 
anti-IgM stimulated murine B cells (Paul, 1991). Parasite and allergen products 
mediate activation of epithelial cells, basophils and DCs and the production of IL-4, IL-
25 and IL-33 in the initiation and amplification of TH2 immune responses in vivo (Paul 
and Zhu, 2010, Sokol and Medzhitov, 2010). Basophils are central to the initiation of 
the polarisation of TH2 immune responses by the production of IL-4 (Paul and Zhu, 
2010, Sokol and Medzhitov, 2010). In mice IL-4 induces the production of IgE (Paul, 
1991). IL-4 acts as an anti-inflammatory cytokine, modulating the immune response by 
suppressing the production of IL-1, IL-6, IFN- and TNF- (Lee et al., 1995a). IL-4 and 
IFN- have antagonistic properties, polarising the T cell response towards TH2 and TH1 
respectively (O'Garra and Arai, 2000). The heterodimeric IL-4 receptor has an  chain 
with the IL-4 extracellular binding domain and a transactivating chain, either the 
common  chain or the 1 chain of the IL-13 receptor (Zhang et al., 2002).  
 
IL-6 can act as both a pro-inflammatory and anti-inflammatory cytokine (Xing et al., 
1998). It is secreted mainly by T cells and macrophages (in response to specific 
pathogen-associated molecular patterns binding to pathogen recognition receptors) 
and stimulates the immune system in response to tissue damage, especially burns. IL-
6 is also produced from muscle, and is elevated by exercise (Pedersen, 2011). 
Osteoblasts secrete IL-6 to stimulate osteoclasts (Eriksen et al., 2010). Smooth muscle 
cells in the tunica media of blood vessels also produce IL-6 where it is pro-
inflammatory. IL-6 is produced early in inflammation and is important for controlling 
acute infection as it initiates the acute phase response and increases C-reactive 
protein (CRP) production from the liver (Heikkila et al., 2007). It also causes fever, as it 
crosses the blood-brain barrier promoting prostaglandin E2 synthesis in the 
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hypothalamus. Its pro-inflammatory properties include maturation and activation of 
neutrophils and macrophages, differentiation and maintenance of CD8+ T cells and NK 
cells, and under some circumstances increased expression of IL-1 and TNF- (Barton, 
1996). IL-6 can also act as an anti-inflammatory cytokine as in certain circumstances it 
can inhibit the pro-inflammatory cytokines TNF- and IL-1, and activate IL-1 receptor 
antagonist and IL-10. IL-6 signals by binding to IL-6R chain (CD126) and the signal-
transducing component gp130 (CD130). Gp130 is expressed in most tissues, whereas 
the expression of IL-6R is more restricted. When IL-6 interacts with its receptor, 
gp130 and IL-6R form a complex, bringing together the intracellular regions of gp130 
to initiate a signal transduction cascade through the transcription factors JAK/STAT 
and MAPK (Heinrich et al., 2003a).  
 
IL-8 is a chemokine which is also known as C-X-C chemokine ligand 8 (CXCL8) 
(Bacon et al., 2002) and it can be secreted by any cells involved in the innate immune 
response with TLRs, especially macrophages, epithelial and endothelial cells. It is 
secreted in response to TLR activation by bacterial products, especially LPS. IL-8 
activates neutrophils and is involved in their migration towards sites of inflammation 
where it can be further produced by neutrophils recruiting monocytes (Curfs et al., 
1997). Both monomer and homodimer forms of IL-8 bind to CXCR1 (IL-8RA) and 
CXCR2 (IL-8RB), with the homodimer being more potent (Bacon et al., 2002). It is 
important in innate immune system chemotaxis, acting as a chemoattractant, and is 
also a potent angiogenic factor. The primary function of IL-8 is to recruit neutrophils to 
phagocytose foreign bodies, the antigens of which trigger TLR’s. 
 
IL-10 is a TH2 cytokine with anti-inflammatory properties (Sabat et al., 2010) which 
inhibits the synthesis of pro-inflammatory TH1 cytokines (IL-2, IFN- and TNF-), MHC 
class II antigens and co-stimulatory molecules on macrophages. Although it down-
regulates T cell-mediated immunity, it enhances B cell survival, proliferation and 
antibody production as well as stimulating NK cell cytotoxicity (Mocellin et al., 2004). IL-
10 is produced primarily by monocytes but also by TH2, Treg and mast cells (Sabat et 
al., 2010). It is also released by cytotoxic T cells in order to inhibit NK cells during the 
immune response to viral infection. Tumours might also utilise a similar mechanism to 
optimise their survival (Szkaradkiewicz et al., 2010). IL-10 is homodimer molecule 
which binds to the IL-10 receptor (IL-10R) which is expressed on many immune cells 
including CD4+ T cells, NK cells and macrophages (Grutz, 2005). Binding of IL-10 to 
the IL-10R activates JAK1 and Try2 tyrosine kinases, phosphorylating STAT1 and 
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STAT3; and can block NF-B activity (Mocellin et al., 2004).  
 
IL-12p70 is a heterodimeric cytokine composed of p35 and p40 subunits that are linked 
by disulphide bonds and the production of the biologically active IL-12p70 requires the 
genes of both subunits to be expressed (Watford et al., 2003). It is primarily produced 
by activated monocytes and B cells and it enhances the proliferation and cytotoxicity of 
T cells and NK cells (Adorini, 2003, Trinchieri, 1994). IL-12p70 promotes the 
differentiation of naïve CD4+ T cell towards the TH1 phenotype and, along with NK cell 
and macrophages, induces T cells to produce IFN- (Watford et al., 2003). IL-12p70 
production early in infection is vital in the control of intracellular pathogens (Biron and 
Gazzinelli, 1995). IL-10 inhibits IL-12p70 production and thereby suppresses the 
development of TH1 responses (Adorini, 2003). The IL-12 receptor is composed of two 
chains IL-12Rß1 and IL-12Rß2, binding of IL-12p70 activates the JAK-STAT4 
signalling pathway (Trinchieri, 2003). 
 
IL-17A along with IL-17B – F comprises the IL-17 family. IL-17A is primarily produced 
by TH17 cells, a recently reported lineage of CD4
+ T cells that are characterised by the 
production of this cytokine (Fouser et al., 2008). IL-17A is involved in inducing and 
mediating pro-inflammatory responses and has an important role in regulating 
granulocytes. It is also important for host defence and is commonly associated with 
allergic and autoimmune diseases (Gaffen, 2009). IL-17 induces the production of 
many other cytokines, including IL-6, IL-1, TGF-, TNF- and IL-8, as well as 
prostaglandins (e.g., prostaglandin E2) from many cell types including fibroblasts, 
endothelial cells, epithelial cells, keratinocytes, and macrophages. IL-17 mobilises 
neutrophils from the bone marrow and promotes production of IL-1. In contrast to the 
restricted expression of IL-17A, the IL-17 receptor A is ubiquitously expressed, and 
thus most cells are potential physiological targets of IL-17A (Gaffen et al., 2006). 
 
IFN- is a homodimer which belongs to the group of interferons. The term interferon 
was originally coined as these cytokines "interfere" with viral replication within host 
cells. There are seven different interferons in humans and IFN- is the only member of 
the type II group (the type I group includes IFN- and ). Interferons activate NK cells 
and cells of the monocyte/macrophages lineage; increase T cell recognition of infection 
and tumour cells by up-regulating antigen presentation (increasing MHC class I and II 
expression, and immunoproteasome activity), and increase the ability of uninfected 
host cells to resist viral infection (Bach et al., 1997). IFN- is produced by TH1 and NK 
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cells. It induces naïve T cell differentiation towards the TH1 polarity, inhibiting TH2 
responses. IFN- antagonises the effect of IL-4 and is itself antagonised by IL-4 
(O'Garra and Arai, 2000). It binds to the IFN- receptor and modulates nearly all 
phases of the immune and inflammatory responses (Farrar and Schreiber, 1993). IFN- 
regulates the production of a variety of other pro-inflammatory cytokines including IL-12 
and TNF- (Bach et al., 1997). IFN- activates the JAK-STAT signalling pathway 
(Platanias, 2005). JAKs associate with IFN receptors and upon binding IFN-, 
phosphorylate STAT1 and STAT2. This results in IFN-stimulated gene factor 3 complex 
(STAT1, STAT2 and IRF9) which translocates into the cell nucleus inducing gene 
transcription (Platanias, 2005). Interferons can activate several other signalling 
cascades including CrkL, a nuclear adaptor for STAT5 that regulates signalling through 
the C3G/Rap1 pathway, as well as the phosphatidylinositol 3-kinase signalling 
pathway, increasing protein synthesis and cell proliferation (Alsayed et al., 2000).  
 
The homotrimer, TNF-, is a pro-inflammatory mediator which promotes systemic 
inflammation, stimulates the acute phase reaction and induces pyrexia. TNF- is 
important for controlling acute infection. It has a plethora of effects including the 
regulation of immune cells, being a chemoattractant for neutrophils and increasing their 
adhesion and migration. In macrophages it stimulates phagocytosis, and production of 
IL-1. TNF- induces apoptotic cell death and inhibits tumorigenesis and viral 
replication. It increases production of corticotrophin-releasing factor which stimulates 
the HPA axis. TNF- is mainly produced by macrophages, but also by lymphoid cells, 
mast cells, endothelial cells, cardiac myocytes, adipose tissue, fibroblasts, and 
neuronal tissue. TNF- is primarily secreted in response to LPS, whereas IL-1, IL-6 
and IL-10 inhibit its secretion (Curfs et al., 1997). TNF- can bind to the TNF-R1 and 
TNF-R2 receptors; the former is ubiquitous whereas the latter is only expressed on 
immune cells. Upon binding to TNF-, the receptors form trimers inducing a 
conformational change, leading to dissociation of the inhibitory protein Silencer of 
Death Domain (SODD) from the intracellular death domain. This dissociation enables 
TNF-R1-associated death domain protein (TRADD) to activate; NF-B, MAPK and 
induction of death signalling pathways (Ihnatko and Kubes, 2007, Wullaert et al., 2006). 
 
IFN- induced protein 10 kDa (IP-10), also known as C-X-C chemokine ligand 10 
(CXCL10), is secreted by monocytes and endothelial cells in response to IFN- (Luster 
et al., 1985). IP-10 has a role in chemoattraction of monocytes/macrophages, T cells, 
NK cells and DCs, promotion of T cell adhesion to endothelial cells, antitumor activity, 
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and inhibition of bone marrow colony formation and angiogenesis (Angiolillo et al., 
1995, Dufour et al., 2002, Rabquer et al., 2011). IP-10 binds to the cell surface 
chemokine receptor CXCR3 (Booth et al., 2002). 
 
Preliminary experiments showed that IL-4, IL-12p70 and IFN- were below the 
detection threshold and these cytokines were not assessed in the main cytokine 
analysis experiments. IL-17A and IP-10 were detected by the same laser and would 
need to be analysed independently, further investigation of these cytokines showed 
that IP-10 was below the level of detection in some of the samples and it would 
therefore be more appropriate to analyse the effect of opioids on IL-17A. For reasons 
that remain unclear, the assay failed to detect IL-2 in any of the samples that were 
analysed and no data for these analyses are therefore available. IL-6 and IL-8 were 
above the highest standard in the standard curve and needed dilution to ensure 
accurate quantification. The final array of cytokines analysed were IL-1, IL-6, IL-8, IL-
10, IL-17A, IFN- and TNF-. 
 
 
2.9 Statistical Analysis 
Statistical analysis was undertaken in collaboration with Kathleen Baster (Senior 
Consultant, Statistical Services Unit, University of Sheffield). Several options exploring 
different analyses methods were undertaken and it was decided that the optimal way to 
analyse the data was with a paired 2-way Student t-test. This test was chosen as each 
assay assessing the effect of an opioid on immune function had a ‘no opioid’ control 
and the paired Student t-test allowed a direct comparison between the effects that are 
induced with each concentration of opioid and it’s no opioid equivalent (baseline). The 
potential of both stimulatory and inhibitory changes induced by opioids could be 
interrogated using the 2-way test.  
 
Initially the Univariate General Linear Model in Statistical package for the Social 
Sciences (SPSS) v15 was used. Homogeneity of variances were checked using the 
one way ANOVA and if these were non-significant (> 0.05) the data were then 
analysed using the Univariate General Linear Model, including subject as a 'random' 
factor. These tests were performed to check for variation between differences in the 
responsiveness of untreated and opioid-treated cells, as well as to check if there was a 
dose-dependent effect from the opioids using the Scheffe Post hoc test. If the 
homogeneity of variance was significant (< 0.05) the data were then log-transformed 
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and then analysed using the Univariate General Linear Model as described above. 
However, on further discussion with the statistician, using this approach meant that all 
of the baselines were treated equally and an average baseline value was generated in 
SPSS and compared with the average of each of the different opioid concentration 
values. As each experiment had its own baseline and not all concentrations of an 
opioid were tested against the same control, thus it is incorrect to combine the 
baselines for comparison. Using the paired 2-way Student t-test each value was 
compared to its appropriate control value. 
 
The data were considered as being normally distributed as the means and medians 
were approximately the same, as a consequence of which the data were analysed as 
such.  
 
Data are presented as mean ± standard error of the mean (SEM), or as individual 
experiments, as indicated. 
 
*P value < 0.05 
**P value < 0.01 
***P value < 0.005 
 
Type I and type II errors 
When testing a statistical hypothesis, two types of incorrect conclusions can be drawn. 
A type I error is when the null hypothesis is inappropriately rejected (false positive), 
indicating a test of poor specificity. A type II error is when the null hypothesis is falsely 
accepted (false negative), indicating a test of poor sensitivity. 
 
As a parametric test, the t-test assumes normal sample distributions and large sample 
sizes are required to make this assumption. However, it has been shown that the use 
of a t-test with small sample sizes and none bell shaped sample distributions does not 
result in an increase of type I errors (Heeren and D'Agostino, 1987). 
 
Although type I errors are considered to be more serious than type II errors, they are 
also important and can be large due to small sample sizes and small differences in the 
means between samples, and large variabilities (Bosshart, 2009).  
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CHAPTER 3 
 
3. RESULTS 
 
3.1 Effect of opioids on natural killer cells 
NK cells are central to innate immune protection against cancer and viral infections. 
The effect of morphine, tramadol, fentanyl, buprenorphine, methadone, oxycodone, 
diamorphine and codeine on IL-2 stimulated NK cell cytotoxicity against K562 human 
erythroleukaemic target cells was assessed at different E:T cell ratios. The effect of 
these opioids on NK cell activation (as determined on the basis of the induction of 
CD69 expression) in response to both IL-2, and also as a bystander effect of Miltenyi 
anti-CD3/anti-CD28 mAb bead stimulation of PBMCs was also explored. Although 
CD69 expression is the most reliable and sensitive marker for CD16+56+ NK cell 
activation, CD25 expression might also be a marker of NK cell responsiveness and 
was also measured. Subsequent experiments evaluated the effect of morphine, 
tramadol and fentanyl on the cytotoxic potential of unstimulated NK cells at an E:T ratio 
of 100:1, and also on their activation status (CD69 expression).  
 
3.1.1 Effect of opioids on IL-2 stimulated natural killer cell cytotoxicity 
Platelet-free PBMCs were isolated from whole blood, freshly taken from healthy 
volunteers, by density gradient centrifugation and incubated for 3 days with IL-2 (100 
U/ml) in the presence or absence of two clinically relevant concentrations of morphine, 
tramadol, fentanyl, buprenorphine, methadone, oxycodone, diamorphine or codeine. 
K562 target cell killing at the different E:T ratios were determined, the amount of 
background (non-specific) target cell death subtracted and the AUCC was calculated. 
The proportion of NK cells in the PBMCs was determined by flow cytometry and these 
data were used to calculate the adjusted AUCC. The data presented below show the 
cytotoxicity of NK cells against K562 target cells (Y axis) for the different E:T ratios (X 
axis) for the opioids (Figure 3-1 - Figure 3-8). Values for the adjusted AUCC means (± 
SEM) for each of the experimental conditions are indicated in the figure legends. 
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Figure 3-1: Effect of morphine on IL-2 induced NK cell cytotoxicity of K562 target cells. 
Isolated PBMCs, without platelets, were incubated for 3 days with IL-2 and morphine or no opioid control 
(there was also an unstimulated control, without IL-2 or morphine). The PBMCs (effector cells) were then 
incubated for 3 hr with K562 (target cells) at the effector:target (E:T) ratios shown on the graph and the 
proportion (%) of killed K562 cells at the different E:T ratios was measured using flow cytometry. The 
adjusted area under the cytotoxic curve (AUCC) was calculated using the formula presented in the 
methods (section 2.5.3.1 and Figure 2-3). Data are means ± SEM of 3 independent experiments. Values 
for the adjusted AUCC for each of the experimental conditions are indicated in the legend. No statistical 
difference in the NK cell cytotoxicity of untreated and morphine-treated PBMCs was observed (paired 
Student t-test). 
 
 
 
 
Figure 3-2: Effect of tramadol on IL-2 induced NK cell cytotoxicity of K562 target cells. 
Isolated PBMCs, without platelets, were incubated for 3 days with IL-2 and tramadol or no opioid control 
(there was also an unstimulated control, without IL-2 or tramadol). The PBMCs (effector cells) were then 
incubated for 3 hr with K562 (target cells) at the effector:target (E:T) ratios shown on the graph and the 
proportion (%) of killed K562 cells at the different E:T ratios was measured using flow cytometry. The 
adjusted area under the cytotoxic curve (AUCC) was calculated using the formula presented in the 
methods (section 2.5.3.1 and Figure 2-3). Data are means ± SEM of 3 independent experiments. Values 
for the adjusted AUCC for each of the experimental conditions are indicated in the legend. No statistical 
difference in the NK cell cytotoxicity of untreated and tramadol-treated PBMCs was observed (paired 
Student t-test). 
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Figure 3-3: Effect of fentanyl on IL-2 induced NK cell cytotoxicity of K562 target cells. 
Isolated PBMCs, without platelets, were incubated for 3 days with IL-2 and fentanyl or no opioid control 
(there was also an unstimulated control, without IL-2 or fentanyl). The PBMCs (effector cells) were then 
incubated for 3 hr with K562 (target cells) at the effector:target (E:T) ratios shown on the graph and the 
proportion (%) of killed K562 cells at the different E:T ratios was measured using flow cytometry. The 
adjusted area under the cytotoxic curve (AUCC) was calculated using the formula presented in the 
methods (section 2.5.3.1 and Figure 2-3). Data are means ± SEM of 3 independent experiments. Values 
for the adjusted AUCC for each of the experimental conditions are indicated in the legend. No statistical 
difference in the NK cell cytotoxicity of untreated and fentanyl-treated PBMCs was observed (paired 
Student t-test). 
 
 
 
 
Figure 3-4: Effect of buprenorphine on IL-2 induced NK cell cytotoxicity of K562 cells. 
Isolated PBMCs, without platelets, were incubated for 3 days with IL-2 and buprenorphine or no opioid 
control (there was also an unstimulated control, without IL-2 or buprenorphine). The PBMCs (effector cells) 
were then incubated for 3 hr with K562 (target cells) at the effector:target (E:T) ratios shown on the graph 
and the proportion (%) of killed K562 cells at the different E:T ratios was measured using flow cytometry. 
The adjusted area under the cytotoxic curve (AUCC) was calculated using the formula presented in the 
methods (section 2.5.3.1 and Figure 2-3). Data are means ± SEM of 3 independent experiments. Values 
for the adjusted AUCC for each of the experimental conditions are indicated in the legend. No statistical 
difference in the NK cell cytotoxicity of untreated and buprenorphine-treated PBMCs was observed (paired 
Student t-test). 
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Figure 3-5: Effect of methadone on IL-2 induced NK cell cytotoxicity of K562 target cells. 
Isolated PBMCs, without platelets, were incubated for 3 days with IL-2 and methadone or no opioid control 
(there was also an unstimulated control, without IL-2 or methadone). The PBMCs (effector cells) were then 
incubated for 3 hr with K562 (target cells) at the effector:target (E:T) ratios shown on the graph and the 
proportion (%) of killed K562 cells at the different E:T ratios was measured using flow cytometry. The 
adjusted area under the cytotoxic curve (AUCC) was calculated using the formula presented in the 
methods (section 2.5.3.1 and Figure 2-3). Data are means ± SEM of 3 independent experiments. Values 
for the adjusted AUCC for each of the experimental conditions are indicated in the legend. No statistical 
difference in the NK cell cytotoxicity of untreated and methadone-treated PBMCs was observed (paired 
Student t-test). 
 
 
 
 
Figure 3-6: Effect of oxycodone on IL-2 induced NK cell cytotoxicity of K562 target cells. 
Isolated PBMCs, without platelets, were incubated for 3 days with IL-2 and oxycodone or no opioid control 
(there was also an unstimulated control, without IL-2 or oxycodone). The PBMCs (effector cells) were then 
incubated for 3 hr with K562 (target cells) at the effector:target (E:T) ratios shown on the graph and the 
proportion (%) of killed K562 cells at the different E:T ratios was measured using flow cytometry. The 
adjusted area under the cytotoxic curve (AUCC) was calculated using the formula presented in the 
methods (section 2.5.3.1 and Figure 2-3). Data are means ± SEM of 3 independent experiments. Values 
for the adjusted AUCC for each of the experimental conditions are indicated in the legend. No statistical 
difference in the NK cell cytotoxicity of untreated and oxycodone-treated PBMCs was observed (paired 
Student t-test). 
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Figure 3-7: Effect of diamorphine on IL-2 induced NK cell cytotoxicity of K562 cells. 
Isolated PBMCs, without platelets, were incubated for 3 days with IL-2 and diamorphine or no opioid 
control (there was also an unstimulated control, without IL-2 or diamorphine). The PBMCs (effector cells) 
were then incubated for 3 hr with K562 (target cells) at the effector:target (E:T) ratios shown on the graph 
and the proportion (%) of killed K562 cells at the different E:T ratios was measured using flow cytometry. 
The adjusted area under the cytotoxic curve (AUCC) was calculated using the formula presented in the 
methods (section 2.5.3.1 and Figure 2-3). Data are means ± SEM of 3 independent experiments. Values 
for the adjusted AUCC for each of the experimental conditions are indicated in the legend. No statistical 
difference in the NK cell cytotoxicity of untreated and diamorphine-treated PBMCs was observed (paired 
Student t-test). 
 
 
 
 
Figure 3-8: Effect of codeine on IL-2 induced NK cell cytotoxicity of K562 target cells. 
Isolated PBMCs, without platelets, were incubated for 3 days with IL-2 and codeine or no opioid control 
(there was also an unstimulated control, without IL-2 or codeine). The PBMCs (effector cells) were then 
incubated for 3 hr with K562 (target cells) at the effector:target (E:T) ratios shown on the graph and the 
proportion (%) of killed K562 cells at the different E:T ratios was measured using flow cytometry. The 
adjusted area under the cytotoxic curve (AUCC) was calculated using the formula presented in the 
methods (section 2.5.3.1 and Figure 2-3). Data are means ± SEM of 3 independent experiments. Values 
for the adjusted AUCC for each of the experimental conditions are indicated in the legend. No statistical 
difference in the NK cell cytotoxicity of untreated and codeine-treated PBMCs was observed (paired 
Student t-test). 
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IL-2 (100 U/ml) enhanced the ability of NK cells to kill K562 target cells. In all 
experiments the higher E:T ratios led to an increased killing of target cells. None of the 
opioids at the concentrations tested had a significant effect on the ability of IL-2 
stimulated cells to kill K562 target cells (two tailed paired Student t-test, Figure 3-1 to 
3.8). This might be because IL-2 potently stimulated the NK cells and the opioids were 
unable to inhibit this, or noticeably enhance it further. The influence of opioids on the 
activation status of unstimulated and IL-2 stimulated NK cells (CD69 expression) was 
also measured, as this might be more sensitive as a measure of effects on NK cell 
functional potential than cytotoxicity. 
 
A relatively fixed cohort of volunteers was used throughout these studies in order to 
minimise the inter- and intra-individual variability in the NK cell cytotoxicity assay which 
has been observed previously (Hopkinson et al., 2007), as this might limit the 
sensitivity of the assay to the effects of opioids. Although some of the potential 
variability in the NK cell cytotoxicity assay was minimised by removing platelets from 
the PBMC preparations, other factors such as genetic, gender, menstrual cycle, 
exercise and diet were not compensated for (Campa et al., 2008, Chandra, 1999, 
Lawson et al., 2010, Manson, 2010). A previous study has shown that when NK cell 
cytotoxicity was assessed weekly in five donors over 3 weeks, variability was up to 
51% in individual subjects and up to 32% for the means of all subjects (Hopkinson et 
al., 2007).  
 
3.1.2 Effect of opioids on the cytotoxic potential of unstimulated natural 
killer cells  
None of the opioids had an effect on the cytotoxicity of IL-2 stimulated NK cells. This 
might be because the immunoregulatory effects of opioids were not capable of 
tempering or enhancing the stimulatory capacity of IL-2. As a consequence, 
experiments assessing the effects of morphine, tramadol and fentanyl on the cytotoxic 
capacity of unstimulated NK cells were performed. For these experiments, isolated 
PBMCs (unstimulated) were incubated for 3 days with two clinically relevant 
concentrations of morphine, tramadol and fentanyl. Using flow cytometry, K562 target 
cell killing at the maximum E:T ratio of 100:1 was determined, as this is the most likely 
ratio to show any effect. The amount of background (non-specific) target cell death was 
subtracted.  
 
147 | P a g e  
 
 
Figure 3-9: Effect of morphine, tramadol and fentanyl on the cytotoxic capacity of 
unstimulated NK cells (3-day incubation). 
Unstimulated PBMCs were incubated with the indicated concentrations of morphine, tramadol and fentanyl 
for 3 days before assessing their ability to kill K562 cells. This is presented as % cytotoxicity using a PBMC 
to K562 (E:T) cell ratio of 100:1. Data are means ± SEM of 3 independent experiments (except 400 ng/ml 
of tramadol and 4 ng/ml of fentanyl, where n=2). 500 ng/ml of morphine for 3 days inhibited unstimulated 
NK cell cytotoxicity compared to untreated PBMCs, * p<0.05 (paired Student t-test).  
 
 
Although 500 ng/ml of morphine significantly inhibited NK cell cytotoxicity, this effect 
was quantitatively very small (Figure 3-9) and unlikely to be of clinical importance. As 
there were no clear effects from the opioids tested, no further opioids were assessed 
using this experimental approach.  
 
Opioid agonists might have a rapid effect on immune function and might induce 
receptor desensitisation, endocytosis and down regulation over time. Thus, the 
immediate effect of opioids on immune cells could be very different from those that are 
observed at later time points (Bidlack et al., 2006). If this remains the case in patients, 
then it is less likely to be a clinically significant problem in those on regular opioids. 
However, these short term effects might be significant for patients administered opioids 
in the acute situation, i.e. for trauma or minor surgery.  
 
Rodent-derived data suggest that the immune effects of single opioid doses can 
dissipate within hours. For example, it has been shown in rats that a single 
subcutaneous injection of morphine suppresses NK cell cytotoxicity within hours, but 
that this suppression lasts less than a day (Nelson et al., 1997). This study indicates 
that the in vivo effects of morphine are dependent on its continuing presence and 
decline following metabolism and excretion.  
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The findings of Nelson’s study might not necessarily be applicable to the current study, 
as it is expected that the concentrations of the opioids are relatively stable during 
culture. Nonetheless, in order to investigate the potential for such effects, some short 
incubation time experiments were performed. As this approach was aimed at screening 
for any potential effect, it was performed with only the higher doses of morphine, 
tramadol and fentanyl used in the NK assays, and only at the 100:1 E:T cell ratio. The 
shorter time point experiments only used unstimulated NK cells. 
 
For these, unstimulated PBMCs were incubated with morphine, tramadol and fentanyl 
for 1, 3 and 24 hr prior to assessing NK cell cytotoxicity against K562 cells. None of the 
opioids had an effect on the cytotoxic capacity of unstimulated NK cells at any time 
point (Figure 3-10), data not shown for the 24-hr incubation. 
 
  
Figure 3-10: Effect of morphine, tramadol and fentanyl on the cytotoxic capacity of 
unstimulated NK cells (1- and 3-hr incubation). 
Unstimulated PBMCs were incubated with 500 ng/ml of morphine, 2000 ng/ml of tramadol and 20 ng/ml of 
fentanyl for 1 hr (left panel) or 3 hr (right panel), before cytotoxicity was measured against K562 target 
cells, using an E:T ratio of 100:1. Data are means ± SEM of 2 independent experiments.  
 
 
The unstimulated NK cell cytotoxicity assay was performed in order to ensure that IL-2 
had not rendered NK cells resistant to opioid-mediated suppression. Although this was 
a limited, screening experiment, only 500 ng/ml of morphine for 3 days inhibited 
unstimulated NK cell cytotoxicity compared to untreated unstimulated PBMCs. 
Although statistically significant, this effect was quantitatively very small. Tramadol and 
fentanyl, like morphine at shorter time points had no effect on the cytotoxic capacity of 
unstimulated CD16+56+ NK cells. As a consequence, buprenorphine, methadone, 
oxycodone, diamorphine and codeine were not investigated. Overall, these findings 
indicate that the opioids tested have no effect on the cytotoxic capacity of NK cells 
against K562 target cells. 
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3.1.3 Effect of opioids on IL-2 stimulated natural killer cell activation 
In addition to evaluating the effects of opioids on NK cell cytotoxicity, their effect on NK 
cell activation was also assessed. CD69 is an early activation marker and has been 
demonstrated to be a good reflection of NK cell activation status (Gerosa et al., 1993).  
 
For these experiments, platelet-free PBMCs were isolated from whole blood by density 
gradient centrifugation and incubated for 3 days with IL-2 (100 U/ml) in the presence or 
absence of two clinically relevant concentrations of morphine, tramadol, fentanyl, 
buprenorphine, methadone, oxycodone, diamorphine and codeine. At the end of the 
culture period, cells were harvested and the proportion (%) of CD16+CD56+ NK cells 
expressing CD69 and the intensity of CD69 expression (MFI) in those positive cells 
were determined using flow cytometry (Figure 3-11 - Figure 3-18). Auto-fluorescence 
and non-specific mAb binding was excluded using unstained and non-reactive isotype 
controls respectively. Although CD69 expression is a sensitive marker for CD16+56+ NK 
cell activation, CD25 expression might also indicate the activation status of these cells. 
However, IL-2 stimulation had no effect on CD25 expression on CD16+CD56+ NK cells 
and this was not influenced by any of the opioids (data not shown).   
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Figure 3-11: Effect of morphine on CD69 expression by IL-2 stimulated NK cells. 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of this expression 
on these positive cells (median channel of fluorescent intensity, MFI; right panel) was determined by 
multi-colour flow cytometry. PBMCs were incubated with the indicated concentrations of morphine for 3 
days, prior to assessing CD69 expression; the stimulated control had no opioid (stim). All cells, other than 
the unstimulated control (unstim), were activated with IL-2 (100 U/ml) for 3 days, added at the same time 
as the opioid. The NK cells are identified as being CD4 and CD8 negative, and CD16
+
 or CD56
+
. Data are 
means ± SEM of 3 independent experiments (n=4 for 100 ng/ml). 500 ng/ml of morphine significantly 
inhibited the proportion of IL-2 stimulated NK cells that expressed CD69 expression, *p<0.05 (paired 
Student t-test). 
 
 
 
 
 
 
Figure 3-12: Effect of tramadol on CD69 expression by IL-2 stimulated NK cells. 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of this expression 
on these positive cells (median channel of fluorescent intensity, MFI; right panel) was determined by 
multi-colour flow cytometry. PBMCs were incubated with the indicated concentrations of tramadol for 3 
days, prior to assessing CD69 expression; the stimulated control had no opioid (stim). All cells, other than 
the unstimulated control (unstim), were activated with IL-2 (100 U/ml) for 3 days, added at the same time 
as the opioid. The NK cells are identified as being CD4 and CD8 negative, and CD16
+
 or CD56
+
. Data are 
means ± SEM of 3 independent experiments. No statistical difference in the proportion of NK cells 
expressing CD69 or the intensity of CD69 expression was observed between no opioid and tramadol-
treated IL-2 stimulated NK cells (paired Student t-test). 
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Figure 3-13: Effect of fentanyl on CD69 expression by IL-2 stimulated NK cells. 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of this expression 
on these positive cells (median channel of fluorescent intensity, MFI; right panel) was determined by 
multi-colour flow cytometry. PBMCs were incubated with the indicated concentrations of fentanyl for 3 
days, prior to assessing CD69 expression; the stimulated control had no opioid (stim). All cells, other than 
the unstimulated control (unstim), were activated with IL-2 (100 U/ml) for 3 days, added at the same time 
as the opioid. The NK cells are identified as being CD4 and CD8 negative, and CD16
+
 or CD56
+
. Data are 
means ± SEM of 3 independent experiments (n=2 for 20 ng/ml for % CD69 expression). No statistical 
difference in the proportion of NK cells expressing CD69 or the intensity of CD69 expression was observed 
between no opioid and fentanyl-treated IL-2 stimulated NK cells (paired Student t-test). 
 
 
 
 
 
 
Figure 3-14: Effect of buprenorphine on CD69 expression by IL-2 stimulated NK cells. 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of this expression 
on these positive cells (median channel of fluorescent intensity, MFI; right panel) was determined by 
multi-colour flow cytometry. PBMCs were incubated with the indicated concentrations of buprenorphine for 
3 days, prior to assessing CD69 expression; the stimulated control had no opioid (stim). All cells, other 
than the unstimulated control (unstim), were activated with IL-2 (100 U/ml) for 3 days, added at the same 
time as the opioid. The NK cells are identified as being CD4 and CD8 negative, and CD16
+
 or CD56
+
. Data 
are means ± SEM of 3 independent experiments. No statistical difference in the proportion of NK cells 
expressing CD69 or the intensity of CD69 expression was observed between no opioid and 
buprenorphine-treated IL-2 stimulated NK cells (paired Student t-test). 
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Figure 3-15: Effect of methadone on CD69 expression by IL-2 stimulated NK cells. 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of this expression 
on these positive cells (median channel of fluorescent intensity, MFI; right panel) was determined by 
multi-colour flow cytometry. PBMCs were incubated with the indicated concentrations of methadone for 3 
days, prior to assessing CD69 expression; the stimulated control had no opioid (stim). All cells, other than 
the unstimulated control (unstim), were activated with IL-2 (100 U/ml) for 3 days, added at the same time 
as the opioid. The NK cells are identified as being CD4 and CD8 negative, and CD16
+
 or CD56
+
. Data are 
means ± SEM of 3 independent experiments. No statistical difference in the proportion of NK cells 
expressing CD69 or the intensity of CD69 expression was observed between no opioid and methadone-
treated IL-2 stimulated NK cells (paired Student t-test). 
 
 
 
 
 
  
Figure 3-16: Effect of oxycodone on CD69 expression by IL-2 stimulated NK cells. 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of this expression 
on these positive cells (median channel of fluorescent intensity, MFI; right panel) was determined by 
multi-colour flow cytometry. PBMCs were incubated with the indicated concentrations of oxycodone for 3 
days, prior to assessing CD69 expression; the stimulated control had no opioid (stim). All cells, other than 
the unstimulated control (unstim), were activated with IL-2 (100 U/ml) for 3 days, added at the same time 
as the opioid. The NK cells are identified as being CD4 and CD8 negative, and CD16
+
 or CD56
+
. Data are 
means ± SEM of 3 independent experiments. No statistical difference in the proportion of NK cells 
expressing CD69 or the intensity of CD69 expression was observed between no opioid and oxycodone-
treated IL-2 stimulated NK cells (paired Student t-test). 
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Figure 3-17: Effect of diamorphine on CD69 expression by IL-2 stimulated NK cells. 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of this expression 
on these positive cells (median channel of fluorescent intensity, MFI; right panel) was determined by 
multi-colour flow cytometry. PBMCs were incubated with the indicated concentrations of diamorphine for 3 
days, prior to assessing CD69 expression; the stimulated control had no opioid (stim). All cells, other than 
the unstimulated control (unstim), were activated with IL-2 (100 U/ml) for 3 days, added at the same time 
as the opioid. The NK cells are identified as being CD4 and CD8 negative, and CD16
+
 or CD56
+
. Data are 
means ± SEM of 3 independent experiments. No statistical difference in the proportion of NK cells 
expressing CD69 or the intensity of CD69 expression was observed between no opioid and diamorphine-
treated IL-2 stimulated NK cells (paired Student t-test). 
 
 
 
 
 
 
Figure 3-18: Effect of codeine on CD69 expression by IL-2 stimulated NK cells. 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of this expression 
on these positive cells (median channel of fluorescent intensity, MFI; right panel) was determined by 
multi-colour flow cytometry. PBMCs were incubated with the indicated concentrations of codeine for 3 
days, prior to assessing CD69 expression; the stimulated control had no opioid (stim). All cells, other than 
the unstimulated control (unstim), were activated with IL-2 (100 U/ml) for 3 days, added at the same time 
as the opioid. The NK cells are identified as being CD4 and CD8 negative, and CD16
+
 or CD56
+
. Data are 
means ± SEM of 3 independent experiments. No statistical difference in the proportion of NK cells 
expressing CD69 or the intensity of CD69 expression was observed between no opioid and codeine-
treated IL-2 stimulated NK cells (paired Student t-test). 
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CD16+56+ NK cells were responsive to IL-2 stimulation, as IL-2 increased the 
proportion and intensity of CD69 expression on NK cells. 500 ng/ml of morphine 
decreased the proportion of CD16+56+ cells expressing CD69 and there was also a 
trend towards morphine decreasing the intensity of this expression, however, none of 
the other opioids had an effect on CD69 expression on IL-2 stimulated CD16+56+ cells. 
It might be that opioids do not have a direct effect on NK cells or because IL-2 
stimulated the NK cells to such an extent that this could not be overcome or enhanced 
by the other opioids. The effects of opioids on unstimulated NK cells were 
subsequently assessed, as were their effects on the expression of activation antigens 
on CD16+56+ NK cells in PBMC cultures that had been activated with Miltenyi anti-
CD3/anti-CD28 mAb coated beads. 
 
3.1.4 Effect of opioids on the activation status of natural killer cells in 
activated peripheral blood mononuclear cells preparations 
The effect of the opioids on the activation status (CD69 and CD25 expression) of 
CD16+56+ NK cells in PBMC cultures that had been stimulated with Miltenyi anti-
CD3/anti-CD28 mAb coated beads for 3 days was assessed. Although these beads do 
not stimulate the NK cells directly, over the 3 days they activate T cells, resulting in a 
milieu which might simulate that which is found during in vivo inflammatory events. 
These beads polyclonally activate T cells via a physiological mechanism which involves 
TCR triggering via interactions with cell surface CD3 and the induction of essential co-
stimulatory signals via binding to CD28. This results in the activation of intracellular 
cascades, including PKC and the transcription of mRNA for several cytokines, including 
IL-2 and IL-6. The aim of these studies was to assess the influence of opioids on NK 
cells that have been activated by a physiologically-relevant combination of cytokines. 
 
Incubation of PBMCs with Miltenyi anti-CD3/anti-CD28 mAb coated beads for 3 days 
increased the proportion of CD16+56+ NK cells expressing CD69 and, to a greater 
extent, the intensity of CD69 expression. Anti-CD3/anti-CD28 mAb coated beads did 
not have an effect on CD25 expression (either the proportion or the intensity of 
response) on CD16+56+ NK cells in PBMC cultures (data not shown). 
 
The data presented below (Figure 3-19 - Figure 3-26) illustrate the effect of the opioids 
on the proportion (%) of CD16+56+ NK cells expressing CD69 and the intensity of this 
expression (MFI) in those positive cells.  
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Figure 3-19: Effect of morphine on CD69 expression by NK cells in anti-CD3/28 mAb 
stimulated PBMC cultures. 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of CD69 
expression on these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs 
were incubated with the indicated concentrations of morphine for 3 days prior to assessing CD69 
expression; the stimulated control group had no morphine (stim). The NK cells are identified as being CD4 
and CD8 negative, and CD16
+
 or CD56
+
. All cells, other than the unstimulated control (unstim), were 
activated with anti-CD3/anti-CD28 mAb coated beads for 3 days, added at the same time as the morphine. 
Data are means ± SEM from 5 independent experiments (highest concentration n=4). No statistically 
significant differences between the responsiveness of morphine-treated and untreated anti-CD3/28 mAb 
stimulated NK cells were observed (paired Student t-test). 
 
 
 
 
 
Figure 3-20: Effect of tramadol on CD69 expression by NK cells in anti-CD3/28 mAb 
stimulated PBMC cultures. 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of CD69 
expression on these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs 
were incubated with the indicated concentrations of tramadol for 3 days prior to assessing CD69 
expression; the stimulated control group had no tramadol (stim). The NK cells are identified as being CD4 
and CD8 negative, and CD16
+
 or CD56
+
. All cells, other than the unstimulated control (unstim), were 
activated with anti-CD3/anti-CD28 mAb coated beads for 3 days, added at the same time as the tramadol. 
Data are means ± SEM from 6 independent experiments (highest concentration n=3). 2000 ng/ml of 
tramadol significantly increased the percentage of anti-CD3/28 mAb stimulated NK cells expressing CD69 
*p<0.05 (paired Student t-test). 
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Figure 3-21: Effect of fentanyl on CD69 expression by NK cells in anti-CD3/28 mAb 
stimulated PBMC cultures. 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of CD69 
expression on these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs 
were incubated with the indicated concentrations of fentanyl for 3 days prior to assessing CD69 
expression; the stimulated control group had no fentanyl (stim). The NK cells are identified as being CD4 
and CD8 negative, and CD16
+
 or CD56
+
. All cells, other than the unstimulated control (unstim), were 
activated with anti-CD3/anti-CD28 mAb coated beads for 3 days, added at the same time as the fentanyl. 
Data are means ± SEM from 6 independent experiments (highest concentration n=3). 4 and 100 ng/ml of 
fentanyl significantly inhibited the intensity of CD69 expression on anti-CD3/28 mAb stimulated NK cells, 
*p<0.05 (paired Student t-test). 
 
 
 
 
 
Figure 3-22: Effect of buprenorphine on CD69 expression by NK cells in anti-CD3/28 mAb 
stimulated PBMC cultures. 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of CD69 
expression on these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs 
were incubated with the indicated concentrations of buprenorphine for 3 days prior to assessing CD69 
expression; the stimulated control group had no buprenorphine (stim). The NK cells are identified as being 
CD4 and CD8 negative, and CD16
+
 or CD56
+
. All cells, other than the unstimulated control (unstim), were 
activated with anti-CD3/anti-CD28 mAb coated beads for 3 days, added at the same time as the 
buprenorphine. Data are means ± SEM from 5 independent experiments (except the top concentration 
which is n=3). No statistically significant differences between the responsiveness of buprenorphine-treated 
and untreated anti-CD3/28 mAb stimulated NK cells were observed (paired Student t-test). 
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Figure 3-23: Effect of methadone on CD69 expression by NK cells in anti-CD3/28 mAb 
stimulated PBMC cultures. 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (upper panel) and the intensity of CD69 
expression on these positive cells (median channel of fluorescent intensity, MFI; lower panel). PBMCs 
were incubated with the indicated concentrations of methadone for 3 days prior to assessing CD69 
expression; the stimulated control group had no methadone (stim). The NK cells are identified as being 
CD4 and CD8 negative, and CD16
+
 or CD56
+
. All cells, other than the unstimulated control (unstim), were 
activated with anti-CD3/anti-CD28 mAb coated beads for 3 days, added at the same time as the 
methadone. Data are means ± SEM from 6 independent experiments (highest concentration n=3). 20 
ng/ml of methadone significantly inhibited the intensity of CD69 expression on anti-CD3/28 mAb stimulated 
NK cells, *p<0.05 (paired Student t-test). 
 
 
 
 
 
Figure 3-24: Effect of oxycodone on CD69 expression by NK cells in anti-CD3/28 mAb 
stimulated PBMC cultures. 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of CD69 
expression on these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs 
were incubated with the indicated concentrations of oxycodone for 3 days prior to assessing CD69 
expression; the stimulated control group had no oxycodone (stim). The NK cells are identified as being 
CD4 and CD8 negative, and CD16
+
 or CD56
+
. All cells, other than the unstimulated control (unstim), were 
activated with anti-CD3/anti-CD28 mAb coated beads for 3 days, added at the same time as the 
oxycodone. Data are means ± SEM from 6 independent experiments (highest concentration n=3). No 
statistically significant differences between the responsiveness of oxycodone-treated and untreated anti-
CD3/28 mAb stimulated NK cells were observed (paired Student t-test). 
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Figure 3-25: Effect of diamorphine on CD69 expression by NK cells in anti-CD3/28 mAb 
stimulated PBMC cultures. 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of CD69 
expression on these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs 
were incubated with the indicated concentrations of diamorphine for 3 days prior to assessing CD69 
expression; the stimulated control group had no diamorphine (stim). The NK cells are identified as being 
CD4 and CD8 negative, and CD16
+
 or CD56
+
. All cells, other than the unstimulated control (unstim), were 
activated with anti-CD3/anti-CD28 mAb coated beads for 3 days, added at the same time as the 
diamorphine. Data are means ± SEM from 6 independent experiments (lowest concentration n=5; highest 
concentration n=3). No statistically significant differences between the responsiveness of diamorphine-
treated and untreated anti-CD3/28 mAb stimulated NK cells were observed (paired Student t-test). 
 
 
Figure 3-26: Effect of codeine on CD69 expression by NK cells in anti-CD3/28 mAb 
stimulated PBMC cultures. 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of CD69 
expression on these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs 
were incubated with the indicated concentrations of codeine for 3 days prior to assessing CD69 
expression; the stimulated control group had no codeine (stim). The NK cells are identified as being CD4 
and CD8 negative, and CD16
+
 or CD56
+
. All cells, other than the unstimulated control (unstim), were 
activated with anti-CD3/anti-CD28 mAb coated beads for 3 days, added at the same time as the codeine. 
Data are means ± SEM from 6 independent experiments (highest concentration n=3). No statistically 
significant differences between the responsiveness of codeine-treated and untreated anti-CD3/28 mAb 
stimulated NK cells were observed (paired Student t-test). 
 
Although 4 and 100 ng/ml of fentanyl and 20 ng/ml of methadone in these cultures 
inhibited the intensity of CD69 expression, and 2000 ng/ml of tramadol increased the 
proportion of NK cells expressing CD69, these were quantitatively small and none of 
the opioids had any consistent effect on NK cell activation in anti-CD3/anti-CD28 
stimulated PBMC cultures.  
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3.1.5 Effect of opioids on the activation status of unstimulated natural 
killer cells 
The observation that none of the opioids had any effect on the activation status of IL-2 
or anti-CD3/anti-CD28 stimulated NK cells might be because these opioids cannot 
overcome the potent stimulatory consequences of IL-2 or anti-CD3/anti-CD28 mAb or, 
if the opioid was to be stimulatory, it might not be potent enough to further enhance IL-
2 or anti-CD3/anti-CD28 mAb induced stimulation. The influence of morphine, tramadol 
and fentanyl on CD69 and CD25 expression by unstimulated CD16+56+ NK cells was 
therefore evaluated. CD25 expression was unaffected by stimulation or opioids (data 
not shown). 
 
For these studies, platelet-free PBMCs were isolated from whole blood by density 
gradient centrifugation and incubated for 3-days with clinically relevant concentrations 
of morphine, tramadol and fentanyl. At the end of the culture period, cells were 
harvested and the proportion of CD16+CD56+ NK cells expressing CD69 and CD25, 
and the intensity of this expression (MFI) were determined using multi-colour flow 
cytometry. Auto-fluorescence and non-specific mAb binding was excluded using 
unstained and non-reactive isotype-matched controls respectively. These experiments 
demonstrated that morphine, tramadol and fentanyl had no effect on the activation 
status (CD69 and CD25) of unstimulated NK cells (Figure 3-27 - Figure 3-29). 
 
 
Figure 3-27: Effect of morphine on CD69 expression by unstimulated NK cells (3-day 
incubation). 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of this expression 
on these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were incubated 
with the indicated concentration of morphine for 3 days prior to assessing CD69 expression. The NK cells 
are identified as being CD4 and CD8 negative, and CD16
+
 or CD56
+
. Data are means ± SEM from 3 
independent experiments. No statistically significant differences between the responsiveness of morphine-
treated and untreated unstimulated NK cells (paired Student t-test). 
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Figure 3-28: Effect of tramadol on CD69 expression by unstimulated NK cells (3-day 
incubation). 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of this expression 
on these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were incubated 
with the indicated concentration of tramadol for 3 days prior to assessing CD69 expression. The NK cells 
are identified as being CD4 and CD8 negative, and CD16
+
 or CD56
+
. Data are means ± SEM from 3 
independent experiments (n=2 for 400 ng/ml of tramadol). No statistically significant differences between 
the responsiveness of tramadol-treated and untreated unstimulated NK cells (paired Student t-test). 
 
 
Figure 3-29: Effect of fentanyl on CD69 expression by unstimulated NK cells (3-day 
incubation). 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of this expression 
on these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were incubated 
with the indicated concentration of fentanyl for 3 days prior to assessing CD69 expression. The NK cells 
are identified as being CD4 and CD8 negative, and CD16
+
 or CD56
+
. Data are means ± SEM from 3 
independent experiments (n=2 for 4 ng/ml of fentanyl). No statistically significant differences between the 
responsiveness of fentanyl-treated and untreated unstimulated NK cells (paired Student t-test). 
 
As there is some evidence to suggest that morphine can suppress NK cell cytotoxicity 
within hours, and that tolerance to this can occur within a day (Nelson et al., 1997), 
additional short-term experiments (1, 3 and 24 hr) which used only the higher doses of 
morphine, tramadol and fentanyl were performed in order to ensure that this effect was 
not missed (Figure 3-30 - Figure 3-32). As IL-2 takes 3 days to elicit its stimulatory 
effect on NK cells, all assays with shorter time points used unstimulated NK cells, as 
adding IL-2 for less than 3 days would not lead to a meaningful activation. 
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Figure 3-30: Effect morphine, tramadol and fentanyl on CD69 expression by unstimulated 
NK cells (1-hr incubation). 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of this expression 
on these positive cells (median channel of fluorescent intensity, MFI; right panel). Unstimulated PBMCs 
were incubated with the indicated opioid (morphine 500 ng/ml, tramadol 2000 ng/ml and fentanyl 20 ng/ml) 
for 1 hr prior to assessing CD69 expression. The NK cells are identified as being CD4 and CD8 negative, 
and CD16
+
 or CD56
+
. Data are means ± SEM from 2 independent experiments.  
 
 
Figure 3-31: Effect of morphine, tramadol and fentanyl on CD69 expression by 
unstimulated NK cells (3-hr incubation). 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of this expression 
on these positive cells (median channel of fluorescent intensity, MFI; right panel). Unstimulated PBMCs 
were incubated with the indicated opioid (morphine 500 ng/ml, tramadol 2000 ng/ml and fentanyl 20 ng/ml) 
for 3 hr prior to assessing CD69 expression. The NK cells are identified as being CD4 and CD8 negative, 
and CD16
+
 or CD56
+
. Data are means ± SEM from 2 independent experiments.  
 
 
Figure 3-32: Effect of morphine, tramadol and fentanyl on CD69 expression in 
unstimulated NK cells (24-hr incubation). 
The proportion (%) of CD16
+
56
+
 NK cells expressing CD69 (left panel) and the intensity of this expression 
on these positive cells (median channel of fluorescent intensity, MFI; right panel). Unstimulated PBMCs 
were incubated with the indicated opioid (morphine 500 ng/ml, tramadol 2000 ng/ml and fentanyl 20 ng/ml) 
for 24 hr prior to assessing CD69 expression. The NK cells are identified as being CD4 and CD8 negative, 
and CD16
+
 or CD56
+
. Data are means ± SEM from 2 independent experiments.   
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This limited, screening experiment, assessed the effects of clinically relevant 
concentrations of morphine, tramadol and fentanyl on the activation (CD69 and CD25 
expression) of unstimulated CD16+56+ NK cells at 1, 3, 24 and 72 hr. It showed that 
none of the opioids had an effect on the expression of CD69 and CD25 on 
unstimulated CD16+56+ NK cells. No additional opioids were therefore assessed. 
 
3.1.6 Effects of opioids on natural killer cells in individual subjects 
None of the opioids tested had a consistent, statistically significant effect on NK cell 
cytotoxicity in IL-2 stimulated or unstimulated PBMCs. They also had no consistent 
effect on the activation status of NK cells in IL-2 or Miltenyi anti-CD3/anti-CD28 mAb 
stimulated PBMCs or unstimulated PBMC cultures. There did however seem to be an 
effect of certain opioids on the NK cells of some individual subjects and there was 
interindividual variability in the observed responses. The genetic and molecular basis to 
interindividual variability to opioids will be discussed in section 4.7. 
 
Most of the opioids had no consistent effect on NK cells in most of the subjects tested. 
Subject 3 was most sensitive to the effect of opioids, with NK cell cytotoxicity and 
intensity of CD69 expression being inhibited by morphine, tramadol and buprenorphine. 
Buprenorphine also reduced NK cell cytotoxicity in subject 1 and 5, but did not 
influence CD69 expression. Fentanyl inhibited NK cell cytotoxicity and CD69 
expression in subject 1. (NB: subject numbers are constant throughout all the 
experiments). 
 
 
3.1.7 Discussion  
Flow cytometry has been used to assess the effects of eight commonly used opioids at 
two concentrations, approximating those found clinically, on the in vitro ability of resting 
and IL-2 activated human NK cells to kill K562 cells. The effect of these opioids on the 
expression of CD69 and CD25 by resting NK cells, IL-2 activated NK cells and also NK 
cells in anti-CD3/anti-CD28 mAb activated PBMC cultures were also assessed. 
 
None of the opioids at the concentrations tested had any effect on the killing of K562 
cells by NK cells in unstimulated and IL-2 stimulated PBMC preparations. Several 
experimental paradigms were explored; both with IL-2 stimulated or unstimulated 
PBMCs over 3 days, and in a series of screening experiments with a shorter incubation 
time with unstimulated PBMCs. As there were small numbers of subjects, this could 
lead to a type II error, but no consistent effect of any of the opioids was detected, thus 
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the number of subjects was not increased. If effects were seen, but they could not be 
demonstrated to be of statistical significance, then there would have been an 
advantage to increase the number of subjects to potentially gain significance. 
 
The activation status, as measured by CD69 and CD25 expression, on unstimulated 
and IL-2 stimulated NK cells, and NK cells in anti-CD3/anti-CD28 mAb stimulated 
PBMC preparations was also determined. There were occasional statistically significant 
effects on CD69 expression at some of the concentrations of the opioids tested in 
these three different experimental paradigms. However, in view of the numerous tests 
performed and that the significant results generally occurred at just one concentration 
of the opioid on one of the measures of NK cell function in one of the experiments, it is 
likely that this occurred by chance, rather than being a real result at low levels of 
significance. Furthermore, these effects tended to be quantitatively small, bringing 
doubt to their potential clinical significance. 
 
The previous in vitro studies assessing the effects of opioids on NK cells are reviewed 
below and then compared to the findings of the current study. It should be noted that 
the previous studies only assessed NK cell cytotoxicity (using unstimulated NK cells), 
not NK cell activation status as was also undertaken herein.  
 
Yeager and colleagues investigated the in vitro effect of morphine on NK cell 
cytotoxicity in 10 healthy volunteers (Yeager et al., 1992). PBMCs were isolated from 
whole blood using density gradient centrifugation, without the removal of platelets. 
These cells were incubated with 10-12 – 10-4 M of morphine (equivalent to 3x10-4 – 
3x104 ng/ml) for 18 hr. NK cell cytotoxicity was measured using a 4-hr incubation of 
PBMCs with 51Cr labelled K562 cells. Only 10-4 M of morphine (≈ 28,500 ng/ml), over 
50x the maximum concentration used in the current study, and far in excess of that 
found clinically, had any significant inhibition on NK cell cytotoxicity, decreasing it by 
18%, individual variability was not discussed (Yeager et al., 1992).  
 
Although Yeager used the same effector cells (healthy human PBMCs) as the current 
study, they were unstimulated and incubated with morphine for a shorter period (18 vs. 
72 hr). However, shorter incubation times with unstimulated PBMCs were also 
assessed in the current study. They also used a 4-hr (as opposed to 3-hr) incubation 
with K562 and a radiolabelled assay rather than flow cytometry. However, as in the 
current study, morphine at the concentrations detected clinically, had no effect on NK 
cell cytotoxicity. 
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Condevaux and colleagues assessed the effect of in vitro morphine on the cytotoxicity 
of splenic NK cells in the Sprague-Dawley rat and PBMCs from the cynomolgus 
monkey (Condevaux et al., 2001). For the rat experiments, NK cells were incubated 
with 0.01, 1 and 1000 nM of morphine (equivalent to 0.003, 0.3 and 285 ng/ml) for 2-hr, 
before being incubated with 51Cr labelled YAC-1 target cells for 4 hr (E:T ratios; 200:1, 
100:1 and 50:1). 51Cr labelled K562 target cells were used in the monkey experiments 
(E:T ratios; 100:1, 50:1 and 25:1). Only 1000 nM of morphine (≈ 285 ng/ml) inhibited 
NK cell cytotoxicity in these experiments, decreasing it by up to 35% in the rat and 
160% in the monkey (Condevaux et al., 2001).  
 
Compared with the current study, Condevaux used effector cells from different species 
which were unstimulated (although the current study also screened for effects from 
unstimulated cells) and had a shorter incubation period with morphine (2 vs. 72 hr), 
although comparable incubation times were also evaluated in the current study. They 
also used a 4-hr (as opposed to 3-hr) incubation with the target cells (which differed in 
the rat experiments YAC-1 vs. K562), and a radiolabelled assay rather than flow 
cytometry. 1000 nM (≈ 285 ng/ml) is comparable to concentrations found clinically and 
overlaps with the current study, where NK cell cytotoxicity was not inhibited, this might 
be due to the different species used.  
 
The in vitro effect of fentanyl was assessed in four healthy volunteers (Jacobs et al., 
1999). PBMCs were isolated and incubated for 45 min with 20 and 40 M of fentanyl 
(equivalent to 5,700 and 11,400 ng/ml). NK cell cytotoxicity was assessed using a 4-hr 
incubation with 51Cr labelled K562 target cells (fentanyl was not removed before this). 
NK cell cytotoxicity was not affected, variability was not reported (Jacobs et al., 1999). 
Although using much higher concentrations of fentanyl with a shorter incubation time 
than the current study, Jacobs also showed fentanyl did not affect NK cell cytotoxicity. 
 
Molitor and colleagues investigated the in vitro effects of methadone on PBMCs 
isolated from five pigs (Molitor et al., 1992). PBMCs were incubated for 48 hr with 10-18 
– 10-6 M of methadone (equivalent to 3x10-10 – 309 ng/ml) and NK cell cytotoxicity was 
measured following a 4-hr incubation with 51Cr-labeled K562 target cells. Higher 
concentrations of methadone (10-9 – 10-6 M; equivalent to 0.3 – 309 ng/ml) decreased 
the ability of NK cells to kill K562 cells by up to four fold (Molitor et al., 1992).  
 
Compared with the current study, Molitor used effector cells from different species 
which were unstimulated, but used a comparable incubation period with methadone (2 
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vs. 3 days). They used a 4-hr (as opposed to 3-hr) incubation with the target cells and 
a radiolabelled assay rather than flow cytometry. 10-9 – 10-6 M is comparable to clinical 
concentrations and overlaps with the current study, in which NK cell cytotoxicity was 
not inhibited, this might be due to the species used or NK cell activation status. 
 
The previous literature assessing the in vitro effect of opioids on NK cell cytotoxicity is 
sparse, with only morphine, fentanyl and methadone having been studied on 
unstimulated NK cells. These studies were in differing species, with different 
concentrations and incubation times with opioids, as well as utilising differing target 
cells. Many previous studies have used 51Cr release detected in the assay supernatant 
by a  counter as a measure of NK cell cytotoxicity; the current study used flow 
cytometry which accurately determined the number of live/dead target cells (as well as 
enabling cell surface activation marker expression to be evaluated). These two 
techniques have been shown to closely correlate (Kane et al., 1996, Shi et al., 1987). 
 
The previous studies all used unstimulated NK cells and the current study screened for 
the effects of morphine, tramadol and fentanyl on unstimulated NK cells. Being part of 
the innate immune system the response of unactivated NK cell might be of some 
importance in the very early stages of disease. However, unstimulated NK cells are 
less likely to be clinically relevant in patients with establishing cancer or infection in 
whom cells are likely to be activated. However, in patients with established cancer, the 
cancer-immune interaction can induce up-regulation of inhibitory NK cell receptors (i.e. 
killer immunoglobulin-like receptor) and down-regulation of stimulatory NK cell 
receptors (i.e. NKG2D), overall inhibiting NK cells in patients with cancer (Al Omar et 
al., 2011, Saito et al., 2011). Even in these patients the continual recruitment of 
activated NK cells into the tumour microenvironment might still be important.  
 
No previous studies have assessed the effects of any opioids on the activation status 
(either CD69 or CD25) expression of NK cells. In the current study, there is no clear 
relationship between any of the opioids and effect on NK cell activation. This may in 
part be due to small numbers of subjects and type II error, however, no effect of any of 
the opioids was seen on any of the individuals and there was variability between the 
individuals, which more likely leads to the lack of statistical effect.  
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3.1.8 Conclusion  
NK cells have a vital role in tumour immunosurveillance and in the control of viral 
infection. Previous in vivo studies have shown that NK cell cytotoxicity can be affected 
by opioids, although there are different effects from the different opioids and between 
the models used (section 1.12.1). From the little previous in vitro evidence available, 
morphine and methadone have been shown to inhibit NK cell cytotoxicity at high 
concentrations. In the current study, eight opioids, at concentrations overlapping those 
detected clinically, were incubated for 3 days (and shorter time points) with 
unstimulated or stimulated (IL-2 or anti-CD3/anti-CD28 mAb) PBMCs before assessing 
NK cell cytotoxicity against K562 cells and NK cell activation using flow cytometry. 
None of the opioids at the concentrations tested had any effect on the cytotoxicity of 
unstimulated or IL-2 stimulated NK cells against the K562 erythroleukaemic cell line. 
They also had no consistent effect on CD69 or CD25 expression on unstimulated or 
stimulated (IL-2 or anti-CD3/anti-CD28 mAb) NK cells over 3 days or, in the screening 
experiments, at shorter time points. These findings indicate that none of the commonly 
used opioids directly inhibit the function of NK cells under these in vitro experimental 
conditions and suggest that any effects that opioids might have in vivo and clinically are 
likely to arise as a consequence of indirect actions, possibly via effects on the SNS and 
HPA axis. 
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3.2 Effect of opioids on neutrophil and monocyte phagocytosis and 
oxidative burst responses 
Neutrophils and monocytes are part of the innate immune system and have a role in 
the defence against bacteria, fungi and foreign particles. Their main functional 
mechanisms in this defence are phagocytosis and the oxidative burst reaction. 
 
Initial experiments investigated the influence of pre-incubating whole blood with a 
single intermediate concentration of opioid (approximating to the clinically relevant 
concentrations that are found in human studies), namely 100 ng/ml of morphine, 400 
ng/ml of tramadol or 4 ng/ml of fentanyl for 0, 30, 60 or 120 min, on neutrophil and 
monocyte phagocytosis and oxidative burst responses. These preliminary experiments 
indicated that opioid-mediated effects were best studied following a 60-min pre-
incubation. On the basis of these findings, all subsequent experiments in which the 
effects of morphine, tramadol, fentanyl, buprenorphine, methadone, oxycodone, 
diamorphine and codeine on phagocytosis and oxidative burst responses were 
evaluated used a pre-incubation time of 60 min at 37°C of whole blood with the opioids 
(see Table 2.12 for the opioid concentrations used for these assays). 
 
The data from the initial set of experiments which explored the effect of time were 
combined with the data that were obtained in subsequent experiments which examined 
the dose-dependent effects of opioids. As different individuals exhibit a range of 
phagocytosis and oxidative burst activity, the no opioid controls for these experiments 
were variable. As a consequence, data were expressed as change from control by 
subtracting the effect of the opioid from the no opioid control. In view of this and the 
variability among the individual subjects tested, further experiments were performed in 
order to ensure that the opioids had been tested on a similar profile of volunteers. This 
was especially important as the initial results demonstrated a difference between the 
intermediate concentration and the other concentrations which were only partially 
corrected for by subtracting the effect of the opioid from the no opioid control. This was 
most likely due to different volunteers being used for the experiments. 
 
3.2.1 Phagocytosis 
The effect of the opioids (60 min incubation) on the ability of neutrophils and 
monocytes to phagocytose FITC-labelled E.coli over 10 min was assessed and the 
data are presented below as change from the no opioid controls. The absolute baseline 
values, without opioid, are given at the top of the graphs (Figure 3-33 - Figure 3-40).  
168 | P a g e  
 
 
 
 
 
Figure 3-33: Effect of morphine on neutrophil and monocyte phagocytosis. 
The proportion of neutrophils and monocytes phagocytosing FITC-E.coli (left panel) and the intensity of 
the phagocytic response (median channel of fluorescent intensity, MFI; right panel), presented as 
absolute differences from the no opioid control. No opioid (baseline) values (mean ± SEM) are stated at 
the top of the graphs. Whole blood was incubated with the indicated concentrations of morphine for 60 min 
prior to assessing the phagocytosis of FITC-E.coli. Data are means ± SEM from 5 independent 
experiments (n=4 for monocytes at 20 and 100 ng/ml of morphine). No statistically significant differences, 
using a paired Student t-test, between the responsiveness of opioid-treated and untreated cells was 
detected. 
 
Figure 3-34: Effect of tramadol on neutrophil and monocyte phagocytosis. 
The proportion of neutrophils and monocytes phagocytosing FITC-E.coli (left panel) and the intensity of 
the phagocytic response (median channel of fluorescent intensity, MFI; right panel), presented as 
absolute differences from the no opioid control. No opioid (baseline) values (mean ± SEM) are stated at 
the top of the graphs. Whole blood was incubated with the indicated concentrations of tramadol for 60 min 
prior to assessing the phagocytosis of FITC-E.coli. Data are means ± SEM from 5 independent 
experiments and no statistically significant differences, using a paired Student t-test, between the 
responsiveness of opioid-treated and untreated cells was detected. 
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Figure 3-35: Effect of fentanyl on neutrophil and monocyte phagocytosis. 
The proportion of neutrophils and monocytes phagocytosing FITC-E.coli (left panel) and the intensity of 
the phagocytic response (median channel of fluorescent intensity, MFI; right panel), presented as 
absolute differences from the no opioid control. No opioid (baseline) values (mean ± SEM) are stated at 
the top of the graphs Whole blood was incubated with the indicated concentrations of fentanyl for 60 min 
prior to assessing the phagocytosis of FITC-E.coli. Data are means ± SEM from 5 independent 
experiments (n=4 for neutrophils at 20ng/ml of fentanyl, n=4 for monocytes at 0.8ng/ml of fentanyl, and 
n=3 for monocytes at 20ng/ml of fentanyl) and no statistically significant differences, using a paired 
Student t-test, between the responsiveness of opioid-treated and untreated cells was detected. 
 
Figure 3-36: Effect of buprenorphine on neutrophil and monocyte phagocytosis. 
The proportion of neutrophils and monocytes phagocytosing FITC-E.coli (left panel) and the intensity of 
the phagocytic response (median channel of fluorescent intensity, MFI; right panel), presented as 
absolute differences from the no opioid control. No opioid (baseline) values (mean ± SEM) are stated at 
the top of the graphs. Whole blood was incubated with the indicated concentrations of buprenorphine for 
60 min prior to assessing the phagocytosis of FITC-E.coli. Data are means ± SEM from 5 independent 
experiments (n=4 for 0.8ng/ml of buprenorphine, and n=6 and 7 for neutrophils and monocytes at 4ng/ml 
of fentanyl respectively). No statistically significant differences, using a paired Student t-test, between the 
responsiveness of opioid-treated and untreated cells was detected. 
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Figure 3-37: Effect of methadone on neutrophil and monocyte phagocytosis. 
The proportion of neutrophils and monocytes phagocytosing FITC-E.coli (left panel) and the intensity of 
the phagocytic response (median channel of fluorescent intensity, MFI; right panel), presented as 
absolute differences from the no opioid control. No opioid (baseline) values (mean ± SEM) are stated at 
the top of the graphs. Whole blood was incubated with the indicated concentrations of methadone for 60 
min prior to assessing the phagocytosis of FITC-E.coli. Data are means ± SEM from 3 independent 
experiments and no statistically significant differences, using a paired Student t-test, between the 
responsiveness of opioid-treated and untreated cells was detected. 
 
Figure 3-38: Effect of oxycodone on neutrophil and monocyte phagocytosis. 
The proportion of neutrophils and monocytes phagocytosing FITC-E.coli (left panel) and the intensity of 
the phagocytic response (median channel of fluorescent intensity, MFI; right panel), presented as 
absolute differences from the no opioid control. No opioid (baseline) values (mean ± SEM) are stated at 
the top of the graphs. Whole blood was incubated with the indicated concentrations of oxycodone for 60 
min prior to assessing the phagocytosis of FITC-E.coli. Data are means ± SEM from 3 independent 
experiments and no statistically significant differences, using a paired Student t-test, between the 
responsiveness of opioid-treated and untreated cells was detected. 
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Figure 3-39: Effect of diamorphine on neutrophil and monocyte phagocytosis. 
The proportion of neutrophils and monocytes phagocytosing FITC-E.coli (left panel) and the intensity of 
the phagocytic response (median channel of fluorescent intensity, MFI; right panel), presented as 
absolute differences from the no opioid control. No opioid (baseline) values (mean ± SEM) are stated at 
the top of the graphs. Whole blood was incubated with the indicated concentrations of diamorphine for 60 
min prior to assessing the phagocytosis of FITC-E.coli. Data are means ± SEM from 3 independent 
experiments and no statistically significant differences, using a paired Student t-test, between the 
responsiveness of opioid-treated and untreated cells was detected. 
 
Figure 3-40: Effect of codeine on neutrophil and monocyte phagocytosis. 
The proportion of neutrophils and monocytes phagocytosing FITC-E.coli (left panel) and the intensity of 
the phagocytic response (median channel of fluorescent intensity, MFI; right panel), presented as 
absolute differences from the no opioid control. No opioid (baseline) values (mean ± SEM) are stated at 
the top of the graphs. Whole blood was incubated with the indicated concentrations of codeine for 60 min 
prior to assessing the phagocytosis of FITC-E.coli. Data are means ± SEM from 3 independent 
experiments and no statistically significant differences, using a paired Student t-test, between the 
responsiveness of opioid-treated and untreated cells was detected. 
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Trends that opioids influenced phagocytosis were apparent, however interindividual 
variability and the limited sample size makes type II errors likely. However, the 
relevance of the relationship between statistical and clinical significance must also be 
considered. The clinical significance of any effect might be more dependent on 
individual rather than group effects and this will be explored in the next section. 
 
3.2.2 Effects of opioids on phagocytosis in individual subjects 
No consistent, statistically significant effect of any of the opioids tested on neutrophil 
and monocyte phagocytosis was detected in the current study. Although there does 
appear to be an effect of certain opioids on phagocytosis for individual subjects, there 
was a large interindividual variability in the observed responses. Baseline phagocytic 
activity was also variable. Although the initial analysis of the data, after three subjects 
had been assessed, demonstrated that morphine, tramadol and fentanyl statistically 
significantly inhibited phagocytosis, this statistical significance was lost when the group 
size was increased to five. For some subjects, some of the opioids markedly inhibited 
or in some cases activated the phagocytic response, whereas no effects were seen in 
others. The genetic and molecular basis to interindividual variability to opioids will be 
discussed in section 4.7. 
 
Below are graphs showing the variability in the response of each individual subject to 
the intermediate concentrations of morphine, tramadol, fentanyl and buprenorphine 
which approximates to those that are found clinically (Figure 3-41 - Figure 3-48). The 
other opioids had no influence on phagocytosis and there was minimal interindividual 
variability. Each graph shows the effect of opioid vs. no opioid for each subject plotted 
separately. To enable comparisons for each subject across the range of opioids for 
which they were tested, they have been allocated a subject number, which remains 
consistent across tests. Not all subjects were tested for each opioid. 
 
The phagocytosis assays have been shown to be reproducible with Coefficients of 
Variation of 0.2% for the proportion of neutrophils phagocytosing E.coli and 1.5% for 
the MFI of this response, and 1.1% for the proportion of monocytes phagocytosing 
E.coli and 3.6% for the MFI of this response (PHAGOBURST
® test kit data sheet, 
Orpegen Pharma). It is thus likely that it is biological rather than experimental variations 
leading to this interindividual effect. 
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Figure 3-41: Effect of morphine on neutrophil phagocytosis for individuals. 
The proportion of neutrophils phagocytosing FITC-E.coli (left panel) and the intensity of the phagocytic 
response (median channel of fluorescent intensity, MFI; right panel), presented for each subject 
individually, with the no opioid control and 100ng/ml of morphine. Whole blood was incubated with either 
no opioid or 100ng/ml of morphine for 60 min prior to assessing the phagocytosis of FITC-E.coli.  
 
 
 
 
 
 
 
 
Figure 3-42: Effect of morphine on monocyte phagocytosis for individuals. 
The proportion of monocytes phagocytosing FITC-E.coli (left panel) and the intensity of the phagocytic 
response (median channel of fluorescent intensity, MFI; right panel), presented for each subject 
individually, with the no opioid control and 100ng/ml of morphine. Whole blood was incubated with either 
no opioid or 100ng/ml of morphine for 60 min prior to assessing the phagocytosis of FITC-E.coli.  
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Figure 3-43: Effect of tramadol on neutrophil phagocytosis for individuals. 
The proportion of neutrophils phagocytosing FITC-E.coli (left panel) and the intensity of the phagocytic 
response (median channel of fluorescent intensity, MFI; right panel), presented for each subject 
individually, with the no opioid control and 400ng/ml of tramadol. Whole blood was incubated with either no 
opioid or 400ng/ml of tramadol for 60 min prior to assessing the phagocytosis of FITC-E.coli.  
 
 
 
 
 
 
 
Figure 3-44: Effect of tramadol on monocyte phagocytosis for individuals. 
The proportion of monocytes phagocytosing FITC-E.coli (left panel) and the intensity of the phagocytic 
response (median channel of fluorescent intensity, MFI; right panel), presented for each subject 
individually, with the no opioid control and 400ng/ml of tramadol. Whole blood was incubated with either no 
opioid or 400ng/ml of tramadol for 60 min prior to assessing the phagocytosis of FITC-E.coli.  
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Figure 3-45: Effect of fentanyl on neutrophil phagocytosis for individuals. 
The proportion of neutrophils phagocytosing FITC-E.coli (left panel) and the intensity of the phagocytic 
response (median channel of fluorescent intensity, MFI; right panel), presented for each subject 
individually, with the no opioid control and 4ng/ml of fentanyl. Whole blood was incubated with either no 
opioid or 4ng/ml of fentanyl for 60 min prior to assessing the phagocytosis of FITC-E.coli.  
 
 
 
 
 
 
 
Figure 3-46: Effect of fentanyl on monocyte phagocytosis for individuals. 
The proportion of monocytes phagocytosing FITC-E.coli (left panel) and the intensity of the phagocytic 
response (median channel of fluorescent intensity, MFI; right panel), presented for each subject 
individually, with the no opioid control and 4ng/ml of fentanyl. Whole blood was incubated with either no 
opioid or 4ng/ml of fentanyl for 60 min prior to assessing the phagocytosis of FITC-E.coli.  
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Figure 3-47: Effect of buprenorphine on neutrophil phagocytosis for individuals. 
The proportion of neutrophils phagocytosing FITC-E.coli (left panel) and the intensity of the phagocytic 
response (median channel of fluorescent intensity, MFI; right panel), presented for each subject 
individually, with the no opioid control and 4ng/ml of buprenorphine. Whole blood was incubated with either 
no opioid or 4ng/ml of buprenorphine for 60 min prior to assessing the phagocytosis of FITC-E.coli.  
 
 
 
 
 
 
 
Figure 3-48: Effect of buprenorphine on monocyte phagocytosis for individuals. 
The proportion of monocytes phagocytosing FITC-E.coli (left panel) and the intensity of the phagocytic 
response (median channel of fluorescent intensity, MFI; right panel), presented for each subject 
individually, with the no opioid control and 4ng/ml of buprenorphine. Whole blood was incubated with either 
no opioid or 4ng/ml of buprenorphine for 60 min prior to assessing the phagocytosis of FITC-E.coli.  
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The tables below summarise the effect of the opioids at all concentrations tested on 
phagocytosis of neutrophils (Table 3.1) and monocytes (Table 3.2) for the individual 
subjects tested. When assessing the effect of individuals across the opioids at a range 
of concentrations for all the different tests of immune function, many potential trends 
could be extrapolated (i.e. only effects at specific concentrations, or u or n shaped 
curves). However, due to the number of permutations, only when an opioid increased 
or inhibited the immune response by at least 20% at most of the concentrations tested 
was this response considered to be a trend.  
 
Table 3.1: Effect of opioids on phagocytosis of neutrophils for individuals.  
Opioid  Morphine Tramadol Fentanyl Buprenorphine Methadone, oxycodone, 
diamorphine, codeine Subject 
1 Increase Increase Increase Increase No effect 
2  Decrease Decrease Decrease No effect 
3 No effect Increase Decrease No effect No effect 
4  Decrease Decrease No effect No effect 
5 Decrease  Decrease Decrease No effect 
6 Decrease Decrease  Decrease No effect 
7 Decrease     
The effect of the opioids on total phagocytosis (MFI) is summarised. Red indicates an inhibitory effect, 
green a stimulatory effect and yellow no effect (boxes are uncoloured if not tested). 
 
Table 3.2: Effect of opioids on phagocytosis of monocytes for individuals.  
Opioid Morphine Tramadol Fentanyl Buprenorphine Methadone, oxycodone, 
diamorphine, codeine Subject 
1 Increase Increase Increase Increase No effect 
2  Decrease Decrease Decrease No effect 
3 No effect Increase Decrease No effect No effect 
4  Decrease Decrease Decrease No effect 
5 Decrease  Decrease Decrease  
6 Decrease Decrease  Decrease  
The effect of the opioids on total phagocytosis (MFI) is summarised. Red indicates an inhibitory effect, 
green a stimulatory effect and yellow no effect (boxes are uncoloured if not tested). 
 
For the opioids that did influence phagocytosis (morphine, tramadol, fentanyl and 
buprenorphine), there were clear differences between individuals, with some opioids 
increasing phagocytosis in some subjects, decreasing it in others, or not having any 
effect. Even though some opioids appeared to have stimulatory properties in some 
subjects, the magnitude of this effect tended to be less than their suppressive effects, 
when these occurred. Subject 1 was most likely to have an enhancing effect from the 
opioids, whereas all of the opioids tended to inhibit responses in the other subjects 
(except tramadol in subject 3). From the opioids that influenced phagocytosis, there 
was no clear pattern in the direction of this effect from the different opioids as any 
effect was more dependent on the subject than the opioid. In general, there was a 
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greater effect on the total amount of phagocytosis (i.e. total number of E.coli ingested, 
denoted as MFI), compared with the number of neutrophils ingesting the bacteria 
(proportion of neutrophils phagocytosing FITC-E.coli). Morphine, tramadol, fentanyl and 
buprenorphine might therefore be detrimental in certain individuals with, or at risk of a 
bacterial infection. Although methadone, oxycodone, diamorphine and codeine did not 
affect phagocytosis, diamorphine and codeine are pro-drugs and in vivo are converted 
to morphine and thus would be expected to have similar immune effects to morphine. 
Methadone and oxycodone might thus be safer, although this hypothesis would need 
confirmation in clinical studies.  
 
3.2.3 Discussion  
The current study used whole blood flow cytometry to assess the effects of a 1-hr 
incubation with eight commonly used opioids at three clinically relevant concentrations 
on the ability of human neutrophils and monocytes to phagocytose E.coli. None of the 
opioids had a statistically significant effect on the ability of neutrophils and monocytes 
to phagocytose E.coli. 
 
Flow cytometry allows both the proportion of neutrophils and monocytes phagocytosing 
the E.coli (i.e. number of cells phagocytosing the bacteria) and intensity of this 
response (i.e. the total fluorescent signal from each cell, which correlates to the 
number of E.coli phagocytosed) to be measured. This enabled the impact of opioids on 
the ability of individual neutrophils and monocytes to be assessed, and the phagocytic 
capacity of the cell population as a whole, as if either fewer cells phagocytose or the 
total number of bacteria phagocytosed is decreased this could impact on host 
immunity. From these results, the intensity of the phagocytic response was a more 
sensitive test than the proportion of cells phagocytosing E.coli to the effects of opioids.  
 
Retrospective power and sample size calculations were performed using DSS research 
programmes as morphine, tramadol, fentanyl and buprenorphine inhibited the total 
amount of phagocytosis (MFI) but these did not reach statistical significance. The 
power calculations used a two-tail, two sample test, using average values and a 95% 
confidence interval, with an appropriate power being 80% or above. The sample size 
calculations used a two samples using average values test with a 95% confidence 
interval. The sample size calculations for neutrophil phagocytosis were around five to 
seven samples for morphine, tramadol and buprenorphine, and around 20 for fentanyl. 
These studies were therefore underpowered (power less than 80%). For the total 
amount of monocyte phagocytosis (MFI) the sample size calculations were around five 
179 | P a g e  
 
to seven samples for morphine, fentanyl and buprenorphine, and several fold higher for 
tramadol. These studies were also generally underpowered, with only some 
concentrations of morphine being above 80%.  
 
Several previous in vitro studies have evaluated the influence of opioids on 
phagocytosis, these are reviewed below and compared to the current study. 
 
Szabo and colleagues investigated the in vitro effect of morphine on the ability of 
murine peritoneal macrophages to phagocytose Candida albicans (Szabo et al., 1993). 
For this study, non-elicited resident peritoneal macrophages were harvested from 
female C3HeB/FeJ mice. Cultured macrophage monolayers were used to assess the 
phagocytosis of Candida albicans (with a yeast to macrophage ratio of 10:1) over 30 
min at 37°C. The proportion of macrophages that had ingested three or more Candida 
cells and the average number of these ingested per macrophage (phagocytic index) 
were counted microscopically. The cultured macrophages were treated with between 
10-10 – 10-6 M of morphine (equivalent to 0.03 – 285 ng/ml). There was a concentration-
dependent decrease in both the percentage of macrophages phagocytosing the 
Candida and the phagocytic index, with a maximum effect of 36% and 40% 
respectively, at the highest concentration of morphine. The same results were obtained 
if cells were pre-treated with morphine for periods up to 2 hr. The authors speculated 
that the opioids could act directly on the living Candida and this might also influence 
phagocytosis (Szabo et al., 1993). 
 
Using concentrations that overlapped with the current study, Szabo and colleagues 
showed that morphine was inhibitory. Although the current study showed that morphine 
inhibited phagocytosis in some individuals, this effect was not statistically significant. 
Szabo used peritoneal macrophages from inbred mice against yeast cells, whereas 
whole blood was used from healthy humans against E.coli in the current study.  
 
Lazaro and colleagues investigated the reversibility of the effects of in vitro morphine 
on murine macrophage phagocytosis (Lazaro et al., 2000). Female C3HeB/FeJ mice 
received intraperitoneal injections of thioglycollate, 5 days after which they were killed 
and their peritoneal macrophages isolated. Thioglycollate initiates macrophage 
recruitment and activation. For the acute exposure experiments, the macrophages 
were incubated with 100 and 500 nM of morphine (equivalent to 28 and 143 ng/ml) for 
between 0 and 30 min before phagocytosis was assessed. To assess the influence of 
chronic exposure, macrophages were incubated for 8 and 17 hr with 100 nM of 
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morphine. Drug withdrawal was assessed by washing the cells to remove the morphine 
or by adding the non-selective opioid receptor antagonist, naloxone. Phagocytosis was 
measured by the ability of the macrophages to ingest opsonised SRBCs over 20 min, 
as measured by microscopic examination. Only a 30 min incubation with 100 nM of 
morphine (≈ 28 ng/ml) inhibited murine macrophage phagocytosis of SRBCs, this was 
by about 18%. Exposure to morphine for >8 hr had no effect on macrophage 
phagocytosis. Opioid withdrawal from tolerant cells resulted in an inhibition of 
phagocytosis which was maximal 1 hr after drug withdrawal. 500 nM morphine had no 
effect at the time points assessed (Lazaro et al., 2000). Although this might be due to 
rapid desensitisation of opioid receptors, it would have had to occur within 5 min 
(Tomei and Renaud, 1997). To assess desensitisation, the 500 nM of morphine was 
removed after 30 min and 100 nM of morphine was added after different times. If 
added within 1 hr, 100 nM of morphine had no effect, but if added after 2 hr, 
phagocytosis was inhibited, as in opioid naïve macrophages, indicating that 
desensitisation had occurred (Lazaro et al., 2000). The effects of in vitro morphine on 
phagocytosis by murine macrophages in this model were dependent on the conditions 
to which the cells are exposed, with short incubation periods inhibiting phagocytosis, 
and longer incubation periods as well as higher doses inducing tolerance. 
 
Lazaro and colleagues demonstrated that morphine inhibited murine macrophage 
phagocytosis of SRBCs, although the effect was quantitatively modest. The current 
study did not have a consistent effect with similar concentrations of morphine, but did 
show that phagocytosis could be inhibited in some individuals. The more consistent 
effect in the study by Lazaro is likely to be due to inbred mice being used. Other 
variations between the studies which could account for the differences include the 
effector and target cell types, incubation times and the analysis method. 
 
In several studies by the same group, the effect morphine and methadone have been 
assessed in various models, using different methodologies (Lipovsky et al., 1998, 
Molitor et al., 1992, Peterson et al., 1995, Sowa et al., 1997). Molitor and colleagues 
investigated the in vitro effects of methadone on swine PBMCs (Molitor et al., 1992). 
Cells were incubated for 48 hr with 10-18 – 10-6 M of methadone (equivalent to 3x10-10 – 
309 ng/ml). Antibody-mediated phagocytosis was measured using 51Cr-labeled 
opsonised SRBCs after a 1-hr incubation. Methadone had no effect on monocyte 
antibody-mediated phagocytosis of opsonised SRBCs (Molitor et al., 1992).  
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Peterson and colleagues investigated the effect of morphine on the phagocytosis of 
Mycobacterium tuberculosis by human fetal microglial cells (Peterson et al., 1995). The 
microglial cells were incubated with 10-14 – 10-6 M of morphine (equivalent to 3x10-6 – 
285 ng/ml) for 24 hr, before being incubated at 37°C for 18 hr with non-opsonised M. 
tuberculosis (with a bacteria to microglia ratio of 10:1). The proportion of microglial cells 
that had phagocytosed any bacilli (% phagocytosis) and the total number of bacteria 
ingested by 100 microglial cells were recorded. At 10-8 M (≈ 2.9 ng/ml), morphine 
stimulated the phagocytosis of M. tuberculosis, increasing the proportion of microglia 
phagocytosing any bacteria from 45 to 75% and the number of bacteria ingested per 
100 microglia from 70 to 120. At all other concentrations tested, morphine had no effect 
on phagocytosis. There was no effect when 10-8 M of morphine (≈ 2.9 ng/ml) was 
added at the same time as the M. tuberculosis, but there was activation with a 6-hr 
incubation, although less than the 24-hr incubation. This was blocked by naloxone, -
funaltrexamine (a MOR alkylating agent) and pertussis toxin, suggesting that a MOR Gi 
protein coupled receptor is involved (Peterson et al., 1995). 
 
Sowa and colleagues investigated the effect of morphine on the phagocytosis of non-
opsonised, heat killed Cryptococcus neoformans by neonatal swine microglia (Sowa et 
al., 1997). The microglial cells were incubated with 10-20 – 10-6 M of morphine 
(equivalent to 3x10-10 – 285 ng/ml) for 24 hr, before being incubated with the 
cryptococci (with a yeast to microglia ratio of 50:1) for 2 hr at 37°C. The proportion of 
microglial cells which had phagocytosed any cryptococci (% phagocytosis) and the 
total number of cryptococci ingested by 100 microglial cells (yeast/100 microglia) were 
assessed. Morphine dose-dependently inhibited the proportion of microglia 
phagocytosing the cryptococci and the total number of organisms that were ingested, 
with a maximal inhibition of 93% at 10-6 M (≈ 285 ng/ml). Morphine had no effect when 
added 3 hr before or at the time of the phagocytosis assay (Sowa et al., 1997). 
 
The same group also investigated the effect of morphine on the phagocytosis of 
Cryptococcus neoformans by human fetal microglial cells (Lipovsky et al., 1998). 
Microglial cells were treated for 18 hr with 10-16 – 10-6 M of morphine (equivalent to 
3x10-8 – 285 ng/ml) before being incubated with Cryptococcus neoformans for 1 hr at 
37°C, Experiments were performed at a yeast to microglia ratio of 10:1. The proportion 
of microglial cells that had phagocytosed the cryptococci were counted using 
fluorescent microscopy. Only opsonised yeast were phagocytosed by human microglia, 
and this was enhanced when yeast were coated with complement. Morphine stimulated 
microglial phagocytosis, with a bell-shaped dose response curve and a maximal 
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increase of 50% at 10-8 M (≈ 2.9 ng/ml). This was reversed by naloxone and -
funaltrexamine. Blocking the complement receptor also blocked the effect of morphine 
(and decreased phagocytosis in both no opioid and opioid groups). Overall this study 
showed that morphine enhanced the ability of human microglia to phagocytose 
Cryptococcus neoformans by a complement receptor-mediated mechanism (Lipovsky 
et al., 1998). As cryptococci survive and replicate inside human microglia after being 
phagocytosed, it is difficult to know how relevant this model is to host defence 
mechanisms (Lee et al., 1995b). 
 
These studies from the same group reported conflicting results that are likely due to 
methodological differences (Lipovsky et al., 1998, Sowa et al., 1997). Three of the 
studies assessed the effect of morphine, in doses overlapping with the current study 
and also much lower concentrations. Although the very low concentrations might be 
less relevant clinically, they might help to establish the dose-response curve. 
Incubation time with morphine and target cells also varied between the above studies 
from between 0 and 30 min up to 24 hr. As demonstrated by some of these studies, 
this dramatically influences the effect of morphine on phagocytosis (Peterson et al., 
1995, Sowa et al., 1997). The current study, after preliminary kinetics experiments, 
incubated whole blood with the opioids for 60 min and then with E.coli for 10 min (the 
manufacturer’s recommended period). Methadone showed a similar lack of effect in 
both the current study and that by Molitor, despite a very different methodology, using 
swine cells and 51Cr-labeled SRBC targets (Molitor et al., 1992). The above studies 
used optical or fluorescent microscopy to count the number of cells phagocytosed, 
whereas the current study used flow cytometry which enabled the fluorescent 
characteristics of thousands of cells to be accurately detected (Kampen et al., 2004). 
 
The effect of morphine on neutrophil phagocytosis was evaluated in 16 male opioid 
naïve rhesus monkeys (Liu et al., 1992). Neutrophils were isolated from the peripheral 
blood of these monkeys and incubated with 50 fM and 50 pM of morphine (equivalent 
to 1.4 x10-5 and 0.014 ng/ml) for 4 hr. Phagocytosis of Candida albicans blastospores 
after a 45-min incubation was measured using fluorescent microscopy. The proportion 
(%) of neutrophils which phagocytosed three or more Candida albicans blastospores 
was not affected by either concentration of morphine (Liu et al., 1992). Despite a very 
different approach, the results of this study correlate with current study, although 
individual variability is nor reported. 
 
The effect of morphine and tramadol on the phagocytosis of latex beads by neutrophils 
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and monocytes isolated from the peripheral blood of 30 healthy volunteers has been 
compared (Beilin et al., 2005). For these studies, cells were incubated with either 
morphine (20, 40 and 80 ng/ml) or tramadol (5,000, 10,000 and 20,000 ng/ml) for 60 
min with no opioid as a control. The proportion of cells phagocytosing the latex 
particles and the number of latex particles phagocytosed by each cell (phagocytic 
index) in 60 min at 37°C (100% humidity, 5% v/v CO2), were counted using a 
microscope. Morphine dose-dependently decreased the proportion of monocytes 
undergoing phagocytosis (by up to 19%) and the phagocytic index (by up to 35%), but 
only decreased the proportion of neutrophils undergoing phagocytosis (by up to 24%). 
Tramadol had no effect on these parameters in neutrophils and monocytes. Despite 
having 30 subjects and showing SEM on the bar charts, there were still errors of up to 
± 15% for baseline, morphine and tramadol. Effects of the opioids on the individuals 
tested were not discussed (Beilin et al., 2005). 
 
The study by Beilin showed a significant inhibition by morphine, which was not 
replicated in the current study, although the effect sizes were comparable, this may be 
due to the number of subjects studied. Although neither this nor the current study 
demonstrated a significant effect of tramadol, there was a trend in the current study for 
tramadol to inhibit phagocytosis. The differential effect of drugs on phagocytosis might 
depend on the phagocytic target (Galley et al., 2000), which might explain some of the 
discrepancy with the effect of tramadol on phagocytosis. Although a major role of 
phagocytes is to kill and remove bacteria, they are also involved in the removal of inert 
particles (Djaldetti et al., 2002). However, in terms of the role of phagocytosis in the 
protection against bacterial infection, E.coli is a more physiologically relevant target.  
 
Although this is the most comparable experiment to the current study, there are certain 
key differences. Beilin and colleagues concentrated and extracted the leukocytes from 
the peripheral venous blood from 30 volunteers, used latex particles as the target for 
phagocytosis and manually counted the proportion of cells undergoing phagocytosis 
and the number of latex particles that had been engulfed by each individual cell. The 
data were averaged from the 100 cells that were counted. The current study used 
whole blood from five volunteers, FITC-labelled E.coli as the phagocytic target and at 
least 5,000 events from the flow cytometric analysis to determine the proportion of cells 
phagocytosing E.coli and the intensity of this response, for each type of phagocyte. 
Although the concentrations of morphine used by Beilin overlapped with the current 
study, they used higher concentrations of tramadol (5,000 – 20,000 ng/ml compared 
with 80 – 2,000 ng/ml). The incubation time in both studies was 60 min at 37°C, 
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however Beilin used a humidified atmosphere containing 5% v/v CO2, whereas 
incubations for the current study were performed in a water bath (Beilin et al., 2005). 
This may have led to differences as a heated atmosphere produces a less direct heat 
and the sample would heat slower; the additional CO2 could generate acidity in the 
sample, although this is more likely to occur during longer incubations. 
 
Although there have been several previous in vitro studies assessing the effect of 
morphine and to a lesser extent tramadol and methadone on phagocytosis, these have 
often been performed in different species (i.e. murine, swine and human) and using 
different effector (phagocytic) cells at different stages of development (i.e. adult human 
peripheral blood vs. neonatal swine vs. fetal human microglia), with different methods 
of cell isolation which modify the responsiveness of cells by pre-activating, priming or 
over-activating cells. (i.e. elicited peritoneal macrophages). The current study used 
whole blood from adult humans which is likely to be more applicable to the clinical 
setting. A range of target cells were also used in the previous studies, these included 
fungi (Candida albicans and Cryptococcus neoformans), bacteria (Mycobacterium 
tuberculosis - with a lipid rich cell wall) and foreign material (SRBCs). In some studies 
these cells were opsonised or killed before phagocytosis. The current study used 
opsonised E.coli as the phagocytic target, which is likely to be more relevant in terms of 
acute sepsis, although anti-fungal immunity is also important.  
 
There were also large differences in the concentrations of morphine used. The current 
study used 20 – 500 ng/ml, which approximate to those found clinically. There were 
different methods of measuring phagocytosis and different target cells leading to 
different results from these studies and difficulty in comparing them. Microscopy counts 
far fewer cells and it is difficult to determine differences in intensity, unless the 
fluorescence is quantitated using image analysis. Although the use of a whole blood 
approach in the current study might also influence the results, whole blood is more 
physiological than isolating or culturing individual cell types as used in some studies. 
 
Although there are many potential methodologies, all with advantages and 
disadvantages (such as short incubation time might be more relevant in patients with 
acute pain and longer incubations in those on chronic opioids), it is very difficult to 
compare the previous studies. Owing to these differences morphine was inhibitory in 
some of the experimental scenarios in some previous studies (Sowa et al., 1997, 
Szabo et al., 1993), it had no effect in others (Liu et al., 1992) and was stimulatory in 
two studies (Lipovsky et al., 1998, Peterson et al., 1995). 
185 | P a g e  
 
3.2.4 Conclusion  
The in vitro effect of eight opioids at three clinically relevant concentrations on 
neutrophil and monocyte phagocytosis was assessed in the whole blood of healthy 
volunteers. None of the opioids had a statistically significant effect on phagocytosis. 
However, by evaluating each subject individually it appears that some subjects may be 
more susceptible to the effects of morphine, tramadol, fentanyl and buprenorphine 
(section 3.2.2). The majority of these effects are on the basis of the total phagocytosis, 
not the proportion of cells phagocytosing. In the cells taken from animals for the 
previous in vitro studies, the animals in each study are genetically very similar, being 
from the same inbred strains. If the response to opioids is, in part at least, driven by 
genetic difference, then any opioid-mediated effects are likely to be more consistent if 
inbred animal strains are used. In the current study in which blood was taken from 
different individuals, there is variability in the responses, leading to large standard 
deviation errors and negating any potential statistical significance. Although it would 
need confirmation in patient studies, these results could mean that some individuals 
exposed to morphine, tramadol, fentanyl or buprenorphine might be more susceptible 
to bacterial and fungal infections and that methadone and oxycodone might be safer 
options. 
 
 
3.2.5 Oxidative burst reaction 
The production of reactive oxygen species (superoxide radical and hydrogen peroxide) 
as part of the oxidative burst response is vital for the killing and degradation of 
phagocytosed bacteria, fungi and particles. The effects of three concentrations of 
morphine, tramadol, fentanyl, buprenorphine, methadone, oxycodone, diamorphine and 
codeine on the proportion of neutrophils and monocytes undergoing the oxidative burst 
response and the intensity of this response, as represented by the MFI for the positive 
cells are shown in the graphs below (Figure 3-49 - Figure 3-64).  
 
Peripheral whole blood was incubated at 37°C with the designated concentration of 
opioid for 60 min before being stimulated with fMLP (a synthetic, chemotactic peptide 
which mimics the activity of bacterially-derived peptides), PMA (an activator of PKC) 
and E.coli for 10 min. As the subjects had differing baseline values for the oxidative 
burst response, the graphs are presented below as absolute differences from the no 
opioid control. The absolute baseline values, without opioid, are given at the top of the 
graphs (Figure 3-49 - Figure 3-64).  
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Figure 3-49: Effect of morphine on neutrophil oxidative burst responses. 
The proportion of neutrophils undergoing the oxidative burst reaction (left panel) and the intensity of this 
response in these positive cells, median channel of fluorescent intensity (MFI, right panel), to fMLP, PMA 
and E.coli. These are presented as absolute differences from the no opioid control. No opioid control 
(baseline) values (mean ± SEM) are included at the top of the graphs. Whole blood was incubated with the 
indicated concentrations of morphine for 60 min prior to assessing the oxidative burst response. Data are 
means ± SEM from 5 independent experiments and statistically significant differences, using a paired 
Student t-test, between the responsiveness of opioid-treated and untreated cells is indicated (* = P<0.05). 
 
 
 
 
 
Figure 3-50: Effect of morphine on monocyte oxidative burst responses. 
The proportion of monocytes (undergoing the oxidative burst reaction (left panel) and the intensity of this 
response in these positive cells (median channel of fluorescent intensity (MFI, right panel), to fMLP, PMA 
and E.coli. These are presented as absolute differences from the no opioid control. No opioid control 
(baseline) values (mean ± SEM) are included in the graph. Whole blood was incubated with the indicated 
concentrations of morphine for 60 min prior to assessing the oxidative burst response. Data are means ± 
SEM from 5 independent experiments (n=4 for MFI with fMLP at 100ng/ml of morphine) and no statistically 
significant differences, using a paired Student t-test, between the responsiveness of opioid-treated and 
untreated cells was detected. 
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Figure 3-51: Effect of tramadol on neutrophil oxidative burst responses. 
The proportion of neutrophils undergoing the oxidative burst reaction (left panel) and the intensity of this 
response in these positive cells, median channel of fluorescent intensity (MFI, right panel), to fMLP, PMA 
and E.coli. These are presented as absolute differences from the no opioid control. No opioid control 
(baseline) values (mean ± SEM) are included at the top of the graphs. Whole blood was incubated with the 
indicated concentrations of tramadol for 60 min prior to assessing the oxidative burst response. Data are 
means ± SEM from 5 independent experiments, no statistically significant differences, using a paired 
Student t-test, between the responsiveness of opioid-treated and untreated cells was detected. 
 
 
 
 
 
Figure 3-52: Effect of tramadol on monocyte oxidative burst responses. 
The proportion of monocytes (undergoing the oxidative burst reaction (left panel) and the intensity of this 
response in these positive cells (median channel of fluorescent intensity (MFI, right panel), to fMLP, PMA 
and E.coli. These are presented as absolute differences from the no opioid control. No opioid control 
(baseline) values (mean ± SEM) are included at the top of the graphs. Whole blood was incubated with the 
indicated concentrations of tramadol for 60 min prior to assessing the oxidative burst response. Data are 
means ± SEM from 5 independent experiments (n=4 for % and MFI with fMLP at 400ng/ml of tramadol) 
and no statistically significant differences, using a paired Student t-test, between the responsiveness of 
opioid-treated and untreated cells was detected. 
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Figure 3-53: Effect of fentanyl on neutrophil oxidative burst responses. 
The proportion of neutrophils undergoing the oxidative burst reaction (left panel) and the intensity of this 
response in these positive cells, median channel of fluorescent intensity (MFI, right panel), to fMLP, PMA 
and E.coli. These are presented as absolute differences from the no opioid control. No opioid control 
(baseline) values (mean ± SEM) are included at the top of the graphs. Whole blood was incubated with the 
indicated concentrations of fentanyl for 60 min prior to assessing the oxidative burst response. Data are 
means ± SEM from 5 independent experiments, no statistically significant differences, using a paired 
Student t-test, between the responsiveness of opioid-treated and untreated cells was detected. 
 
 
 
 
 
Figure 3-54: Effect of fentanyl on monocyte oxidative burst responses. 
The proportion of monocytes (undergoing the oxidative burst reaction (left panel) and the intensity of this 
response in these positive cells (median channel of fluorescent intensity (MFI, right panel), to fMLP, PMA 
and E.coli. These are presented as absolute differences from the no opioid control. No opioid control 
(baseline) values (mean ± SEM) are included at the top of the graphs. Whole blood was incubated with the 
indicated concentrations of fentanyl for 60 min prior to assessing the oxidative burst response. Data are 
means ± SEM from 5 independent experiments and statistically significant differences, using a paired 
Student t-test, between the responsiveness of opioid-treated and untreated cells is indicated (* = P<0.05). 
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Figure 3-55: Effect of buprenorphine on neutrophil oxidative burst responses. 
The proportion of neutrophils undergoing the oxidative burst reaction (left panel) and the intensity of this 
response in these positive cells, median channel of fluorescent intensity (MFI, right panel), to fMLP, PMA 
and E.coli. These are presented as absolute differences from the no opioid control. No opioid control 
(baseline) values (mean ± SEM) are included at the top of the graphs. Whole blood was incubated with the 
indicated concentrations of buprenorphine for 60 min prior to assessing the oxidative burst response. Data 
are means ± SEM from 5 independent experiments (n=4 for 20 ng/ml and n=3 for 0.8 ng/ml of 
buprenorphine), no statistically significant differences, using a paired Student t-test, between the 
responsiveness of opioid-treated and untreated cells was detected. 
 
 
 
 
 
Figure 3-56: Effect of buprenorphine on monocyte oxidative burst responses. 
The proportion of monocytes (undergoing the oxidative burst reaction (left panel) and the intensity of this 
response in these positive cells (median channel of fluorescent intensity (MFI, right panel), to fMLP, PMA 
and E.coli. These are presented as absolute differences from the no opioid control. No opioid control 
(baseline) values (mean ± SEM) are included at the top of the graphs. Whole blood was incubated with the 
indicated concentrations of buprenorphine for 60 min prior to assessing the oxidative burst response. Data 
are means ± SEM from 4 independent experiments (n=3 for 0.8 ng/ml of buprenorphine) and statistically 
significant differences, using a paired Student t-test, between the responsiveness of opioid-treated and 
untreated cells is indicated (* = P<0.05; ** = P<0.01). 
 
190 | P a g e  
 
 
Figure 3-57: Effect of methadone on neutrophil oxidative burst responses. 
The proportion of neutrophils undergoing the oxidative burst reaction (left panel) and the intensity of this 
response in these positive cells, median channel of fluorescent intensity (MFI, right panel), to fMLP, PMA 
and E.coli. These are presented as absolute differences from the no opioid control. No opioid control 
(baseline) values (mean ± SEM) are included at the top of the graphs. Whole blood was incubated with the 
indicated concentrations of methadone for 60 min prior to assessing the oxidative burst response. Data are 
means ± SEM from 3 independent experiments and statistically significant differences, using a paired 
Student t-test, between the responsiveness of opioid-treated and untreated cells is indicated (*** = 
P<0.001). 
 
 
 
 
 
Figure 3-58: Effect of methadone on monocyte oxidative burst responses. 
The proportion of monocytes (undergoing the oxidative burst reaction (left panel) and the intensity of this 
response in these positive cells (median channel of fluorescent intensity (MFI, right panel), to fMLP, PMA 
and E.coli. These are presented as absolute differences from the no opioid control. No opioid control 
(baseline) values (mean ± SEM) are included at the top of the graphs. Whole blood was incubated with the 
indicated concentrations of methadone for 60 min prior to assessing the oxidative burst response. Data are 
means ± SEM from 3 independent experiments and statistically significant differences, using a paired 
Student t-test, between the responsiveness of opioid-treated and untreated cells is indicated (** = P<0.01). 
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Figure 3-59: Effect of oxycodone on neutrophil oxidative burst responses. 
The proportion of neutrophils undergoing the oxidative burst reaction (left panel) and the intensity of this 
response in these positive cells, median channel of fluorescent intensity (MFI, right panel), to fMLP, PMA 
and E.coli. These are presented as absolute differences from the no opioid control. No opioid control 
(baseline) values (mean ± SEM) are included at the top of the graphs. Whole blood was incubated with the 
indicated concentrations of oxycodone for 60 min prior to assessing the oxidative burst response. Data are 
means ± SEM from 3 independent experiments, no statistically significant differences, using a paired 
Student t-test, between the responsiveness of opioid-treated and untreated cells was detected. 
 
 
 
 
 
Figure 3-60: Effect of oxycodone on monocyte oxidative burst responses. 
The proportion of monocytes (undergoing the oxidative burst reaction (left panel) and the intensity of this 
response in these positive cells (median channel of fluorescent intensity (MFI, right panel), to fMLP, PMA 
and E.coli. These are presented as absolute differences from the no opioid control. No opioid control 
(baseline) values (mean ± SEM) are included at the top of the graphs. Whole blood was incubated with the 
indicated concentrations of oxycodone for 60 min prior to assessing the oxidative burst response. Data are 
means ± SEM from 3 independent experiments and statistically significant differences, using a paired 
Student t-test, between the responsiveness of opioid-treated and untreated cells is indicated (* = P<0.05). 
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Figure 3-61: Effect of diamorphine on neutrophil oxidative burst responses. 
The proportion of neutrophils undergoing the oxidative burst reaction (left panel) and the intensity of this 
response in these positive cells, median channel of fluorescent intensity (MFI, right panel), to fMLP, PMA 
and E.coli. These are presented as absolute differences from the no opioid control. No opioid control 
(baseline) values (mean ± SEM) are included at the top of the graphs. Whole blood was incubated with the 
indicated concentrations of diamorphine for 60 min prior to assessing the oxidative burst response. Data 
are means ± SEM from 3 independent experiments, no statistically significant differences, using a paired 
Student t-test, between the responsiveness of opioid-treated and untreated cells was detected. 
 
 
 
 
  
Figure 3-62: Effect of diamorphine on monocyte oxidative burst responses. 
The proportion of monocytes (undergoing the oxidative burst reaction (left panel) and the intensity of this 
response in these positive cells (median channel of fluorescent intensity (MFI, right panel), to fMLP, PMA 
and E.coli. These are presented as absolute differences from the no opioid control. No opioid control 
(baseline) values (mean ± SEM) are included at the top of the graphs. Whole blood was incubated with the 
indicated concentrations of diamorphine for 60 min prior to assessing the oxidative burst response. Data 
are means ± SEM from 3 independent experiments and no statistically significant differences, using a 
paired Student t-test, between the responsiveness of opioid-treated and untreated cells was detected. 
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Figure 3-63: Effect of codeine on neutrophil oxidative burst responses. 
The proportion of neutrophils undergoing the oxidative burst reaction (left panel) and the intensity of this 
response in these positive cells, median channel of fluorescent intensity (MFI, right panel), to fMLP, PMA 
and E.coli. These are presented as absolute differences from the no opioid control. No opioid control 
(baseline) values (mean ± SEM) are included at the top of the graphs. Whole blood was incubated with the 
indicated concentrations of codeine for 60 min prior to assessing the oxidative burst response. Data are 
means ± SEM from 3 independent experiments and statistically significant differences, using a paired 
Student t-test, between the responsiveness of opioid-treated and untreated cells is indicated (* = P<0.05). 
 
 
 
 
 
Figure 3-64: Effect of codeine on monocyte oxidative burst responses. 
The proportion of monocytes (undergoing the oxidative burst reaction (left panel) and the intensity of this 
response in these positive cells (median channel of fluorescent intensity (MFI, right panel), to fMLP, PMA 
and E.coli. These are presented as absolute differences from the no opioid control. No opioid control 
(baseline) values (mean ± SEM) are included at the top of the graphs. Whole blood was incubated with the 
indicated concentrations of codeine for 60 min prior to assessing the oxidative burst response. Data are 
means ± SEM from 3 independent experiments and no statistically significant differences, using a paired 
Student t-test, between the responsiveness of opioid-treated and untreated cells was detected. 
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The data presented above show the absolute change from the no opioid control 
samples in order to compensate for the differing control values for the oxidative burst 
response between subjects. The unstimulated controls all have very low levels of 
activation, comparable to fMLP (the weak stimulus). None of the opioids had an effect 
on unstimulated neutrophils or monocytes (data not shown). They also had no effect on 
fMLP stimulated neutrophils or monocytes, which was principally used to look for 
activating properties of the opioids and/or their effects on ‘primed’ cells. This indicates 
that none of the assessed opioids enhanced the oxidative burst capacity of neutrophils 
or monocytes in this assay. The potent PMA stimulus, which is principally used to 
evaluate inhibiting properties of the opioids, caused virtually all of the neutrophils and 
monocytes to be stimulated. The magnitude of this activation was high in the 
neutrophils, but comparatively low in the monocytes. This activation (either proportion 
of cells activated or intensity of activation) was unaffected by any of the opioids. This 
could, at least in part, be due to the potent capacity of PMA to activate the oxidative 
burst response via PKC induction. The physiological bacterial stimulus, E.coli, induced 
an intermediate activation and there were occasional effects from some of the opioids 
on the oxidative burst response induced by E.coli: 
 
However, as these statistically significant results do not have a clear pattern to them it 
might be that they occurred by chance rather than the opioid having an effect at that 
concentration. However, some of the opioids seemed to non-significantly influence the 
oxidative burst response, but due to interindividual variability and the limited sample 
size, type II errors were possible. A trend for an effect across the range of doses for 
some of the opioids (morphine, tramadol, fentanyl, buprenorphine and methadone) was 
apparent and although the significance of these results should not be overstated, it 
could be that a larger sample size might have made this trend statistically significant. 
There may also be a difference between statistical significance and what might be 
clinically significant. For example 20 ng/ml of methadone significantly decreased the 
total neutrophil oxidative burst reaction to E.coli and 100 ng/ml of oxycodone 
significantly inhibited the response of monocytes to E.coli, but the effect size was very 
small and is unlikely to be clinically significant. The clinical significance may also be 
dependent on the individual and this will be explored in the following section. 
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3.2.6 Effects of opioids on the oxidative burst reaction in individual 
subjects 
There is no consistent statistically significant effect of any of the opioids tested on 
neutrophil and monocyte oxidative burst response. For some individuals there appears 
to be an effect of morphine, tramadol, fentanyl, buprenorphine and methadone on the 
oxidative burst reaction, although any statistical effect is removed when the results are 
grouped and analysed together due to interindividual variability. There is not only 
variability in the response to the opioids, but also in the individuals’ baseline phagocytic 
activity. The genetic and molecular basis to interindividual variability to opioids will be 
discussed in section 4.7. The influence of morphine, tramadol, fentanyl and 
buprenorphine on the oxidative burst response for neutrophils and monocytes for the 
individual subjects tested is illustrated below (Figure 3-65 - Figure 3-72). The subject 
numbers are consistent across experiments. 
 
The oxidative burst response assays have been shown to be reproducible with 
Coefficients of Variation of 0.1% for the proportion of neutrophils undergoing the 
oxidative burst reaction to E.coli and 4.8% for the MFI of this response, and 1.1% for 
the proportion of monocytes undergoing the oxidative burst reaction to E.coli and 6.5% 
for the MFI of this response (PHAGOBURST
® test kit data sheet, Orpegen Pharma). It 
is thus likely that it is biological rather than experimental variations leading to this 
interindividual effect. 
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Figure 3-65: Effect of morphine on neutrophil oxidative burst for individuals. 
The proportion of neutrophils undergoing the oxidative burst reaction to E.coli (left panel) and the intensity 
of this response (median channel of fluorescent intensity, MFI; right panel), presented for each subject 
individually, with the no opioid control and 100ng/ml of morphine. Whole blood was incubated with either 
no opioid or 100ng/ml of morphine for 60 min prior to assessing the oxidative burst reaction to E.coli.  
 
 
 
 
 
 
 
Figure 3-66: Effect of morphine on monocyte oxidative burst for individuals. 
The proportion of monocytes undergoing the oxidative burst reaction to E.coli (left panel) and the intensity 
of this response (median channel of fluorescent intensity, MFI; right panel), presented for each subject 
individually, with the no opioid control and 100ng/ml of morphine. Whole blood was incubated with either 
no opioid or 100ng/ml of morphine for 60 min prior to assessing the oxidative burst reaction to E.coli.  
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Figure 3-67: Effect of tramadol on neutrophil oxidative burst for individuals. 
The proportion of neutrophils undergoing the oxidative burst reaction to E.coli (left panel) and the intensity 
of this response (median channel of fluorescent intensity, MFI; right panel), presented for each subject 
individually, with the no opioid control and 400ng/ml of tramadol. Whole blood was incubated with either no 
opioid or 400ng/ml of tramadol for 60 min prior to assessing the oxidative burst reaction to E.coli.  
 
 
 
 
 
 
 
Figure 3-68: Effect of tramadol on monocyte oxidative burst for individuals. 
The proportion of monocytes undergoing the oxidative burst reaction to E.coli (left panel) and the intensity 
of this response (median channel of fluorescent intensity, MFI; right panel), presented for each subject 
individually, with the no opioid control and 400ng/ml of tramadol. Whole blood was incubated with either no 
opioid or 400ng/ml of tramadol for 60 min prior to assessing the oxidative burst reaction to E.coli.  
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Figure 3-69: Effect of fentanyl on neutrophil oxidative burst for individuals. 
The proportion of neutrophils undergoing the oxidative burst reaction to E.coli (left panel) and the intensity 
of this response (median channel of fluorescent intensity, MFI; right panel), presented for each subject 
individually, with the no opioid control and 4ng/ml of fentanyl. Whole blood was incubated with either no 
opioid or 4ng/ml of fentanyl for 60 min prior to assessing the oxidative burst reaction to E.coli.  
 
 
 
 
 
 
 
Figure 3-70: Effect of fentanyl on monocyte oxidative burst for individuals. 
The proportion of monocytes undergoing the oxidative burst reaction to E.coli (left panel) and the intensity 
of this response (median channel of fluorescent intensity, MFI; right panel), presented for each subject 
individually, with the no opioid control and 4ng/ml of fentanyl. Whole blood was incubated with either no 
opioid or 4ng/ml of fentanyl for 60 min prior to assessing the oxidative burst reaction to E.coli.  
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Figure 3-71: Effect of buprenorphine on neutrophil oxidative burst for individuals. 
The proportion of neutrophils undergoing the oxidative burst reaction to E.coli (left panel) and the intensity 
of this response (median channel of fluorescent intensity, MFI; right panel), presented for each subject 
individually, with the no opioid control and 4ng/ml of buprenorphine. Whole blood was incubated with either 
no opioid or 4ng/ml of buprenorphine for 60 min prior to assessing the oxidative burst reaction to E.coli.  
 
 
 
Figure 3-72: Effect of buprenorphine on monocyte oxidative burst for individuals. 
The proportion of monocytes undergoing the oxidative burst reaction to E.coli (left panel) and the intensity 
of this response (median channel of fluorescent intensity, MFI; right panel), presented for each subject 
individually, with the no opioid control and 4ng/ml of buprenorphine. Whole blood was incubated with either 
no opioid or 4ng/ml of buprenorphine for 60 min prior to assessing the oxidative burst reaction to E.coli.  
 
 
Oxycodone, diamorphine and codeine had no effect on neutrophil and monocyte 
oxidative burst responses to E.coli in any of the subjects, methadone decreased the 
intensity of the oxidative burst reaction only in subject 4 (Table 3.3). There are clear 
differences in the oxidative burst response to opioids between the individuals tested. In 
general, responses for an individual, to least some of the opioids, are either stimulatory 
(subject 1 and 3) or inhibitory (all other subjects). For some individuals, the effect is 
marginal, but for others (i.e. subject 2 and 5 to fentanyl) this is marked and could 
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potentially translate to a clinically important effect. Even though some opioids appeared 
to be stimulatory in some individuals, the magnitude of this effect tended to be less 
than their suppressive effects.  
 
Due to these differences between individuals, any potentially important effects might be 
diminished when statistical analysis is performed across the whole group. Both the total 
amount of oxidative burst reaction occurring and the number of neutrophils and 
monocytes performing this reaction were affected in varying amounts by the different 
opioids across the individuals. In certain individuals some opioids might be detrimental 
if they were to have a bacterial or fungal infection, whereas in other individuals some 
opioids may have no effect or even be beneficial. The effects of the opioids, at all 
concentrations tested, on the oxidative burst reaction of neutrophils and monocytes to 
E.coli for the individual subjects are summarised below (Table 3.3 - Table 3.4). When 
assessing the effect of individuals across the range of opioid concentrations for the 
oxidative burst reaction, only when an opioid increased or inhibited the immune 
response by at least 20% across the range of the concentrations tested was this 
response considered to be a trend and represent as so in the tables below. 
 
Table 3.3: Effect of opioids on the oxidative burst reaction of neutrophils for individuals.  
Opioid Morphine Tramadol Fentanyl Buprenorphine Methadone Oxycodone, 
diamorphine, 
codeine 
Subject 
1 No effect Increase No effect  No effect No effect 
2  Decrease Decrease Decrease No effect No effect 
3 No effect Increase Decrease No effect  No effect 
4  Decrease No effect No effect Decrease No effect 
5 Decrease  Decrease Decrease   
6 Decrease Decrease     
7 Decrease      
The effect of the opioids on total neutrophil oxidative burst reaction (MFI) to E.coli for individual subjects. 
Red indicates an inhibitory effect, green a stimulatory effect and yellow no effect (boxes are uncoloured if 
not tested). 
 
Table 3.4: Effect of opioids on the oxidative burst reaction of monocytes for individuals.  
Opioid Morphine Tramadol Fentanyl Buprenorphine Methadone Oxycodone, 
diamorphine, 
codeine 
Subject 
1 No effect No effect No effect  No effect No effect 
2  Decrease Decrease No effect No effect No effect 
3 No effect No effect No effect No effect  No effect 
4  No effect Decrease Decrease Decrease No effect 
5 No effect  No effect    
6 No effect No effect     
7 No effect      
The effect of the opioids on total monocyte oxidative burst reaction (MFI) to E.coli for individual subjects. 
Red indicates an inhibitory effect, green a stimulatory effect and yellow no effect (boxes are uncoloured if 
not tested). 
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For the opioids that did influence the oxidative burst reaction (morphine, tramadol, 
fentanyl, buprenorphine and methadone) this was more dependent on the subject than 
on the opioid. Although these opioids suppressed neutrophil oxidative burst reaction in 
most individuals, the majority of the monocytes had no sizable consistent effect from 
any of the opioids. The majority of the effects were inhibitory and only tramadol had 
stimulatory effects in two subjects and these were marginal. Sometimes there was an 
effect on the proportion of neutrophils and monocytes undergoing the oxidative burst 
reaction, without much effect on the total oxidative burst reaction (i.e. total amount of 
oxygen reduction in neutrophils and monocytes, denoted as MFI). There was not 
always correlation between the two and although both are important, the latter is more 
likely to be relevant to bacterial killing and this is what was tabulated (Table 3.3 - Table 
3.4). It may be that morphine, tramadol, fentanyl, buprenorphine and methadone by 
decreasing bacterial killing in certain individuals may be detrimental if they had a 
bacterial or fungal infection. Although oxycodone, diamorphine and codeine did not 
affect oxidative burst when evaluated on a group or individual basis, diamorphine and 
codeine are pro-drugs and as they are converted to morphine in vivo they will have the 
immune effects of morphine as well as any intrinsic effect they may have themselves. 
Although 100 ng/ml of oxycodone statistically significantly inhibited the oxidative burst 
response of monocytes to E.coli, the effect size was very small and would unlikely be 
clinically significant. Oxycodone might have less of an effect on oxidative burst in some 
individuals and might be safer, but this hypothesis would need confirmation in clinical 
studies and with larger numbers of subjects. 
 
3.2.7 Discussion 
The current study assessed the effects of eight commonly used opioids at three 
concentrations which approximated to those found clinically, on the in vitro ability of 
human neutrophils and monocytes to undergo the oxidative burst reaction in response 
to fMLP, PMA and E.coli as measured by flow cytometry. There were no consistent 
statistically significant effect from any of the opioids, but variability between individuals 
was detected.  
 
Retrospective power and sample size calculations were performed using DSS research 
programmes, as some of the opioids seemed to have an effect which did not reach 
statistical significance and others were statistically significant, but with a very small 
effect size. The power calculations used a two-tail, two sample test, using average 
values and a 95% confidence interval. The sample size calculations used a two 
samples using average values test with a 95% confidence interval. The sample size 
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calculations for those concentrations of opioids which seemed to have a non-
statistically significant effect (i.e. for morphine), showed that although the power was 
low (less than 80%) the sample size needed to potentially detect an effect was as low 
as six, which is comparable with the number of samples undertaken for some of these 
assays. For other samples, even those that were statistically significant (i.e. 
oxycodone) the power was very low (5%). For many of the tests, with either very small 
effects from the opioids, or large standard deviations due to interindividual variability, 
the power was low and sample sizes required consequently high. 
 
The previous in vitro studies which assessed the effect of opioids on the oxidative burst 
reaction are reviewed below and their findings brought into context with the current 
study. 
 
The effect of morphine on neutrophil killing has been evaluated in 16 male rhesus 
monkeys (Liu et al., 1992). Neutrophils were isolated from the blood of opioid naïve 
rhesus monkeys and incubated with 50 fM and 50 pM of morphine (equivalent to 1.4 
x10-5 and 0.014 ng/ml) for 4 hr, before being incubated with Candida albicans 
blastospores for 45 min. Blastospore viability was assessed using fluorescent 
microscopy. The killing of the blastospores was inhibited by the pM (≈ 0.014 ng/ml), but 
not fM (≈ 1.4 x10-5 ng/ml) concentrations of morphine and the inhibition was reversed 
by naloxone (Liu et al., 1992).  
 
Compared with the current study, this experiment by Liu and colleagues assessed the 
effect of much lower concentrations of morphine on isolated neutrophils from a different 
species on killing of fungal blastospores (as opposed to oxygen free radial production). 
There is an advantage in the study by Liu as the function of these cells against a 
potentially pathogenic fungus was assessed. The concentrations used were far below 
those that are detected clinically and the use of isolated neutrophils could prime or 
influence their activation status and function. Furthermore, neutrophil isolation removes 
the complex immune interactions which occur in whole blood. 
 
Peterson and colleagues evaluated the effect of morphine on the oxidative burst 
reaction of PBMCs and monocytes from three healthy volunteers (Peterson et al., 
1987). Human PBMCs and purified monocytes were incubated with 10-10 – 10-6 M of 
morphine (equivalent to 0.03 – 285 ng/ml) for 48 hr and were then stimulated with a 60-
min incubation with opsonised zymosan or PMA. Variable incubation times (1, 2, 3 and 
24 hr) with 10-8 M of morphine (≈ 2.9 ng/ml) were then assessed on zymosan-
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stimulated O2
-
 release. O2
-
 generation was evaluated by a superoxide dismutase 
inhibitable reduction of ferricytochrome c using a photometer. H2O2 production was 
measured using the horseradish peroxidase-mediated oxidation of phenol red using a 
photometer. 10-6 M of morphine increased resting O2
-
 and H2O2 production. All 
concentrations of morphine suppressed the response to zymosan and PMA stimulation 
by over 50%. This was blocked by naloxone. The longer the incubation with 10-8 M of 
morphine the more the suppression of zymosan-stimulated O2
-
 production, with less 
than 20% suppression within 3 hr, increasing to 83% at 48 hr (Peterson et al., 1987).  
 
This study by Peterson and colleagues used similar effector cells to the current study 
(although the cells were purifying as opposed to using whole blood), but used a longer 
incubation period (48 hr vs. 1 hr) with overlapping concentration of morphine (although 
they also used much lower concentrations). When Peterson and colleagues used 1 or 
2 hr incubations with morphine, they too showed minimal inhibition of the oxidative 
burst reaction (Peterson et al., 1987). They also demonstrated an increased response 
of unstimulated cells to 10-6 M of morphine, but only after a 1-hr incubation. Differences 
between Peterson’s study and the current study include the method of stimulation and 
the measurement technique. Although the current study did not show any significant 
results, there was a trend for morphine to inhibit the proportion (but not the total 
response) of monocytes undergoing the oxidative burst reaction to the PMA stimulus. 
 
From the same laboratory, Molitor and colleagues investigated the in vitro effects of 
methadone on swine PBMCs (Molitor et al., 1992). Cells were incubated for 48 hr with 
10-18 – 10-6 M of methadone (equivalent to 3x10-10 – 285 ng/ml). O2
-
 produced by 
PBMCs was determined using the superoxide dismutase-inhibitable reduction of 
ferricytochrome c. PBMCs were stimulated with a 60-min incubation with PMA. A 
spectrophotometer was used to determine O2
- release. Oxidative burst was dose-
dependently suppressed by methadone (significantly at concentrations above 10-12 M), 
becoming almost completely blocked at 10-6 M, with similar results from all 10 pigs. 
This effect was blocked by naloxone (Molitor et al., 1992).  
 
The current study only showed a decrease in the E.coli stimulated neutrophil and 
monocyte oxidative burst reaction by 20 ng/ml of methadone (and no effect of 
methadone on the PMA stimulated cells). In contrast, Molitor reported that methadone 
inhibited monocytes at concentrations which overlapped with those used in the current 
study, and also much lower concentrations. Molitor used a longer incubation time (48 
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hr vs. 1 hr) and only used PMA stimulation. The current study also used the 
physiological E.coli stimulus. The measurement technique also differed. Probably the 
most important difference between the studies was the species investigated (swine vs. 
human) which might have caused the discrepancy in the results. 
 
Jaeger and colleagues evaluated the effect of fentanyl on oxidative burst responses in 
10 healthy volunteers (Jaeger et al., 1998). Leukocytes were isolated from the venous 
blood of 10 healthy volunteers by density gradient sedimentation. The cells were 
incubated with 5 and 50 ng/ml of fentanyl for 15 min, after which their oxidative burst 
capacity was assessed following stimulation with PMA, E.coli or priming by TNF- 
followed by stimulation with fMLP for 20 min. Superoxide anion formed during the 
oxidative burst was measured by intracellular oxidation of dihydrorhodamine to 
rhodamine and the proportion of activated neutrophils was measured by flow 
cytometry. Fentanyl had no significant effect on human neutrophil oxidative burst 
responses at clinically relevant and 10 fold higher concentrations, irrespective of the 
activation stimulus. The variability for E. coli stimulation, with and without fentanyl, was 
about 40% between individuals (Jaeger et al., 1998). 
 
This study by Jaeger and colleagues is similar to the current study, with the exception 
of isolating leukocytes as opposed to using whole blood (the latter is more 
physiological). Nevertheless, the results are similar, with fentanyl at doses comparable 
to the current study having no effect on the neutrophil oxidative burst reaction to any of 
the stimuli, although there was a trend for inhibition in the current study to the E.coli 
stimulus. A similar level of variability was detected in both this and the current study. A 
limitation, as in the current study, is that healthy volunteers were used as the 
neutrophils in patients with cancer or infection are likely to be modulated by these as 
well as by host immune processes. 
 
3.2.8 Conclusions 
The effect of three concentrations of eight opioids on the ability of neutrophils and 
monocytes to perform the oxidative burst reaction was assessed in the whole blood of 
healthy volunteers. None of the opioids had a consistent statistically significant effect 
on the oxidative burst response; however, by evaluating each subject individually it 
seems that some subjects might be more susceptible to the in vitro effects of morphine, 
tramadol, fentanyl, buprenorphine and methadone rather than oxycodone, diamorphine 
and codeine (see section 3.2.6). As diamorphine and codeine are pro-drugs of 
morphine, and thus potentially have similar effects in vivo, oxycodone might be the 
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opioid with the least impact on the oxidative burst reaction in some individuals. This 
could be relevant in terms of bacterial and fungal infection but would need confirmation 
in clinical studies. 
 
 
3.3 Effect of opioids on T cell activation 
T cells are central to the adaptive immune response. CD4+ T cells coordinate the 
immune response, whereas CD8+ T cells are involved in selected killing of tumour 
cells, virally infected cells and transplanted tissue to which the adaptive immune 
response has been primed. One of the means by which the immune response is 
controlled and target cell killing is enhanced or down regulated is via the production of 
specific cytokines (results in section 3.4). The effect of opioids on CD25 and CD69 
expression on T cells is discussed in this section. 
 
3.3.1 Effect of opioids on the activation of anti-CD3/anti-CD28 mAb 
stimulated T cells 
For these experiments, PBMCs were incubated with Miltenyi anti-CD3/anti-CD28 mAb-
coated beads (at a 1:1 bead:PBMC ratio) for 3 days, in order to induce a cellular 
activation cascade which mimics the responses that are induced when TCRs are 
triggered and essential co-stimulatory molecules are delivered following T cell 
interactions with APCs. The influence of morphine, tramadol, fentanyl, buprenorphine, 
methadone, oxycodone, diamorphine and codeine, added at the same time as the 
beads, on CD4+ and CD8+ T cell activation, on the basis of CD69 and CD25 
expression, was determined by flow cytometry (Figure 3-73 - Figure 3-88). 
 
Using FACSDiva™ data analysis software, T cells were selected on the basis of their 
size, granularity and expression of CD4 or CD8 (see Figure 2-4). CD25 and CD69 
expression was subsequently analysed and the proportion of CD4+ and CD8+ cells 
expressing CD25 and CD69 was determined (Figure 2-22). From this positive 
population the total amount (MFI) of CD25 and CD69 mAb bound to these CD4+ and 
CD8+ cells was measured. The total CD25 and CD69 expression by all CD4+ and CD8+ 
cells was also measured (data not shown). As there is a population of activated cells 
and the proportion of CD25+ and CD69+ cells and the intensity of expression by these 
cells give more useful information than the composite measure of intensity in all cells. 
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Figure 3-73: Effect of morphine on CD25 expression by CD4
+
 and CD8
+
 T cells. 
The proportion (%) of CD4
+
 and CD8
+
 cells expressing CD25 (left panel) and the intensity of this 
expression in these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with the indicated concentrations of morphine for 3 days prior to assessing CD25 expression. All 
cells, other than the unstimulated control, were activated with anti-CD3/anti-CD28 mAb coated beads for 3 
days, added at the same time as the opioid. Data are means ± SEM from 5 independent experiments. No 
statistical difference between the responsiveness of opioid-treated and untreated anti-CD3/anti-CD28 mAb 
stimulated cells was observed (paired Student t-test). 
  
 
 
 
 
Figure 3-74: Effect of morphine on CD69 expression in CD4
+
 and CD8
+
 T cells. 
The proportion (%) of CD4
+
 and CD8
+
 cells expressing CD69 (left panel) and the intensity of this 
expression in these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with the indicated concentrations of morphine for 3 days prior to assessing CD69 expression. All 
cells, other than the unstimulated control, were activated with anti-CD3/anti-CD28 mAb coated beads for 3 
days, added at the same time as the opioid. Data are means ± SEM from 5 independent experiments. No 
statistical difference between the responsiveness of opioid-treated and untreated anti-CD3/anti-CD28 mAb 
stimulated cells was observed (paired Student t-test). 
 
0
10
20
30
40
50
60
70
80
90
100
unstim stim 20 100 500 2500 25,000
P
ro
p
o
rt
io
n
 o
f 
c
e
ll
s
 e
x
p
re
s
s
in
g
 C
D
2
5
, %
Morphine concentration (ng/ml)
CD4 
CD8
0
2000
4000
6000
8000
10000
12000
unstim stim 20 100 500 2500 25,000
In
te
n
s
it
y
 o
f 
C
D
2
5
 e
x
p
re
s
s
io
n
, M
F
I 
 
Morphine concentration (ng/ml)
CD4
CD8
0
10
20
30
40
50
60
70
80
90
100
unstim stim 20 100 500 2500 25,000
P
ro
p
o
rt
io
n
 o
f 
c
e
ll
s
 e
x
p
re
s
s
in
g
 C
D
6
9
, %
Morphine concentration (ng/ml)
CD4
CD8
0
20000
40000
60000
80000
100000
unstim stim 20 100 500 2500 25,000
In
te
n
s
it
y
 o
f 
C
D
6
9
 e
x
p
re
s
s
io
n
, M
F
I 
 
Morphine concentration (ng/ml)
CD4
CD8
207 | P a g e  
 
 
Figure 3-75: Effect of tramadol on CD25 expression by CD4
+
 and CD8
+
 T cells. 
The proportion (%) of CD4
+
 and CD8
+
 cells expressing CD25 (left panel) and the intensity of this 
expression in these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with the indicated concentrations of tramadol for 3 days prior to assessing CD25 expression. All 
cells, other than the unstimulated control, were activated with anti-CD3/anti-CD28 mAb coated beads for 3 
days, added at the same time as the opioid. Data are means ± SEM from 5 independent experiments. No 
statistical difference between the responsiveness of opioid-treated and untreated anti-CD3/anti-CD28 mAb 
stimulated cells was observed (paired Student t-test). 
 
 
 
 
 
Figure 3-76: Effect of tramadol on CD69 expression by CD4
+
 and CD8
+
 T cells. 
The proportion (%) of CD4
+
 and CD8
+
 cells expressing CD69 (left panel) and the intensity of this 
expression in these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with the indicated concentrations of tramadol for 3 days prior to assessing CD69 expression. All 
cells, other than the unstimulated control, were activated with anti-CD3/anti-CD28 mAb coated beads for 3 
days, added at the same time as the opioid. Data are means ± SEM from 5 independent experiments. 
100,000 ng/ml of tramadol significantly inhibited the intensity of CD69 expression in anti-CD3/anti-CD28 
mAb stimulated CD8
+
 cells (* = P<0.05; paired Student t-test). 
 
 
0
10
20
30
40
50
60
70
80
90
100
unstim stim 80 400 2,000 10,000 100,000
P
ro
p
o
rt
io
n
 o
f 
c
e
ll
s
 e
x
p
re
s
s
in
g
 C
D
2
5
, %
Tramadol concentration (ng/ml)
CD4 
CD8
0
2000
4000
6000
8000
10000
12000
unstim stim 80 400 2,000 10,000 100,000
In
te
n
s
it
y
 o
f 
C
D
2
5
 e
x
p
re
s
s
io
n
, M
F
I 
 
Tramadol concentration (ng/ml)
CD4
CD8
0
10
20
30
40
50
60
70
80
90
100
unstim stim 80 400 2,000 10,000 100,000
P
ro
p
o
rt
io
n
 o
f 
c
e
ll
s
 e
x
p
re
s
s
in
g
 C
D
6
9
, %
Tramadol concentration (ng/ml)
CD4
CD8
0
20000
40000
60000
80000
100000
unstim stim 80 400 2,000 10,000 100,000
In
te
n
s
it
y
 o
f 
C
D
6
9
 e
x
p
re
s
s
io
n
, M
F
I 
 
Tramadol concentration (ng/ml)
CD4
CD8
*
208 | P a g e  
 
 
Figure 3-77: Effect of fentanyl on CD25 expression by CD4
+
 and CD8
+
 T cells. 
The proportion (%) of CD4
+
 and CD8
+
 cells expressing CD25 (left panel) and the intensity of this 
expression in these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with the indicated concentrations of fentanyl for 3 days prior to assessing CD25 expression. All 
cells, other than the unstimulated control, were activated with anti-CD3/anti-CD28 mAb coated beads for 3 
days, added at the same time as the opioid. Data are means ± SEM from 5 independent experiments. No 
statistical difference between the responsiveness of opioid-treated and untreated anti-CD3/anti-CD28 mAb 
stimulated cells was observed (paired Student t-test). 
 
 
 
 
 
Figure 3-78: Effect of fentanyl on CD69 expression by CD4
+
 and CD8
+
 T cells. 
The proportion (%) of CD4
+
 and CD8
+
 cells expressing CD69 (left panel) and the intensity of this 
expression in these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with the indicated concentrations of fentanyl for 3 days prior to assessing CD69 expression. All 
cells, other than the unstimulated control, were activated with anti-CD3/anti-CD28 mAb coated beads for 3 
days, added at the same time as the opioid. Data are means ± SEM from 5 independent experiments. 
1000 ng/ml of fentanyl significantly inhibited the intensity of CD69 expression in anti-CD3/anti-CD28 mAb 
stimulated CD8
+
 cells (* = P<0.05; paired Student t-test). 
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Figure 3-79: Effect of buprenorphine on CD25 expression by CD4
+
 and CD8
+
 T cells. 
The proportion (%) of CD4
+
 and CD8
+
 cells expressing CD25 (left panel) and the intensity of this 
expression in these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with the indicated concentrations of buprenorphine for 3 days prior to assessing CD25 
expression. All cells, other than the unstimulated control, were activated with anti-CD3/anti-CD28 mAb 
coated beads for 3 days, added at the same time as the opioid. Data are means ± SEM from 5 
independent experiments. No statistical difference between the responsiveness of opioid-treated and 
untreated anti-CD3/anti-CD28 mAb stimulated cells was observed (paired Student t-test). 
 
 
 
 
 
Figure 3-80: Effect of buprenorphine on CD69 expression by CD4
+
 and CD8
+
 T cells. 
The proportion (%) of CD4
+
 and CD8
+
 cells expressing CD69 (left panel) and the intensity of this 
expression in these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with the indicated concentrations of buprenorphine for 3 days prior to assessing CD69 
expression. All cells, other than the unstimulated control, were activated with anti-CD3/anti-CD28 mAb 
coated beads for 3 days, added at the same time as the opioid. Data are means ± SEM from 5 
independent experiments. No statistical difference between the responsiveness of opioid-treated and 
untreated anti-CD3/anti-CD28 mAb stimulated cells was observed (paired Student t-test). 
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Figure 3-81: Effect of methadone on CD25 expression by CD4
+
 and CD8
+
 T cells. 
The proportion (%) of CD4
+
 and CD8
+
 cells expressing CD25 (left panel) and the intensity of this 
expression in these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with the indicated concentrations of methadone for 3 days prior to assessing CD25 expression. 
All cells, other than the unstimulated control, were activated with anti-CD3/anti-CD28 mAb coated beads 
for 3 days, added at the same time as the opioid. Data are means ± SEM from 5 independent experiments. 
No statistical difference between the responsiveness of opioid-treated and untreated anti-CD3/anti-CD28 
mAb stimulated cells was observed (paired Student t-test). 
 
 
 
 
 
Figure 3-82: Effect of methadone on CD69 expression by CD4
+
 and CD8
+
 T cells. 
The proportion (%) of CD4
+
 and CD8
+
 cells expressing CD69 (left panel) and the intensity of this 
expression in these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with the indicated concentrations of methadone for 3 days prior to assessing CD69 expression. 
All cells, other than the unstimulated control, were activated with anti-CD3/anti-CD28 mAb coated beads 
for 3 days, added at the same time as the opioid. Data are means ± SEM from 5 independent experiments. 
No statistical difference between the responsiveness of opioid-treated and untreated anti-CD3/anti-CD28 
mAb stimulated cells was observed (paired Student t-test). 
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Figure 3-83: Effect of oxycodone on CD25 expression by CD4
+
 and CD8
+
 T cells. 
The proportion (%) of CD4
+
 and CD8
+
 cells expressing CD25 (left panel) and the intensity of this 
expression in these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with the indicated concentrations of oxycodone for 3 days prior to assessing CD25 expression. 
All cells, other than the unstimulated control, were activated with anti-CD3/anti-CD28 mAb coated beads 
for 3 days, added at the same time as the opioid. Data are means ± SEM from 5 independent experiments. 
No statistical difference between the responsiveness of opioid-treated and untreated anti-CD3/anti-CD28 
mAb stimulated cells was observed (paired Student t-test). 
 
 
 
 
 
Figure 3-84: Effect of oxycodone on CD69 expression by CD4
+
 and CD8
+
 T cells. 
The proportion (%) of CD4
+
 and CD8
+
 cells expressing CD69 (left panel) and the intensity of this 
expression in these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with the indicated concentrations of oxycodone for 3 days prior to assessing CD69 expression. 
All cells, other than the unstimulated control, were activated with anti-CD3/anti-CD28 mAb coated beads 
for 3 days, added at the same time as the opioid. Data are means ± SEM from 5 independent experiments. 
20 and 100 ng/ml of oxycodone significantly increased the % of anti-CD3/anti-CD28 mAb stimulated CD4
+
 
cells expressing CD69 (* = P<0.05; paired Student t-test). 
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Figure 3-85: Effect of diamorphine on CD25 expression by CD4
+
 and CD8
+
 T cells. 
The proportion (%) of CD4
+
 and CD8
+
 cells expressing CD25 (left panel) and the intensity of this 
expression in these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with the indicated concentrations of diamorphine for 3 days prior to assessing CD25 expression. 
All cells, other than the unstimulated control, were activated with anti-CD3/anti-CD28 mAb coated beads 
for 3 days, added at the same time as the opioid. Data are means ± SEM from 5 independent experiments. 
No statistical difference between the responsiveness of opioid-treated and untreated anti-CD3/anti-CD28 
mAb stimulated cells was observed (paired Student t-test). 
 
 
 
 
 
Figure 3-86: Effect of diamorphine on CD69 expression by CD4
+
 and CD8
+
 T cells. 
The proportion (%) of CD4
+
 and CD8
+
 cells expressing CD69 (left panel) and the intensity of this 
expression in these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with the indicated concentrations of diamorphine for 3 days prior to assessing CD69 expression. 
All cells, other than the unstimulated control, were activated with anti-CD3/anti-CD28 mAb coated beads 
for 3 days, added at the same time as the opioid. Data are means ± SEM from 5 independent experiments. 
250 ng/ml of diamorphine significantly increased the proportion of anti-CD3/anti-CD28 mAb stimulated 
CD4
+
 cells expressing CD69 (* = P<0.05; paired Student t-test). 
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Figure 3-87: Effect of codeine on CD25 expression by CD4
+
 and CD8
+
 T cells. 
The proportion (%) of CD4
+
 and CD8
+
 cells expressing CD25 (left panel) and the intensity of this 
expression in these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with the indicated concentrations of codeine for 3 days prior to assessing CD25 expression. All 
cells, other than the unstimulated control, were activated with anti-CD3/anti-CD28 mAb coated beads for 3 
days, added at the same time as the opioid. Data are means ± SEM from 5 independent experiments. No 
statistical difference between the responsiveness of opioid-treated and untreated anti-CD3/anti-CD28 mAb 
stimulated cells was observed (paired Student t-test). 
 
 
 
 
 
Figure 3-88: Effect of codeine on CD69 expression by CD4
+
 and CD8
+
 T cells. 
The proportion (%) of CD4
+
 and CD8
+
 cells expressing CD69 (left panel) and the intensity of this 
expression in these positive cells (median channel of fluorescent intensity, MFI; right panel). PBMCs were 
incubated with the indicated concentrations of codeine for 3 days prior to assessing CD69 expression. All 
cells, other than the unstimulated control, were activated with anti-CD3/anti-CD28 mAb coated beads for 3 
days, added at the same time as the opioid. Data are means ± SEM from 5 independent experiments. 400 
and 2000 ng/ml of codeine significantly increased the proportion of anti-CD3/anti-CD28 mAb stimulated 
CD4
+
 cells expressing CD69 (* = P<0.05; paired Student t-test). 
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The above data illustrate that opioids have no consistent effect on T cell activation 
(CD25 and CD69 expression) which is induced following a 3-day incubation of PBMCs 
with anti-CD3/anti-CD28 mAb coated beads. Although occasional results were of 
statistical significance, the lack of consistency across a range of doses for an opioid or 
in both the proportion and intensity of response suggests that in view of the number of 
tests carried out this is likely due to chance. As there were small numbers of subjects, 
this might have caused a type II error, but as there was no consistent effect of any 
opioids, increasing the number of subjects would not have led to meaningful, 
statistically significant results. 
 
3.3.2 Effect of opioids on the activation of anti-CD3/anti-CD28 mAb pre-
stimulated T cells 
Opioids had no effect on T cell activation when added at the same time as the Miltenyi 
anti-CD3/anti-CD28 mAb coated beads. It may be that opioids were just having no 
effect, or that any effect of the opioids could not overcome the effect of the Miltenyi 
anti-CD3/anti-CD28 mAb coated beads when they were added together. The lack of 
observed effect might also be due to MOR regulation and that the T cells needed to be 
activated for receptor expression and for the opioids to have a direct effect (Borner et 
al., 2008). Thus, additional experiments determined the effect of opioids on the 
activation status of pre-stimulated T cell populations. 
 
For these, PBMCs were stimulated for 1 day with Miltenyi anti-CD3/anti-CD28 mAb 
coated beads (at a 1:1 bead:PBMC ratio) before the addition of opioids for a further 2 
days. Cells were harvested and stained at this point (after 3 days in total) and the 
expression of CD25 and CD69 by CD4+ and CD8+ T cells was determined by flow 
cytometry and analysed using FACSDiva™ data analysis software.  
 
Morphine, tramadol, fentanyl, buprenorphine, methadone, oxycodone, diamorphine and 
codeine were assessed at five concentrations, the same as in the previous experiment. 
None of the opioids had an effect on the proportion or intensity of CD25 and CD69 
expression by CD4+ and CD8+ T cells pre-stimulated with Miltenyi anti-CD3/anti-CD28 
mAb coated beads (data not shown). 
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3.3.3 Effect of pre-incubation of T cells with opioids before anti-CD3/anti-
CD28 mAb-coated bead stimulation 
Opioids had no effect on T cell activation when added at the same time or 1 day after 
the anti-CD3/anti-CD28 mAb coated beads. As it might be that the stimulation was too 
potent to be overcome by the opioids, additional experiments evaluated the activation 
status of T cells, when PBMCs were pre-incubated with opioids prior to polyclonal 
stimulation with Miltenyi anti-CD3/anti-CD28 mAb coated beads. 
 
For these experiments the opioids were added to the PBMCs and incubated for 1 day 
before the Miltenyi anti-CD3/anti-CD28 mAb coated beads (at a 1:1 bead:PBMC ratio) 
were added to this culture. Cells were incubated for a further 3 days, after which CD25 
and CD69 expression by CD4+ and CD8+ T cells was determined by flow cytometry. All 
eight opioids were assessed at five concentrations, the same as in the previous 
experiments. None of the opioids had an effect on the proportion or intensity of CD25 
and CD69 expression by CD4+ and CD8+ T cells (data not shown). 
 
3.3.4 Effect of opioids on the activation of anti-CD3/anti-CD28 mAb 
stimulated T cells, without platelet removal 
When opioids were added at the same time, 1 day after or 1 day before the anti-
CD3/anti-CD28 mAb coated beads they had no effect on T cell activation. It is likely 
that either the opioids were not having a direct effect on T cells. However, as other 
studies have used PBMC preparations which contained platelets, and Platelet-derived 
Growth Factor has been shown to modulate the T cell response (Daynes et al., 1991), 
one further experimental paradigm was used to ensure that the platelet removal step 
was not affecting the potential effect of opioids on T cell activation. 
 
For these experiments, the opioids and Miltenyi anti-CD3/anti-CD28 mAb coated 
beads, were added at the same time to the PBMCs (which did not undergo the second 
density gradient centrifugation, which is to remove the platelets) and incubated for 3 
days. Cells were then harvested and stained for the expression of CD25 and CD69 by 
CD4+ and CD8+ T cells which was determined by flow cytometry. None of the opioids 
tested had any effect on the proportion or intensity of the expression of CD25 and 
CD69 by CD4+ and CD8+ T cells (data not shown). 
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3.3.5 Effects of opioids on the activation T cells in individual subjects 
The data in the previous sections are the pooled data for the effect of opioids on T cell 
activation and show no clear trends for statistical significance from any of the opioids. 
There is however interindividual variability reducing any potential for a statistically 
significant effect. For an individual, the effects of certain opioids on the activation of T 
cells might be clinically significant. When PBMCs were stimulated for 3 days with 
Miltenyi anti-CD3/anti-CD28 mAb coated beads at the same time as being incubated 
with opioids, they mostly had no consistent effect on T cells in most of the subjects 
tested. When the opioids had an effect, this was more dependent on the individual than 
the opioid used. Subject 1 was generally unaffected by any of the opioids tested. In 
subjects 2, 4 and 5 most of the opioids tended to increase the proportion of CD4+ and 
CD8+ T cells expressing CD25 and CD69, with only occasional increases in the MFI. In 
subject 3 almost all of the opioids increased the proportion of CD4+ and CD8+ T cells 
expressing CD25 and CD69, with a reduction in the total expression (MFI) of these cell 
surface markers. 
 
3.3.6 Discussion  
None of the opioids, at clinically relevant concentrations, had a consistent effect on the 
activation of T cells by Miltenyi anti-CD3/anti-CD28 mAb coated beads. Several 
experimental paradigms were used with the opioids added at the same time as the 
beads, 1 day before the beads and 1 day after the beads. In this series of experiments, 
some of the opioids at certain concentrations reached the p<0.05 level of significance 
on some of the parameters tested, but in view of multiple statistical testing and that 
there was no statistical consistency across the concentrations of any opioid tested on 
the different measures of activation, it is probable that these occurred by chance and 
would not be clinically relevant. Despite the small sample size, there was no clear trend 
from any of the opioids and thus increasing numbers would be unlikely to lead to a 
statistical, or potential clinical, significant effect. It is likely that if opioids are to influence 
T cell activation and proliferation in vivo that they will do this via indirect mechanisms 
(e.g. via the SNS and HPA axis), rather than a direct effect on T cells. 
 
Despite many previous studies on the effect of opioids on the activation of T cells in 
vivo, both in animal models and clinically (reviewed in section 1.12.4), and the 
consequences on cytokine production (reviewed in sections 1.12.5 and 3.4), no 
previous in vitro studies have assessed the effect of opioids on the activation of T cells 
using CD25 and CD69 expression as an index of activation. Other research groups 
have assessed the effect of morphine, methadone and diamorphine on the cytotoxicity 
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of T cells, these are described below. No study has evaluated the direct effects of 
opioids on the activation and function of CD4+ T cell populations. 
 
Murine splenic lymphocytes from female B6C3F1 mice were stimulated in vitro for 5 
days with mitomycin C-inactivated P815 cells and 0.0001 – 100 M of morphine 
(equivalent to 0.03 – 28,530 ng/ml) (Thomas et al., 1995a). These cells were then 
incubated with radiolabelled P815 target cells for 4 hr. Cytotoxic T cell activity was 
assessed by the radioactivity released into the supernatant as measured by a  
counter. Cytotoxicity was not affected by any of the concentrations of morphine 
(Thomas et al., 1995a). 
 
The same group also evaluated the potential effects of methadone and diamorphine 
using a similar methodology, with a 5-day incubation of murine splenocytes with 0.0001 
– 100 M of methadone (equivalent to 0.03 – 30,940 ng/ml) or diamorphine (equivalent 
to 0.03 – 36,940 ng/ml) (Thomas et al., 1995b). Only 100 M of diamorphine (≈ 36,940 
ng/ml), which far exceeds that found clinically, inhibited cytotoxic T cell activity, by 
about 50%. Methadone had no effect. The responses to both methadone and 
diamorphine were reported as variable between mice (Thomas et al., 1995b). 
 
A further study from the same group evaluated the in vitro effect of 0.0001 – 100 M of 
fentanyl (equivalent to 0.03 – 33,650 ng/ml) on cytotoxic T cell killing using splenocytes 
from female B6C3Fl mice (House et al., 1995). For these experiments, splenocytes 
were cultured with fentanyl and mitomycin C-inactivated P815 cells for 5 days. The 
resultant effector cells were harvested and incubated with 51Cr labelled P815 target 
cells for 4 hr. Only the highest concentration of fentanyl (100 M; equivalent to 33,650 
ng/ml), which far exceeds that found clinically, inhibited cytotoxic T cell killing, which 
was by 60% (House et al., 1995).  
 
Compared to the current study, these three similar studies by the same group used a 
different species and cell type (murine splenic vs. human peripheral blood 
lymphocytes) incubated with a large range of morphine, fentanyl, methadone and 
diamorphine concentrations, (overlapping with those used in the current study) for a 
longer duration (5 vs. 3 days). The stimuli used differed (anti-CD3 vs. anti-CD3/anti-
CD28 mAb), as did the cytotoxicity detection method, with these using a functional 
measurement. The results of these studies were consistent with the current study, as 
none of the opioids had an effect on CD8+ cytotoxic T cells at clinically relevant 
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concentrations (although supra-pharmacological concentrations of diamorphine and 
fentanyl were inhibitory in the studies by Thomas and House). 
 
The effect of morphine on T cell proliferation has been evaluated using cells from 
CB6F1/J, Balb/c female and 3C57BL/6 male mice (Wang et al., 2001). Lymph node T 
cells were incubated with between 1 nM – 10 M of morphine (equivalent to 0.3 – 
3,365 ng/ml) and stimulated with Con A for 48 hr. Proliferation was measured with a 
3H-thymidine uptake assay. 10 nM – 10 M of morphine inhibited T cell proliferation in 
a dose-dependent manner, by up to 60% (Wang et al., 2001). Compared with the 
current study, this study by Wang and colleagues has a very different methodology with 
different species, cells, stimulation and a functional outcome measure. Although, the 
concentrations of morphine overlapped, this study had very different results compared 
with the current study, showing that non-physiologically stimulated murine cytotoxic T 
cells were inhibited by morphine, whereas it had no effect on activation markers in the 
current study. This is likely to be due to the differing species, cells and stimulation 
method used, as activation marker expression has been demonstrated to correlate to T 
cell proliferation (Maino et al., 1995, Mardiney et al., 1996, Simms and Ellis, 1996).  
 
Other groups have assessed the effect of opioids on T cells using non physiological 
activation pathways (i.e. Con A) and have shown no effect (personal communication: 
Dr Nick Gough, University College London, UK).  
 
3.3.7 Conclusion 
In this series of experiments the effect of morphine, tramadol, fentanyl, buprenorphine, 
methadone, oxycodone, diamorphine and codeine on T cell activation (CD25 and 
CD69 expression) was assessed. T cells were stimulated with Miltenyi anti-CD3/anti-
CD28 mAb coated beads, added before, at the same time or after the opioids. There 
was good activation of both CD4+ and CD8+ T cells by the beads but none of the 
opioids had a consistent effect on the activation of T cells. Despite using different 
methodologies, the results from previous in vitro studies mostly correlate to those of the 
current study. The effect of morphine in previous in vivo experiments was therefore 
unlikely to be a result of a direct effect of the opioids on the T cells, but an indirect 
effect, possibly via the SNS or HPA axis.  
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3.4 Effect of opioids on cytokine production 
Cytokines are intercellular signalling molecules that play a pivotal role in the regulation 
of immune function. The effect of morphine, tramadol, fentanyl, buprenorphine, 
methadone, oxycodone, diamorphine and codeine on the production of a range of 
cytokines in unstimulated, IL-2 stimulated and Miltenyi anti-CD3/anti-CD28 mAb coated 
bead stimulated PBMCs were assessed. For these experiments, PBMCs were 
incubated with four concentrations of each opioids and 100U/ml IL-2 or Miltenyi anti-
CD3/anti-CD28 mAb beads (at a 1:1 bead:PBMC ratio) for 3 days before the 
supernatants were removed and stored at -80°C until cytokine analysis using BD 
Bioscience CBAs and a BD FACSArray™ flow cytometer. 
 
The cytokines analysed in the supernatants of activated PBMC cultures were IL-1, IL-
2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IFN-, IFN-, TNF- and IP-10. Cytokine 
levels in the unstimulated samples were at, or below the detection limit of the 
respective assays and opioids had no effect on these (data not shown). IL-4, IL-12p70, 
IP10 and IFN- were below the detection limit of the IL-2 and Miltenyi anti-CD3/anti-
CD28 mAb stimulated assays and no data were obtained for IL-2. The results 
presented below are for IL-1, IL-6, IL-8, IL-10, IL-17A, IFN- and TNF- (Figure 3-89 - 
Figure 3-96). The major comparison to be considered in the following data sets is the 
change from the “no opioid” stimulated baseline, rather than the absolute 
concentrations.   
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Figure 3-89: Effect of morphine on cytokine production. 
Effect of morphine on cytokine production by IL-2 (left Y axis, blue) and Miltenyi anti-CD3/anti-CD28 mAb 
coated bead (right Y axis, red) stimulated PBMCs. IL-1 (top left panel), IL-17A (top right panel), IL-10 
(upper middle left panel), IFN- (upper middle right panel), TNF- (lower middle right panel), IL-6 
(lower middle left panel) and IL-8 (bottom left panel) concentrations are presented on the y axes, in 
pg/ml. PBMCs were incubated with the indicated concentration of morphine for 3 days, with either IL-2 or 
anti-CD3/anti-CD28 mAb coated beads. Unstimulated (unstim) and stimulated (stim) controls without 
morphine are included. Data are means ± SEM from 3 independent experiments for IL-2 stimulated and 4 
independent experiments (except IL-6 and 8 at 20 ng/ml where n=3) for anti-CD3/28 stimulated. No 
statistical differences between the cytokine concentrations of opioid-treated and untreated anti-CD3/anti-
CD28 mAb stimulated cells were observed (paired Student t-test). 20 ng/ml of morphine significantly 
decreased IL-1 and IL-8 levels and 500 ng/ml of morphine increased IL-17A levels in IL-2 
stimulated PBMCs (P<0.05; paired Student t-test). 
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Figure 3-90: Effect of tramadol on cytokine production. 
Effect of tramadol on cytokine production by IL-2 (left Y axis, blue) and Miltenyi anti-CD3/anti-CD28 mAb 
coated bead (right Y axis, red) stimulated PBMCs. IL-1 (top left panel), IL-17A (top right panel), IL-10 
(upper middle left panel), IFN- (upper middle right panel), TNF- (lower middle right panel), IL-6 
(lower middle left panel) and IL-8 (bottom left panel) concentrations are presented on the y axes, in 
pg/ml. PBMCs were incubated with the indicated concentration of tramadol for 3 days, with either IL-2 or 
anti-CD3/anti-CD28 mAb coated beads. Unstimulated (unstim) and stimulated (stim) controls without 
tramadol are included. Data are means ± SEM from 3 independent experiments for IL-2 stimulated (except 
at 2,000 and 10,000 ng/ml where n=2) and 3 independent experiments (except for IL-6 and 8 where n=4) 
for anti-CD3/28 stimulated. No statistical differences between the cytokine concentrations of opioid-treated 
and untreated anti-CD3/anti-CD28 mAb stimulated cells were observed (paired Student t-test). 80 ng/ml of 
tramadol significantly decreased IL-8 levels in IL-2 stimulated PBMCs (P<0.05; paired Student t-test). 
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Figure 3-91: Effect of fentanyl on cytokine production. 
Effect of fentanyl on cytokine production by IL-2 (left Y axis, blue) and Miltenyi anti-CD3/anti-CD28 mAb 
coated bead (right Y axis, red) stimulated PBMCs. IL-1 (top left panel), IL-17A (top right panel), IL-10 
(upper middle left panel), IFN- (upper middle right panel), TNF- (lower middle right panel), IL-6 
(lower middle left panel) and IL-8 (bottom left panel) concentrations are presented on the y axes, in 
pg/ml. PBMCs were incubated with the indicated concentration of fentanyl for 3 days, with either IL-2 or 
anti-CD3/anti-CD28 mAb coated beads. Unstimulated (unstim) and stimulated (stim) controls without 
fentanyl are included. Data are means ± SEM from 3 independent experiments for IL-2 stimulated and 4 
independent experiments (except at 20 ng/ml where n=3) for anti-CD3/28 stimulated. No statistical 
differences between the cytokine concentrations of opioid-treated and untreated anti-CD3/anti-CD28 mAb 
stimulated cells were observed (paired Student t-test). 20 ng/ml of fentanyl significantly decreased IL-6 
levels in IL-2 stimulated PBMCs (P<0.05; paired Student t-test). 
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Figure 3-92: Effect of buprenorphine on cytokine production. 
Effect of buprenorphine on cytokine production by IL-2 (left Y axis, blue) and Miltenyi anti-CD3/anti-CD28 
mAb coated bead (right Y axis, red) stimulated PBMCs. IL-1 (top left panel), IL-17A (top right panel), 
IL-10 (upper middle left panel), IFN- (upper middle right panel), TNF- (lower middle right panel), 
IL-6 (lower middle left panel) and IL-8 (bottom left panel) concentrations are presented on the y axes, in 
pg/ml. PBMCs were incubated with the indicated concentration of buprenorphine for 3 days, with either IL-
2 or anti-CD3/anti-CD28 mAb coated beads. Unstimulated (unstim) and stimulated (stim) controls without 
buprenorphine are included. Data are means ± SEM from 3 independent experiments for IL-2 stimulated 
and between 3 and 5 independent experiments for anti-CD3/28 stimulated. No statistical differences 
between the cytokine concentrations of opioid-treated and untreated anti-CD3/anti-CD28 mAb stimulated 
cells were observed (paired Student t-test). 20 ng/ml of buprenorphine significantly increased IFN- 
levels in IL-2 stimulated PBMCs (P<0.05; paired Student t-test). 
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Figure 3-93: Effect of methadone on cytokine production. 
Effect of methadone on cytokine production in IL-2 (left Y axis, blue) and Miltenyi anti-CD3/anti-CD28 
mAb coated bead (right Y axis, red) stimulated PBMCs. IL-1 (top left panel), IL-17A (top right panel), 
IL-10 (upper middle left panel), IFN- (upper middle right panel), TNF- (lower middle right panel), 
IL-6 (lower middle left panel) and IL-8 (bottom left panel) concentrations are presented on the y axes, in 
pg/ml. PBMCs were incubated with the indicated concentration of methadone for 3 days, with either IL-2 or 
anti-CD3/anti-CD28 mAb coated beads. Unstimulated (unstim) and stimulated (stim) controls without 
methadone are included. Data are means ± SEM from 3 independent experiments for IL-2 stimulated and 
5 independent experiments (except for IL-6 and 8 where n=4) for anti-CD3/28 stimulated. No statistical 
differences between the cytokine concentrations of opioid-treated and untreated anti-CD3/anti-CD28 mAb 
stimulated cells were observed (paired Student t-test). Methadone at all concentrations decreased IL-6 
levels; 10 and 250 ng/ml decreased IL-8 levels and 50 ng/ml decreased IFN- levels in IL-2 
stimulated PBMCs (P<0.05; paired Student t-test). 
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Figure 3-94: Effect of oxycodone on cytokine production. 
Effect of oxycodone on cytokine production in IL-2 (left Y axis, blue) Miltenyi anti-CD3/anti-CD28 mAb 
coated bead (right Y axis, red) stimulated PBMCs. IL-1 (top left panel), IL-17A (top right panel), IL-10 
(upper middle left panel), IFN- (upper middle right panel), TNF- (lower middle right panel), IL-6 
(lower middle left panel) and IL-8 (bottom left panel) concentrations are presented on the y axes, in 
pg/ml. PBMCs were incubated with the indicated concentration of oxycodone for 3 days, with either IL-2 or 
anti-CD3/anti-CD28 mAb coated beads. Unstimulated (unstim) and stimulated (stim) controls without 
oxycodone are included. Data are means ± SEM from 3 independent experiments for IL-2 stimulated and 
between 3 and 5 independent experiments (n=4 for IL-6 and 8) for anti-CD3/28 stimulated. No statistical 
differences between the cytokine concentrations of opioid-treated and untreated anti-CD3/anti-CD28 mAb 
stimulated cells were observed (paired Student t-test). 4, 20 and 500 ng/ml of oxycodone decreased IL-
6 levels; 4 and 500 ng/ml of oxycodone decreased IL-8 levels; 4 ng/ml of oxycodone decreased IL-
10 and IFN-; and 20 ng/ml of oxycodone decreased IL-17A levels in IL-2 stimulated PBMCs 
(P<0.05; paired Student t-test). 
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Figure 3-95: Effect of diamorphine on cytokine production. 
Effect of diamorphine on cytokine production in IL-2 (left Y axis, blue) and Miltenyi anti-CD3/anti-CD28 
mAb coated bead (right Y axis, red) stimulated PBMCs. IL-1 (top left panel), IL-17A (top right panel), 
IL-10 (upper middle left panel), IFN- (upper middle right panel), TNF- (lower middle right panel), 
IL-6 (lower middle left panel) and IL-8 (bottom left panel) concentrations are presented on the y axes, in 
pg/ml. PBMCs were incubated with the indicated concentration of diamorphine for 3 days, with either IL-2 
or anti-CD3/anti-CD28 mAb coated beads. Unstimulated (unstim) and stimulated (stim) controls without 
diamorphine are included. Data are means ± SEM from 3 independent experiments (except n=2 for 1250 
ng/ml; n=3 for IL-6 and 8) for IL-2 stimulated and 3 independent experiments (except n=2 for 10ng/ml and 
n=5 for IL-6 and 8 [n=4 for 10ng/ml]) for anti-CD3/28 stimulated. No statistical differences between the 
cytokine concentrations of opioid-treated and untreated anti-CD3/anti-CD28 mAb stimulated cells were 
observed (paired Student t-test). 10, 50 and 1250 ng/ml of diamorphine decreased IL-6 levels and 50 
and 1250 ng/ml of diamorphine decreased IL-8 levels in IL-2 stimulated PBMCs (P<0.05; paired 
Student t-test). 
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Figure 3-96: Effect of codeine on cytokine production. 
Effect of codeine on cytokine production in IL-2 (left Y axis, blue) Miltenyi anti-CD3/anti-CD28 mAb 
coated bead (right Y axis, red) stimulated PBMCs. IL-1 (top left panel), IL-17A (top right panel), IL-10 
(upper middle left panel), IFN- (upper middle right panel), TNF- (lower middle right panel), IL-6 
(lower middle left panel) and IL-8 (bottom left panel) concentrations are presented on the y axes, in 
pg/ml. PBMCs were incubated with the indicated concentration of codeine for 3 days, with either IL-2 or 
anti-CD3/anti-CD28 mAb coated beads. Unstimulated (unstim) and stimulated (stim) controls without 
codeine are included. Data are means ± SEM from 3 independent experiments for IL-2 stimulated and 3 or 
4 independent experiments (except n=2 for 400ng/ml for IL-17A, [n=5 for IL-6 and 8, except for 400 and 
2,000ng/ml where n=4]) for anti-CD3/28 stimulated. No statistical differences between the cytokine 
concentrations of opioid-treated and untreated anti-CD3/anti-CD28 mAb stimulated cells were observed 
(paired Student t-test). 10 and 1250 ng/ml of codeine decreased IL-6 and IL-8 levels, 1250 ng/ml of 
codeine also decreased IL-10 and IFN- levels in IL-2 stimulated PBMCs (P<0.05; paired Student t-
test). 
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Stimulation of PBMCs with IL-2 increased the production of IL-1, IL-6, IL-8, IL-17A, IL-
10, IFN- and TNF-. This was more variable with the Miltenyi anti-CD3/anti-CD28 
mAb coated bead stimulation. This increased IL-17A, did not affect IL-1, IL-6 and IL-8, 
and either did not affect or increased IL-10, IFN- and TNF- production, depending on 
the subject. This is considered in more detail in the following section and in Table 3.13.  
 
None of the opioids had a statistically significant effect on cytokine secretion in PBMCs 
stimulated with Miltenyi anti-CD3/anti-CD28 mAb coated beads. Some of the cytokine 
concentrations in the supernatants of IL-2 stimulated PBMCs were significantly 
influenced by certain concentrations of some opioids but the only clear trends in the 
statistical significance were for methadone, oxycodone and diamorphine which all 
decreased IL-6 production from IL-2 stimulated PBMCs at several concentrations. 
Although conventionally considered a pro-inflammatory cytokine as IL-6 initiates the 
acute phase response during infection and after trauma, it can also have anti-
inflammatory effects as it can inhibit IL-1 and TNF- (Xing et al., 1998). Thus the 
potential clinical impact of IL-6 inhibition by these opioids would depend on various 
other factors including the hosts level of immune activation, the concentrations of other 
cytokines and cytokine regulators such as the suppressor of cytokine signalling-3 
(Croker et al., 2011). As IL-6 induces CRP production in the liver by activating JAKs 
(Heikkila et al., 2007), it is possible the inhibition of IL-6 production by these opioids 
might inhibit the acute phase response which is important during infection and after 
trauma. However inflammation, along with CRP and IL-6, is associated with poor 
prognosis and decreased survival in some solid and haematological malignancies 
(Heikkila et al., 2007, Nikiteas et al., 2005, Pine et al., 2011). IL-6 is also a myokine, 
being produced from muscles during exercise, to increase lipolysis and fat oxidation 
(Pedersen, 2011), and is also secreted by osteoblasts to stimulate osteoclasts and 
promote new bone formation (Eriksen et al., 2010). IL-6 is ubiquitous with many actions 
and inhibiting its production could potentially have widespread effects. 
 
Even though there were these statistically significant effects, this does not mean that 
they will translate into clinical significance as they might be due to chance in view of the 
large number of tests performed (eight opioids, four concentrations, two stimuli and 
seven cytokines measured) or even a significant effect statistically might only be a 
small actual effect which may not impact on clinical outcome. Furthermore, the lack of 
statistical significance was in part due to interindividual variability in cytokine production 
in response to the different opioids. 
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3.4.1 Effects of opioids on cytokine production in individual subjects 
The graphs in the previous section show the pooled data for the effect of each of the 
opioids on each cytokine; there is however interindividual variability causing large 
standard error of the mean and reducing any potential statistical significant effect. 
However, for an individual the effects of certain opioids on the production of certain 
cytokines might be clinically significant and the trends for each individual are explored 
in the sections below. 
 
3.4.1.1 Effects of opioids on IL-2 stimulated cytokine production in 
individual subjects 
The results for IL-2 stimulated cytokine production presented in the graphs of the 
previous section only show occasional effects of the opioids tested, which is in part due 
to differences between the individuals tested. In this section the effects of each of the 
opioids on cytokine production by each individual is described in the tables below 
(Table 3.5 - Table 3.12). The tables have been colour coded for whether each opioid 
(at two or more concentrations) has an inhibitory or stimulatory effect in each of the 
individuals on the different cytokine concentrations. 
 
IL-2 stimulation increased the production of all cytokines in all of the individuals tested, 
the combined data are presented in the graphs of the previous section (individual data 
not shown). 
 
 
Table 3.5: Effect of morphine on IL-2 stimulated cytokine production for individuals.  
Cytokine IL-1 IL-6 IL-8 IL-10 IL-17A IFN- TNF- 
Subject 
1 Decrease  Decrease Decrease  No effect No effect No effect No effect 
2 No effect Decrease  Decrease  No effect No effect Decrease  Decrease  
3 No effect Decrease Decrease  No effect No effect No effect No effect 
Red indicates an inhibitory effect, green a stimulatory effect and yellow no consistent effect. 
 
 
Table 3.6: Effect of tramadol on IL-2 stimulated cytokine production for individuals.  
Cytokine IL-1 IL-6 IL-8 IL-10 IL-17A IFN- TNF- 
Subject 
1 Decrease  Decrease Decrease  No effect No effect No effect No effect 
2 No effect No effect Decrease  No effect No effect No effect No effect 
3 Decrease  Decrease Decrease  No effect Decrease No effect No effect 
Red indicates an inhibitory effect, green a stimulatory effect and yellow no consistent effect. 
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Table 3.7: Effect of fentanyl on IL-2 stimulated cytokine production for individuals.  
Cytokine IL-1 IL-6 IL-8 IL-10 IL-17A IFN- TNF- 
Subject 
1 Decrease  Decrease Decrease Decrease  No effect No effect Decrease 
2 Decrease Decrease Decrease No effect No effect No effect Decrease 
3 Decrease Decrease Decrease Decrease No effect No effect Decrease 
Red indicates an inhibitory effect, green a stimulatory effect and yellow no consistent effect. 
 
 
Table 3.8: Effect of buprenorphine on IL-2 stimulated cytokine production for individuals.  
Cytokine IL-1 IL-6 IL-8 IL-10 IL-17A IFN- TNF- 
Subject 
1 Decrease Decrease Decrease No effect Increase  No effect Decrease 
2 Decrease Decrease Decrease No effect Increase  No effect Decrease 
3 Decrease Decrease Decrease No effect No effect No effect No effect 
Red indicates an inhibitory effect, green a stimulatory effect and yellow no consistent effect. 
 
 
Table 3.9: Effect of methadone on IL-2 stimulated cytokine production for individuals.  
Cytokine IL-1 IL-6 IL-8 IL-10 IL-17A IFN- TNF- 
Subject 
1 Decrease Decrease Decrease Decrease  No effect Decrease  No effect 
2 Decrease Decrease No effect Decrease No effect Decrease Decrease 
3 Decrease Decrease Decrease Decrease No effect No effect Decrease 
Red indicates an inhibitory effect, green a stimulatory effect and yellow no consistent effect. 
 
 
Table 3.10: Effect of oxycodone on IL-2 stimulated cytokine production for individuals.  
Cytokine IL-1 IL-6 IL-8 IL-10 IL-17A IFN- TNF- 
Subject 
1 Decrease Decrease Decrease Decrease No effect No effect No effect 
2 Decrease Decrease Decrease Decrease Decrease Decrease Decrease 
3 Decrease Decrease Decrease Decrease No effect No effect Decrease 
Red indicates an inhibitory effect, green a stimulatory effect and yellow no consistent effect. 
 
 
Table 3.11: Effect of diamorphine on IL-2 stimulated cytokine production for individuals.  
Cytokine IL-1 IL-6 IL-8 IL-10 IL-17A, IFN- TNF- 
Subject 
1 Decrease  Decrease Decrease No effect No effect No effect No effect 
2 Decrease Decrease  Decrease  Decrease  No effect No effect Decrease 
3 No effect Decrease Decrease Decrease Decrease  No effect Decrease 
Red indicates an inhibitory effect, green a stimulatory effect and yellow no consistent effect. 
 
 
Table 3.12: Effect of codeine on IL-2 stimulated cytokine production for the individuals.  
Cytokine IL-1 IL-6 IL-8 IL-10 IL-17A IFN- TNF- 
Subject 
1 Decrease Decrease Decrease Decrease No effect Decrease Decrease 
2 Decrease  No effect No effect Decrease No effect Decrease Decrease 
3 Decrease Decrease Decrease Decrease No effect No effect Decrease 
Red indicates an inhibitory effect, green a stimulatory effect and yellow no consistent effect. 
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In general the production of IL-1, IL-6, IL-8, IL-10 and TNF- were inhibited by most of 
the opioids in most individuals. IL-17A and IFN- were less affected, only being 
inhibited by some opioids in some individuals. 
 
For the IL-2 stimulated samples, the same three subjects were used for all the opioids 
and although the effects of the different opioids varied between the subjects’, in general 
all the opioids decreased IL-1, IL-6 and IL-8.  
 
3.4.1.2 Effects of opioids on anti-CD3/anti-CD28 mAb stimulated cytokine 
production in individual subjects 
The results for the Miltenyi anti-CD3/anti-CD28 mAb coated bead stimulated cytokine 
production presented in the graphs previously show variability between subjects, as 
indicated by the large error bars, and thereby reduced the potential for statistical 
significance. In this section, the effect of the opioids on cytokine levels for each 
individual is explored.  
 
In some individuals, the Miltenyi anti-CD3/anti-CD28 mAb coated bead stimulation did 
not increase cytokine levels, and on occasions (especially for Subject 5) it decreased 
the concentration of some cytokines (Table 3.13). The tables have been colour coded 
for whether each opioid (at two or more concentrations) has an inhibitory or stimulatory 
effect in each of the individuals on the different cytokine concentrations. 
 
 
Table 3.13: Effect of anti-CD3/28 stimulation on cytokine production for individuals.  
Cytokine IL-1 IL-6 IL-8 IL-10 IL-17A IFN- TNF- 
Subject 
1 Decreased No effect Decreased    Decreased 
2 Increased No effect No effect Increased Increased No effect Increased 
3 Increased Increased Increased  Increased  Increased 
4 Increased No effect Increased Increased Increased Increased Increased 
5 Decreased Decreased Decreased Decreased Increased No effect Increased 
Assessing the effect of anti-CD3/28 stimulated, compared with unstimulated, production of cytokines for 
individuals. Red indicates an inhibitory effect, green a stimulatory effect and yellow no effect or no 
consistent effect. 
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The effect of opioids on cytokine production for each individual is described in the 
tables below (Table 3.14 - Table 3.21). 
 
Table 3.14: Effect of morphine on anti-CD3/28 stimulated cytokine production for 
individuals.  
Cytokine IL-1 IL-6 IL-8 IL-10 IL-17A IFN- TNF- 
Subject 
2 No effect Decreased Decreased No effect Increased Increased Increased  
3 Increased Increased Increased Increased Increased Increased Increased  
4 Decreased Decreased Decreased No effect Decreased  Increased  Decreased  
Red indicates an inhibitory effect, green a stimulatory effect and yellow no consistent effect. 
 
 
Table 3.15: Effect of tramadol on anti-CD3/28 stimulated cytokine production for 
individuals.  
Cytokine IL-1 IL-6 IL-8 IL-10 IL-17A IFN- TNF- 
Subject 
2 No effect Decreased Decreased No effect Increased Increased Increased 
3 Increased Increased Increased No effect Increased Increased Increased 
4 Decreased Decreased No effect Decreased Decreased Decreased  Decreased 
Red indicates an inhibitory effect, green a stimulatory effect and yellow no consistent effect. 
 
 
Table 3.16: Effect of fentanyl on anti-CD3/28 stimulated cytokine production for 
individuals.  
Cytokine IL-1 IL-6 IL-8 IL-10 IL-17A IFN- TNF- 
Subject 
2 No effect Decreased Decreased  No effect Increased Increased Increased 
3 Increased No effect No effect Increased Increased Increased Increased 
4 Decreased Decreased No effect Decreased Decreased Decreased Decreased 
Red indicates an inhibitory effect, green a stimulatory effect and yellow no consistent effect. 
 
 
Table 3.17: Effect of buprenorphine on anti-CD3/28 stimulated cytokine production for 
individuals.  
Cytokine IL-1 IL-6 IL-8 IL-10 IL-17A IFN- TNF- 
Subject 
2 Decreased  No effect No effect No effect No effect Decreased  No effect 
3 Increased Increased Increased Increased Increased Increased Increased 
4 Decreased Decreased Decreased  Decreased Decreased No effect Decreased 
Red indicates an inhibitory effect, green a stimulatory effect and yellow no consistent effect. 
 
 
Table 3.18: Effect of methadone on anti-CD3/28 stimulated cytokine production for 
individuals.  
Cytokine IL-1 IL-6 IL-8 IL-10 IL-17A IFN- TNF- 
Subject 
2 No effect Decreased Decreased  No effect Increased Increased Increased 
3 Increased Increased Increased Increased Increased Increased Increased 
4 Decreased Decreased No effect Decreased Decreased Decreased  Decreased 
Red indicates an inhibitory effect, green a stimulatory effect and yellow no consistent effect. 
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Table 3.19: Effect of oxycodone on anti-CD3/28 stimulated cytokine production for 
individuals.  
Cytokine IL-1 IL-6 IL-8 IL-10 IL-17A IFN- TNF- 
Subject 
2 No effect Decreased Decreased No effect Increased Increased Increased 
3 Increased Increased Increased  Increased Increased Increased Increased 
4 Decreased No effect Increased Decreased Decreased No effect Decreased 
Red indicates an inhibitory effect, green a stimulatory effect and yellow no consistent effect. 
 
 
Table 3.20: Effect of diamorphine on anti-CD3/28 stimulated cytokine production for 
individuals.  
Cytokine IL-1 IL-6 IL-8 IL-10 IL-17A IFN- TNF- 
Subject 
2 Decreased Decreased Decreased No effect Increased  No effect No effect 
3 Increased Increased Increased Increased Increased Increased Increased 
4 Decreased Decreased  Decreased  Decreased Decreased  No effect Decreased 
Red indicates an inhibitory effect, green a stimulatory effect and yellow no consistent effect. 
 
 
Table 3.21: Effect of codeine on anti-CD3/28 stimulated cytokine production for 
individuals.  
Cytokine IL-1 IL-6 IL-8 IL-10 IL-17A IFN- TNF- 
Subject 
2 No effect Decreased Decreased Decreased  Increased Increased Increased 
3 Increased Increased Increased Increased Increased Increased Increased 
4 Decreased Decreased  Increased Decreased Decreased Decreased Decreased 
Red indicates an inhibitory effect, green a stimulatory effect and yellow no consistent effect. 
 
 
The effect of Miltenyi anti-CD3/anti-CD28 mAb coated bead stimulation was more 
variable between individuals compared with IL-2 stimulation. This was mainly studied in 
subjects 2, 3 and 4. In subject 2, most of the opioids inhibited IL-6 and IL-8 production, 
increased IL-17A, IFN- and TNF- levels, and had little effect on IL-1 and IL-10 
concentrations. In subject 3, production of all of these cytokines tended to be increased 
by all opioids. Whereas in subject 4, they were mostly inhibited. 
 
Although opioids had variable effects on the secretion of the cytokines analysed, the 
variation was more related to the individual rather than the opioid (especially in 
subjects 3 and 4). Thus for an individual subject the effect of all the opioids tested was 
generally inhibitory, stimulatory or neutral, with minor variations between the opioids. 
Subjects 3 and 4 had a similar effect from the opioid across all the cytokines tested, so 
in general, opioids either stimulated (for subject 3) or inhibited (for subject 4) an 
individual’s capacity to produce the array of cytokines which were analysed.  
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The effect of opioids on cytokine production in pre-stimulated PBMCs (1-day incubation 
with Miltenyi anti-CD3/anti-CD28 mAb coated beads before a further 2-day incubation 
with opioids and the beads), as well as a pre-opioid incubation (1-day incubation with 
opioids before a further 3-day incubation with Miltenyi anti-CD3/anti-CD28 mAb coated 
beads and the opioids) was also assessed. There was no consistent effect of the 
opioids on cytokines in these experiments (data not shown). In the pre-stimulated 
experiments, there were some trends for each individual. In Subject 2, diamorphine 
decreased IL-17A and IFN-; codeine increased IL-6 and IL-8. In Subject 3, all opioids 
decreased IL-17A and IFN-, although buprenorphine had less effect on IFN-.  
 
3.4.2 Discussion 
In the current study, PBMCs from healthy volunteers were stimulated with IL-2 or 
Miltenyi anti-CD3/anti-CD28 mAb coated beads for 3 days and the effect of clinically 
relevant concentrations, of eight opioids on the production of cytokines (IL-1, IL-6, IL-
8, IL-10, IL-17A, IFN- and TNF-) was evaluated. IL-4, IL-12p70, IP10 and IFN- were 
also analysed but were below the detection threshold. 
 
IL-2 more potently and consistently stimulated baseline cytokine production compared 
with Miltenyi anti-CD3/anti-CD28 mAb coated beads, which showed interindividual 
variability (Table 3.13). Whereas IL-2 directly activated the T cells to induce a cascade 
of cytokine production, anti-CD3/anti-CD28 mAb need to activate the TCR and its co-
receptor in order to trigger intracellular activation cascades and IL-2 secretion before 
other cytokines could be produced as a secondary result of this. Thus, although 3 days 
might have been long enough to activate T cells, it might not have been long enough to 
induce cytokine secretion and the subsequent activation cascades from these. 
However, this approach might have led to a more sensitive detection of potential 
stimulatory effects of the opioids, as if they promoted the transduction signalling 
pathways then this may have resulted in higher levels of cytokines. 
 
There were occasional statistically significant effects from all opioids on some of the 
cytokines (previously described in section 3.4) although due to multiple statistical tests 
being performed on the vast numbers of data analysed, it is difficult to determine if this 
is more by chance or truly significant. Some of the significance is potently lost due to 
the variability of the subjects tested, as when looked at individually some of the opioids 
affected cytokine levels several fold, which may be clinically significant for that 
individual (an example of which is shown in Figure 3-97 and Figure 3-98).  
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Figure 3-97: Effect of methadone on individual IL-6 production. 
Effect of methadone on IL-6 production in different subjects’ PBMCs stimulated with Miltenyi anti-CD3/anti-
CD28 mAb coated beads. The (left panel) shows all four subjects tested, but due to the very high levels of 
IL-6 in subject 5, this is removed to show trends for the other subjects (middle panel), two subjects have 
much lower levels of IL-6 and subject 4 is removed to enable the trends to be shown in subjects 2 and 3 
(right panel). 
 
 
 
Figure 3-98: Effect of methadone on individual IL-8 production. 
Effect of methadone on IL-8 production in different subjects’ PBMCs stimulated with Miltenyi anti-CD3/anti-
CD28 mAb coated beads. The (left panel) shows all four subjects tested, but due to the high levels of IL-8 
in subjects 4 and 5, these are removed to show trends for subjects 2 and 3 (right panel). 
 
 
The variation between individuals at baseline, their differential response to Miltenyi 
anti-CD3/anti-CD28 mAb coated bead stimulation (increasing cytokine levels in some 
subjects and inhibiting production in others) and the effects of opioids on this are 
impossible to unravel for the population studied. It is therefore likely to be the case that 
in a population of patients that some will be very sensitive to certain opioids and others 
will have minimal opioid derived immune effects. For example, methadone at most 
concentrations caused about a 50% reduction in IL-6 levels in three out of four subjects 
tested (Subjects 2, 4 and 5), whereas methadone at intermediate concentrations 
doubled IL-6 levels in subject 3. Faced with such variability in absolute concentrations 
of these cytokines and the wide variety of effects induced by opioids in the subjects 
tested, it cannot be known if these are by chance or could be clinically significant for 
that subject (providing these in vitro changes were to be replicated in a clinical study). 
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There is also a paucity of data in the literature as to what change (or absolute 
concentration) of the cytokines would lead to a difference in clinical outcome. Long 
term clinical studies are needed, in which cytokine levels are measured and the course 
of the patients’ illness is monitored. 
 
Several previous studies have assessed the effect of certain opioids on the production 
of cytokines. The in vivo studies have been discussed in the introduction (section 
1.12.5) and the in vitro studies are described below and compared to the current study.  
 
The effect of morphine on IL-4 production has been assessed in splenocytes from 
C57/S129 mice that have been depleted of B cells and CD8+ T cells (Roy et al., 2005). 
For these experiments, splenocytes were incubated for 2-hr with 200 ng/ml of morphine 
and then stimulated with BD Pharmingen anti-CD3/anti-CD28 mAbs for 3 days. IL-4 
was measured using an ELISA. Morphine increased IL-4 synthesis three fold in splenic 
CD4+ T cells (Roy et al., 2005). IL-4 was below the detection threshold in all samples 
analysed in the current study, this might be due to differences in potency of the beads. 
 
In a study from the same group, the in vitro effect of morphine on IL-2, IL-4, IL-5 and 
IFN- production by healthy human PBMCs and CB6F1/J murine splenocytes was 
evaluated (Roy et al., 2001). PBMCs and splenocytes were incubated for 4 days with 
10, 30 and 100 ng/ml of morphine and then stimulated with anti-CD3/anti-CD28 mAbs 
(bead type and duration not stated). Cytokines were measured using ELISAs. 
Morphine dose-dependently decreased PBMC production of IL-2 (up to 50%) and IFN- 
(up to 70%), and increased IL-4 (up to 10x) and IL-5 (up to 3x) production. Similar 
results were detected in murine splenocytes, with morphine inhibiting IFN- (up to 70%) 
and stimulating IL-4 (up to 4x) production. These effects were abolished in MOR-/- mice 
(Roy et al., 2001).  
 
These in vitro studies demonstrated that morphine treatment of murine and human 
cells results in polarisation of cytokine production towards the TH2 phenotype (Roy et 
al., 2001, Roy et al., 2005), potentially inhibiting cell mediated immunity. The current 
study evaluated the effect of comparable doses of morphine on IL-2, IL-4 and IFN- 
production from healthy human PBMCs. However, IL-4 was below the detection limit of 
the assay used and although IFN- levels were increased several fold, this effect was 
not statistically significant. These differences might be accounted for by the duration 
and exact stimulation method. 
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The effect of morphine on IL-2 and IFN- production has been evaluated using 
CB6F1/J, Balb/c female and 3C57BL/6 male mice (Wang et al., 2001). Lymph node 
cells were incubated with 1 nM – 10 M of morphine (equivalent to 0.3 – 3,365 ng/ml) 
for 2 hr and then stimulated with Con A for 24 hr. IL-2 and IFN- were measured using 
ELISAs. IL-2 was inhibited (up to 50%) by 1 nM – 10 M of morphine and IFN- was 
inhibited (up to 70%) by 100 nM – 10 M of morphine (Wang et al., 2001). Despite 
using overlapping concentrations of morphine, this is in contrast to the current study, 
which may be due to the species and cell type used (lymph node vs. peripheral 
lymphocytes) and the method and duration of stimulation. 
 
Qian and colleagues assessed the effect of morphine and tramadol on the in vitro 
differentiation of TH cells taken from 20 human adult outpatients without immune 
disorders (Qian et al., 2005). Whole blood or PBMCs were stimulated with PMA and 
Ionomycin, and then incubated with morphine or tramadol for 48 hr (concentrations not 
stated). The ratio of CD4+ T cells with the intracellular cytokines IFN- and IL-2 (TH1 
cells) to CD4+ cells with IL-4 and IL-10 (TH2 cells) was analysed by flow cytometry. 
Morphine, and to a lesser extent tramadol, dose-dependently increased IL-4 and IL-10 
levels, and decreased IL-2 and IFN-, compared with no opioid control groups (effect 
size is not stated). Opioids might thus direct naïve TH cells toward the TH2 phenotype, 
suppressing cell-mediated immunity (Qian et al., 2005). 
 
This study differed from the current study as it used patients (their illness was not 
reported) rather than healthy volunteers. Whole blood as well as PBMCs were used 
and stimulated differently (PMA and Ionomycin vs. IL-2 or anti-CD3/anti-CD28 mAbs), 
and intracellular rather than secreted cytokine levels were measured. These studies 
cannot be directly compared as, surprisingly, the concentrations of opioids that were 
used were not stated. In the current study, neither morphine nor tramadol consistently 
affected the concentrations of any cytokine, which contrasts to the study by Qian and 
colleagues. The difference may be due to the subjects used or the intracellular 
measurement. 
 
Murine splenic lymphocytes and peritoneal macrophages from female B6C3F1 mice 
have been stimulated in vitro by anti-CD3 mAb and incubated for 48 hr with 0.0001 – 
100 M of morphine (equivalent to 0.03 – 28,530 ng/ml) (Thomas et al., 1995a). IL-2 
production was measured using a CTLL-2 proliferation assay, and IL-4 and IL-6 by 
spectroscopy. Only low concentrations of morphine (0.0001 – 0.1 M; equivalent to 
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0.03 – 29 ng/ml) enhanced macrophage production of IL-6, with a maximal effect of 8% 
(which occurred at 0.0001 M). Splenic lymphocyte production of IL-2 was decreased 
(by up to 8%) by occasional concentrations of morphine (0.0001, 1 and 10 M). IL-4 
was unaffected at all concentrations tested (Thomas et al., 1995a). 
 
The effect of 0.0001 – 100 M of methadone (equivalent to 0.03 – 30,940 ng/ml) and 
diamorphine (equivalent to 0.03 – 36,940 ng/ml) on IL-2, IL-4 and IL-6 production has 
been evaluated in female B6C3F1 mice (Thomas et al., 1995b). The opioids were 
cultured with murine splenocytes and thioglycolate-elicted peritoneal macrophages 
which were stimulated for 48 hr with anti-CD3 mAb and LPS, respectively. IL-2 was 
measured using the CTLL-2 proliferation assay and IL-4 and IL-6 by spectroscopy. 
Although the production of IL-2 was slightly, but significantly, suppressed by most 
concentrations of diamorphine (generally by around 10%, maximum 23%) and 
methadone (generally by around 15%, maximum 43%), this did not follow any dose 
relationship. IL-4 production was reduced only by the maximum concentration of 
diamorphine (by 20%) and methadone (by 88%). IL-6 production by LPS-stimulated 
peritoneal macrophages was reduced (by 15%) by 0.001 and 100M of methadone (≈ 
0.3 and 30,940 ng/ml) (Thomas et al., 1995b). 
 
These two studies by the same group incubated cells from different species (murine 
splenic vs. human peripheral blood lymphocytes) with a large range of morphine, 
methadone and diamorphine concentrations which overlapped with those used in the 
current study for a similar duration (2 vs. 3 days). The stimulation used differed (anti-
CD3 vs. anti-CD3/anti-CD28), as did the cytokine detection method. The current study 
did not assess macrophage cytokine production and measurable levels of IL-4 were not 
detected. The only effect seen in both studies was that methadone reduced IL-6 
production, albeit inconsistently in the study by Thomas. 
 
Peng and colleagues assessed the in vitro and in vivo effects of morphine on IL-12 
production (Peng et al., 2000). For the in vitro studies, murine peritoneal macrophages 
from female C3HeB/FeJ mice were incubated with 10-10 – 10-6 M of morphine 
(equivalent to 0.03 – 285 ng/ml) for 2 hr before stimulation with LPS plus IFN- for 48 
hr. IL-12 was measured in the supernatants by an ELISA. In vitro morphine had no 
effect on IL-12 production. For the in vivo study, female C3HeB/FeJ mice were 
implanted with a 75 mg morphine pellet, with or without a naloxone pellet for 48 hr, 
after which peritoneal macrophages were harvested and stimulated in vitro with LPS 
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plus IFN- for 48 hr. Cytokine levels were measured by an ELISA. Morphine increased 
the production of IL-12 (by 4x) and TNF- (by 2x), but inhibited IL-10 production (by 
50%) from peritoneal macrophages. The authors suggested that the modulation of IL-
12 by morphine was not a direct effect on macrophages, and that the enhancement of 
the pro-inflammatory cytokines production by macrophages during morphine treatment 
was due to morphine-induced occult bacteraemia (Peng et al., 2000). This was 
demonstrated in their previous study, in which morphine increased bacteria 
translocating from the gastrointestinal tract, which might act as a stimulus in vivo to 
prime macrophages to increase production of inflammatory cytokines (Hilburger et al., 
1997). 
 
These studies potentially elucidate further differences between the in vitro and in vivo 
effects of morphine as being more than just the neuro-immune mechanisms. This 
makes it very difficult to dissect the mechanisms that underlie the effects that have 
been observed in in vivo models. This study used different species, stimulation and 
measurement compared with the current study, but did not have an effect on IL-12. In 
the current study IL-12p70 was below the detection threshold in all samples analysed. 
 
Rao and colleagues incubated whole blood from seven healthy male and female 
volunteers for 6 hr with morphine (2,000 and 200,000 ng/ml) or fentanyl (20 and 2,000 
ng/ml) in the presence or absence of LPS. IL-6 and TNF- concentrations were 
measured using ELISAs. LPS increased IL-6 and TNF- concentrations. These opioids 
did not affect unstimulated cytokine production. Both concentrations of morphine and 
fentanyl inhibited LPS induced expression of IL-6 (by around 30%) and TNF- (by 
around 60%) (Rao et al., 2004). This could have a detrimental effect on the pro-
inflammatory immune response. 
 
The same group has investigated the effect of fentanyl on LPS-induced IL-6, IL-10 and 
TNF- secretion in whole blood from 10 healthy volunteers (Wu et al., 2009). Whole 
blood was incubated for 6 hr with fentanyl (2, 20 and 200 ng/ml) in the absence or 
presence of LPS. IL-6, IL-10 and TNF- concentrations were measured using ELISAs. 
The production of all three cytokines was increased by LPS. Fentanyl dose-
dependently reduced the production of IL-6 (by up to 85%), IL-10 (by up to 85%) and 
TNF- (by up to 40%) in LPS stimulated, but not unstimulated samples. There was 
variability of both control and opioid tests by up to ± 50% (Wu et al., 2009). By inhibiting 
both pro- and anti-inflammatory cytokines, the net effect of fentanyl might be neutral, 
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however the balance of cytokines in the inflammatory microenvironment is under 
careful control and such significant changes might induce immune dysregulation. 
 
These two studies by the same group used whole blood (as opposed to PBMCs) from 
similar donors, a shorter incubation time (6 vs. 72 hr) and very high opioid 
concentrations which overlapped the highest concentrations used in the current study. 
Different stimuli (LPS vs. IL-2 or anti-CD3/anti-CD28 mAbs) and measurement assays 
(ELISA vs. CBA) were used. Both ELISAs and CBAs are comparable, provided the 
same clones of antibodies are used (Elshal and McCoy, 2006). As in the current study, 
unstimulated cytokine production was unaffected. However, in the current study only 20 
ng/ml of fentanyl decreased IL-6 in IL-2 stimulated PBMCs, and IL-10 and TNF- 
secretion was unaffected by either opioid. This might be due to the different stimulation 
method in whole blood, with LPS binding to TLR4 on macrophages and the release of 
pro-inflammatory cytokines being inhibited by morphine and fentanyl (Hutchinson et al., 
2010). 
 
Bonnet and colleagues incubated PBMCs from 11 healthy volunteers with 10-5 M of 
morphine (equivalent to 2854 ng/ml) for 3 hr, before culture with peptidoglycan for 2 hr. 
TNF and IL-6 were measured using ELISAs (Bonnet et al., 2008). Morphine inhibited 
the production of TNF (by 55%), but not IL-6. The MOR was not involved in this 
morphine-induced TNF inhibition in PBMCs as it was not blocked by CTOP, a MOR 
antagonist (Bonnet et al., 2008). 
 
Bonnet and colleagues used the same cells that were used in the current study, but 
with a shorter incubation time and a higher concentration of morphine. They also used 
different stimulation (peptidoglycan vs. IL-2 or anti-CD3/anti-CD28 mAbs) for a shorter 
duration (2 vs. 72 hr). As in the current study, they showed that morphine did not inhibit 
the production of IL-6. However, TNF production was not inhibited in the current study, 
which may be due to the different stimulation, the duration of incubation or the 
concentration of morphine used. 
 
Peterson and colleagues stimulated PBMCs isolated from six healthy male volunteers 
with Con A for 72 hr with or without 10-8 M of morphine (≈ 3 ng/ml) and measured IFN- 
secretion using a radioimmunoassay. Morphine slightly (by 14%), but significantly 
decreased IFN- production (Peterson et al., 1989). In this similar experiment to the 
current study, Peterson and colleagues incubated PBMCs for the same duration as the 
current study but with a lower concentration of morphine (3 vs 20 ng/ml) and stimulated 
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the PBMCs with Con A (as opposed to IL-2 or anti-CD3/anti-CD28 mAbs). IFN- was 
significantly decreased in this study, although the effect size was small. It was 
statistically unaffected in the current study, although numerically it was increased 
several fold by morphine in the anti-CD3/anti-CD28 mAb stimulated cultures. This 
might be due to the different morphine concentration or stimulation. 
 
Nair and colleagues incubated PBMCs isolated from healthy donors with 10-15 – 10-5 M 
of morphine (equivalent to 3x10-7 – 2,853 ng/ml) for 4 hr (Nair et al., 1997). Cells were 
then infected with Sendai virus and 24 hr later IFN- and IFN- levels were measured 
spectrophotometrically. Morphine inhibited production of IFN- (by up to 93%) and IFN-
 (by up to 95%) by PBMCs. IFN- inhibition was maximal at intermediate doses of 
morphine (10-7 – 10-11 M; equivalent to 0.003 – 29 ng/ml) (Nair et al., 1997).  
 
Although this study used the same cells and a range of morphine concentrations which 
overlapped with the current study, the incubation period and mode of stimulation 
(Sendai virus infection vs. IL-2 or anti-CD3/anti-CD28 mAbs) differed. Interestingly, in 
this study intermediate concentrations of morphine maximally inhibited IFN-. In the 
current study IFN- was below the detection threshold and IFN- was not assessed. 
 
Chao and colleagues incubated PBMCs isolated from eight male and 12 female 
healthy volunteers with 0.1 fM – 10 nM of morphine (equivalent to 3x10-5 – 3 ng/ml) for 
24 hr prior to the addition of LPS or PHA for a further 24 hr (Chao et al., 1993). TNF 
was measured by a cytotoxicity assay using L929 mouse cells. Morphine had no effect 
on TNF production from unstimulated PBMCs. Although there was much interindividual 
variability, morphine reduced TNF production with LPS (by up to 30%) and PHA (by up 
to 50%), but only the inhibitory effect of morphine to the PHA stimulation was reversed 
by naloxone (Chao et al., 1993), indicating a non-opioid receptor mediated effect from 
morphine in LPS stimulated PBMCs. Although not explored in this study it could 
possibly involve TLRs (Hutchinson et al., 2010).  
 
In this experiment the same cells were used as in current study, but were pre-
incubated for a shorter duration with lower concentration of morphine (their maximum 
was about one tenth that used in the current study) before being stimulated with LPS or 
PHA (as opposed to IL-2 or anti-CD3/anti-CD28 mAbs). TNF was measured using a 
cytotoxicity assay rather than an ELISA. Morphine decreased TNF production by 
stimulated PBMCs in this study, whereas it was unaffected in the current study. This 
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could be due to the stimulation used, the concentration of morphine or the duration of 
stimulation. In the current study, pre-incubation with opioids was also assessed, 
however this did not influence the effect of morphine on TNF-.  
 
3.4.3 Conclusion 
The current study analysed how a range of cytokines produced by unstimulated and 
stimulated (both IL-2 and anti-CD3/28 for 3 days) PBMCs from healthy volunteers was 
influenced by eight opioids at four concentrations. Although there were individual 
differences, with some individuals being sensitive to the effects of some opioids, the 
differences noted were more dependent on the individual than the opioid or cytokine 
analysed. There were several statistically significant differences in some of the 
cytokines to some opioids (see section 3.4); however, the only consistent trends were 
that methadone, oxycodone and diamorphine all significantly decreased IL-6 levels at 
several concentrations, which might impact on the acute phase response to infection 
and trauma.  
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CHAPTER 4 
 
4. DISCUSSION 
 
4.1 Introduction 
A range of opioid analgesics are used for the management of patients with moderate to 
severe pain in clinical practice. These opioids exert actions on most organ systems and 
can elicit a range of effects and side-effects. The effects of opioids on the immune 
system might be especially important in patients with cancer, infection and those 
undergoing surgery. Morphine, tramadol, fentanyl, buprenorphine, methadone, 
oxycodone, diamorphine and codeine are some of the most commonly used opioids. 
Although all of these interact with opioid receptors, they have very different 
physicochemical and pharmacodynamic properties which might explain their different 
clinical effects and potentially different immunoregulatory properties. They can also 
have effects via different non-opioid receptors. Furthermore, some opioids might have 
direct effects on immune responsiveness, as morphine, fentanyl, buprenorphine, 
methadone and oxycodone are also TLR4 agonists (Hutchinson et al., 2010).  
 
The key properties of these opioids are: 
 
 Morphine is a naturally-occurring alkaloid, moderately potent hydrophilic MOR 
agonist  
 Tramadol is a synthetic, relatively weak MOR agonist (with 1/6000th the affinity of 
morphine), with noradrenergic and serotinergic re-uptake inhibitory actions 
 Fentanyl is a very potent (over 100x the potency of morphine) synthetic, lipophilic 
MOR agonist 
 Buprenorphine is a synthetic, potent MOR partial agonist, a partial KOR 
antagonist, a DOR antagonist and an ORL1 agonist, without effect on the SNS 
and HPA axis 
 Methadone is a synthetic, moderately potent, lipophilic MOR agonist, with NMDA 
antagonistic properties 
 Oxycodone is a synthetic, moderately potent, hydrophilic KOR and MOR agonist 
 Diamorphine is a synthetically derived lipophilic pro-drug of morphine, which may 
also have a specific MOR subtype to which it can bind 
 Codeine is a naturally-occurring alkaloid, which is converted to morphine to have 
its principal effects 
 
Although studies have previously shown that these opioids have differential effects on 
the immune system, these effects depend on the model being used. Furthermore, none 
of these effects have been directly compared and investigated in a systematic manner.  
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Studies investigating the mechanisms which underlie the immunomodulatory actions of 
opioids suggest that these are manifested via direct effects on immune cell opioid 
receptors (Wang et al., 2002, Wu et al., 2009) and non-opioid receptors (Roy et al., 
1998a, Roy et al., 1998b) as well as via indirect actions that are mediated by the CNS 
(Weber and Pert, 1989). The centrally mediated effects depend on the duration of 
opioid use. In the short term, these depend on the SNS and the systemic release of 
immunosuppressive amines, whereas in the longer term they involve the production of 
glucocorticoids which are induced by the action of opioids on the HPA axis (Mellon and 
Bayer, 1998). 
 
The overall purpose of this PhD programme was to systematically analyse the in vitro 
(direct) effects of commonly used opioids on the aspects of innate and adaptive 
immunity that are involved in anti-tumour immune surveillance and protective immunity 
against viral and bacterial infection. This is the first study to systematically compare a 
range of commonly used opioids at clinically relevant concentrations across a range of 
innate and adaptive immune tests. 
 
Although this is an in vitro study, the aim was to undertake experiments that were as 
relevant as possible to the clinical setting. The concentrations of the opioids used 
throughout the study are representative of those detected in patient groups. Fresh 
human blood was used, albeit from healthy volunteers and not patients. The analysis of 
phagocytosis and oxidative burst responses was undertaken using a whole blood 
approach and phagocytosis was triggered using E.coli bacteria. The analysis of the 
oxidative burst used three stimuli, including E.coli. Although platelet-free PBMC 
preparations were used in order to remove the inhibitory effect of platelet activating 
factor on the NK cell assay, further isolation of NK or T cell populations were not 
performed in order to allow interactions between the different mononuclear cell 
populations. T cells were activated physiologically via the TCR and co-receptor 
signalling using anti-CD3/anti-CD28 mAbs.  
 
Lymphocytes were analysed using multiparameter flow cytometric analysis in order to 
enable specific activation markers on defined NK cells and T cell subsets to be 
evaluated without the need to isolate individual sub-populations. Older studies often 
used tritiated thymidine radioisotope incorporation to detect DNA synthesis, which does 
not allow the responsiveness of individual cell subsets in a more physiologically-
relevant mixed cell population to be monitored. It has been demonstrated that there is a 
good correlation between measurements of proliferation that are made using 
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radionuclide incorporation assays and the measurement of activation on the basis of 
CD69 expression, with the latter being more sensitive (Simms and Ellis, 1996). 
 
A major difference from the clinical situation in which opioids are prescribed was that 
this study used blood from healthy volunteers and it might be that the immune status of 
patients with cancer, infection or inflammatory conditions might influence the 
responsiveness to opioid mediated effects. Furthermore, opioids were not metabolised 
as they would be in vivo and the effect of metabolites could not be evaluated with this 
experimental regimen. Likewise, any potential centrally mediated actions via the SNS 
or HPA axis could not be assessed by these in vitro assays. Notwithstanding these 
limitations, the experimental approach adopted tests the hypothesis that opioids have 
direct, immunoregulatory effects on innate and adaptive immune responses. 
 
 
4.2 Natural killer cell cytotoxicity 
NK cells, which are part of the innate immune system, are important in 
immunosurveillance and control of tumour development and viral infections. They 
constitute about 10 – 15% of the PBMC fraction of whole blood. This study assessed 
the effects of opioids on the activation status (CD69 and CD25 expression) and 
cytotoxic capacity of unstimulated and IL-2 stimulated NK cells. The effects of opioids 
on the activation status of NK cells in anti-CD3/anti-CD28 mAbs stimulated cultures 
were also determined.  
 
None of the opioids at the concentrations tested had any direct effect on the activation 
status or cytotoxic capacity of unstimulated and stimulated human NK cells in the 
PBMC preparations. There was variability between individuals, with occasional effects 
from some opioids on some subjects (section 3.1.6) which most likely resulted from 
phenotypic differences rather experimental variability, as the assay which was used is 
standardised and the activity of NK cells is known to vary between individuals, even 
when directed against the NK cell sensitive K562 cells (Hopkinson et al., 2007). 
 
Although results from in vivo studies in animal, healthy human and patient groups are 
conflicting, in general the published literature reports that morphine (Weber et al., 2006, 
Yeager et al., 1995), fentanyl (Martucci et al., 2004, Shavit et al., 2004), methadone 
(Van Der Laan et al., 1996) and diamorphine (Novick et al., 1989) all decrease NK cell 
cytotoxicity. Buprenorphine does not affect NK cell cytotoxicity (Martucci et al., 2004) 
and tramadol enhances it (Gaspani et al., 2002, Sacerdote et al., 2000). Exceptions are 
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that acute fentanyl in humans increases NK cell numbers and cytotoxicity (Jacobs et 
al., 1999, Yeager et al., 2002), low-dose morphine stimulates NK cell cytotoxicity in 
pigs (Borman et al., 2009) and morphine selectively stimulates peritoneal and 
pulmonary NK cells in rats (Van Der Laan et al., 1996). Interestingly, in a clinical study, 
morphine has been reported to have no effect on NK cell function (Sacerdote et al., 
2000). This change in NK cell cytotoxicity has been demonstrated to correlate with 
tumour growth and metastasis in animal models (Gaspani et al., 2002, Shavit et al., 
2004). Although this might also hold true for patients, the magnitude of change in NK 
cell cytotoxicity which is needed to produce a clinically relevant effect is unknown. 
 
There is no clear clinical correlation between NK cell cytotoxicity and clinical outcome 
to cancer or infection, it is also unclear what change in NK cell cytotoxicity could be 
considered clinically significant. It is therefore difficult to definitively attribute a decrease 
in NK cell cytotoxicity with poorer outcomes in patients with cancer. However, animal 
studies have shown there to be a relationship between NK cell cytotoxicity and cancer, 
in that Gaspani and colleagues showed that tramadol prevents the effect of surgery on 
NK cell cytotoxicity and reduces metastasis in rats (Gaspani et al., 2002). Furthermore, 
Shavit and colleagues have shown that fentanyl decreases NK cell cytotoxicity and 
increases cancer burden in rats (Shavit et al., 2004). NK cell activity is also considered 
to be a critical endpoint in the immunotoxicological evaluation of pharmaceuticals 
(European Medicines Evaluation Agency. Note for Guidance on Repeated Dose 
Toxicity. CPMP/SWP/1042/99. EMEA: London, 2000) and a Consensus Statement 
proposes that the effects of opioids on immune function should be considered, 
recommending buprenorphine over morphine and fentanyl (Pergolizzi et al., 2008).  
 
The results of the current study generally correlate with the previous in vitro studies, 
but conflict with reported effects of opioids in vivo. One of the major limitations of the 
current study is that in whole animal and human studies, the effects of opioids may be 
mediated indirectly by their action on the CNS and release of immunomodulatory 
mediators. From this study, the effects of clinically-relevant concentrations of opioids 
on NK cells are not being mediated by direct effects on these cells. Thus the effects 
opioids have in vivo are more likely to be due to a systemic action (via the SNS or HPA 
axis) and an indirect effect on NK cell cytotoxicity. This would have occurred in the 
volunteer studies in which fentanyl increased NK cell numbers and cytotoxicity (Jacobs 
et al., 1999, Yeager et al., 2002), in the animal studies in which morphine inhibited NK 
cell cytotoxicity (Weber et al., 2006) and in animal and clinical studies in which 
tramadol enhanced NK cell cytotoxicity, (Gaspani et al., 2002, Sacerdote et al., 2000). 
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It is likely that the immune enhancing effects of tramadol are predominant in vivo, as 
tramadol increases serotonin levels by inhibiting its reuptake into cells, having most of 
its effect in the CNS. To have a direct effect on the immune cells in vitro serotonin 
would need to be released in the cell culture and its re-uptake inhibited. Although 
serotonin might be produced by immune cells, it is likely to be more relevant as a 
neuro-immune modulator in vivo (Mossner and Lesch, 1998). 
 
It is important for future work to systematically analyse a range of opioids in in vivo 
models. It would be preferable if these studies were performed in defined patient 
groups, as this would enable evaluation of the indirect, as well as the direct, effects of 
opioids on immune cells, which have been physiologically activated in vivo by disease. 
The findings of such studies would be more readily applicable to patients than further in 
vitro and animal studies. 
 
 
4.3 Neutrophil and monocyte phagocytosis  
Neutrophils and monocytes have a central role in the control of bacterial and fungal 
infections and the removal of foreign particles. After being brought into proximity with 
the pathogen/particle by chemotaxis, they then engulf this material and move it into a 
phagosome for subsequent degradation, a process called phagocytosis. As 
phagocytosis is critical for a number of immunological processes, the effects of opioids 
on neutrophil and monocyte phagocytosis were assessed using concentrations of 
opioids that are consistent with those that are found in patients’ plasma and a 
physiological approach was used for measuring phagocytosis. 
 
Although initial experiments (n=3) showed that morphine, tramadol and fentanyl 
inhibited the ability of neutrophils and monocytes to phagocytose E.coli, this statistical 
significance was negated when subsequent volunteers were added (n=5). This 
prompted the analysis of individual responses to opioids which showed that there is 
marked variation in the sensitivity of phagocytic responses to morphine, tramadol, 
fentanyl and buprenorphine between individual subjects. For these potentially 
suppressive opioids, the interindividual variability was more dependent on the 
individual tested rather than the opioid to which their blood had been exposed. 
 
Overall, although no statistically significant effects were observed, results from the 
current study suggest that morphine, tramadol, fentanyl and buprenorphine had the 
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capacity to inhibit neutrophil and monocyte phagocytosis in some individuals. The 
apparent ability of tramadol to suppress phagocytosis in some individuals has not been 
reported in other studies. It is possible that these opioids could negatively impact on 
the outcome of some patients to bacterial and fungal infections, although this 
hypothesis would need confirmation in clinical studies. Methadone, oxycodone, 
diamorphine and codeine had no consistent effect on phagocytosis in any of the 
subjects tested.  
 
In vivo, morphine has been demonstrated to suppress murine and rabbit phagocytosis 
(Rojavin et al., 1993, Shirzad et al., 2009, Tubaro et al., 1987), although acutely it may 
initially be stimulatory (Pacifici et al., 1994). In rhesus monkeys neutrophil phagocytosis 
was not affected by morphine (Liu et al., 1992). In intravenous drug users morphine 
reduced phagocytic activity (Tubaro et al., 1985). The majority of previous in vitro 
studies have shown morphine to be inhibitory (Beilin et al., 2005, Sowa et al., 1997, 
Szabo et al., 1993), although other studies have shown either no effect (Liu et al., 
1992) or stimulation of phagocytosis by morphine (Lee et al., 1995b, Peterson et al., 
1995). In vitro tramadol had no effect on healthy volunteer phagocytosis (Beilin et al., 
2005), but in vivo enhanced it in mice (Shirzad et al., 2009). Fentanyl has not been 
assessed in this way before, however it has been reported not to affect phagocytosis in 
a healthy volunteer study (Yeager et al., 2002). Methadone has been reported to have 
no effect on phagocytosis in in vitro and in vivo animal models (Molitor et al., 1992, 
Pacifici et al., 1994), but did reduce it at intermediate concentrations in hMDMs 
(Delgado-Velez et al., 2008). Chronic methadone suppressed murine and rabbit 
phagocytosis (Tubaro et al., 1987). In rehabilitated intravenous heroin users who were 
maintained on methadone, there was no effect on phagocytosis (Tubaro et al., 1985). 
Oxycodone, diamorphine and codeine have not previously been studied in this context. 
 
From the current study, future research should initially focus on exploring the 
prevalence of sensitive subjects to morphine, tramadol, fentanyl and buprenorphine. 
Clinical studies should focus on the impact of these four opioids on clinical outcome. If 
in larger studies, these opioids were proven to be inhibitory, further laboratory research 
could try and elucidate the mechanism of action, including studies into phagocyte 
activation, such as effects on CD64 (Fc gamma receptor, which mediates phagocytosis 
of opsonised particles) and CD66 (neutrophil activation marker) cell surface expression 
and the intracellular signalling events that follow cell surface ligation events. 
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4.4 Neutrophil and monocyte oxidative burst reaction 
Following phagocytosis, neutrophils and monocytes generate toxic oxygen free radicals 
as part of the oxidative burst reaction which is aimed at killing phagocytosed 
organisms. This too is an important element of anti-bacterial and anti-fungal defence 
and the influence of opioids on this reaction was evaluated. The oxidative burst 
reaction was stimulated with fMLP (a synthetic, chemotactic peptide which mimics the 
activity of bacterially-derived peptides) which is a mild stimulus, PMA (an activator of 
PKC) which is a potent stimulus and E.coli which is a physiological stimulus of 
moderate potency. fMLP did not induce many of the neutrophils or monocytes to 
undergo the oxidative burst reaction, and of those cells that did, it was at a very low 
level. This weak stimulus was included in the study as it might have enabled opioid-
mediated stimulatory effects to be identified. However, no stimulatory effects were 
detected. 
 
For the neutrophils, the intensity of the oxidative burst response was dramatically 
increased by the PMA stimulus, however no measurable opioid-mediated effects were 
observed. PMA, by activating PKC, might have been too potent a stimulus for the 
opioids to overcome. Opioids also exert some of their intracellular effects by inhibiting 
PKC, although they are likely to be far less potent than PMA. E.coli induced over 80% 
of the neutrophils to undergo the oxidative burst reaction, and this was at an 
intermediate intensity, as defined by the MFI. This was significantly inhibited by 500 
ng/ml of morphine and 20 ng/ml of methadone, and stimulated by 16 ng/ml of codeine. 
However, there were no consistent effects across the range of opioid concentrations 
that were used. For the monocytes, about 50% of cells underwent the oxidative burst 
reaction in response to PMA and E.coli, although the intensity of this reaction was low 
for all stimuli. Although some of the inhibitory effects of morphine, tramadol, fentanyl, 
buprenorphine, oxycodone and methadone on the oxidative burst response induced by 
E.coli were statistically significant, there were no consistent effects across the range of 
concentrations tested and the statistical power of some of the effects was quantitatively 
low.  
 
There were marked differences between individuals, both in their baseline oxidative 
burst response and the effect of certain opioids on the oxidative burst reaction. 
Although not statistically significant, it is possible that, morphine, tramadol, fentanyl, 
buprenorphine and methadone might have an effect on the oxidative burst response for 
certain individuals. Although this was mostly inhibitory, morphine and tramadol 
marginally increased the proportion and intensity of neutrophils and monocytes 
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undergoing the oxidative burst reaction in two of the subjects. The response of an 
individual to these potentially immunologically active opioids, depended more on the 
individual than the opioid, as each individual tended to respond in a similar way to 
these five opioids. None of the subjects had any effect from oxycodone, diamorphine 
and codeine. 
 
Previous in vitro studies have shown that low concentrations of morphine inhibited the 
oxidative burst reaction and killing by neutrophils and monocytes (Liu et al., 1992, 
Peterson et al., 1987). In vivo morphine inhibited murine and rabbit oxidative burst 
activity (Tubaro et al., 1987), and the killing capacity of monkey neutrophils (Liu et al., 
1992). Acute administration of morphine has been shown to stimulate the killing 
capacity of murine neutrophils, although it was inhibited at 24 hr (Pacifici et al., 1994). 
In opioid addicts, morphine reduced the ability of neutrophils and monocytes to kill, 
whereas superoxide anion production is only decreased in neutrophils (Tubaro et al., 
1985). Fentanyl did not affect neutrophil oxidative burst responses in healthy 
volunteers (Jacobs et al., 1999, Jaeger et al., 1998). Both in vitro swine, and in vivo 
murine and rabbit studies have reported methadone to suppress the oxidative burst 
reaction (Molitor et al., 1992, Tubaro et al., 1987), although this was unaffected in 
another murine study (Pacifici et al., 1994). In intravenous drug users, methadone 
reduced the ability of neutrophils and increased the capacity of monocytes to kill, 
whereas superoxide anion production was decreased only in neutrophils, but to a 
lesser degree than with morphine (Tubaro et al., 1985). 
 
In summary, none of the opioids tested in the current study had a consistent 
statistically significant effect on the oxidative burst reaction of neutrophils and 
monocytes when they were stimulated with fMLP, PMA or E.coli. However, when E.coli 
was used as the stimulus, morphine, tramadol, fentanyl, buprenorphine and methadone 
were inhibitory for some individuals. If these results were to hold true in in vivo studies, 
then these data suggest that opioid choice might influence oxidative burst capacity and 
this could impact on an individual’s susceptibility to bacterial and fungal infections. 
However, this hypothesis would need confirmation in clinical studies, which should 
focus on these five opioids and evaluate the prevalence of their immune effects and 
how they impact on clinical endpoints as well as their mechanism of inhibition, possibly 
via TLRs. 
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4.5 T cell activation 
T cells are part of the regulatory arm (CD4+ cells) and cytotoxic arm (CD8+ cells) of the 
adaptive immune response. CD4+ cells are critical in ensuring that the rest of the 
immune system produces an appropriate response to pathogens without causing 
inappropriate damage to host tissue. CD8+ T cells form part of this effector response. 
The activation of both of these T cell types is critical in the maintenance of an intact 
immune system and interference with this could be detrimental to the host.  
 
The effect of opioids on the activation status of T cells was evaluated in several 
experimental regimens. Isolated PBMCs were incubated with Miltenyi anti-CD3/anti-
CD28 mAb-coated beads, added before, at the same time as or after the opioids, and T 
cell activation status was evaluated by measuring CD69 and CD25 expression, 
determined by flow cytometry. There was good activation of both CD4+ and CD8+ T 
cells by the beads but none of the opioids had a consistent effect on their activation.  
 
Previous in vitro studies are sparse, but despite using very different methodologies, 
they generally agree with the current study, in that T cell-mediated cytotoxicity of 
murine spleen cells is unaffected by clinically relevant concentrations of morphine, 
methadone and diamorphine (House et al., 1995, Thomas et al., 1995a, Thomas et al., 
1995b). However, in one study morphine inhibited the proliferation of murine lymph 
node T cells (Wang et al., 2001). There have not been any studies using human cells. 
  
The in vivo effects of morphine, tramadol, fentanyl, methadone and diamorphine on T 
cell function have also been assessed. In mice, morphine caused atrophy of the spleen 
and thymus, decreased mitogen-stimulated T cell proliferation and reduced the thymic 
CD4+:CD8+ cell ratio (Bryant et al., 1987, Bryant et al., 1988, Fecho et al., 1996, 
Gaveriaux-Ruff et al., 1998, Singhal et al., 1998, Weber et al., 2006). Morphine has 
also decreased splenic and peritoneal cytotoxic T cell activity (Carpenter et al., 1995, 
Carpenter et al., 1994). In rats, morphine has been shown to suppress mitogen-
stimulated splenic T cell proliferation, (West et al., 1997). In healthy volunteers, 
fentanyl increased in the percentage of CD8+ cells in the circulation in one study 
(Yeager et al., 2002), but not in another (Jacobs et al., 1999). One drug addiction study 
reported that diamorphine increased lymphocyte numbers and that methadone had no 
effect (Novick et al., 1989). In a surgical study, morphine suppressed T cell proliferation 
more than tramadol (Sacerdote et al., 2000). 
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There have not been enough previous in vitro or in vivo studies into the effects of 
opioids on T cells to draw any definitive conclusions. However, the current study did 
not detect any direct effects of opioids on T cells and it is likely that the effects detected 
in vivo are by indirect mechanisms, via central pathways, such as the SNS and HPA 
axis. This is in contrast to the detection of opioid receptors on activated T cells (Kraus, 
2009), although there is some debate as to the presence of these receptors on T cells 
(Williams et al., 2007) and the presence and function of opioid receptors can be difficult 
to determine in the immune system as they are in much lower numbers than in the 
CNS (Borner et al., 2007), reviewed in section 1.6. Comparative clinical studies are 
essential in order to establish if opioids influence T cell function and if so, the relative 
impact of each opioid. These would ideally include surgical and substance abuse 
groups, as well as patients with cancer and infection. 
 
 
4.6 Cytokine production 
Cytokines are cell signalling molecules which are used, amongst other functions, to 
regulate immune function. They are secreted by a wide range of cells types and their 
concentration can increase by several orders of magnitude during immune system 
activation. In the current study, the effect of clinically relevant concentrations of the 
opioids was assessed on the production of IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, 
IL-17A, IFN-, IFN-, TNF- and IP-10 in unstimulated, IL-2 stimulated and Miltenyi 
anti-CD3/anti-CD28 mAb coated bead stimulated PBMCs, using BD Bioscience CBAs 
and a BD FACSArray™ flow cytometer. 
 
The current study revealed several statistically significant effects from opioids on 
cytokine production, but the only consistent effect was that several concentrations of 
methadone, oxycodone and diamorphine significantly decreased IL-6 concentration. 
Although IL-6 is often considered a pro-inflammatory cytokine and its levels are 
correlated with the acute phase reactant, CRP (Heikkila et al., 2007), it can also have 
anti-inflammatory effects (Xing et al., 1998). This makes it difficult to predict what the 
net effect of these opioids would be. They are however likely to reduce the acute phase 
inflammatory response and might therefore impair the immune response to infection. 
As IL-6 also influences lipid (Pedersen, 2011) and bone metabolism (Eriksen et al., 
2010), any inhibition of its production could have downstream effects on several organ 
systems. 
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In the current study, there were differences between individuals in cytokine production, 
both at baseline and to the opioids. However, the differences in response reflected 
more on the individual than on the opioid tested, with some individuals being sensitive 
(either stimulated or inhibited) to a range of opioids and other being resistant. This is 
explored in the following section. 
 
From the previous studies described earlier, morphine generally decreased the 
production of IL-1, IL-2, IL-4, IL-6, IL-12 and IFN- in mice (Bhargava et al., 1994, 
Martucci et al., 2007, Roy et al., 1998a, Wang et al., 2002). Whereas they show mixed 
effects of morphine on IL-10 and TNF levels (Martucci et al., 2007, Wang et al., 2002). 
Fentanyl decreased IL-2 and IFN- production in mice, whereas buprenorphine had no 
effect (Martucci et al., 2004). Codeine increased the production of IL-8 and TNF- in 
human derived mast cells (Sheen et al., 2007). Diamorphine addicts exhibit lower IL-4, 
IFN- and TNF- levels, normal IL-2 levels and increased IL-10 levels (Azarang et al., 
2007), these were normalised by methadone and buprenorphine treatment (Sacerdote 
et al., 2008). In post-operative studies, morphine has been shown to inhibit IL-2, 
whereas this was unaffected by fentanyl and either unaffected or increased by 
tramadol (Liu et al., 2006, Wang et al., 2005a). 
 
From these heterogeneous studies in a variety of models, it appears that morphine has 
mixed effects on pro- and anti-inflammatory cytokines in mice, making it difficult to draw 
definitive conclusions about its overall effect. However, it did decrease IL-2 production 
following surgery (Liu et al., 2006) and this could potentially be clinically deleterious as 
IL-2 stimulates the proliferation, differentiation and survival of lymphocytes. Although 
the data on the other opioids are sparse, buprenorphine is likely to be immune neutral 
in terms of cytokine production and tramadol enhances IL-2 levels and could even have 
beneficial clinical effects. These sporadic clinical findings would need confirmation in 
long term patient studies.  
 
It is important that the effect of these opioids are assessed on a range of cytokines in 
various clinical scenarios in which immune regulation is critical, as in patients with 
cancer, infection and autoimmune disease.  
 
  
254 | P a g e  
 
4.7 Individual variability 
In the current study none of the opioids at the concentrations tested had a consistent 
statistically significant effect on immune function (apart from methadone, oxycodone 
and diamorphine inhibiting IL-6). There were however variable effects between 
individuals both in their baseline immune function and in their responses to the different 
opioids, this was more pronounced with the phagocytosis and oxidative burst assays. 
These findings concur with the clinical observations that the analgesic and toxic effects 
of opioids vary markedly between individuals (Campa et al., 2008, Oertel et al., 2006, 
Rakvag et al., 2005, Somogyi et al., 2007). This could arise from multiple single-
nucleotide polymorphisms (SNPs), and the potential genetic and molecular basis 
underlying this is explored below. 
 
The multifactorial nature of pain and its expression makes it difficult to quantify the 
genetic influences on the analgesic response which are reported by the patient. The 
total opioid doses that are needed for analgesia are often used in studies assessing the 
effect of genetic variations on pain. In the studies outlined below, total opioid doses are 
sometimes used as a surrogate for analgesic response of individuals. As these studies 
are assessing the effect of a limited number of SNPs, a major limitation is that the other 
variable genetic (and environmental) factors will induce further variability, also 
confounding this measurement. 
 
In addition to patients exhibiting large variations in their response to opioids, it should 
be noted that these drugs also have a narrow therapeutic index (Somogyi et al., 2007). 
The pharmacokinetics and pharmacodynamics of opioids are regulated by genetic 
factors which contribute to this variability. There are many variants within the MOR 
gene, OPRM1, the most studied being the c.118A>G SNP. Healthy volunteers with one 
or two copies of the G allele experience ~33% of the analgesic effect of alfentanil to 
experimental pain and ~10% of the respiratory depressant effect of this opioid, 
compared to people with no copies of the G allele (Oertel et al., 2006).  
 
The c.118A>G SNP was studied in patients with cancer on morphine. Four patients 
who had two copies of the G variant allele required a higher dose (mean ± SD; 225 ± 
143 mg/day) compared to 17 patients with one copy of the variant (66 ± 50 mg/day) or 
78 patients with no copy (97 ± 89 mg/day) (Klepstad et al., 2004). However, the 
number of homozygous variants was small and there was a large variability in dosages 
between patients. 
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In a study of the c.118A>G SNP in 175 patients with cancer pain being initiated on 
morphine, the G variant allele number had no effect of on the opioid dose. However, 
after one week patients with two copies of this allele experienced a smaller change in 
pain (mean 0.2 unit change on an 11 point scale), compared to those with one copy 
(1.8 unit change) and those with no copies (3.8 unit change) (Campa et al., 2008). 
 
The c.118A>G SNP G variant allele occurs in 10 – 15% of Caucasians and almost 50% 
of Asians (Tan et al., 2009). In a study of post-operative pain in almost 1,000 women 
undergoing elective caesarean section under spinal anaesthesia from Singapore, the 
morphine dose (adjusted for weight) in the homozygous variant (GG) group was 10.9 
g/kg, almost twice that of the wild-type (AA) group, 5.8 g/kg. Usage was intermediate 
(8.8 g/kg) in the heterozygotes (AG) (Tan et al., 2009).  
 
In a meta-analysis the c.118A>G SNP showed no consistent association with 
phenotype (Walter and Lotsch, 2009). However, the studies that were included 
originated from diverse patient groups, including chronic cancer and non-cancer pain, 
as well as post-operative and labour pain, often with small numbers of patients.  
 
The COMT (catechol-O-methytransferase) enzyme system metabolises 
catecholamines (noradrenaline, adrenaline and dopamine). In animal models, COMT 
inhibitors are pronociceptive in acute and inflammatory pain (Kambur et al., 2010). The 
Val158Met polymorphism of the human COMT gene influences morphine requirements 
in cancer pain patients, with the Met form being less active (Rakvag et al., 2005, 
Rakvag et al., 2008). COMT knockout mice are more sensitive to nociceptive stimuli, 
whereas mice with a high COMT activity have a decreased sensitivity to pain (Kambur 
and Mannisto, 2010). Low COMT activity, associated with the met allele, increases the 
availability of opioid receptors and might enhance opioid analgesia in cancer pain 
(Kambur and Mannisto, 2010). In 207 patients with cancer, those with the Met-Met 
genotype required less morphine (mean ± SD; 95 ± 99 mg/day) than those with the 
Met-Val genotype (117 ± 100 mg/day). Those with the Val-Val genotype required the 
highest doses of morphine (155 ± 160 mg/day) (Rakvag et al., 2005).  
 
P-glycoprotein is a member of the ATP-binding cassette (ABC) efflux transporters, 
which is in the blood-brain barrier and limits the entry of certain opioids (morphine, 
fentanyl and methadone) into the CNS (Mercer and Coop, 2010). In acute pain, a 
variant of the gene that encodes for p-glycoprotein (ABCB1) has been shown to cause 
more respiratory depression following a single intravenous dose of fentanyl (Park et al., 
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2007). Haplotype (multiple SNP) analysis for ABCB1 has shown that dosage 
requirements of methadone in opioid dependence maintenance treatment were related 
to the number of copies of the variant haplotypes c.3435C>T and c.2677G>T. Patients 
with two wild-type alleles required twice the methadone dose compared to those with 
both variant alleles (Coller et al., 2006). In 175 patients with cancer pain starting on 
morphine, patients with two copies of the ABCB1 variant allele c.3435C>T experienced 
an increased analgesic effect with a decrease in pain score of 4.4 (on an 11 point 
scale), compared to those with one variant whose decrease in pain score was 3.2 and 
those with wild-type with a decrease in pain score of 2.3 (Campa et al., 2008).  
 
The combination of variants in OPRM1 and ABCB1 can have opposite effects on the 
effect of opioids, including analgesia. Thus, the overall analgesic response in an 
individual will depend on which combination of these two genetic variants are present. 
Campa and colleagues showed that the best response to morphine in patients with 
cancer was in those with a combination of wild-type OPRM1 plus ABCB1 variant with a 
4.8 unit change in pain score and the worst response was in those with a combination 
of OPRM1 variant and wild-type ABCB1 with a 1.3 unit change in pain score (Campa et 
al., 2008).  
 
Opioids that are O-demethylated to more potent opioid metabolites by the polymorphic 
CYP2D6 enzyme, such as codeine to morphine, tramadol to O-desmethyltramadol and 
oxycodone to oxymorphone, have variable effects in subjects with mutations in the 
CYP2D6 gene (de Leon et al., 2003, Maddocks et al., 1996, Somogyi et al., 2007). 
These mutations may result in the poor metaboliser (PM) phenotype which comprises 
about 7% of the Caucasian population who do not convert the opioid to the more active 
form, or ultrarapid metabolisers (UM), comprising about 2% of Caucasians, having 
multiple copies of the CYP2D6 gene, who rapidly produce the more potent opioid. In 
UMs, more adverse effects have been reported due to increased conversion of codeine 
to morphine (Dalen et al., 1997). Adverse CNS reactions to oxycodone have been 
reported in patients with the UM phenotype (de Leon et al., 2003). CYP2D6 PMs 
administered codeine had a reduced analgesic response to experimental pain and less 
respiratory depression (Somogyi et al., 2007). In post-operative patients, there has 
been shown to be a higher number of non-responders to tramadol among PMs (81%) 
compared to extensive metabolisers (17%) (Stamer et al., 2007). In a small study with 
oxycodone, the patient who required the highest dose of oxycodone and the most 
breakthrough analgesia was the only PM (Maddocks et al., 1996). 
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GTP cyclohydrolase 1 (GCH1) is the rate-limiting enzyme in the synthesis of 
tetrahydrobiopterin, a cofactor in the biosynthesis of serotonin, noradrenaline and NO. 
In over 250 patients with cancer, a reduced-function GCH1 variant delayed the onset of 
pain and need for opioid therapy (Lotsch et al., 2010). In an observational study of 100 
patients, associations between COMT, MOR and GCH1 genes and the development of 
pain 3 months after third molar extraction showed that seven patients experienced 
persistent pain. There were associations between SNPs in these genes, post-operative 
pain and effect of analgesia. In patients after surgery, the number of days until effective 
analgesia was associated with GCH1 SNPs (Lee et al., 2011). 
 
In summary, people with the OPRM1 gene variant c.118A>G SNP have a reduced 
response, those with variants in the p-glycoprotein efflux transporter gene ABCB1 have 
an enhanced response and those with CYP2D6 gene mutations can have a variable 
response to certain opioids (Coller et al., 2009). Reduced function of GCH1 tends to 
reduce pain and opioid use and patients with the COMT SNP c.474G>A require less 
morphine. However, the clinical usefulness of pharmacogenetic testing for predicting 
analgesic response to opioids remains uncertain (Peiro et al., 2010). 
 
Although just a few of the most common mutations have been covered here, there are 
numerous other genetic factors which can affect the analgesic and adverse effect 
profile of the different opioids used clinically (Droney et al., 2011, Kadiev et al., 2008, 
Ross et al., 2006). There is so much genetic variation that when studied together the 
effect of an individual SNP may be impossible to determine, especially as some of the 
variants increase response to a particular opioid and others reduce it. A recent study in 
over 2,000 cancer pain patients found no relationship between doses of opioids and 
112 SNPs in 25 genes involved in the effect of opioids and pain. (Klepstad et al., 2011). 
 
In addition to differences at the genetic level potentially having a vital role in individual 
responses to opioid effects, there is also evidence that interindividual variation in 
responses to opioids can occur at a molecular level due to differing receptor 
dimerisations (Chakrabarti et al., 2010). Dimerisation can be between opioid receptors 
of the same class (i.e. two MORs – homodimerisation) or between opioid receptors of 
different classes (i.e. MOR and KOR – heterodimerisation) and this changes the 
activation and response of these receptor compounds to opioids (Chakrabarti et al., 
2010, Faras-Melainis et al., 2009, Rozenfeld and Devi, 2007).  
 
 
258 | P a g e  
 
Variability between subjects has been alluded to in previous immunological studies 
although it is rarely directly reported. Jacobs and colleagues assessed the in vivo 
effects of fentanyl on NK cells in volunteers. Fentanyl increased the number of 
circulating NK cells by more than 250% in four out of seven subjects. Naloxone was 
administered to these four volunteers, which blocked the increase in NK cells in only 
two of these subjects (Jacobs et al., 1999). A study assessing the effect of morphine on 
the release of TNF from PBMCs isolated from healthy volunteers has also alluded to 
variability between subjects. They showed that individuals differed in both their 
baseline TNF production (to LPS and PHA) and in the sensitivity of this to the 
suppressive effects of morphine (Chao et al., 1993). In a study assessing PHA and 
LPS stimulated IFN- and IL-10 production in whole blood from healthy controls and 
heroin (diamorphine) addicts, there was marked variability in the production of these 
cytokines in both groups (Azarang et al., 2007). In healthy volunteers, as well as in 
morphine and methadone treated drug addicts, there was large variation between 
individuals in their neutrophil and monocyte phagocytic and oxidative burst capacity 
(Tubaro et al., 1985). Yeager and colleagues investigated the in vitro effect of -
endorphin on NK cell cytotoxicity and showed that 26 of the 34 subjects had an 
enhancement of NK cell cytotoxicity, only these subjects were used for the subsequent 
analysis of the interaction of -endorphin with morphine, in a type of enrichment 
methodology (Yeager et al., 1992). In rhesus monkeys, the in vivo inter- and intra- 
individual variability in neutrophil phagocytosis was up to 50% over the 30 week study. 
There was also a variable effect of morphine with some monkeys showing inhibition at 
some time points and others showing an increased phagocytic capacity, although this 
was not consistent over time (Liu et al., 1992). 
 
In clinical studies of analgesics, an enrichment methodology is sometimes used to 
select those patients who respond to a drug and only putting these responders into the 
main drug trial (Gilron et al., 2011, Hale et al., 2010, Schwartz et al., 2011), illustrating 
the interindividual response to analgesics in various clinical settings. 
 
In both animal and human studies, gender also affects the sensitivity to pain and the 
responsiveness to treatment, with differences in the effects of opioids between 
individuals (Andreassen et al., 2011, Mogil and Bailey, 2010, Paller et al., 2009). This 
may in part be due to sex hormones which have a complex role in inflammatory 
processes and the pain response (Manson, 2010), the types of opioid receptor present 
(Chakrabarti et al., 2010) and the effects of KOR agonists (Lawson et al., 2010).  
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Many animal studies use a single strain of a species, which is likely either to respond to 
opioids or not. This is certainly true in pain research, with different animal strains 
exhibiting a different response to opioids pain (Lariviere and Mogil, 2010). This is 
compounded, as the sensitivity to pain varies depending on the social context with 
social threat modulating pain behaviour in a sex-specific manner, even in mice 
(Langford et al., 2011). It is likely only those that have an effect from opioids will be 
published and further researched. 
 
The effect of morphine on different types of pain is variable between mouse strains 
(Lacroix-Fralish and Mogil, 2009). This variability has also been reported for social 
investigation behaviour (social responsiveness and motivated behaviour), especially 
during adolescence (Kennedy et al., 2011). It may be that the different effects between 
species and even individual strains are due to alterations in the endogenous opioid 
systems. Studying a single inbred strain removes the variability which was seen in the 
current study and clinically, allowing for specific genetic variability to be assessed. 
However, it does not reflect the vast genetic differences that lead to different responses 
between patients.  
 
In the current study there was variability between the different subjects, but as their 
immune function was only evaluated once, this will need verification. All the assays will 
have some intrinsic variability, as will the subjects, so confirmation of this potential 
effect is essential. Much of the variability did not follow a consistent pattern across 
different opioid concentrations and although this could represent a u or n shaped 
effect, at this stage it has to be considered that opioids have no overall net in vitro 
effect.  
 
There was a trend for many of the immune function tests performed (i.e. phagocytosis 
and oxidative burst) to be influenced more by the individual than the opioid, leading to 
no clear effect between subjects and no statistical significance when the data were 
combined for analysis. Although diamorphine and codeine did have some small direct 
effect on immune cells, it is likely in vivo these will have the same effect as morphine. 
Methadone and oxycodone were generally immune neutral for most subjects and any 
effects they did have were quantitatively very small. If these results were replicated 
clinically, it might be that these would be immunologically safer options.  
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4.8 Effect of pain on immune function 
From a clinical perspective, it is believed that pain itself is immunosuppressive (Page, 
2003, Page et al., 2001) and that the reduction of pain might also attenuate an 
immunosuppressed state (Gaspani et al., 2002). In the case of potentially 
immunosuppressive opioids, there will undoubtedly be a complex balance between the 
immunosuppressive effect of the opioid and the reduction of putative 
immunosuppression of pain (Figure 4-1) (Page, 2005, Rittner et al., 2008). As 
cytokines not only influence immune activity, but also modulate pain signalling (Gordin, 
2010, Hutchinson et al., 2008), and with immune cells producing endogenous morphine 
when activated (Glattard et al., 2010), there are likely to be complex tri-directional 
interactions between pain, analgesia (especially opioids) and the immune response. 
 
 
Figure 4-1: Complexity of the action of opioids on immunity and cancer.  
a) Pain is immunosuppressive and may worsen outcome in cancer and infection (Page, 2003, Page et al., 
2001). b) Opioids, by reducing pain, might have a beneficial effect on immune function, cancer and 
infection (Gaspani et al., 2002, Page, 2005). Some opioids might have a suppressive effect on immune 
function; this may in turn decrease anti-tumour and anti-infective immunity and promote the development 
of cancer or infection (Shavit et al., 2004, Wang et al., 2008). The balance between the immune enhancing 
and suppressing effects of prescribed opioids is therefore complex (red arrows represent a detrimental 
effect and blue arrows a beneficial effect).  
 
In a retrospective analysis of two clinical trials of patients with cancer cachexia, the 
relationship between cancer pain and systemic inflammation (measured by CRP) was 
evaluated. Pain (using the pain subscale of the European Organisation for Research 
and Treatment of Cancer Quality of Life Questionnaire C-30) was statistically 
correlated with CRP (Laird et al., 2011).  
 
In male Wistar rats administered chronic morphine, spinal IL-1, IL-6 and TNF- gene 
expression was increased (Shen et al., 2011). These pro-inflammatory cytokines were 
normalised by TNF- blockade with etanercept acting on microglia, as determined by 
spinal cord immunocytochemistry. Etanercept also reduced tolerance and restored the 
antinociceptive effect of morphine (Shen et al., 2011). Opioids, by acting on glial TLR4, 
can antagonise their own neuronal MOR-mediated analgesic effect and increase opioid 
a) 
b) 
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tolerance (Watkins et al., 2009). Glial TLR4 are also involved in neuropathic pain. Thus 
the beneficial effects of opioids (mediated via the opioid receptor) may have a different 
mechanism from some of the unwanted toxicities (TLR4 and glial mediated) and this 
leads to further potential interactions between opioids, pain and the immune system 
(Watkins et al., 2009).  
 
Several retrospective clinical studies assessed the opioid-sparing effect of regional 
analgesia with general anaesthesia on the recurrence rate in the surgical removal of 
tumours. Exadaktylos and colleagues looked retrospectively at 129 medical records of 
patients that had undergone mastectomy for primary breast cancer and found lower 
cancer recurrence and metastasis at 3 years in patients receiving paravertebral 
analgesia with general anaesthesia compared to those that that had received general 
anaesthesia alone (Exadaktylos et al., 2006). Biki and colleagues showed that in 225 
patients undergoing radical prostatectomy, general anaesthesia with epidural analgesia 
(as opposed to systemic opioids) was associated with a lower risk of biochemical 
cancer recurrence (prostate-specific antigen increase), over 3 – 13 years (Biki et al., 
2008). In 177 patients undergoing colonic cancer resection, epidural analgesia with 
general anaesthesia increased survival rate in patients with non-metastatic, but not 
metastatic, disease (Christopherson et al., 2008). However, several other retrospective 
studies have not shown any recurrence or mortality benefits for regional analgesia in 
prostate, colorectal, and cervical cancers even though there was a reduced need for 
postoperative opioids (Gottschalk et al., 2010, Ismail et al., 2010, Tsui et al., 2010). A 
prospective multicentre randomised, controlled clinical trial of 503 patients undergoing 
abdominal surgery for cancer resection, compared the effect of general anaesthesia 
with either epidural analgesia or postoperative systemic opioids. This showed no 
difference between the two groups in cancer recurrence and mortality at 2 – 3 years 
(Myles et al., 2011). 
 
Although there are many potential toxicities associated with opioids (outlined in Table 
1.1) and each of the opioids can produce any of these toxicities, it is likely that certain 
opioids cause some toxicities more than others. We have some understanding of the 
relative risk of some opioids in certain patient groups for some of their toxicities, i.e. 
fentanyl is less constipating and less sedating that morphine, and there is a difference 
in response between patients with cancer pain and non-cancer pain (Clark et al., 
2004). However, the relative adverse effect profile for each opioid for the whole range 
of toxicities still needs to be elucidated, this is particularly true for the immunological 
effects of the opioids. 
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There is likely to be a different risk:benefit ratio for the clinically used opioids for 
different patients. In the context of this study there will be patients who need an opioid 
analgesic and in whom immune suppression would be very detrimental (i.e. some 
patients with cancer or infection and pain). For these patients, potential immune effects 
from opioids could form a necessary part of the decision making process in analgesic 
prescribing. 
 
 
4.9 Limitations of study 
Although this is a comprehensive study of a range of opioids on several aspects of 
immunity, several key factors currently limit its impact on clinical practice. Despite using 
physiologically-relevant concentrations of opioids, this is an in vitro study using healthy 
volunteers which does not take into account the existing immune status of individual 
patients, the influence of drug metabolism or effects that involve the SNS and HPA 
axis. It is also unknown what in vitro effect size might correlate to a potential clinical 
effect. 
 
With regards to the NK cell cytotoxicity assay, a potential limitation was that this was 
based on the killing of NK cell sensitive K562 cells, which were used as these cells are 
MHC class I negative and can be used as targets for NK cells in PBMC preparations. 
Although the use of appropriate solid tumour cell lines that have variable sensitivities to 
NK cells could have been used, some of these are MHC class I positive and therefore 
sensitive to CD8+ T cells in the PBMC preparation. The use of such targets would 
require the isolation of NK cells from PBMCs. The removal of opioids from the PBMCs 
before incubation with the K562 cells (to ensure the opioid did not affect K562 cells) 
might also influence the NK cells by causing opioid withdrawal. 
 
The T cell studies assessed the effect of opioids over several days and opioids might 
only transiently affect immune function by inducing receptor desensitisation and down 
regulation. Thus, the acute effect of opioids on immune cells could be very different 
from those applied over days (Bidlack et al., 2006). However, opioids are often 
prescribed to patients over days or often much longer and if immune tolerance occurs 
to opioids, then this is less likely to be a clinically significant problem in patients on 
regular opioids. It may, however, be problematic to patients given short term opioids, 
for trauma or surgery. 
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Another potential limitation is that activation markers were used to assess T cell 
activation rather than using functional tests. However, a profile of cytokines was also 
analysed to give a balanced picture of T cell activation; additionally previous studies 
have correlated activation marker expression with T cell proliferation (Maino et al., 
1995, Mardiney et al., 1996, Simms and Ellis, 1996). Although using activation marker 
expression with multiparameter flow cytometric analysis did not give a direct measure 
of cell proliferation, it allowed the activation of lymphocyte subsets to be analysed 
simultaneously. 
 
Although the majority of previous in vivo studies show that opioids have an effect on 
some aspects of immune function, many in vitro studies show no effect from opioids at 
clinically relevant concentrations, and often those that show an effect used inbred 
animals. It is not possible to draw clear, statistically supported, conclusions between 
the opioids in the current study due to variability between the subjects being used in 
the study. The effect of all of the opioids on the range of immune assays could be 
assessed in larger numbers of subjects, but they are all likely to be variable and thus 
the clinical relevance of this would not inform decision making for any individual patient. 
 
A key finding of this study is the differential sensitivities of the subjects to the 
modulatory effects of the opioids. However a major limitation with this is that each 
subject has only been tested once, with the results from several subjects being pooled 
for the analysis. As individual differences were potentially detected, confirmation of this 
effect over time in the same individuals would be needed. 
 
Being a small study, this could have led to the analysis being underpowered and 
caution is needed as to not over-interpret the results. However, retrospective power 
and sample size calculations have been performed for those assays for which opioids 
potentially showed an effect and some of these calculations have a power greater than 
80% and a sample size compatible with that performed. Other experiments, which did 
not seem to show an effect of opioids, are very poorly powered and would need many 
samples to confidently show significance or non-significance. However, the need for 
very large sample sizes draw into doubt the clinical relevance of any observed effect at 
the patient level. 
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4.10 Potential impact of this study 
Currently, opioids are primarily prescribed on the basis of their overtly clinically 
recognisable toxicities (i.e. sedation, constipation, nausea and vomiting) and the 
preferences of the clinical team, which may be based on familiarity and cost. The 
findings that opioids differentially influence neutrophil and monocyte phagocytosis and 
oxidative burst and IL-6 production for some subjects, means that if these in vitro 
results are replicated in vivo, then opioid choice would have to take into account the 
immune status and risk for certain patients, including those with bacterial infection. 
 
If opioids do indeed affect immune function and this in turn influences infection or 
cancer progression, then the prescription of opioids should be based on a better 
understanding of their immunobiological properties. Although the clinical impact of 
opioids on immune function cannot yet be quantified (Manchikanti et al., 2011), clinical 
guidelines now include a consideration for opioid mediated immune suppression 
(Pergolizzi et al., 2008). 
 
In the previous literature, there have been many differences in the methodologies used 
between the studies, including: incubation times and concentrations of opioids; opioid 
tolerance/withdrawal; peripheral blood vs. splenic/peritoneal cells; isolation of specific 
cells vs. PBMCs vs. whole blood; the cell isolation method; baseline activation status; 
stimulation methods at variable concentrations and durations; animals/species; male 
vs. female. Furthermore, there are variances in methodology for each assay type, i.e. 
for NK cell cytotoxicity differences between previous studies include: E:T ratios; total 
cell numbers; effector cells; target cells; incubation times and methods of measuring 
NK cell cytotoxicity. Unfortunately, not all studies mention all the relevant variables in 
their methodology which makes it even more difficult to compare and extrapolate their 
results. 
 
This is the first study to systematically assess the in vitro effect of a range of opioids on 
both innate and adaptive immunity using standardised assays, and is the first to have 
evaluated the immune effects of certain opioids, such as oxycodone. It has highlighted 
that morphine, tramadol, fentanyl and buprenorphine could be more likely to inhibit 
phagocytosis in some individuals; and that morphine, tramadol, fentanyl, 
buprenorphine and methadone could inhibit the oxidative burst reaction of neutrophils 
and monocytes in some individuals (statistically oxycodone was also inhibitory but this 
was quantitatively very small). It also demonstrated that methadone, oxycodone and 
diamorphine inhibited IL-6 production in IL-2 stimulated PBMC cultures, which could 
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compromise the acute phase response to infection. This study has also reinforced the 
need to systematically analyse a range of opioids in in vivo models as it is likely that 
the indirect effects of opioids are essential to evaluate, along with their direct effects. 
 
One advantage of studying opioids in vitro is that it reduces many of the influences 
relating to the enzymatic metabolism of drugs (e.g. codeine by CYP2D6) and the 
transport of drugs (e.g. fentanyl by p-glycoprotein) which cause interindividual 
variability. Other factors such as renal function (relevant in the elimination of many 
opioids), liver function (important for the elimination of oxycodone) and interactions with 
other drugs (such as those that induce or inhibit the cytochrome P450 enzymes) are 
eliminated in vitro. Although this means that in vitro data may not be directly applicable 
to patients, it does enable a more focused assessment of specific elements of a 
biological effect and provides insight into the comparative influence of the opioids. 
 
This systematic in vitro study, using cells from healthy humans, provides a “clean” 
baseline from which future clinical studies can be compared. In patient studies, there 
are many potential modulations of the immune system caused by different diseases, 
presence of infection and effects of treatment (i.e. chemotherapy). 
 
In previous studies variability has been alluded to, but is rarely reported, even though 
there are large error bars, even when SEM is being reported (Azarang et al., 2007, 
Beilin et al., 2005, Chao et al., 1993, Jacobs et al., 1999, Tubaro et al., 1985). Many of 
the animal studies used inbred animals, which are genetically similar, leading to less 
variability than would be found in a heterogeneous human population. Many previous 
studies also only examined one or sometimes two opioids and thus it would be difficult 
to know if the effect of the opioid studied was a group effect (which would occur with all 
opioids) or an effect from that specific opioid. 
 
The main finding of this study is the disparate effects that certain opioids can have at a 
cellular level on immune function, especially phagocytosis, oxidative burst and IL-6 
production at an individual level. This means that some patients might be put at risk if 
they are administered immune suppressing opioids during a time when they are 
susceptible to infection. As this effect might only be relevant for an as yet undetermined 
proportion of patients, it would be difficult to detect them clinically. If future clinical 
studies were to confirm this effect, it may be possible to detect these patients prior to 
the administration of opioids, and if patients were at risk of immune suppression and 
needed an opioid, it might be that oxycodone would be a safer option.  
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From this study it is possible to hypothesis that administering opioids to human 
subjects could lead to three possible effects on their immune function: a) adversely 
affect aspects of their immune function; b) improve immune function; c) no effect of 
opioids on their immune function. Larger studies will be needed in order to evaluate the 
relative proportion of people in each group and to potentially evaluate the risk to the 
whole population. However, if the results from the whole population are combined they 
may show no difference due to the differences between the groups. It is also currently 
not known what in vitro effect size would be of clinical significance. 
 
Furthermore, it seems likely that as there are individual variations in the direction and 
magnitude of the effect of opioids on aspects of the immune response, that randomised 
controlled trials might hide the variations in group results. Thus, other methodologies 
(i.e. phenotypic screening) may be needed to study these effects. 
 
 
4.11 Future Work 
If opioids do differentially affect immune function for some individuals, then it is of vital 
importance to ascertain the clinical significance of this. There have been a few in vivo 
human studies, some in volunteers and others in different patient groups. The clinical 
studies assessing the effects of opioids on immune function have included cancer 
patients and surgical patients, but hard clinical endpoints (such as survival or disease 
recurrence) are often lacking. There is an urgent need for well-designed long term 
clinical studies in various patient groups that are aimed at better understanding the 
impact of the commonly used opioids on disease progression and patient outcome. 
Although the latter will not be answered as part of this project, the results generated will 
provide preliminary data on which to base such clinical studies. 
 
From the previous literature and data from the current study, a range of opioids need to 
be systematically analysed in defined patient groups, as this would enable evaluation 
of the indirect, as well as the direct, effects of opioids on immune cells, which have 
been physiologically activated in vivo by disease. In the evaluation of neutrophil and 
monocyte phagocytosis, morphine, tramadol, fentanyl and buprenorphine had the 
capacity to inhibit in some subjects and in the oxidative burst reaction of neutrophils 
and monocytes to E.coli, morphine, tramadol, fentanyl, buprenorphine and methadone 
were inhibitory in some individuals, future research in patients should focus on these 
opioids on clinical outcome. A range of clinical studies are essential in order to confirm 
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any effect of opioids in patient groups and these would ideally include surgical and 
substance abuse groups, as well as patients with cancer and infection. 
 
There are countless permutations for all of the in vitro assays with different durations of 
stimulation, shorter and longer incubations with opioids and different incubation times 
with target cells. The effect of further agents including the endogenous opioids, ORL1 
agonists and opioid antagonists (as well as the combinations of these) could be 
assessed. The underlying mechanisms for any detectable effects, including CD64 (Fc 
gamma receptor) and CD66 (neutrophil activation marker) expression on neutrophils 
and NO production as well as intracellular pathways (i.e. NFB) could be elucidated. 
However, the in vitro work should ideally have functional endpoints (i.e. target cell 
killing), as alterations in markers and messengers are only indicative of a change in cell 
function.  
 
The current study indicates that there is individual effects of some opioids on neutrophil 
and monocyte phagocytosis and oxidative burst reaction; however the frequency of 
these effects in the general population is unknown. As each subject was only tested 
once, individuals would need to be studied over time to determine the stability of the 
effects. Although the intra-assay precision has been shown to be high by the 
manufacturers (PHAGOBURST
® test kit data sheets, Orpegen Pharma) and a 
consistent measurement for baseline phagocytosis and oxidative burst responses over 
time has been demonstrated in the host laboratory, it would need to be confirmed for 
the effect of opioids on phagocytosis and oxidative burst in five separate samples from 
the same individuals. Once confirmed, to take this study forward, the prevalence of the 
potential immune effects of opioids in individuals could be evaluated in 50 healthy 
subjects and 50 patients with cancer, where they would be phenotyped into having 
stimulatory, inhibitory or no effect from in vitro morphine, tramadol, fentanyl, 
buprenorphine and methadone on their neutrophil and monocyte phagocytosis and 
oxidative burst response. This would enable initial identification of the prevalence of 
this effect and the distribution of the response, as if a large number of people are 
potentially at risk then the effect would be more relevant to the population. 
 
A subsequent study could phenotype the effect of these opioids on the in vitro 
phagocytosis and oxidative burst reaction in patients who had an infective complication 
after surgery and compare these to matched controls without infections. The in vitro 
and in vivo effects of the opioids having the most effect in these studies could then be 
evaluated in the same patient group. If the effects of the in vitro and in vivo studies 
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correlated, then a simple in vitro assay could detect the patients who would have a 
detrimental response to certain opioids before they are administered (i.e. pre-
operatively) and these could be avoided and alternative analgesics used. If these 
studies replicate the results of the current study and the inhibition of phagocytosis and 
oxidative burst is shown to correlate with infective complications in patients, then by 
screening patients this could reduce potentially serious infections, antibiotic use and 
duration of hospital admission. 
 
Despite opioid receptors being present on activated immune cells, it might be that the 
SNS and HPA axis are the principal mediators of the effects of opioids on the immune 
system (especially NK and T cells) and that future studies should be focused on the in 
vivo effects of opioids in humans. To make this most clinically relevant, this would need 
to be in appropriate patient groups, where their immune system is activated and the 
interaction of pain, opioids and immunity can be explored.  
 
A clinical study which would help elucidate this, would evaluate the immune effects of 
morphine vs. tramadol vs. oxycodone in patients undergoing curative resection of 
breast carcinoma. In view of potential variability between patients, if a randomised 
controlled trial is used (as this is considered the “gold standard”), either immune 
phenotyping may be necessary to identify at risk patients to be entered into the study, 
or the results might have to be analysed as subsets (responders vs. non responders). 
These patients would all need intra- and post-operative analgesia and the effects of 
morphine, tramadol and oxycodone could be evaluated on NK cell cytotoxicity and 
activation, neutrophil and monocyte phagocytosis and oxidative burst and T cell 
activation and cytokine production. 
 
Preliminary studies would assess the kinetics of this response to opioids, before a 
larger trial measuring the effect of these opioids at a specific time point. Using a whole 
blood approach, the activation status of CD16+ and CD56+ NK cells (using CD69 and 
CD107A), and CD3+/CD4+ and CD3+/CD8+ T cells (using CD25 and CD69) could be 
evaluated using multiparameter flow cytometry. PBMCs could be isolated from the 
sample and cytokine levels in the supernatants measured by CBAs. The cytotoxic 
capacity of the NK cells in the PBMCs could also be measured. Neutrophil and 
monocyte activation could be evaluated by measuring functional capacity of these cells 
to phagocytose labelled E.coli and the cell surface expression of CD64 and CD66 
using multiparameter flow cytometry. Their killing capacity could be measured by their 
production of oxygen free radicals and NO to E.coli. Alongside this, long-term clinical 
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follow-up would elucidate if the opioids affected clinical outcome, including, infective 
complications, tumour recurrence and mortality rate.  
 
It is important to use a defined patient group as the intrinsic immune activation in 
patients with different cancers or inflammatory and infective conditions might vary as 
might the outcome to different opioids. The results of such studies in a defined patient 
group might not however be applicable to other patients with different diseases. 
 
The optimisation of patient care requires the clarification of where opioids lie in the 
spectrum of toxicities and the sensitivity of a particular patient to the influences of a 
given opioid, such that the opioid which maximises benefit and minimises risk for the 
individual patient can be prescribed. This would need systematic clinical studies in 
patients with cancer and other chronic illness both before starting opioids and while on 
opioids, comparing the effects of opioids on infection and tumour progression, with 
clinical outcome, as well as immunological, endpoints (Afsharimani et al., 2011, Brack 
et al., 2011, Roy et al., 2011, Sacerdote, 2008). 
 
 
4.12 Conclusion 
This systematic analysis assessed the effect of eight commonly used opioids, at 
concentrations found in the clinical setting, on both innate and adaptive immunity. The 
only consistent significant effect detected, was that methadone, oxycodone and 
diamorphine decreased IL-6 levels in IL-2 stimulated PBMCs. One of the major findings 
of this study is that there is cellular level interindividual variability in the response to 
morphine, tramadol, fentanyl and buprenorphine for phagocytosis, and morphine, 
tramadol, fentanyl, buprenorphine and methadone (although oxycodone had a 
significant effect, it was quantitatively very small) for the oxidative burst reaction, and 
that these changes were not in a common direction, although they were generally 
inhibitory. Furthermore, the change in immune function with opioids was more 
dependent on the individual rather than the opioid, such that if an opioid was to 
influence immune function and whether this was enhancing or suppressive, would 
depend more on the individual subject than the opioid used. 
 
IL-6 production by IL-2 stimulated PBMCs was decreased by methadone, oxycodone 
and diamorphine, which could potentially inhibit the acute phase response to infection. 
There was less effect of the opioids tested on NK cells and T cells, and it may be that 
these cells are principally affected indirectly in vivo, by neuro-immune effects (via the 
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SNS and HPA axis). However, this study used a small sample size and although it has 
been detected that variability could exist, it has not been possible to quantify the 
variability or the distribution of response.  
 
Despite being a systematic in vitro analysis of a range of opioids, the current study 
does not enable clear stratification of the risk of the different opioids on all the aspects 
of immune function studied. Drawing together the previous studies, from the diverse 
and often discrepant literature, it may be that there is a spectrum of opioid 
immunomodulation (Figure 4-2). Although this is speculative at this stage, further 
comparative studies between the opioids in various clinical settings and clinical studies 
with defined immunological endpoints could allow such stratification. Eventually, this 
could then potentially be combined with relative risks of the other toxicities from the 
various opioids (for the individual patient) to enable a clearer risk:benefit ratio to be 
devised for an individual, to help inform optimal (safety and efficacy) prescribing of 
opioids. Without large, controlled, clinical studies in appropriate patient populations, it is 
necessary to try to synthesis the results from diverse literature in an attempt to stratify 
the opioids into their likely effect on immune function.  
 
 
 
Figure 4-2: Speculative distribution of the effect of opioids on immune function. 
Although difficult to quantify with the currently available data, it is likely that there is a spectrum of opioid 
immunomodulation, with morphine, methadone and codeine being more immunosuppressive than 
oxycodone and buprenorphine and tramadol being immune enhancing, although this is likely to vary 
between different aspects of immune function and between individuals. 
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Taking this work forward, a larger sample of volunteers would enable elucidation of the 
distribution of response to the effects of morphine, tramadol, fentanyl and 
buprenorphine on phagocytosis and morphine, tramadol, fentanyl, buprenorphine and 
methadone on the oxidative burst reaction. If a large proportion of people are 
potentially at risk of suppression from these opioids and this could be correlated to 
infective complications, this would be very relevant on a population level.  
 
In view of interindividual variability in aspects of the immune response to opioids and 
the relatively small effect sizes, future clinical studies would need large numbers of 
patients. It might also be necessary to analyse the results as subsets (responders vs. 
non responders) or use immune phenotyping to identify at risk patients. Infection or 
antibiotic use would be the most relevant clinical outcome, however long-term follow up 
would capture other clinical end-points, such as malignancy and mortality.  
 
Unlike with most of the effects of opioids, their potential immune effects may take a 
long time to become apparent, yet the harm might be done during their acute 
administration. This leads to one of the ultimate clinical challenges in pain 
management, which is how to distinguish which patients will have a deleterious or 
beneficial response to which opioids.  
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5. Appendix 
 
Related presentations, abstract publications and manuscripts in progress. 
 
Presentations: 
The data generated in this thesis has been presented at both local, national and 
international meetings including: 
 Association of palliative medicine conference, Dublin 2011. The in vitro effect of 
opioids on adaptive and innate immunity. 
 Association of palliative medicine research meeting, Bristol 2011. Research in 
Palliative medicine. 
 Transpennine research meeting, Sheffield 2010. Effect of morphine and fentanyl on 
innate and adaptive immune function. 
 6th Annual Conference of the Canadian Society of Palliative Care Physicians 2009. 
The Immunomodulatory Effects of Opioids.  
 Presented locally at palliative medicine, immunobiology, section of oncology and 
medical school meetings, Sheffield 2009 - 2011. 
 
Key Abstract publications: 
 Boland J., Foulds G., Ahmedzai S.H., Pockley A.G. Influence of opioids on the 
phagocytic activity of peripheral blood neutrophils and monocytes: a systematic in 
vitro analysis. Immunology, 2010; 131 (supplement 1): 79. 
 Boland J, Foulds G, Ahmedzai SH, Pockley AG. A systematic analysis of the in vitro 
effects of opioids on natural killer cell function. Support Care Cancer 2010; 18 (Suppl 
3):S67–S220 (15-135) 
 Boland J, Foulds G, Ahmedzai SH, Pockley AG. Effect of morphine and fentanyl on 
immune function. Palliat Med, 2010; 24. 4 suppl S5-S239 
 Boland J, Foulds G, Hopkinson K, Newton S, Ahmedzai SH, Pockley AG. 
Establishing an in vitro assay for evaluating the influence of opioids on T cell 
activation. Eur J immunol 2009; S1/09; 757 
 Boland J, Ahmedzai SH. Are opioids good for cancer? A review of the 
immunomodulatory effects of opioids. Support Care Cancer. 2007; 15 (6) 713 
 
Manuscripts in preparation: 
 Boland J, Ahmedzai SH, Pockley AG. A review of the effects of opioids on innate 
and adaptive immune function. 
 Boland J, Foulds G, Ahmedzai SH, Pockley AG. A systematic analysis of the in vitro 
effects of opioids on innate and adaptive immune function. 
 
  
273 | P a g e  
 
References 
 
Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. 
Nature reviews. Immunology 2003; 3: 939-51. 
Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. 
Nature 2000; 406: 782-7. 
Adorini L. Cytokine-based immunointervention in the treatment of autoimmune diseases. Clin 
Exp Immunol 2003; 132: 185-92. 
Afsharimani B, Cabot P, Parat MO. Morphine and tumor growth and metastasis. Cancer 
Metastasis Rev 2011. 
Ahn S, Kim J, Lucaveche CL, Reedy MC, Luttrell LM, Lefkowitz RJ, Daaka Y. Src-dependent 
tyrosine phosphorylation regulates dynamin self-assembly and ligand-induced 
endocytosis of the epidermal growth factor receptor. J Biol Chem 2002; 277: 26642-51. 
Al Omar SY, Marshall E, Middleton D, Christmas SE. Increased killer immunoglobulin-like 
receptor expression and functional defects in natural killer cells in lung cancer. 
Immunology 2011; 133: 94-104. 
Alexander M, Daniel T, Chaudry IH, Schwacha MG. Opiate analgesics contribute to the 
development of post-injury immunosuppression. J.Surg.Res. 2005; 129: 161-68. 
Alhashemi JA, Kaki AM. Effect of intrathecal tramadol administration on postoperative pain after 
transurethral resection of prostate. Br J Anaesth 2003; 91: 536-40. 
Alsayed Y, Uddin S, Ahmad S, Majchrzak B, Druker BJ, Fish EN, Platanias LC. IFN-gamma 
activates the C3G/Rap1 signaling pathway. Journal of immunology 2000; 164: 1800-6. 
Ambach A, Bonnekoh B, Gollnick H. Perforin granule release from cytotoxic lymphocytes ex 
vivo is inhibited by ciclosporin but not by methotrexate. Skin Pharmacol Appl Skin 
Physiol 2001; 14: 249-60. 
Ames IH, Gates CE, Garcia AM, John PA, Hennig AK, Tomar RH. Lysis of fresh murine 
mammary tumor cells by syngeneic natural killer cells and lymphokine-activated killer 
cells. Cancer Immunol Immunother 1987; 25: 161-8. 
Amu S, Saunders SP, Kronenberg M, Mangan NE, Atzberger A, Fallon PG. Regulatory B cells 
prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in 
a murine model. J Allergy Clin Immunol 2010; 125: 1114-24 e8. 
Andreassen TN, Klepstad P, Davies A, Bjordal K, Lundstrom S, Kaasa S, Dale O. Influences on 
the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult 
cancer patients. European journal of clinical pharmacology 2011; 67: 493-506. 
Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman 
GH, Tosato G. Human interferon-inducible protein 10 is a potent inhibitor of 
angiogenesis in vivo. The Journal of experimental medicine 1995; 182: 155-62. 
Appel NM, Kiritsy-Roy JA, van Loon GR. Mu receptors at discrete hypothalamic and brainstem 
sites mediate opioid peptide-induced increases in central sympathetic outflow. Brain 
Res 1986; 378: 8-20. 
Azarang A, Mahmoodi M, Rajabalian S, Shekari MA, Nosratabadi J, Rezaei N. T-helper 1 and 2 
serum cytokine assay in chronic opioid addicts. Eur.Cytokine Netw. 2007; 18: 210-14. 
Azaryan AV, Coughlin LJ, Buzas B, Clock BJ, Cox BM. Effect of chronic cocaine treatment on 
mu- and delta-opioid receptor mRNA levels in dopaminergically innervated brain 
regions. J Neurochem. 1996; 66: 443-48. 
Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor 
signaling. Annu Rev Immunol 1997; 15: 563-91. 
Bacon K, Baggiolini M, Broxmeyer H, Horuk R, Lindley I, Mantovani A, Maysushima K, Murphy 
P, Nomiyama H, Oppenheim J, Rot A, Schall T, Tsang M, Thorpe R, Van Damme J, 
Wadhwa M, Yoshie O, Zlotnik A, Zoon K. Chemokine/chemokine receptor 
nomenclature. J Interferon Cytokine Res 2002; 22: 1067-8. 
Barton BE. The biological effects of interleukin 6. Med Res Rev 1996; 16: 87-109. 
Bedoui S, Lechner S, Gebhardt T, Nave H, Beck-Sickinger AG, Straub RH, Pabst R, von 
Horsten S. NPY modulates epinephrine-induced leukocytosis via Y-1 and Y-5 receptor 
activation in vivo: sympathetic co-transmission during leukocyte mobilization. J 
Neuroimmunol 2002; 132: 25-33. 
Beilin B, Grinevich G, Yardeni IZ, Bessler H. Tramadol does not impair the phagocytic capacity 
of human peripheral blood cells. Can.J Anaesth. 2005; 52: 1035-39. 
274 | P a g e  
 
Beilin B, Shavit Y, Hart J, Mordashov B, Cohn S, Notti I, Bessler H. Effects of anesthesia based 
on large versus small doses of fentanyl on natural killer cell cytotoxicity in the 
perioperative period. Anesth Analg 1996; 82: 492-7. 
Ben-Eliyahu S, Page GG, Schleifer SJ. Stress, NK cells, and cancer: Still a promissory note. 
Brain Behav Immun 2007; 21: 881-7. 
Ben-Eliyahu S, Page GG, Yirmiya R, Taylor AN. Acute alcohol intoxication suppresses natural 
killer cell activity and promotes tumor metastasis. Nat Med 1996; 2: 457-60. 
Benschop RJ, Rodriguez-Feuerhahn M, Schedlowski M. Catecholamine-induced leukocytosis: 
early observations, current research, and future directions. Brain Behav Immun 1996; 
10: 77-91. 
Benschop RJ, Schedlowski M, Wienecke H, Jacobs R, Schmidt RE. Adrenergic control of 
natural killer cell circulation and adhesion. Brain Behav Immun 1997; 11: 321-32. 
Bhargava HN, Thomas PT, Thorat S, House RV. Effects of morphine tolerance and abstinence 
on cellular immune function. Brain Res. 1994; 642: 1-10. 
Bhaskaran M, Kapasi AA, Reddy K, Singhal PC. Morphine priming rescues high-dose 
morphine-induced biological perturbations. J Infect Dis 2007; 195: 1860-9. 
Bianchi M, Panerai AE. Anti-hyperalgesic effects of tramadol in the rat. Brain Res 1998; 797: 
163-6. 
Bidlack JM, Khimich M, Parkhill AL, Sumagin S, Sun B, Tipton CM. Opioid receptors and 
signaling on cells from the immune system. J Neuroimmune.Pharmacol 2006; 1: 260-
69. 
Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ. Anesthetic technique for 
radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. 
Anesthesiology 2008; 109: 180-7. 
Bird L. Antiviral immunity: Ageing immune systems work too hard. Nat Rev Immunol 2010; 10: 
6-7. 
Biron CA, Gazzinelli RT. Effects of IL-12 on immune responses to microbial infections: a key 
mediator in regulating disease outcome. Curr Opin Immunol 1995; 7: 485-96. 
Bonnet MP, Beloeil H, Benhamou D, Mazoit JX, Asehnoune K. The mu opioid receptor 
mediates morphine-induced tumor necrosis factor and interleukin-6 inhibition in toll-like 
receptor 2-stimulated monocytes. Anesth.Analg. 2008; 106: 1142-9, table. 
Booth V, Keizer DW, Kamphuis MB, Clark-Lewis I, Sykes BD. The CXCR3 binding chemokine 
IP-10/CXCL10: structure and receptor interactions. Biochemistry 2002; 41: 10418-25. 
Borgland SL. Acute opioid receptor desensitization and tolerance: is there a link? Clin Exp 
Pharmacol Physiol 2001; 28: 147-54. 
Borman A, Ciepielewski Z, Wrona D, Stojek W, Glac W, Leszkowicz E, Tokarski J. Small doses 
of morphine can enhance NK cell cytotoxicity in pigs. Int.Immunopharmacol. 2009; 9: 
277-83. 
Borner C, Hollt V, Kraus J. Involvement of activator protein-1 in transcriptional regulation of the 
human mu-opioid receptor gene. Mol.Pharmacol 2002; 61: 800-05. 
Borner C, Hollt V, Kraus J. Cannabinoid receptor type 2 agonists induce transcription of the mu-
opioid receptor gene in Jurkat T cells. Mol.Pharmacol 2006; 69: 1486-91. 
Borner C, Kraus J, Bedini A, Schraven B, Hollt V. T-cell receptor/CD28-mediated activation of 
human T lymphocytes induces expression of functional mu-opioid receptors. 
Mol.Pharmacol 2008; 74: 496-504. 
Borner C, Kraus J, Schroder H, Ammer H, Hollt V. Transcriptional regulation of the human mu-
opioid receptor gene by interleukin-6. Mol.Pharmacol. 2004; 66: 1719-26. 
Borner C, Stumm R, Hollt V, Kraus J. Comparative analysis of mu-opioid receptor expression in 
immune and neuronal cells. J.Neuroimmunol. 2007; 188: 56-63. 
Borner C, Warnick B, Smida M, Hartig R, Lindquist JA, Schraven B, Hollt V, Kraus J. 
Mechanisms of opioid-mediated inhibition of human T cell receptor signaling. J 
Immunol. 2009; 183: 882-89. 
Borst SE, Hui KK, Conolly ME. Beta-adrenergic receptors on human lymphocytes: comparison 
of down-regulation in vivo and in vitro. Pharmacology 1990; 40: 325-9. 
Bosshart H. Morphine-mediated suppression of phagocytosis. Int Immunopharmacol 2009. 
Bots M, Medema JP. Granzymes at a glance. J Cell Sci 2006; 119: 5011-4. 
Bower S. The uptake of fentanyl by erythrocytes. J Pharm Pharmacol 1982; 34: 181-5. 
Brack A, Rittner HL, Stein C. Immunosuppressive Effects of Opioids-Clinical Relevance. Journal 
of neuroimmune pharmacology : the official journal of the Society on NeuroImmune 
Pharmacology 2011. 
275 | P a g e  
 
Brand JM, Kirchner H, Poppe C, Schmucker P. The effects of general anesthesia on human 
peripheral immune cell distribution and cytokine production. Clin Immunol 
Immunopathol 1997; 83: 190-4. 
Bryant HU, Bernton EW, Holaday JW. Immunosuppressive effects of chronic morphine 
treatment in mice. Life Sci. 1987; 41: 1731-38. 
Bryant HU, Bernton EW, Holaday JW. Morphine pellet-induced immunomodulation in mice: 
temporal relationships. J.Pharmacol.Exp.Ther. 1988; 245: 913-20. 
Bubenik J. Tumour MHC class I downregulation and immunotherapy (Review). Oncol Rep 2003; 
10: 2005-8. 
Budd K. Pain management: is opioid immunosuppression a clinical problem? 
Biomed.Pharmacother. 2006; 60: 310-17. 
Cadet P, Mantione KJ, Stefano GB. Molecular identification and functional expression of mu 3, 
a novel alternatively spliced variant of the human mu opiate receptor gene. J Immunol. 
2003; 170: 5118-23. 
Callahan RJ, Au JD, Paul M, Liu C, Yost CS. Functional inhibition by methadone of N-methyl-D-
aspartate receptors expressed in Xenopus oocytes: stereospecific and subunit effects. 
Anesth Analg 2004; 98: 653-9, table of contents. 
Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene 
polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008; 83: 559-66. 
Cantacuzene J. Nouvelles recherches sur le mode de destruction des vibrions dans 
l’organisme. Ann. Inst. Pasteur 1898; 12: 274–300. 
Carpenter GW, Breeden L, Carr DJ. Acute exposure to morphine suppresses cytotoxic T-
lymphocyte activity. Int.J Immunopharmacol. 1995; 17: 1001-06. 
Carpenter GW, Garza HH, Jr., Gebhardt BM, Carr DJ. Chronic morphine treatment suppresses 
CTL-mediated cytolysis, granulation, and cAMP responses to alloantigen. Brain 
Behav.Immun. 1994; 8: 185-203. 
Carrigan KA, Lysle DT. Morphine-6 beta-glucuronide induces potent immunomodulation. Int 
Immunopharmacol 2001; 1: 821-31. 
Casellas AM, Guardiola H, Renaud FL. Inhibition by opioids of phagocytosis in peritoneal 
macrophages. Neuropeptides 1991; 18: 35-40. 
Castriconi R, Dondero A, Cilli M, Ognio E, Pezzolo A, De Giovanni B, Gambini C, Pistoia V, 
Moretta L, Moretta A, Corrias MV. Human NK cell infusions prolong survival of 
metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunol Immunother 
2007; 56: 1733-42. 
Chakrabarti S, Liu NJ, Gintzler AR. Formation of {micro}-/{kappa}-opioid receptor heterodimer is 
sex-dependent and mediates female-specific opioid analgesia. Proc Natl Acad Sci U S 
A 2010. 
Chambers WH, Vujanovic NL, DeLeo AB, Olszowy MW, Herberman RB, Hiserodt JC. 
Monoclonal antibody to a triggering structure expressed on rat natural killer cells and 
adherent lymphokine-activated killer cells. J Exp Med 1989; 169: 1373-89. 
Chandra RK. Nutrition and immunology: from the clinic to cellular biology and back again. Proc 
Nutr Soc 1999; 58: 681-3. 
Chao CC, Molitor TW, Close K, Hu S, Peterson PK. Morphine inhibits the release of tumor 
necrosis factor in human peripheral blood mononuclear cell cultures. Int J 
Immunopharmacol 1993; 15: 447-53. 
Chiou LC, Liao YY, Fan PC, Kuo PH, Wang CH, Riemer C, Prinssen EP. Nociceptin/orphanin 
FQ peptide receptors: pharmacology and clinical implications. Curr Drug Targets 2007; 
8: 117-35. 
Christopherson R, James KE, Tableman M, Marshall P, Johnson FE. Long-term survival after 
colon cancer surgery: a variation associated with choice of anesthesia. Anesthesia and 
analgesia 2008; 107: 325-32. 
Christrup LL. Morphine metabolites. Acta Anaesthesiol Scand 1997; 41: 116-22. 
Clancy J, Jr., Petrovic LM, Gordon BH, Handa RJ, Campbell DB, Lorens SA. Effects of 
subchronic d-fenfluramine on splenic immune functions in young and old male and 
female Fischer 344 rats. Int J Immunopharmacol 1991; 13: 1203-12. 
Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, Simpson K. Efficacy and 
safety of transdermal fentanyl and sustained-release oral morphine in patients with 
cancer and chronic non-cancer pain. Curr Med Res Opin 2004; 20: 1419-28. 
Clark JD. Understanding methadone metabolism: a foundation for safer use. Anesthesiology 
2008; 108: 351-2. 
276 | P a g e  
 
Clarke RW, Ward RE. The role of 5-HT(1A)-receptors in fentanyl-induced bulbospinal inhibition 
of a spinal withdrawal reflex in the rabbit. Pain 2000; 85: 239-45. 
Codd EE, Shank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting 
activity of centrally acting analgesics: structural determinants and role in 
antinociception. J Pharmacol Exp Ther 1995; 274: 1263-70. 
Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and 
methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 
2006; 80: 682-90. 
Coller JK, Christrup LL, Somogyi AA. Role of active metabolites in the use of opioids. Eur J Clin 
Pharmacol 2009; 65: 121-39. 
Condevaux F, Guichard J, Forichon A, Aujoulat M, Descotes J. Compared effects of morphine 
and nickel chloride on NK cell activity in vitro in rats and monkeys. J Appl Toxicol 2001; 
21: 431-4. 
Cone EJ, Holicky BA, Grant TM, Darwin WD, Goldberger BA. Pharmacokinetics and 
pharmacodynamics of intranasal "snorted" heroin. J Anal Toxicol 1993; 17: 327-37. 
Costigan M, Moss A, Latremoliere A, Johnston C, Verma-Gandhu M, Herbert TA, Barrett L, 
Brenner GJ, Vardeh D, Woolf CJ, Fitzgerald M. T-cell infiltration and signaling in the 
adult dorsal spinal cord is a major contributor to neuropathic pain-like hypersensitivity. J 
Neurosci 2009; 29: 14415-22. 
Cotran RS, Kumar V, Robbins SL. Robbins and Cotran pathologic basis of disease. 8th edition 
ed. Philadelphia, Pa: Saunders Elsevier, 2010. 
Cox WI, Holbrook NJ, Grasso RJ, Specter S, Friedman H. Suppression of the natural killer cell 
activity of murine spleen cell cultures by dexamethasone (41489). Proc Soc Exp Biol 
Med 1982; 171: 146-50. 
Crary B, Borysenko M, Sutherland DC, Kutz I, Borysenko JZ, Benson H. Decrease in mitogen 
responsiveness of mononuclear cells from peripheral blood after epinephrine 
administration in humans. J Immunol 1983; 130: 694-7. 
Croker BA, Kiu H, Pellegrini M, Toe J, Preston S, Metcalf D, O'Donnell JA, Cengia LH, McArthur 
K, Nicola NA, Alexander WS, Roberts AW. IL-6 promotes acute and chronic 
inflammatory disease in the absence of SOCS3. Immunology and cell biology 2011. 
Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ 2010; 17: 
616-23. 
Curfs JH, Meis JF, Hoogkamp-Korstanje JA. A primer on cytokines: sources, receptors, effects, 
and inducers. Clin Microbiol Rev 1997; 10: 742-80. 
Cutolo M, Sulli A, Villaggio B, Seriolo B, Accardo S. Relations between steroid hormones and 
cytokines in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 
1998; 57: 573-7. 
D'Elia M, Patenaude J, Hamelin C, Garrel DR, Bernier J. No detrimental effect from chronic 
exposure to buprenorphine on corticosteroid-binding globulin and corticosensitive 
immune parameters. Clin Immunol 2003; 109: 179-87. 
Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M. 
Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in 
humans and rats. Br J Anaesth 2005; 94: 825-34. 
Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M. Buprenorphine 
induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006; 96: 
627-32. 
Dalen P, Frengell C, Dahl ML, Sjoqvist F. Quick onset of severe abdominal pain after codeine in 
an ultrarapid metabolizer of debrisoquine. Ther Drug Monit 1997; 19: 543-4. 
Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, Mitsdoerffer M, Strom TB, 
Elyaman W, Ho IC, Khoury S, Oukka M, Kuchroo VK. IL-4 inhibits TGF-beta-induced 
Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T 
cells. Nature immunology 2008; 9: 1347-55. 
Darwish M, Kirby M, Robertson P, Jr., Tracewell W, Jiang JG. Pharmacokinetic properties of 
fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-
dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin.Ther. 2006; 28: 
707-14. 
Daynes RA, Dowell T, Araneo BA. Platelet-derived growth factor is a potent biologic response 
modifier of T cells. The Journal of experimental medicine 1991; 174: 1323-33. 
de Leon J, Dinsmore L, Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in 
CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol 2003; 23: 420-1. 
277 | P a g e  
 
Delgado-Velez M, Lugo-Chinchilla A, Lizardo L, Morales I, Robles Y, Bruno N, Rodriguez JW, 
Rios-Olivares E, Correa M, Renaud FL. Chronic exposure of human macrophages in 
vitro to morphine and methadone induces a putative tolerant/dependent state. J 
Neuroimmunol 2008; 196: 94-100. 
Desai A, Grolleau-Julius A, Yung R. Leukocyte function in the aging immune system. J Leukoc 
Biol 2010. 
Dietis N, Rowbotham DJ, Lambert DG. Opioid receptor subtypes: fact or artifact? British journal 
of anaesthesia 2011; 107: 8-18. 
Dinarello CA. The biological properties of interleukin-1. Eur Cytokine Netw 1994; 5: 517-31. 
Dinauer MC. Disorders of neutrophil function: an overview. Methods Mol Biol 2007; 412: 489-
504. 
Djaldetti M, Salman H, Bergman M, Djaldetti R, Bessler H. Phagocytosis--the mighty weapon of 
the silent warriors. Microsc Res Tech 2002; 57: 421-31. 
Driessen B, Reimann W. Interaction of the central analgesic, tramadol, with the uptake and 
release of 5-hydroxytryptamine in the rat brain in vitro. Br J Pharmacol 1992; 105: 147-
51. 
Driessen B, Reimann W, Giertz H. Effects of the central analgesic tramadol on the uptake and 
release of noradrenaline and dopamine in vitro. Br J Pharmacol 1993; 108: 806-11. 
Droney J, Riley J, Ross JR. Evolving knowledge of opioid genetics in cancer pain. Clinical 
oncology 2011; 23: 418-28. 
Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 
10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation 
and trafficking. Journal of immunology 2002; 168: 3195-204. 
Dyer KR, White JM, Foster DJ, Bochner F, Menelaou A, Somogyi AA. The relationship between 
mood state and plasma methadone concentration in maintenance patients. J Clin 
Psychopharmacol 2001; 21: 78-84. 
Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-
competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. 
Neurosci Lett 1995; 187: 165-8. 
Elftman MD, Hunzeker JT, Mellinger JC, Bonneau RH, Norbury CC, Truckenmiller ME. Stress-
Induced Glucocorticoids at the Earliest Stages of Herpes Simplex Virus-1 Infection 
Suppress Subsequent Antiviral Immunity, Implicating Impaired Dendritic Cell Function. J 
Immunol 2010; 184: 1867-75. 
Elshal MF, McCoy JP. Multiplex bead array assays: performance evaluation and comparison of 
sensitivity to ELISA. Methods 2006; 38: 317-23. 
Eriksen CG, Olsen H, Husted LB, Sorensen L, Carstens M, Soballe K, Langdahl BL. The 
expression of IL-6 by osteoblasts is increased in healthy elderly individuals: stimulated 
proliferation and differentiation are unaffected by age. Calcif Tissue Int 2010; 87: 414-
23. 
Escher M, Daali Y, Chabert J, Hopfgartner G, Dayer P, Desmeules J. Pharmacokinetic and 
pharmacodynamic properties of buprenorphine after a single intravenous administration 
in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study. 
Clin.Ther. 2007; 29: 1620-31. 
Esplugues E, Vega-Ramos J, Cartoixa D, Vazquez BN, Salaet I, Engel P, Lauzurica P. 
Induction of tumor NK-cell immunity by anti-CD69 antibody therapy. Blood 2005; 105: 
4399-406. 
Evans HC, Easthope SE. Transdermal buprenorphine. Drugs 2003; 63: 1999-2010; discussion 
11-2. 
Everhart ET, Cheung P, Shwonek P, Zabel K, Tisdale EC, Jacob P, 3rd, Mendelson J, Jones 
RT. Subnanogram-concentration measurement of buprenorphine in human plasma by 
electron-capture capillary gas chromatography: application to pharmacokinetics of 
sublingual buprenorphine. Clin Chem 1997; 43: 2292-302. 
Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. Can anesthetic technique for 
primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 2006; 
105: 660-4. 
Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, Cianfarani F, Odorisio T, 
Traidl-Hoffmann C, Behrendt H, Durham SR, Schmidt-Weber CB, Cavani A. Th22 cells 
represent a distinct human T cell subset involved in epidermal immunity and 
remodeling. The Journal of clinical investigation 2009; 119: 3573-85. 
278 | P a g e  
 
Faras-Melainis K, Gomes I, Rozenfeld R, Zachariou V, Devi L. Modulation of opioid receptor 
function by protein-protein interactions. Front Biosci. 2009; 14: 3594-607. 
Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and its receptor. Annu 
Rev Immunol 1993; 11: 571-611. 
Fecho K, Dykstra LA, Lysle DT. Evidence for beta adrenergic receptor involvement in the 
immunomodulatory effects of morphine. J Pharmacol Exp Ther 1993; 265: 1079-87. 
Fecho K, Maslonek KA, Dykstra LA, Lysle DT. Evidence for sympathetic and adrenal 
involvement in the immunomodulatory effects of acute morphine treatment in rats. J 
Pharmacol Exp Ther 1996; 277: 633-45. 
Feierman DE, Lasker JM. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver 
microsomes. Role of CYP3A4. Drug Metab Dispos 1996; 24: 932-9. 
Felten DL, Felten SY, Carlson SL, Olschowka JA, Livnat S. Noradrenergic and peptidergic 
innervation of lymphoid tissue. J Immunol 1985; 135: 755s-65s. 
Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor 
desensitization and signaling. Pharmacol Rev 2001; 53: 1-24. 
Ferraccioli G, Zizzo G. The potential role of Th17 in mediating the transition from acute to 
chronic autoimmune inflammation: rheumatoid arthritis as a model. Discovery medicine 
2011; 11: 413-24. 
Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone--metabolism, pharmacokinetics and 
interactions. Pharmacol Res 2004; 50: 551-9. 
Findlay JW, Jones EC, Butz RF, Welch RM. Plasma codeine and morphine concentrations after 
therapeutic oral doses of codeine-containing analgesics. Clin Pharmacol Ther 1978; 24: 
60-8. 
Finn AK, Whistler JL. Endocytosis of the mu opioid receptor reduces tolerance and a cellular 
hallmark of opiate withdrawal. Neuron 2001; 32: 829-39. 
Fouser LA, Wright JF, Dunussi-Joannopoulos K, Collins M. Th17 cytokines and their emerging 
roles in inflammation and autoimmunity. Immunol Rev 2008; 226: 87-102. 
Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. 
Clin.Microbiol.Rev. 2003; 16: 209-19. 
Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B. Influence of tramadol on 
neurotransmitter systems of the rat brain. Arzneimittelforschung 1996; 46: 1029-36. 
Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996; 8: 
271-80. 
Fuggetta MP, Di FP, Falchetti R, Cottarelli A, Rossi L, Tricarico M, Lanzilli G. Effect of morphine 
on cell-mediated immune responses of human lymphocytes against allogeneic 
malignant cells. J.Exp.Clin.Cancer Res. 2005; 24: 255-63. 
Fujioka N, Nguyen J, Chen C, Li Y, Pasrija T, Niehans G, Johnson KN, Gupta V, Kratzke RA, 
Gupta K. Morphine-Induced Epidermal Growth Factor Pathway Activation in Non-Small 
Cell Lung Cancer. Anesthesia and analgesia 2011. 
Gabay E, Wolf G, Shavit Y, Yirmiya R, Tal M. Chronic blockade of interleukin-1 (IL-1) prevents 
and attenuates neuropathic pain behavior and spontaneous ectopic neuronal activity 
following nerve injury. Eur J Pain 2010. 
Gabrilovac J, Marotti T. Gender-related differences in murine T- and B-lymphocyte proliferative 
ability in response to in vivo [Met(5)]enkephalin administration. Eur.J.Pharmacol. 2000; 
392: 101-08. 
Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009; 9: 556-
67. 
Gaffen SL, Kramer JM, Yu JJ, Shen F. The IL-17 cytokine family. Vitam Horm 2006; 74: 255-82. 
Galley HF, DiMatteo MA, Webster NR. Immunomodulation by anaesthetic, sedative and 
analgesic agents: does it matter? Intensive Care Med 2000; 26: 267-74. 
Gan SH, Ismail R, Wan Adnan WA, Wan Z. Correlation of tramadol pharmacokinetics and 
CYP2D6*10 genotype in Malaysian subjects. J Pharm.Biomed.Anal. 2002; 30: 189-95. 
Garcia-Quetglas E, Azanza JR, Sadaba B, Munoz MJ, Gil I, Campanero MA. Pharmacokinetics 
of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 
phenotype. Pharmacol Res. 2007; 55: 122-30. 
Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer 
Res 2001; 83: 117-58. 
Gaspani L, Bianchi M, Limiroli E, Panerai AE, Sacerdote P. The analgesic drug tramadol 
prevents the effect of surgery on natural killer cell activity and metastatic colonization in 
rats. J.Neuroimmunol. 2002; 129: 18-24. 
279 | P a g e  
 
Gaveriaux-Ruff C, Matthes HW, Peluso J, Kieffer BL. Abolition of morphine-immunosuppression 
in mice lacking the mu-opioid receptor gene. Proc.Natl.Acad.Sci.U.S.A 1998; 95: 6326-
30. 
George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, O'Dowd BF. Oligomerization of mu- and 
delta-opioid receptors. Generation of novel functional properties. J Biol Chem 2000; 
275: 26128-35. 
Gerosa F, Tommasi M, Benati C, Gandini G, Libonati M, Tridente G, Carra G, Trinchieri G. 
Differential effects of tyrosine kinase inhibition in CD69 antigen expression and lytic 
activity induced by rIL-2, rIL-12, and rIFN-alpha in human NK cells. Cell Immunol 1993; 
150: 382-90. 
Gilron I, Wajsbrot D, Therrien F, Lemay J. Pregabalin for peripheral neuropathic pain: a 
multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. The 
Clinical journal of pain 2011; 27: 185-93. 
Glattard E, Welters ID, Lavaux T, Muller AH, Laux A, Zhang D, Schmidt AR, Delalande F, 
Laventie BJ, Dirrig-Grosch S, Colin DA, Van Dorsselaer A, Aunis D, Metz-Boutigue MH, 
Schneider F, Goumon Y. Endogenous morphine levels are increased in sepsis: a partial 
implication of neutrophils. PLoS One 2010; 5: e8791. 
Gleeson M. Immune function in sport and exercise. J Appl Physiol 2007; 103: 693-9. 
Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, Devi LA. Heterodimerization of mu and 
delta opioid receptors: A role in opiate synergy. J Neurosci 2000; 20: RC110. 
Gomez-Flores R, Weber RJ. Differential effects of buprenorphine and morphine on immune and 
neuroendocrine functions following acute administration in the rat mesencephalon 
periaqueductal gray. Immunopharmacology 2000; 48: 145-56. 
Gonzalez FM, Vargas JA, Lopez-Cortijo C, Castejon R, Gorriz C, Ramirez-Camacho R, Millan I, 
Durantez A. Prognostic significance of natural killer cell activity in patients with laryngeal 
carcinoma. Arch Otolaryngol Head Neck Surg 1998; 124: 852-6. 
Gordin V. The role of cytokines in chronic pain processing and opioid tolerance: an Australian 
study. Pain Med 2010; 11: 562-3. 
Gottschalk A, Ford JG, Regelin CC, You J, Mascha EJ, Sessler DI, Durieux ME, Nemergut EC. 
Association between epidural analgesia and cancer recurrence after colorectal cancer 
surgery. Anesthesiology 2010; 113: 27-34. 
Greeneltch KM, Kelly-Welch AE, Shi Y, Keegan AD. Chronic morphine treatment promotes 
specific Th2 cytokine production by murine T cells in vitro via a Fas/Fas ligand-
dependent mechanism. J.Immunol. 2005; 175: 4999-5005. 
Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell 
phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-
activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 
1823-41. 
Grond S, Meuser T, Uragg H, Stahlberg HJ, Lehmann KA. Serum concentrations of tramadol 
enantiomers during patient-controlled analgesia. Br J Clin Pharmacol 1999; 48: 254-7. 
Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin.Pharmacokinet. 2004; 43: 879-
923. 
Grutz G. New insights into the molecular mechanism of interleukin-10-mediated 
immunosuppression. Journal of leukocyte biology 2005; 77: 3-15. 
Guan L, Townsend R, Eisenstein TK, Adler MW, Rogers TJ. Both T cells and macrophages are 
targets of kappa-opioid-induced immunosuppression. Brain Behav.Immun. 1994; 8: 
229-40. 
Hale M, Khan A, Kutch M, Li S. Once-daily OROS hydromorphone ER compared with placebo 
in opioid-tolerant patients with chronic low back pain. Current medical research and 
opinion 2010; 26: 1505-18. 
Handa K, Suzuki R, Matsui H, Shimizu Y, Kumagai K. Natural killer (NK) cells as a responder to 
interleukin 2 (IL 2). II. IL 2-induced interferon gamma production. J Immunol 1983; 130: 
988-92. 
Hatsukari I, Hitosugi N, Ohno R, Hashimoto K, Nakamura S, Satoh K, Nagasaka H, Matsumoto 
I, Sakagami H. Induction of apoptosis by morphine in human tumor cell lines in vitro. 
Anticancer Res 2007; 27: 857-64. 
He SQ, Zhang ZN, Guan JS, Liu HR, Zhao B, Wang HB, Li Q, Yang H, Luo J, Li ZY, Wang Q, 
Lu YJ, Bao L, Zhang X. Facilitation of mu-opioid receptor activity by preventing delta-
opioid receptor-mediated codegradation. Neuron 2011; 69: 120-31. 
280 | P a g e  
 
Heeren T, D'Agostino R. Robustness of the two independent samples t-test when applied to 
ordinal scaled data. Stat Med 1987; 6: 79-90. 
Heikkila K, Ebrahim S, Rumley A, Lowe G, Lawlor DA. Associations of circulating C-reactive 
protein and interleukin-6 with survival in women with and without cancer: findings from 
the British Women's Heart and Health Study. Cancer epidemiology, biomarkers & 
prevention : a publication of the American Association for Cancer Research, 
cosponsored by the American Society of Preventive Oncology 2007; 16: 1155-9. 
Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of 
interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003a; 374: 1-
20. 
Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of 
interleukin (IL)-6-type cytokine signalling and its regulation. Biochem.J 2003b; 374: 1-
20. 
Henney CS, Kuribayashi K, Kern DE, Gillis S. Interleukin-2 augments natural killer cell activity. 
Nature 1981; 291: 335-38. 
Henry DJ, Grandy DK, Lester HA, Davidson N, Chavkin C. Kappa-opioid receptors couple to 
inwardly rectifying potassium channels when coexpressed by Xenopus oocytes. Mol 
Pharmacol 1995; 47: 551-7. 
Hernandez MC, Flores LR, Bayer BM. Immunosuppression by morphine is mediated by central 
pathways. J.Pharmacol.Exp.Ther. 1993; 267: 1336-41. 
Hilburger ME, Adler MW, Truant AL, Meissler JJ, Jr., Satishchandran V, Rogers TJ, Eisenstein 
TK. Morphine induces sepsis in mice. J Infect Dis 1997; 176: 183-8. 
Hjelm Skog AL, Wadhwa M, Hassan M, Gharizadeh B, Bird C, Ragnhammar P, Thorpe R, 
Mellstedt H. Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 
antibodies induced after treatment of colorectal carcinoma patients with a combination 
of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and 
IL-2. Clin Cancer Res 2001; 7: 1163-70. 
Hoehe MR, Kopke K, Wendel B, Rohde K, Flachmeier C, Kidd KK, Berrettini WH, Church GM. 
Sequence variability and candidate gene analysis in complex disease: association of 
mu opioid receptor gene variation with substance dependence. Hum.Mol.Genet. 2000; 
9: 2895-908. 
Hopkinson K, Williams EA, Fairburn B, Forster S, Flower DJ, Saxton JM, Pockley AG. A 
MitoTracker Green-based flow cytometric assay for natural killer cell activity: variability, 
the influence of platelets and a comparison of analytical approaches. Exp Hematol 
2007; 35: 350-7. 
Hou J, Schindler U, Henzel WJ, Ho TC, Brasseur M, McKnight SL. An interleukin-4-induced 
transcription factor: IL-4 Stat. Science 1994; 265: 1701-06. 
House RV, Thomas PT, Bhargava HN. In vitro evaluation of fentanyl and meperidine for 
immunomodulatory activity. Immunol.Lett. 1995; 46: 117-24. 
Huang P, Kehner GB, Cowan A, Liu-Chen LY. Comparison of pharmacological activities of 
buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J 
Pharmacol Exp Ther 2001; 297: 688-95. 
Hutchinson MR, Coats BD, Lewis SS, Zhang Y, Sprunger DB, Rezvani N, Baker EM, Jekich 
BM, Wieseler JL, Somogyi AA, Martin D, Poole S, Judd CM, Maier SF, Watkins LR. 
Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain 
Behav.Immun. 2008. 
Hutchinson MR, Somogyi AA. Diacetylmorphine degradation to 6-monoacetylmorphine and 
morphine in cell culture: implications for in vitro studies. Eur J Pharmacol 2002; 453: 27-
32. 
Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, Slivka PF, Coats 
BD, Rezvani N, Wieseler J, Hughes TS, Landgraf KE, Chan S, Fong S, Phipps S, Falke 
JJ, Leinwand LA, Maier SF, Yin H, Rice KC, Watkins LR. Evidence that opioids may 
have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 2010; 24: 83-95. 
Ihnatko R, Kubes M. TNF signaling: early events and phosphorylation. Gen Physiol Biophys 
2007; 26: 159-67. 
Ikeda K, Kobayashi T, Kumanishi T, Niki H, Yano R. Involvement of G-protein-activated inwardly 
rectifying K (GIRK) channels in opioid-induced analgesia. Neurosci Res 2000; 38: 113-
6. 
Inturrisi CE. Pharmacology of methadone and its isomers. Minerva Anestesiol 2005; 71: 435-7. 
281 | P a g e  
 
Inturrisi CE, Max MB, Foley KM, Schultz M, Shin SU, Houde RW. The pharmacokinetics of 
heroin in patients with chronic pain. N Engl J Med 1984; 310: 1213-7. 
Irwin M, Hauger RL, Brown M, Britton KT. CRF activates autonomic nervous system and 
reduces natural killer cytotoxicity. Am J Physiol 1988; 255: R744-7. 
Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Hokita S, Aikou T. 
Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000; 
88: 577-83. 
Ismail H, Ho KM, Narayan K, Kondalsamy-Chennakesavan S. Effect of neuraxial anaesthesia 
on tumour progression in cervical cancer patients treated with brachytherapy: a 
retrospective cohort study. British journal of anaesthesia 2010; 105: 145-9. 
Jacobs R, Karst M, Scheinichen D, Bevilacqua C, Schneider U, Heine J, Schedlowski M, 
Schmidt RE. Effects of fentanyl on cellular immune functions in man. Int.J 
Immunopharmacol. 1999; 21: 445-54. 
Jaeger K, Scheinichen D, Heine J, Andre M, Bund M, Piepenbrock S, Leuwer M. Remifentanil, 
fentanyl, and alfentanil have no influence on the respiratory burst of human neutrophils 
in vitro. Acta Anaesthesiol Scand 1998; 42: 1110-3. 
Jager MJ, Hurks HM, Levitskaya J, Kiessling R. HLA expression in uveal melanoma: there is no 
rule without some exception. Human immunology 2002; 63: 444-51. 
Joncker NT, Fernandez NC, Treiner E, Vivier E, Raulet DH. NK cell responsiveness is tuned 
commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat 
model. J Immunol 2009; 182: 4572-80. 
Kadiev E, Patel V, Rad P, Thankachan L, Tram A, Weinlein M, Woodfin K, Raffa RB, Nagar S. 
Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin 
Drug Metab Toxicol 2008; 4: 77-91. 
Kambur O, Mannisto PT. Catechol-o-methyltransferase and pain. Int Rev Neurobiol 2010; 95: 
227-79. 
Kambur O, Talka R, Ansah O, Kontinen V, Pertovaara A, Kalso E, Mannisto P. Inhibitors of 
catechol-O-methyltransferase sensitize mice to pain. Br J Pharmacol 2010; 161: 1553-
65. 
Kampen AH, Tollersrud T, Larsen S, Roth JA, Frank DE, Lund A. Repeatability of flow 
cytometric and classical measurement of phagocytosis and respiratory burst in bovine 
polymorphonuclear leukocytes. Veterinary immunology and immunopathology 2004; 97: 
105-14. 
Kane KL, Ashton FA, Schmitz JL, Folds JD. Determination of natural killer cell function by flow 
cytometry. Clinical and diagnostic laboratory immunology 1996; 3: 295-300. 
Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 
2003; 3: 984-93. 
Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-
like receptors. Nat Immunol 2010; 11: 373-84. 
Kawasaki T, Ogata M, Kawasaki C, Okamoto K, Sata T. Effects of epidural anaesthesia on 
surgical stress-induced immunosuppression during upper abdominal surgery. 
Br.J.Anaesth. 2007; 98: 196-203. 
Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein 
pharmacology by ligand chemistry. Nat Biotechnol 2007; 25: 197-206. 
Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos 
RC, Tran TB, Whaley R, Glennon RA, Hert J, Thomas KL, Edwards DD, Shoichet BK, 
Roth BL. Predicting new molecular targets for known drugs. Nature 2009; 462: 175-81. 
Keith DE, Anton B, Murray SR, Zaki PA, Chu PC, Lissin DV, Monteillet-Agius G, Stewart PL, 
Evans CJ, von Zastrow M. mu-Opioid receptor internalization: opiate drugs have 
differential effects on a conserved endocytic mechanism in vitro and in the mammalian 
brain. Mol Pharmacol 1998; 53: 377-84. 
Keller M, Mazuch J, Abraham U, Eom GD, Herzog ED, Volk HD, Kramer A, Maier B. A circadian 
clock in macrophages controls inflammatory immune responses. Proc Natl Acad Sci U 
S A 2009; 106: 21407-12. 
Kelly E, Bailey CP, Henderson G. Agonist-selective mechanisms of GPCR desensitization. Br J 
Pharmacol 2008; 153 Suppl 1: S379-88. 
Kennedy BC, Panksepp JB, Wong JC, Krause EJ, Lahvis GP. Age-dependent and strain-
dependent influences of morphine on mouse social investigation behavior. Behavioural 
pharmacology 2011. 
282 | P a g e  
 
Khan MM, Sansoni P, Silverman ED, Engleman EG, Melmon KL. Beta-adrenergic receptors on 
human suppressor, helper, and cytolytic lymphocytes. Biochem Pharmacol 1986; 35: 
1137-42. 
Kidd S, Brennan S, Stephen R, Minns R, Beattie T. Comparison of morphine concentration-time 
profiles following intravenous and intranasal diamorphine in children. Arch Dis Child 
2009; 94: 974-8. 
Kilpatrick GJ, Smith TW. Morphine-6-glucuronide: actions and mechanisms. Med Res Rev 
2005; 25: 521-44. 
Kim I, Barnes AJ, Oyler JM, Schepers R, Joseph RE, Jr., Cone EJ, Lafko D, Moolchan ET, 
Huestis MA. Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral 
codeine administration. Clin Chem 2002; 48: 1486-96. 
Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. 
Immunology 2007; 121: 1-14. 
Kin NW, Sanders VM. It takes nerve to tell T and B cells what to do. J Leukoc Biol 2006; 79: 
1093-104. 
Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lotsch J, Roots I, Brockmoller J. 
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers 
due to CYP2D6 duplication. Pharmacogenomics J 2007; 7: 257-65. 
Klein TW, Newton C, Larsen K, Chou J, Perkins I, Lu L, Nong L, Friedman H. Cannabinoid 
receptors and T helper cells. J Neuroimmunol. 2004; 147: 91-94. 
Klepstad P, Fladvad T, Skorpen F, Bjordal K, Caraceni A, Dale O, Davies A, Kloke M, 
Lundstrom S, Maltoni M, Radbruch L, Sabatowski R, Sigurdardottir V, Strasser F, 
Fayers PM, Kaasa S. Influence from genetic variability on opioid use for cancer pain: a 
European genetic association study of 2294 cancer pain patients. Pain 2011. 
Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, Baar C, Vikan T, Krokan 
HE, Skorpen F. The 118 A > G polymorphism in the human mu-opioid receptor gene 
may increase morphine requirements in patients with pain caused by malignant 
disease. Acta Anaesthesiol Scand 2004; 48: 1232-9. 
Koodie L, Ramakrishnan S, Roy S. Morphine suppresses tumor angiogenesis through a HIF-
1alpha/p38MAPK pathway. The American journal of pathology 2010; 177: 984-97. 
Kraus J. Regulation of mu-opioid receptors by cytokines. Front Biosci.(Schol.Ed) 2009; 1: 164-
70. 
Kraus J, Borner C, Giannini E, Hickfang K, Braun H, Mayer P, Hoehe MR, Ambrosch A, Konig 
W, Hollt V. Regulation of mu-opioid receptor gene transcription by interleukin-4 and 
influence of an allelic variation within a STAT6 transcription factor binding site. J Biol 
Chem. 2001; 276: 43901-08. 
Kraus J, Borner C, Giannini E, Hollt V. The role of nuclear factor kappaB in tumor necrosis 
factor-regulated transcription of the human mu-opioid receptor gene. Mol.Pharmacol 
2003; 64: 876-84. 
Kraus J, Borner C, Lendeckel U, Hollt V. Interferon-gamma down-regulates transcription of the 
mu-opioid receptor gene in neuronal and immune cells. J Neuroimmunol 2006; 181: 13-
8. 
Kraus J, Horn G, Zimprich A, Simon T, Mayer P, Hollt V. Molecular cloning and functional 
analysis of the rat mu opioid receptor gene promoter. Biochem.Biophys.Res.Commun. 
1995; 215: 591-97. 
Kristensen K, Christensen CB, Christrup LL. The mu1, mu2, delta, kappa opioid receptor 
binding profiles of methadone stereoisomers and morphine. Life Sci 1995; 56: PL45-50. 
Kuno K, Matsushima K. The IL-1 receptor signaling pathway. J Leukoc Biol 1994; 56: 542-7. 
Labuz D, Schmidt Y, Schreiter A, Rittner HL, Mousa SA, Machelska H. Immune cell-derived 
opioids protect against neuropathic pain in mice. J Clin.Invest 2009; 119: 278-86. 
Labuz D, Schreiter A, Schmidt Y, Brack A, Machelska H. T lymphocytes containing beta-
endorphin ameliorate mechanical hypersensitivity following nerve injury. Brain Behav 
Immun 2010. 
Lacroix-Fralish ML, Mogil JS. Progress in genetic studies of pain and analgesia. Annual review 
of pharmacology and toxicology 2009; 49: 97-121. 
Laird BJ, Scott AC, Colvin LA, McKeon AL, Murray GD, Fearon KC, Fallon MT. Cancer pain and 
its relationship to systemic inflammation: an exploratory study. Pain 2011; 152: 460-3. 
Langford DJ, Tuttle AH, Briscoe C, Harvey-Lewis C, Baran I, Gleeson P, Fischer DB, Buonora 
M, Sternberg WF, Mogil JS. Varying perceived social threat modulates pain behavior in 
283 | P a g e  
 
male mice. The journal of pain : official journal of the American Pain Society 2011; 12: 
125-32. 
Lariviere WR, Mogil JS. The genetics of pain and analgesia in laboratory animals. Methods in 
molecular biology 2010; 617: 261-78. 
Larsen B, Hoff G, Wilhelm W, Buchinger H, Wanner GA, Bauer M. Effect of intravenous 
anesthetics on spontaneous and endotoxin-stimulated cytokine response in cultured 
human whole blood. Anesthesiology 1998; 89: 1218-27. 
Law PY, Wong YH, Loh HH. Molecular mechanisms and regulation of opioid receptor signaling. 
Annu Rev Pharmacol Toxicol 2000; 40: 389-430. 
Lawson KP, Nag S, Thompson AD, Mokha SS. Sex-specificity and estrogen-dependence of 
kappa opioid receptor-mediated antinociception and antihyperalgesia. Pain 2010; 151: 
806-15. 
Lazaro MI, Tomassini N, Gonzalez I, Renaud FL. Reversibility of morphine effects on 
phagocytosis by murine macrophages. Drug Alcohol Depend. 2000; 58: 159-64. 
Lee JD, Rhoades K, Economou JS. Interleukin-4 inhibits the expression of tumour necrosis 
factors alpha and beta, interleukins-1 beta and -6 and interferon-gamma. Immunol Cell 
Biol 1995a; 73: 57-61. 
Lee PJ, Delaney P, Keogh J, Sleeman D, Shorten GD. Catecholamine-o-methyltransferase 
polymorphisms are associated with postoperative pain intensity. The Clinical journal of 
pain 2011; 27: 93-101. 
Lee SC, Kress Y, Zhao ML, Dickson DW, Casadevall A. Cryptococcus neoformans survive and 
replicate in human microglia. Lab Invest 1995b; 73: 871-9. 
Lehmann KA, Kratzenberg U, Schroeder-Bark B, Horrichs-Haermeyer G. Postoperative patient-
controlled analgesia with tramadol: analgesic efficacy and minimum effective 
concentrations. Clin J Pain 1990; 6: 212-20. 
Lenz H, Sandvik L, Qvigstad E, Bjerkelund CE, Raeder J. A comparison of intravenous 
oxycodone and intravenous morphine in patient-controlled postoperative analgesia after 
laparoscopic hysterectomy. Anesth Analg 2009; 109: 1279-83. 
Lewis SS, Hutchinson MR, Rezvani N, Loram LC, Zhang Y, Maier SF, Rice KC, Watkins LR. 
Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-
like receptor 4/MD-2 and interleukin-1beta. Neuroscience 2010; 165: 569-83. 
Li D, Xu XN. NKT cells in HIV-1 infection. Cell Res. 2008; 18: 817-22. 
Liang D, Shi X, Qiao Y, Angst MS, Yeomans DC, Clark JD. Chronic morphine administration 
enhances nociceptive sensitivity and local cytokine production after incision. Mol Pain 
2008; 4: 7. 
Liew FY. T(H)1 and T(H)2 cells: a historical perspective. Nat Rev Immunol 2002; 2: 55-60. 
Liljefors M, Nilsson B, Hjelm Skog AL, Ragnhammar P, Mellstedt H, Frodin JE. Natural killer 
(NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated 
with the monoclonal antibody 17-1A. Int J Cancer 2003; 105: 717-23. 
Lipovsky MM, Gekker G, Hu S, Hoepelman AI, Peterson PK. Morphine enhances complement 
receptor-mediated phagocytosis of Cryptococcus neoformans by human microglia. Clin 
Immunol Immunopathol 1998; 87: 163-7. 
Liu Y, Blackbourn DJ, Chuang LF, Killam KF, Jr., Chuang RY. Effects of in vivo and in vitro 
administration of morphine sulfate upon rhesus macaque polymorphonuclear cell 
phagocytosis and chemotaxis. J Pharmacol Exp Ther 1992; 263: 533-9. 
Liu Z, Gao F, Tian Y. Effects of morphine, fentanyl and tramadol on human immune response. J 
Huazhong Univ Sci Technolog Med Sci 2006; 26: 478-81. 
Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. 
Immunology today 1990; 11: 237-44. 
Logani MK, Alekseev S, Bhopale MK, Slovinsky WS, Ziskin MC. Effect of millimeter waves and 
cyclophosphamide on cytokine regulation. Immunopharmacology and 
immunotoxicology 2011. 
Lopez-Gimenez JF, Milligan G. Opioid regulation of mu receptor internalisation: relevance to the 
development of tolerance and dependence. CNS & neurological disorders drug targets 
2010; 9: 616-26. 
Lotsch J, Klepstad P, Doehring A, Dale O. A GTP cyclohydrolase 1 genetic variant delays 
cancer pain. Pain 2010; 148: 103-6. 
Lotsch J, Skarke C, Schmidt H, Rohrbacher M, Hofmann U, Schwab M, Geisslinger G. 
Evidence for morphine-independent central nervous opioid effects after administration 
284 | P a g e  
 
of codeine: contribution of other codeine metabolites. Clin Pharmacol Ther 2006; 79: 
35-48. 
Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human 
infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996; 9: 532-62. 
Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat 
Rev Immunol 2010; 10: 236-47. 
Luster AD, Unkeless JC, Ravetch JV. Gamma-interferon transcriptionally regulates an early-
response gene containing homology to platelet proteins. Nature 1985; 315: 672-6. 
Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-
protein-coupled receptor signals. J Cell Sci 2002; 115: 455-65. 
Lysle DT, Coussons ME, Watts VJ, Bennett EH, Dykstra LA. Morphine-induced alterations of 
immune status: dose dependency, compartment specificity and antagonism by 
naltrexone. J Pharmacol Exp Ther 1993; 265: 1071-8. 
Lysle DT, Hoffman KE, Dykstra LA. Evidence for the involvement of the caudal region of the 
periaqueductal gray in a subset of morphine-induced alterations of immune status. J 
Pharmacol Exp Ther 1996; 277: 1533-40. 
Ma CS, Tangye SG, Deenick EK. Human Th9 cells: inflammatory cytokines modulate IL-9 
production through the induction of IL-21. Immunology and cell biology 2010; 88: 621-3. 
Machelska H, Stein C. Leukocyte-derived opioid peptides and inhibition of pain. 
J.Neuroimmune.Pharmacol. 2006; 1: 90-97. 
Maddocks I, Somogyi A, Abbott F, Hayball P, Parker D. Attenuation of morphine-induced 
delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom 
Manage 1996; 12: 182-9. 
Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I, Durrant LG. High expression of Lewis y/b 
antigens is associated with decreased survival in lymph node negative breast 
carcinomas. Breast cancer research : BCR 2005; 7: R780-7. 
Magazine HI, Chang J, Goumon Y, Stefano GB. Rebound from nitric oxide inhibition triggers 
enhanced monocyte activation and chemotaxis. J Immunol 2000; 165: 102-7. 
Magazine HI, Liu Y, Bilfinger TV, Fricchione GL, Stefano GB. Morphine-induced conformational 
changes in human monocytes, granulocytes, and endothelial cells and in invertebrate 
immunocytes and microglia are mediated by nitric oxide. J Immunol 1996; 156: 4845-
50. 
Maguire P, Tsai N, Kamal J, Cometta-Morini C, Upton C, Loew G. Pharmacological profiles of 
fentanyl analogs at mu, delta and kappa opiate receptors. European journal of 
pharmacology 1992; 213: 219-25. 
Maino VC, Suni MA, Ruitenberg JJ. Rapid flow cytometric method for measuring lymphocyte 
subset activation. Cytometry 1995; 20: 127-33. 
Makman MH, Dvorkin B, Stefano GB. Murine macrophage cell lines contain mu 3-opiate 
receptors. Eur J Pharmacol 1995; 273: R5-6. 
Manchikanti L, Vallejo R, Manchikanti KN, Benyamin RM, Datta S, Christo PJ. Effectiveness of 
long-term opioid therapy for chronic non-cancer pain. Pain physician 2011; 14: E133-
56. 
Manson JE. Pain: sex differences and implications for treatment. Metabolism 2010; 59 Suppl 1: 
S16-20. 
Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation 
of innate and adaptive immunity. Nature reviews. Immunology 2011; 11: 519-31. 
Mardiney M, 3rd, Brown MR, Fleisher TA. Measurement of T-cell CD69 expression: a rapid and 
efficient means to assess mitogen- or antigen-induced proliferative capacity in normals. 
Cytometry 1996; 26: 305-10. 
Martin JL, Charboneau R, Barke RA, Roy S. Chronic morphine treatment inhibits LPS-induced 
angiogenesis: implications in wound healing. Cellular immunology 2010; 265: 139-45. 
Martini L, Whistler JL. The role of mu opioid receptor desensitization and endocytosis in 
morphine tolerance and dependence. Curr.Opin.Neurobiol. 2007; 17: 556-64. 
Martucci C, Franchi S, Lattuada D, Panerai AE, Sacerdote P. Differential involvement of RelB in 
morphine-induced modulation of chemotaxis, NO, and cytokine production in murine 
macrophages and lymphocytes. J.Leukoc.Biol. 2007; 81: 344-54. 
Martucci C, Panerai AE, Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: 
similar analgesic profile but different effects on immune responses. Pain 2004; 110: 
385-92. 
285 | P a g e  
 
Mazoit JX, Butscher K, Samii K. Morphine in postoperative patients: pharmacokinetics and 
pharmacodynamics of metabolites. Anesth.Analg. 2007; 105: 70-78. 
Mazzardo-Martins L, Martins DF, Marcon R, Dos Santos UD, Speckhann B, Gadotti VM, Sigwalt 
AR, Guglielmo LG, Soares Santos AR. High-Intensity Extended Swimming Exercise 
Reduces Pain-Related Behavior in Mice: Involvement of Endogenous Opioids and the 
Serotonergic System. J Pain 2010. 
Meert TF, Vermeirsch HA. A preclinical comparison between different opioids: antinociceptive 
versus adverse effects. Pharmacol Biochem Behav 2005; 80: 309-26. 
Mellon RD, Bayer BM. Role of central opioid receptor subtypes in morphine-induced alterations 
in peripheral lymphocyte activity. Brain Res. 1998; 789: 56-67. 
Menon AG, Janssen-van Rhijn CM, Morreau H, Putter H, Tollenaar RA, van de Velde CJ, 
Fleuren GJ, Kuppen PJ. Immune system and prognosis in colorectal cancer: a detailed 
immunohistochemical analysis. Lab Invest 2004; 84: 493-501. 
Menon AG, Morreau H, Tollenaar RA, Alphenaar E, Van Puijenbroek M, Putter H, Janssen-Van 
Rhijn CM, Van De Velde CJ, Fleuren GJ, Kuppen PJ. Down-regulation of HLA-A 
expression correlates with a better prognosis in colorectal cancer patients. Lab Invest 
2002; 82: 1725-33. 
Mercadante S, Bianchi M, Villari P, Ferrera P, Casuccio A, Fulfaro F, Gebbia V. Opioid plasma 
concentration during switching from morphine to methadone: preliminary data. Support 
Care Cancer 2003; 11: 326-31. 
Mercadante S, Villari P, Ferrera P, Casuccio A, Gambaro V. Opioid plasma concentrations 
during a switch from transdermal fentanyl to methadone. J Palliat.Med. 2007; 10: 338-
44. 
Mercer SL, Coop A. Opioid Analgesics and P-glycoprotein Efflux Transporters: A Potential 
Systems-Level Contribution to Analgesic Tolerance. Curr Top Med Chem 2010. 
Meuldermans WE, Hurkmans RM, Heykants JJ. Plasma protein binding and distribution of 
fentanyl, sufentanil, alfentanil and lofentanil in blood. Arch Int Pharmacodyn Ther 1982; 
257: 4-19. 
Mignat C, Wille U, Ziegler A. Affinity profiles of morphine, codeine, dihydrocodeine and their 
glucuronides at opioid receptor subtypes. Life sciences 1995; 56: 793-9. 
Mika J. Modulation of microglia can attenuate neuropathic pain symptoms and enhance 
morphine effectiveness. Pharmacol.Rep. 2008; 60: 297-307. 
Mitchell TB, Lintzeris N, Bond A, Strang J. Feasibility and acceptability of an intranasal 
diamorphine spray as an alternative to injectable diamorphine for maintenance 
treatment. Eur Addict Res 2006; 12: 91-5. 
Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M. The multifaceted relationship between IL-10 
and adaptive immunity: putting together the pieces of a puzzle. Cytokine & growth factor 
reviews 2004; 15: 61-76. 
Mody M, Lazarus AH, Semple JW, Freedman J. Preanalytical requirements for flow cytometric 
evaluation of platelet activation: choice of anticoagulant. Transfusion medicine 1999; 9: 
147-54. 
Mogil JS, Bailey AL. Sex and gender differences in pain and analgesia. Progress in brain 
research 2010; 186: 141-57. 
Mohan S, Davis RL, DeSilva U, Stevens CW. Dual regulation of mu opioid receptors in SK-N-
SH neuroblastoma cells by morphine and interleukin-1beta: evidence for opioid-immune 
crosstalk. Journal of neuroimmunology 2010; 227: 26-34. 
Molina PE, Hashiguchi Y, Meijerink WJ, Naukam RJ, Boxer R, Abumrad NN. Modulation of 
endogenous opiate production: effect of fasting. Biochem Biophys Res Commun 1995; 
207: 312-7. 
Molitor TW, Murtaugh MP, Click RE, Gekker G, Chao C, Peterson PK. Functional alterations of 
swine peripheral blood mononuclear cells by methadone. J Leukoc Biol 1992; 51: 124-
8. 
Molloy S. Innate immunity: The stress connection. Nat Rev Micro 2010; 8: 387-87. 
Morita CT, Mariuzza RA, Brenner MB. Antigen recognition by human gamma delta T cells: 
pattern recognition by the adaptive immune system. Springer seminars in 
immunopathology 2000; 22: 191-217. 
Mossner R, Lesch KP. Role of serotonin in the immune system and in neuroimmune 
interactions. Brain Behav Immun 1998; 12: 249-71. 
286 | P a g e  
 
Motzer SA, Tsuji J, Hertig V, Johnston SK, Scanlan J. Natural killer cell cytotoxicity: a methods 
analysis of 51chromium release versus flow cytometry. Biological research for nursing 
2003; 5: 142-52. 
Mucci-LoRusso P, Berman BS, Silberstein PT, Citron ML, Bressler L, Weinstein SM, Kaiko RF, 
Buckley BJ, Reder RF. Controlled-release oxycodone compared with controlled-release 
morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group 
study. Eur.J Pain 1998; 2: 239-49. 
Myles PS, Peyton P, Silbert B, Hunt J, Rigg JR, Sessler DI. Perioperative epidural analgesia for 
major abdominal surgery for cancer and recurrence-free survival: randomised trial. BMJ 
2011; 342: d1491. 
Nair MP, Schwartz SA, Polasani R, Hou J, Sweet A, Chadha KC. Immunoregulatory effects of 
morphine on human lymphocytes. Clin Diagn Lab Immunol 1997; 4: 127-32. 
Nair MP, Schwartz SA, Wu K, Kronfol Z. Effect of neuropeptide Y on natural killer activity of 
normal human lymphocytes. Brain Behav Immun 1993; 7: 70-8. 
Nakamura H, Kawasaki N, Hagiwara M, Saito M, Konaka C, Kato H. Cellular immunologic 
parameters related to age, gender, and stage in lung cancer patients. Lung Cancer 
2000; 28: 139-45. 
Negus S, Woods J. Reinforcing effects, discriminative stimulus effects and physical 
dependence liability of buprenorphine. In: Cowan A, Lewis J, eds. Buprenorphine; 
Combatting Drug Abuse with a Unique Opioid. New York: Wiley-Liss, Inc; 1995:71–101. 
Nelson CJ, Dykstra LA, Lysle DT. Comparison of the time course of morphine's analgesic and 
immunologic effects. Anesth Analg 1997; 85: 620-6. 
Nelson CJ, Schneider GM, Lysle DT. Involvement of central mu- but not delta- or kappa-opioid 
receptors in immunomodulation. Brain Behav.Immun. 2000; 14: 170-84. 
Nestler EJ. Historical review: Molecular and cellular mechanisms of opiate and cocaine 
addiction. Trends Pharmacol Sci 2004; 25: 210-8. 
Nielsen DA, Yuferov V, Hamon S, Jackson C, Ho A, Ott J, Kreek MJ. Increased OPRM1 DNA 
methylation in lymphocytes of methadone-maintained former heroin addicts. 
Neuropsychopharmacology 2009; 34: 867-73. 
Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, Kostakis A, Peros 
G. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: 
prognostic implications. World journal of gastroenterology : WJG 2005; 11: 1639-43. 
Nikolarakis KE, Pfeiffer A, Stalla GK, Herz A. Facilitation of ACTH secretion by morphine is 
mediated by activation of CRF releasing neurons and sympathetic neuronal pathways. 
Brain Res 1989; 498: 385-8. 
Novick DM, Ochshorn M, Ghali V, Croxson TS, Mercer WD, Chiorazzi N, Kreek MJ. Natural 
killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term 
methadone maintenance patients. J Pharmacol Exp Ther 1989; 250: 606-10. 
Nüssler NC, Stange BJ, Petzold M, Nussler AK, Glanemann M, Guckelberger O. Reduced NK-
Cell Activity in Patients with Metastatic Colon Cancer. EXCLI Journal 2007: 1-9. 
O'Garra A, Arai N. The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends 
Cell Biol 2000; 10: 542-50. 
O'Neill LA. Interleukin-1 signal transduction. International journal of clinical & laboratory 
research 1995; 25: 169-77. 
Obar JJ, Molloy MJ, Jellison ER, Stoklasek TA, Zhang W, Usherwood EJ, Lefrancois L. CD4+ T 
cell regulation of CD25 expression controls development of short-lived effector CD8+ T 
cells in primary and secondary responses. Proc Natl Acad Sci U S A 2010; 107: 193-8. 
Oda Y, Kharasch ED. Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by 
human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal 
metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther 2001; 
298: 1021-32. 
Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lotsch J. The mu-opioid receptor gene 
polymorphism 118A>G depletes alfentanil-induced analgesia and protects against 
respiratory depression in homozygous carriers. Pharmacogenet Genomics 2006; 16: 
625-36. 
Orditura M, Romano C, De Vita F, Galizia G, Lieto E, Infusino S, De Cataldis G, Catalano G. 
Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: 
relationship with response to therapy and survival. Cancer Immunol Immunother 2000; 
49: 530-6. 
287 | P a g e  
 
Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E. Oxycodone: a pharmacological and 
clinical review. Clin Transl Oncol 2007; 9: 298-307. 
Pacifici R, di Carlo S, Bacosi A, Pichini S, Zuccaro P. Pharmacokinetics and cytokine production 
in heroin and morphine-treated mice. Int J Immunopharmacol 2000; 22: 603-14. 
Pacifici R, Patrini G, Venier I, Parolaro D, Zuccaro P, Gori E. Effect of morphine and methadone 
acute treatment on immunological activity in mice: pharmacokinetic and 
pharmacodynamic correlates. J Pharmacol Exp Ther 1994; 269: 1112-6. 
Page GG. The immune-suppressive effects of pain. Adv.Exp.Med.Biol. 2003; 521: 117-25. 
Page GG. Immunologic effects of opioids in the presence or absence of pain. J.Pain 
Symptom.Manage. 2005; 29: S25-S31. 
Page GG, Blakely WP, Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the 
tumor-promoting effects of surgery in rats. Pain 2001; 90: 191-99. 
Paldyova E, Bereczki E, Santha M, Wenger T, Borsodi A, Benyhe S. Altered gene expression 
and functional activity of opioid receptors in the cerebellum of CB1 cannabinoid receptor 
knockout mice after acute treatments with cannabinoids. Acta biologica Hungarica 
2007; 58 Suppl: 113-29. 
Paller CJ, Campbell CM, Edwards RR, Dobs AS. Sex-based differences in pain perception and 
treatment. Pain Med 2009; 10: 289-99. 
Palm S, Mignat C, Kuhn K, Umbreit H, Barth J, Stuber F, Maier C. Phytohemagglutinin-
dependent T-cell proliferation is not impaired by morphine. Methods Find Exp Clin 
Pharmacol 1996; 18: 159-65. 
Pan YX. Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing 
and promoters. DNA Cell Biol 2005; 24: 736-50. 
Pan YX, Xu J, Mahurter L, Bolan E, Xu M, Pasternak GW. Generation of the mu opioid receptor 
(MOR-1) protein by three new splice variants of the Oprm gene. Proc Natl Acad Sci U S 
A 2001; 98: 14084-9. 
Park HJ, Shinn HK, Ryu SH, Lee HS, Park CS, Kang JH. Genetic polymorphisms in the ABCB1 
gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther 2007; 81: 539-46. 
Patrini G, Massi P, Ricevuti G, Mazzone A, Fossati G, Mazzucchelli I, Gori E, Parolaro D. 
Changes in opioid receptor density on murine splenocytes induced by in vivo treatment 
with morphine and methadone. J Pharmacol Exp Ther 1996; 279: 172-6. 
Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 1991; 77: 1859-70. 
Paul WE, Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat Rev 
Immunol 2010; 10: 225-35. 
Paust S, Senman B, Andrian UHv. Adaptive immune responses mediated by natural killer cells. 
Immunological Reviews 2010; 235: 286-96. 
Pawelec G. Tumour escape: antitumour effectors too much of a good thing? Cancer Immunol 
Immunother 2004; 53: 262-74. 
Pedersen BK. Muscular IL-6 and Its Role as an Energy Sensor. Medicine and science in sports 
and exercise 2011. 
Peiro AM, Margarit C, Gimenez P, Horga JF. Pharmacogenetic testing is of limited utility for 
predicting analgesic response to morphine. J Pain Symptom Manage 2010; 39: e8-e11. 
Peng X, Mosser DM, Adler MW, Rogers TJ, Meissler JJ, Jr., Eisenstein TK. Morphine enhances 
interleukin-12 and the production of other pro-inflammatory cytokines in mouse 
peritoneal macrophages. J Leukoc Biol 2000; 68: 723-8. 
Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, 
Raffa RB, Sacerdote P. Opioids and the management of chronic severe pain in the 
elderly: consensus statement of an International Expert Panel with focus on the six 
clinically most often used World Health Organization step III opioids (buprenorphine, 
fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008; 8: 287-
313. 
Peroutka SJ, Howell TA. The molecular evolution of G protein-coupled receptors: focus on 5-
hydroxytryptamine receptors. Neuropharmacology 1994; 33: 319-24. 
Pesonen A, Suojaranta-Ylinen R, Hammaren E, Tarkkila P, Seppala T, Rosenberg PH. 
Comparison of effects and plasma concentrations of opioids between elderly and 
middle-aged patients after cardiac surgery. Acta Anaesthesiol Scand 2009; 53: 101-8. 
Peterson PK, Gekker G, Brummitt C, Pentel P, Bullock M, Simpson M, Hitt J, Sharp B. 
Suppression of human peripheral blood mononuclear cell function by methadone and 
morphine. J.Infect.Dis. 1989; 159: 480-87. 
288 | P a g e  
 
Peterson PK, Gekker G, Hu S, Sheng WS, Molitor TW, Chao CC. Morphine stimulates 
phagocytosis of Mycobacterium tuberculosis by human microglial cells: involvement of a 
G protein-coupled opiate receptor. Adv Neuroimmunol 1995; 5: 299-309. 
Peterson PK, Molitor TW, Chao CC. The opioid-cytokine connection. J.Neuroimmunol. 1998; 
83: 63-69. 
Peterson PK, Sharp B, Gekker G, Brummitt C, Keane WF. Opioid-mediated suppression of 
cultured peripheral blood mononuclear cell respiratory burst activity. J Immunol 1987; 
138: 3907-12. 
Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL, Bowman ED, Engels 
EA, Caporaso NE, Harris CC. Increased levels of circulating interleukin 6, interleukin 8, 
C-reactive protein, and risk of lung cancer. Journal of the National Cancer Institute 
2011; 103: 1112-22. 
Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev 
Immunol 2005; 5: 375-86. 
Qian YN, Jin WJ, Wang L, Wang HJ. Effect of different concentrations of morphine and 
tramadol on the differentiation of human helper T cells in vitro. Br.J Anaesth. 2005; 95: 
277. 
Quinones-Jenab V, Jenab S, Ogawa S, Inturrisi C, Pfaff DW. Estrogen regulation of mu-opioid 
receptor mRNA in the forebrain of female rats. Brain Res.Mol.Brain Res. 1997; 47: 134-
38. 
Rabquer BJ, Tsou PS, Hou Y, Thirunavukkarasu E, Haines GK, 3rd, Impens AJ, Phillips K, 
Kahaleh B, Seibold JR, Koch AE. Dysregulated expression of MIG/CXCL9, IP-
10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis research & 
therapy 2011; 13: R18. 
Raffa RB. A novel approach to the pharmacology of analgesics. Am J Med 1996; 101: 40S-46S. 
Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL, Jacoby HI, Selve N. 
Complementary and synergistic antinociceptive interaction between the enantiomers of 
tramadol. J Pharmacol Exp Ther 1993; 267: 331-40. 
Rakvag TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S, Krokan HE, Skorpen F. The 
Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene 
may influence morphine requirements in cancer pain patients. Pain 2005; 116: 73-8. 
Rakvag TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P. Genetic variation in the 
catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer 
patients with pain. Mol Pain 2008; 4: 64. 
Ramnath N, Tan D, Li Q, Hylander BL, Bogner P, Ryes L, Ferrone S. Is downregulation of MHC 
class I antigen expression in human non-small cell lung cancer associated with 
prolonged survival? Cancer immunology, immunotherapy : CII 2006; 55: 891-9. 
Rao Y, Wang YL, Li JG, Ke JJ. Effects of morphine and fentanyl on tumor necrosis factor-alpha 
and interleukin-6 concentrations in human whole blood in vitro. Chin Med J (Engl) 2004; 
117: 303-4. 
Reiman JM, Kmieciak M, Manjili MH, Knutson KL. Tumor immunoediting and immunosculpting 
pathways to cancer progression. Semin.Cancer Biol 2007; 17: 275-87. 
Rentsch KM, Kullak-Ublick GA, Reichel C, Meier PJ, Fattinger K. Arterial and venous 
pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics. Clin 
Pharmacol Ther 2001; 70: 237-46. 
Rittner HL, Brack A, Stein C. Pain and the immune system. Br.J.Anaesth. 2008; 101: 40-44. 
Robinson SL, Rowbotham DJ, Smith G. Morphine compared with diamorphine. A comparison of 
dose requirements and side-effects after hip surgery. Anaesthesia 1991; 46: 538-40. 
Rojavin M, Szabo I, Bussiere JL, Rogers TJ, Adler MW, Eisenstein TK. Morphine treatment in 
vitro or in vivo decreases phagocytic functions of murine macrophages. Life Sci 1993; 
53: 997-1006. 
Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH. Pharmacokinetics and 
pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr 
Clin Pharmacol 2006; 1: 109-18. 
Roozafzoon R, Goodarzi A, Vousooghi N, Sedaghati M, Yaghmaei P, Zarrindast MR. 
Expression of NMDA receptor subunits in human peripheral blood lymphocytes in opioid 
addiction. Eur J Pharmacol 2010; 638: 29-32. 
Ross JR, Riley J, Quigley C, Welsh KI. Clinical pharmacology and pharmacotherapy of opioid 
switching in cancer patients. Oncologist 2006; 11: 765-73. 
289 | P a g e  
 
Rossi GC, Brown GP, Leventhal L, Yang K, Pasternak GW. Novel receptor mechanisms for 
heroin and morphine-6 beta-glucuronide analgesia. Neurosci Lett 1996; 216: 1-4. 
Rossi S, Furlan R, De Chiara V, Muzio L, Musella A, Motta C, Studer V, Cavasinni F, Bernardi 
G, Martino G, Cravatt BF, Lutz B, Maccarrone M, Centonze D. Cannabinoid CB1 
receptors regulate neuronal TNF-alpha effects in experimental autoimmune 
encephalomyelitis. Brain, behavior, and immunity 2011. 
Roth BL, Willins DL. What's all the RAVE about receptor internalization? Neuron 1999; 23: 629-
31. 
Rothe G, Valet G. Flow cytometric assays of oxidative burst activity in phagocytes. Methods 
Enzymol 1994; 233: 539-48. 
Roy S, Balasubramanian S, Sumandeep S, Charboneau R, Wang J, Melnyk D, Beilman GJ, 
Vatassery R, Barke RA. Morphine directs T cells toward T(H2) differentiation. Surgery 
2001; 130: 304-9. 
Roy S, Barke RA, Loh HH. MU-opioid receptor-knockout mice: role of mu-opioid receptor in 
morphine mediated immune functions. Brain Res.Mol.Brain Res. 1998a; 61: 190-94. 
Roy S, Cain KJ, Chapin RB, Charboneau RG, Barke RA. Morphine modulates NF kappa B 
activation in macrophages. Biochem Biophys Res Commun 1998b; 245: 392-6. 
Roy S, Ninkovic J, Banerjee S, Charboneau RG, Das S, Dutta R, Kirchner VA, Koodie L, Ma J, 
Meng J, Barke RA. Opioid Drug Abuse and Modulation of Immune Function: 
Consequences in the Susceptibility to Opportunistic Infections. Journal of neuroimmune 
pharmacology : the official journal of the Society on NeuroImmune Pharmacology 2011. 
Roy S, Wang J, Charboneau R, Loh HH, Barke RA. Morphine induces CD4+ T cell IL-4 
expression through an adenylyl cyclase mechanism independent of the protein kinase A 
pathway. J Immunol 2005; 175: 6361-7. 
Rozenfeld R, Devi LA. Receptor heterodimerization leads to a switch in signaling: beta-
arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J 
2007; 21: 2455-65. 
Rubovitch V, Gafni M, Sarne Y. The mu opioid agonist DAMGO stimulates cAMP production in 
SK-N-SH cells through a PLC-PKC-Ca++ pathway. Brain Res Mol Brain Res 2003; 110: 
261-6. 
Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J. Biology of interleukin-
10. Cytokine & growth factor reviews 2010; 21: 331-44. 
Sacerdote P. Opioid-induced immunosuppression. Curr.Opin.Support.Palliat.Care 2008; 2: 14-
18. 
Sacerdote P, Bianchi M, Gaspani L, Manfredi B, Maucione A, Terno G, Ammatuna M, Panerai 
AE. The effects of tramadol and morphine on immune responses and pain after surgery 
in cancer patients. Anesth.Analg. 2000; 90: 1411-14. 
Sacerdote P, Bianchi M, Gaspani L, Panerai AE. Effects of tramadol and its enantiomers on 
Concanavalin-A induced-proliferation and NK activity of mouse splenocytes: 
involvement of serotonin. Int.J Immunopharmacol. 1999; 21: 727-34. 
Sacerdote P, Franchi S, Gerra G, Leccese V, Panerai AE, Somaini L. Buprenorphine and 
methadone maintenance treatment of heroin addicts preserves immune function. Brain 
Behav.Immun. 2008; 22: 606-13. 
Sacerdote P, Manfredi B, Mantegazza P, Panerai AE. Antinociceptive and immunosuppressive 
effects of opiate drugs: a structure-related activity study. Br.J.Pharmacol. 1997; 121: 
834-40. 
Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, Hill BJ, Noto A, Ancuta P, Peretz 
Y, Fonseca SG, Van Grevenynghe J, Boulassel MR, Bruneau J, Shoukry NH, Routy JP, 
Douek DC, Haddad EK, Sekaly RP. Programmed death-1-induced interleukin-10 
production by monocytes impairs CD4+ T cell activation during HIV infection. Nature 
medicine 2010; 16: 452-9. 
Saito H, Osaki T, Ikeguchi M. Decreased NKG2D expression on NK cells correlates with 
impaired NK cell function in patients with gastric cancer. Gastric cancer : official journal 
of the International Gastric Cancer Association and the Japanese Gastric Cancer 
Association 2011. 
Salmon AY, Goren Z, Avissar Y, Soreq H. Human erythrocyte but not brain acetylcholinesterase 
hydrolyses heroin to morphine. Clin Exp Pharmacol Physiol 1999; 26: 596-600. 
Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, 
Hochstrasser D, Dayer P, Desmeules JA. Genetic polymorphisms and drug interactions 
290 | P a g e  
 
modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic 
efficacy and safety. Br J Pharmacol 2010; 160: 919-30. 
Sancho D, Gomez M, Sanchez-Madrid F. CD69 is an immunoregulatory molecule induced 
following activation. Trends Immunol 2005; 26: 136-40. 
Sancho D, Gomez M, Viedma F, Esplugues E, Gordon-Alonso M, Garcia-Lopez MA, de la 
Fuente H, Martinez AC, Lauzurica P, Sanchez-Madrid F. CD69 downregulates 
autoimmune reactivity through active transforming growth factor-beta production in 
collagen-induced arthritis. J Clin Invest 2003; 112: 872-82. 
Sandel MH, Speetjens FM, Menon AG, Albertsson PA, Basse PH, Hokland M, Nagelkerke JF, 
Tollenaar RA, van de Velde CJ, Kuppen PJ. Natural killer cells infiltrating colorectal 
cancer and MHC class I expression. Mol Immunol 2005; 42: 541-6. 
Santos V, Lopez KJ, Santos LM, Yonamine M, Carmona MJ, Santos SR. Determining plasma 
morphine levels using GC-MS after solid phase extraction to monitor drug levels in the 
postoperative period. Clinics. 2008; 63: 307-14. 
Saurer TB, Carrigan KA, Ijames SG, Lysle DT. Suppression of natural killer cell activity by 
morphine is mediated by the nucleus accumbens shell. J.Neuroimmunol. 2006a; 173: 3-
11. 
Saurer TB, Ijames SG, Lysle DT. Neuropeptide Y Y1 receptors mediate morphine-induced 
reductions of natural killer cell activity. J.Neuroimmunol. 2006b; 177: 18-26. 
Schantz SP, Ordonez NG. Quantitation of natural killer cell function and risk of metastatic poorly 
differentiated head and neck cancer. Nat Immun Cell Growth Regul 1991; 10: 278-88. 
Schedlowski M, Hosch W, Oberbeck R, Benschop RJ, Jacobs R, Raab HR, Schmidt RE. 
Catecholamines modulate human NK cell circulation and function via spleen-
independent beta 2-adrenergic mechanisms. J Immunol 1996; 156: 93-9. 
Schneemilch CE, Hachenberg T, Ansorge S, Ittenson A, Bank U. Effects of different anaesthetic 
agents on immune cell function in vitro. Eur.J Anaesthesiol. 2005; 22: 616-23. 
Schramm CL, Honda CN. Co-administration of delta- and mu-opioid receptor agonists promotes 
peripheral opioid receptor function. Pain 2010; 151: 763-70. 
Schutze GE, Hall MA, Baker CJ, Edwards MS. Role of neutrophil receptors in 
opsonophagocytosis of coagulase-negative staphylococci. Infect Immun 1991; 59: 
2573-8. 
Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, Rauschkolb C. 
Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral 
neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Current 
medical research and opinion 2011; 27: 151-62. 
Schwartz Y, Avraham R, Benish M, Rosenne E, Ben-Eliyahu S. Prophylactic IL-12 treatment 
reduces postoperative metastasis: mediation by increased numbers but not cytotoxicity 
of NK cells. Breast Cancer Res Treat 2008; 107: 211-23. 
Sergeeva MG, Grishina ZV, Varfolomeyev SD. Morphine effect on proliferation of normal and 
tumor cells of immune origin. Immunology letters 1993; 36: 215-8. 
Serreze DV, Chapman HD, Post CM, Johnson EA, Suarez-Pinzon WL, Rabinovitch A. Th1 to 
Th2 cytokine shifts in nonobese diabetic mice: sometimes an outcome, rather than the 
cause, of diabetes resistance elicited by immunostimulation. Journal of immunology 
2001; 166: 1352-9. 
Shah JC, Mason WD. Plasma codeine and morphine concentrations after a single oral dose of 
codeine phosphate. J Clin Pharmacol 1990; 30: 764-6. 
Shalev I, Schmelzle M, Robson SC, Levy G. Making sense of regulatory T cell suppressive 
function. Seminars in immunology 2011. 
Shavit Y, Ben-Eliyahu S, Zeidel A, Beilin B. Effects of fentanyl on natural killer cell activity and 
on resistance to tumor metastasis in rats. Dose and timing study. 
Neuroimmunomodulation. 2004; 11: 255-60. 
Shavit Y, Depaulis A, Martin FC, Terman GW, Pechnick RN, Zane CJ, Gale RP, Liebeskind JC. 
Involvement of brain opiate receptors in the immune-suppressive effect of morphine. 
Proc Natl Acad Sci U S A 1986; 83: 7114-7. 
Shavit Y, Lewis JW, Terman GW, Gale RP, Liebeskind JC. Opioid peptides mediate the 
suppressive effect of stress on natural killer cell cytotoxicity. Science 1984; 223: 188-
90. 
Sheen CH, Schleimer RP, Kulka M. Codeine induces human mast cell chemokine and cytokine 
production: involvement of G-protein activation. Allergy 2007; 62: 532-8. 
291 | P a g e  
 
Sheeran TP, Jackson FR, Dawes PT, Collins M, Shadforth MF. Measurement of natural killer 
cell cytotoxicity by area under a cytotoxic curve. A method suitable for rheumatoid 
arthritis. J Immunol Methods 1988; 115: 95-8. 
Shen CH, Tsai RY, Shih MS, Lin SL, Tai YH, Chien CC, Wong CS. Etanercept restores the 
antinociceptive effect of morphine and suppresses spinal neuroinflammation in 
morphine-tolerant rats. Anesthesia and analgesia 2011; 112: 454-9. 
Shephard RJ, Shek PN. Exercise, immunity, and susceptibility to infection: a j-shaped 
relationship? Phys Sportsmed 1999; 27: 47-71. 
Shi TX, Tong MJ, Bohman R. The application of flow cytometry in the study of natural killer cell 
cytotoxicity. Clinical immunology and immunopathology 1987; 45: 356-65. 
Shiow LR, Rosen DB, Brdickova N, Xu Y, An J, Lanier LL, Cyster JG, Matloubian M. CD69 acts 
downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from 
lymphoid organs. Nature 2006; 440: 540-4. 
Shirzad H, Shahrani M, Rafieian-Kopaei M. Comparison of morphine and tramadol effects on 
phagocytic activity of mice peritoneal phagocytes in vivo. Int.Immunopharmacol. 2009; 
9: 968-70. 
Simms PE, Ellis TM. Utility of flow cytometric detection of CD69 expression as a rapid method 
for determining poly- and oligoclonal lymphocyte activation. Clin Diagn Lab Immunol 
1996; 3: 301-4. 
Singhal PC, Sharma P, Kapasi AA, Reddy K, Franki N, Gibbons N. Morphine enhances 
macrophage apoptosis. J Immunol 1998; 160: 1886-93. 
Skov Madsen P, Hokland P, Hokland M. Secretory products from thrombin-stimulated human 
platelets exert an inhibitory effect on NK-cytotoxic activity. Acta Pathol Microbiol 
Immunol Scand C 1986; 94: 193-200. 
Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annual review of immunology 
2009; 27: 591-619. 
Smith TW, Binning AR, Dahan A. Efficacy and safety of morphine-6-glucuronide (M6G) for 
postoperative pain relief: a randomized, double-blind study. Eur J Pain 2009; 13: 293-9. 
Sokol CL, Medzhitov R. Emerging functions of basophils in protective and allergic immune 
responses. Mucosal Immunol 2010; 3: 129-37. 
Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 
81: 429-44. 
Sowa G, Gekker G, Lipovsky MM, Hu S, Chao CC, Molitor TW, Peterson PK. Inhibition of swine 
microglial cell phagocytosis of Cryptococcus neoformans by femtomolar concentrations 
of morphine. Biochem Pharmacol 1997; 53: 823-8. 
Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol 
and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin.Pharmacol 
Ther. 2007; 82: 41-47. 
Stefano GB, Cadet P, Kream RM, Zhu W. The presence of endogenous morphine signaling in 
animals. Neurochem.Res. 2008a; 33: 1933-39. 
Stefano GB, Digenis A, Spector S, Leung MK, Bilfinger TV, Makman MH, Scharrer B, Abumrad 
NN. Opiate-like substances in an invertebrate, an opiate receptor on invertebrate and 
human immunocytes, and a role in immunosuppression. Proc.Natl.Acad.Sci.U.S.A 
1993; 90: 11099-103. 
Stefano GB, Kream RM, Mantione KJ, Sheehan M, Cadet P, Zhu W, Bilfinger TV, Esch T. 
Endogenous morphine/nitric oxide-coupled regulation of cellular physiology and gene 
expression: implications for cancer biology. Semin Cancer Biol 2008b; 18: 199-210. 
Stein C, Lang LJ. Peripheral mechanisms of opioid analgesia. Curr Opin Pharmacol 2009; 9: 3-
8. 
Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, Ganz T, Thoma-
Uszynski S, Melian A, Bogdan C, Porcelli SA, Bloom BR, Krensky AM, Modlin RL. An 
antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998; 282: 
121-5. 
Suzuki S, Chuang LF, Yau P, Doi RH, Chuang RY. Interactions of opioid and chemokine 
receptors: oligomerization of mu, kappa, and delta with CCR5 on immune cells. 
Exp.Cell Res. 2002; 280: 192-200. 
Suzuki S, Miyagi T, Chuang TK, Chuang LF, Doi RH, Chuang RY. Morphine upregulates mu 
opioid receptors of human and monkey lymphocytes. Biochem Biophys Res Commun 
2000; 279: 621-8. 
292 | P a g e  
 
Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo 
JL, Kohler RH, Chudnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, 
Weissleder R, Pittet MJ. Identification of splenic reservoir monocytes and their 
deployment to inflammatory sites. Science 2009; 325: 612-6. 
Szabo I, Rojavin M, Bussiere JL, Eisenstein TK, Adler MW, Rogers TJ. Suppression of 
peritoneal macrophage phagocytosis of Candida albicans by opioids. J Pharmacol Exp 
Ther 1993; 267: 703-6. 
Szkaradkiewicz A, Karpinski TM, Drews M, Borejsza-Wysocki M, Majewski P, Andrzejewska E. 
Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in 
patients with gastric cancer. J Biomed Biotechnol 2010; 2010: 901564. 
Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T, Sugimachi K. Natural killer cell activity 
in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. 
Cancer 1998; 83: 58-63. 
Tan EC, Lim EC, Teo YY, Lim Y, Law HY, Sia AT. Ethnicity and OPRM variant independently 
predict pain perception and patient-controlled analgesia usage for post-operative pain. 
Mol Pain 2009; 5: 32. 
Tandonnet F, Bourgain JL, McGee K, Comoy E, Truffa-Bachi J. Hemodynamic and 
catecholamine response to isoflurane versus droperidol in complement to fentanyl 
anaesthesia. Acta Anaesthesiol Scand 1991; 35: 123-8. 
Tassinari D, Sartori S, Tamburini E, Scarpi E, Raffaeli W, Tombesi P, Maltoni M. Adverse 
effects of transdermal opiates treating moderate-severe cancer pain in comparison to 
long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat 
Med 2008; 11: 492-501. 
Taub DD, Eisenstein TK, Geller EB, Adler MW, Rogers TJ. Immunomodulatory activity of mu- 
and kappa-selective opioid agonists. Proc.Natl.Acad.Sci.U.S.A 1991; 88: 360-64. 
Teixeira LK, Fonseca BP, Barboza BA, Viola JP. The role of interferon-gamma on immune and 
allergic responses. Mem Inst Oswaldo Cruz 2005; 100 Suppl 1: 137-44. 
Testi R, D'Ambrosio D, De Maria R, Santoni A. The CD69 receptor: a multipurpose cell-surface 
trigger for hematopoietic cells. Immunol Today 1994; 15: 479-83. 
Thomas PT, Bhargava HN, House RV. Immunomodulatory effects of in vitro exposure to 
morphine and its metabolites. Pharmacology 1995a; 50: 51-62. 
Thomas PT, House RV, Bhargava HN. Direct cellular immunomodulation produced by 
diacetylmorphine (heroin) or methadone. Gen.Pharmacol. 1995b; 26: 123-30. 
Thomson IR, Harding G, Hudson RJ. A comparison of fentanyl and sufentanil in patients 
undergoing coronary artery bypass graft surgery. J Cardiothorac.Vasc.Anesth. 2000; 
14: 652-56. 
Tomassini N, Renaud F, Roy S, Loh HH. Morphine inhibits Fc-mediated phagocytosis through 
mu and delta opioid receptors. J Neuroimmunol. 2004; 147: 131-33. 
Tomassini N, Renaud FL, Roy S, Loh HH. Mu and delta receptors mediate morphine effects on 
phagocytosis by murine peritoneal macrophages. J Neuroimmunol 2003; 136: 9-16. 
Tomei EZ, Renaud FL. Effect of morphine on Fc-mediated phagocytosis by murine 
macrophages in vitro. J Neuroimmunol 1997; 74: 111-6. 
Toskulkao T, Pornchai R, Akkarapatumwong V, Vatanatunyakum S, Govitrapong P. Alteration 
of lymphocyte opioid receptors in methadone maintenance subjects. Neurochem Int 
2010; 56: 285-90. 
Trabold B, Gruber M, Frohlich D. Functional and phenotypic changes in polymorphonuclear 
neutrophils induced by catecholamines. Scandinavian cardiovascular journal : SCJ 
2007; 41: 59-64. 
Trafton JA, Abbadie C, Marek K, Basbaum AI. Postsynaptic signaling via the [mu]-opioid 
receptor: responses of dorsal horn neurons to exogenous opioids and noxious 
stimulation. J Neurosci. 2000; 20: 8578-84. 
Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with 
immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic 
lymphocytes. Blood 1994; 84: 4008-27. 
Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat 
Rev Immunol 2003; 3: 133-46. 
Tso PH, Wong YH. Molecular basis of opioid dependence: role of signal regulation by G-
proteins. Clin Exp Pharmacol Physiol 2003; 30: 307-16. 
293 | P a g e  
 
Tsui BC, Rashiq S, Schopflocher D, Murtha A, Broemling S, Pillay J, Finucane BT. Epidural 
anesthesia and cancer recurrence rates after radical prostatectomy. Canadian journal of 
anaesthesia = Journal canadien d'anesthesie 2010; 57: 107-12. 
Tsujikawa H, Shoda T, Mizota T, Fukuda K. Morphine induces DNA damage and P53 activation 
in CD3(+) T cells. Biochim.Biophys.Acta 2009. 
Tubaro E, Avico U, Santiangeli C, Zuccaro P, Cavallo G, Pacifici R, Croce C, Borelli G. 
Morphine and methadone impact on human phagocytic physiology. Int J 
Immunopharmacol 1985; 7: 865-74. 
Tubaro E, Santiangeli C, Belogi L, Borelli G, Cavallo G, Croce C, Avico U. Methadone vs 
morphine: comparison of their effect on phagocytic functions. Int J Immunopharmacol 
1987; 9: 79-88. 
Twycross RG. Symptom management in advanced cancer. Abingdon, Oxon, UK: Radcliffe 
Medical Press, 1997. 
Vallejo R, Barkin RL, Wang VC. Pharmacology of opioids in the treatment of chronic pain 
syndromes. Pain physician 2011; 14: E343-60. 
Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a 
review. Am.J.Ther. 2004; 11: 354-65. 
van de Veerdonk FL, Gresnigt MS, Kullberg BJ, van der Meer JW, Joosten LA, Netea MG. Th17 
responses and host defense against microorganisms: an overview. BMB reports 2009; 
42: 776-87. 
Van Der Laan JW, Timmerman H, Van Loveren H. Comparison of the in vivo effects of 
morphine and methadone on natural killer cell activity in spleen, peritoneal cavity, and 
lungs in rats. International Journal of Immunopharmacology 1996; 18: 401-07. 
van Leeuwen MT, Webster AC, McCredie MR, Stewart JH, McDonald SP, Amin J, Kaldor JM, 
Chapman JR, Vajdic CM, Grulich AE. Effect of reduced immunosuppression after 
kidney transplant failure on risk of cancer: population based retrospective cohort study. 
BMJ 2010; 340: c570. 
Van Loon GR, Appel NM, Ho D. beta-Endorphin-induced stimulation of central sympathetic 
outflow: beta-endorphin increases plasma concentrations of epinephrine, 
norepinephrine, and dopamine in rats. Endocrinology 1981; 109: 46-53. 
van Pelt LJ, van Zwieten R, Weening RS, Roos D, Verhoeven AJ, Bolscher BG. Limitations on 
the use of dihydrorhodamine 123 for flow cytometric analysis of the neutrophil 
respiratory burst. J Immunol Methods 1996; 191: 187-96. 
van Rijn RM, Whistler JL, Waldhoer M. Opioid-receptor-heteromer-specific trafficking and 
pharmacology. Current opinion in pharmacology 2010; 10: 73-9. 
Vidal EL, Patel NA, Wu G, Fiala M, Chang SL. Interleukin-1 induces the expression of mu opioid 
receptors in endothelial cells. Immunopharmacology 1998; 38: 261-66. 
Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, Zuil M, Callol L. 
Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients 
with squamous cell lung cancer. Lung Cancer 2002; 35: 23-8. 
Von Hoff DD, Kuhn JG, Burris HA, III, Miller LJ. Does intraosseous equal intravenous? A 
pharmacokinetic study. Am.J Emerg.Med. 2008; 26: 31-38. 
von Zastrow M, Svingos A, Haberstock-Debic H, Evans C. Regulated endocytosis of opioid 
receptors: cellular mechanisms and proposed roles in physiological adaptation to opiate 
drugs. Curr Opin Neurobiol 2003; 13: 348-53. 
Vousooghi N, Goodarzi A, Roushanzamir F, Sedaghati T, Zarrindast MR, Noori-Daloii MR. 
Expression of mu opioid receptor splice variants mRNA in human blood lymphocytes: A 
peripheral marker for opioid addiction studies. Int.Immunopharmacol. 2009. 
Walter C, Lotsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for 
pain treatment. Pain 2009; 146: 270-5. 
Wan YY, Flavell RA. How diverse--CD4 effector T cells and their functions. Journal of molecular 
cell biology 2009; 1: 20-36. 
Wang G, Weng Y, Ishiguro Y, Sakamoto H, Morita S. The effect of tramadol on serum cytokine 
response in patients undergoing pulmonary lobectomy. J.Clin.Anesth. 2005a; 17: 444-
50. 
Wang J, Barke RA, Charboneau R, Roy S. Morphine impairs host innate immune response and 
increases susceptibility to Streptococcus pneumoniae lung infection. J.Immunol. 2005b; 
174: 426-34. 
Wang J, Barke RA, Ma J, Charboneau R, Roy S. Opiate abuse, innate immunity, and bacterial 
infectious diseases. Arch.Immunol.Ther.Exp.(Warsz.) 2008; 56: 299-309. 
294 | P a g e  
 
Wang J, Charboneau R, Balasubramanian S, Barke RA, Loh HH, Roy S. Morphine modulates 
lymph node-derived T lymphocyte function: role of caspase-3, -8, and nitric oxide. J 
Leukoc Biol 2001; 70: 527-36. 
Wang J, Charboneau R, Balasubramanian S, Barke RA, Loh HH, Roy S. The 
immunosuppressive effects of chronic morphine treatment are partially dependent on 
corticosterone and mediated by the mu-opioid receptor. J.Leukoc.Biol. 2002; 71: 782-
90. 
Wang X, Douglas SD, Peng JS, Zhou DJ, Wan Q, Ho WZ. An in vitro model of morphine 
withdrawal manifests the enhancing effect on human immunodeficiency virus infection 
of human T lymphocytes through the induction of substance P. Am.J.Pathol. 2006; 169: 
1663-70. 
Watford WT, Moriguchi M, Morinobu A, O'Shea JJ. The biology of IL-12: coordinating innate and 
adaptive immune responses. Cytokine Growth Factor Rev 2003; 14: 361-8. 
Watkins LR, Hutchinson MR, Rice KC, Maier SF. The "toll" of opioid-induced glial activation: 
improving the clinical efficacy of opioids by targeting glia. Trends in pharmacological 
sciences 2009; 30: 581-91. 
Watkins LR, Maier SF, Goehler LE. Immune activation: the role of pro-inflammatory cytokines in 
inflammation, illness responses and pathological pain states. Pain 1995; 63: 289-302. 
Watson B, Meng F, Akil H. A chimeric analysis of the opioid receptor domains critical for the 
binding selectivity of mu opioid ligands. Neurobiol Dis 1996; 3: 87-96. 
Weber RJ, Gomez-Flores R, Sora I, Uhl GR. Loss of Morphine-induced Suppression of NK Cell 
activity and T-cell Functions in mu Opioid Receptor Knockout Mice. American Journal of 
Immunology 2006; 2: 35-39. 
Weber RJ, Pert A. The periaqueductal gray matter mediates opiate-induced 
immunosuppression. Science 1989; 245: 188-90. 
Wei G, Moss J, Yuan CS. Opioid-induced immunosuppression: is it centrally mediated or 
peripherally mediated? Biochem.Pharmacol. 2003; 65: 1761-66. 
Welters ID, Menzebach A, Goumon Y, Cadet P, Menges T, Hughes TK, Hempelmann G, 
Stefano GB. Morphine inhibits NF-kappaB nuclear binding in human neutrophils and 
monocytes by a nitric oxide-dependent mechanism. Anesthesiology 2000a; 92: 1677-
84. 
Welters ID, Menzebach A, Goumon Y, Langefeld TW, Teschemacher H, Hempelmann G, 
Stefano GB. Morphine suppresses complement receptor expression, phagocytosis, and 
respiratory burst in neutrophils by a nitric oxide and mu(3) opiate receptor-dependent 
mechanism. J Neuroimmunol 2000b; 111: 139-45. 
West JP, Lysle DT, Dykstra LA. Tolerance development to morphine-induced alterations of 
immune status. Drug Alcohol Depend 1997; 46: 147-57. 
Whistler JL, Chuang HH, Chu P, Jan LY, von Zastrow M. Functional dissociation of mu opioid 
receptor signaling and endocytosis: implications for the biology of opiate tolerance and 
addiction. Neuron 1999; 23: 737-46. 
Williams JP, Thompson JP, McDonald J, Barnes TA, Cote T, Rowbotham DJ, Lambert DG. 
Human peripheral blood mononuclear cells express nociceptin/orphanin FQ, but not 
mu, delta, or kappa opioid receptors. Anesth.Analg. 2007; 105: 998-1005, table. 
Williams LT, Snyderman R, Lefkowitz RJ. Identification of beta-adrenergic receptors in human 
lymphocytes by (-) (3H) alprenolol binding. J Clin Invest 1976; 57: 149-55. 
Wong MT, Ye JJ, Alonso MN, Landrigan A, Cheung RK, Engleman E, Utz PJ. Regulation of 
human Th9 differentiation by type I interferons and IL-21. Immunology and cell biology 
2010; 88: 624-31. 
Wrona D. Neural-immune interactions: an integrative view of the bidirectional relationship 
between the brain and immune systems. J Neuroimmunol 2006; 172: 38-58. 
Wu Y, Wang Y, Zhan J. Effects of remifentanyl and fentanyl on LPS-induced cytokine release in 
human whole blood in vitro. Mol Biol Rep 2009; 36: 1113-7. 
Wullaert A, Heyninck K, Beyaert R. Mechanisms of crosstalk between TNF-induced NF-kappaB 
and JNK activation in hepatocytes. Biochem Pharmacol 2006; 72: 1090-101. 
Wybran J, Appelboom T, Famaey JP, Govaerts A. Suggestive evidence for receptors for 
morphine and methionine-enkephalin on normal human blood T lymphocytes. J 
Immunol 1979; 123: 1068-70. 
Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, Achong MK. IL-6 is an 
antiinflammatory cytokine required for controlling local or systemic acute inflammatory 
responses. The Journal of clinical investigation 1998; 101: 311-20. 
295 | P a g e  
 
Yaksh TL. Pharmacology and mechanisms of opioid analgesic activity. Acta Anaesthesiol 
Scand 1997; 41: 94-111. 
Yates A, Bergmann C, Van Hemmen JL, Stark J, Callard R. Cytokine-modulated regulation of 
helper T cell populations. Journal of theoretical biology 2000; 206: 539-60. 
Yeager MP, Colacchio TA, Yu CT, Hildebrandt L, Howell AL, Weiss J, Guyre PM. Morphine 
inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. 
Anesthesiology 1995; 83: 500-08. 
Yeager MP, Procopio MA, DeLeo JA, Arruda JL, Hildebrandt L, Howell AL. Intravenous fentanyl 
increases natural killer cell cytotoxicity and circulating CD16(+) lymphocytes in humans. 
Anesth.Analg. 2002; 94: 94-9. 
Yeager MP, Yu CT, Campbell AS, Moschella M, Guyre PM. Effect of morphine and beta-
endorphin on human Fc receptor-dependent and natural killer cell functions. Clin 
Immunol Immunopathol 1992; 62: 336-43. 
Yoshida O, Akbar SM, Chen S, Miyake T, Abe M, Murakami H, Hiasa Y, Onji M. Regulatory 
natural killer cells in murine liver and their immunosuppressive capacity. Liver Int 2010. 
Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M. Polymorphic 
CYP2B6: molecular mechanisms and emerging clinical significance. 
Pharmacogenomics 2007; 8: 743-59. 
Zarbock A, Ley K. Mechanisms and consequences of neutrophil interaction with the 
endothelium. Am J Pathol 2008; 172: 1-7. 
Zhang H, Cui Y, Voong N, Sabatino M, Stroncek DF, Morisot S, Civin CI, Wayne AS, Levine BL, 
Mackall CL. Activating signals dominate inhibitory signals in CD137L/IL-15 activated 
natural killer cells. Journal of immunotherapy 2011; 34: 187-95. 
Zhang JL, Simeonowa I, Wang Y, Sebald W. The high-affinity interaction of human IL-4 and the 
receptor alpha chain is constituted by two independent binding clusters. J Mol Biol 
2002; 315: 399-407. 
Zhang Y, Du LN, Wu GC, Cao XD. Modulation of intrathecal morphine-induced 
immunosuppression by microinjection of naloxone into periaqueductal gray. Zhongguo 
Yao Li Xue.Bao. 1998; 19: 519-22. 
Zhu W, Cadet P, Baggerman G, Mantione KJ, Stefano GB. Human white blood cells synthesize 
morphine: CYP2D6 modulation. J.Immunol. 2005; 175: 7357-62. 
Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, Meyer CR, Koeppe RA, 
Stohler CS. Regional mu opioid receptor regulation of sensory and affective dimensions 
of pain. Science 2001; 293: 311-5. 
 
 
 
 
 
 
